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Abstract 
 
Schizophrenia is a potentially devastating mental illness with a complex aetiology, in which 
the odds ratios for environmental risk factors for the disorder are greater than the odds ratios 
of any single gene hitherto identified.  Within schizophrenia, striatal dopamine dysfunction has 
been proposed to underlie the development of psychosis.  The Aberrant Salience hypothesis 
provides an explanatory model based on empirical findings to explain how psychotic symptoms 
may arise from striatal hyperdopaminergia, whereby multiple risk factors converge to elevate 
striatal dopamine synthesis capacity as the Final Common Pathway to psychosis. 
 
Two important epidemiological risk factors for the disorder are chronic cannabis use and long-
term psychosocial stress, both of which have evidence supporting effects on the dopamine 
system. Environmental risk factors are by their very nature modifiable, and so this thesis 
examined whether these environmental risk factors were associated with the same 
dopaminergic abnormalities that have been observed in schizophrenia with 3,4-dihydroxy-6-
[18F]-fluoro-l-phenylalanine Positron Emission Tomography.  This thesis also examined 
whether cannabis users exhibit aberrant salience processing using a behavioural task, the 
Salience Attribution Task. 
 
This thesis found that long-term cannabis use was associated with reduced dopamine synthesis 
capacity and no relationship was found between striatal dopamine synthesis capacity and 
cannabis-induced psychotic-like symptoms.  Whilst cannabis use was not associated with 
increased aberrant salience processing, there was a relationship between cannabis-induced 
psychotic-like symptoms and aberrant salience processing.  This thesis found that long-term 
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psychosocial stress is associated with reduced dopamine synthesis capacity, although this 
finding may be due confounding factors.  However, a positive relationship was observed 
between childhood and recent adult stressors and dopamine synthesis capacity.   
 
These findings call into question the hypothesis that cannabis increases the risk of psychosis 
by inducing the same changes observed in schizophrenia, although there some evidence to 
support the hypothesis that psychosocial stressors do increase risk via this mechanism.  
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Chapter 1: Background 
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1.1 Schizophrenia and Psychosis: Historical Context 
 
The word “psychosis” is defined by the Oxford English Dictionary (2014) as “a severe 
mental disorder in which thought and emotions are so impaired that contact is lost with 
external reality” and first began to be used in the mid-Nineteenth century.   It was around this 
time that the modern medical study of mental disorders began.  Bénédict Morel (1809-1873) 
coined the term démence precoce, literally a “precocious dementia”, to describe a cognitive 
disorder he had observed in young people.  Later it was Aloysius Alzheimer’s (1864-1915) 
supervisor, Emil Kraepelin (1856-1926), who adapted the term and applied it to patients who 
developed a significant cognitive and social impairment at a young age, calling this dementia 
praecox, in comparison to the senile dementia affecting older adults. Post-mortem 
neuropathological examination of the brains of patients with late onset dementia revealed the 
now cardinal lesions of the disorder i.e. neurofibrillary tangles and senile plaques. Kraepelin 
called this disorder Alzheimer’s disease to differentiate it from dementia praecox.  At the time 
he believed it would be possible to identify the neuropathology typical of dementia praecox 
(Kraepelin et al. 1919), although the technology with which to achieve this remained out of his 
grasp.  Writing on dementia praecox, what we would now call schizophrenia, Kraeplin said:   
“If it should be confirmed that the disease attacks by preference the frontal areas of 
the brain, the central convolutions and the temporal lobes, this distribution would in a 
certain measure agree with our present views about the site of the psychic 
mechanisms which are principally injured by the disease…  it is easy to believe that 
the frontal cortex, which is specially well developed in man, stands in closer relation 
to his higher intellectual abilities, and these are the faculties which in our patients 
invariably suffer profound loss…  On the other hand, the peculiar speech disorder 
 
38 
 
resembling sensory aphasia and the auditory hallucinations, which play such a large 
part, probably point to the temporal lobe being involved.” 
 
Eugen Bleuler (1857–1939) later modified the concept of dementia praecox to include 
symptoms that were not based on external reality and were therefore, by the contemporary 
definition given above, psychotic.  These were hallucinations (seemingly real perceptions in 
the absence of apparent sensory stimuli) and delusions (abnormal beliefs that are maintained 
despite contradiction from evidence in reality or rational argument).  Bleuler called this 
disorder Schizophrenia (skhiz- 'to split' + phrēn- 'mind') to reflect the fragmenting of mental 
functions which were then seen as underlying the internal psychological mechanisms of the 
disorder (Bleuler 1911).    
 
Around the same time, the British Neurologist Sir John Reynolds (1828-1896) who 
wrote extensively on the clinical diagnosis of brain disorders, coined the terms “positive 
symptoms” and “negative symptoms” to describe symptoms that were added by a disorder or 
lesion and those that were taken away by a disorder or lesion, respectively (Berrios 1985).   
Reynold’s contemporary John Hughlings-Jackson (1835 – 1911), at the time based at the 
National Hospital for Paralysis and Epilepsy in London’s Queen Square (now the National 
Hospital for Neurology and Neurosurgery),  developed an evolutionary hierarchical 
organization of the nervous system which he used to explain why some patients have particular 
constellations of positive and/or negative neurological symptoms (Berrios 1991).  Hughlings-
Jackson’s theories were later highly influential for leading continental psychiatrists of the age 
(Berrios 1977) resulting in their application to schizophrenia.  Examples of positive and 
negative symptoms of schizophrenia as used in contemporary Psychiatry are given in Box .11.  
 
39 
 
This thesis is primarily concerned with the neurobiology underlying positive symptoms and 
will use the term “psychotic symptoms” to mean positive symptoms throughout, unless 
otherwise stated.     
  
Box 1.1 Examples of positive and negative symptoms of schizophrenia from the 
Positive and Negative Syndrome Scale (PANSS) for schizophrenia (Kay et al. 1997) 
Positive symptoms: Delusions 
 Conceptual disorganization 
 Hallucinations 
 Excitement 
 Grandiosity 
 Suspiciousness (Paranoia) 
Negative symptoms: Blunted affect 
 Emotional withdrawal 
 Poor Rapport 
 Passive-apathetic social withdrawal 
 Difficulty in abstract thinking 
 Lack of spontaneity and flow of conversation 
 Stereotyped thinking 
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1.2 Introduction: Schizophrenia, Psychosis & Dopamine 
 
Schizophrenia, a leading global cause of disability (WHO, 2008), is a clinical syndrome 
characterised by episodic psychosis composed of hallucinations, delusions and disordered 
thinking. It is associated with increased risk of early death from suicide (Palmer et al. 2005).  
The commonest feature of acute schizophrenic psychosis is loss of insight.  The constellation 
of signs and symptoms that can give rise to a diagnosis of schizophrenia were standardised 
over the course of the Twentieth century into the World Health Organization’s International 
Classification of Disease 10th Edition (ICD-10) (1992) and the American Psychiatric 
Association’s Diagnostic and Statistical Manual 4th Edition Text Revision (DSM-IV-TR) 
(2000).  Whilst the ICD-10 is widely used internationally and is the standard used in clinical 
practice in the United Kingdom, for historical reasons the DSM-IV-TR is more commonly used 
in the research literature.  The American Psychiatric Association has since published a 5th 
Edition of their Diagnostic and Statistical Manual (DSM-5) (2013).  However, the DSM-5 has 
received substantial criticism over doubts about the scientific validity and reliability of its 
diagnostic constructs and the “medicalisation of… natural and normal responses to… 
experiences” (British Psychological Society, 2011).  Therefore, DSM-IV-TR diagnoses will 
be used throughout this thesis unless otherwise stated. The DSM-IV-TR diagnostic criteria for 
schizophrenia are reported in Box 1.2.   
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Box 1.2: DSM-IV(TR) Diagnostic Criteria for Schizophrenia (American Psychiatric Association 2000)  
A:  Characteristic Symptoms: Two or more of the following, each present for a significant portion of time during a one 
month period (or less if successfully treated): 
(1) Delusions 
(2) Hallucinations 
(3) Disorganised speech (e.g. frequent derailment or incoherence) 
(4) Grossly disorganised or catatonic behaviour  
(5) Negative symptoms i.e. affective flattening, alogia (poverty of speech) or avolition 
Note: Only one Criterion A symptom is required if delusions are bizarre or hallucinations consist of a voice 
keeping up a running commentary on the person’s behaviour or thoughts, or two or more voices conversing with 
each other. 
B:  Social/occupational dysfunction: For a significant portion of the time since the onset of the disturbance, one or 
more major areas of functioning such as work, interpersonal relations, or self-care are markedly below the level 
achieved prior to the onset (or when the onset is in childhood or adolescence, failure to achieve expected level of 
interpersonal, academic, or occupational achievement).   
C: Duration: Continuous signs of the disturbance persist for at least 6 months.  This 6 month period must include at 
least 1 month of symptoms (or less if successfully treated) that meet criterion A (i.e. active-phase symptoms) and 
may include periods of prodromal or residual symptoms/ During these prodromal or residual periods, the signs of 
the disturbance may be manifested by only negative symptoms or two or more symptoms listed in Criterion A 
present in an attenuated form (e.g. odd beliefs, unusual perceptual experiences). 
D: Schizoaffective and Mood Disorder Exclusion: Schizoaffective Disorder and Mood Disorder with Psychotic 
Features have been ruled out because either (1) no Major Depressive, Manic, or Mixed Episodes have occurred 
concurrently with the active-phase symptoms; or (2) if mood episodes have occurred during active-phase 
symptoms, their total duration has been brief relative to the duration of the active and residual periods.   
E:  Substance/general medical condition exclusion: The disturbance is not due to the direct physiological effects of a 
substance (e.g. drug of abuse, a medication) or a general medical condition. 
F: Relationship to a Pervasive Developmental Disorder: If there is a history of Autistic Disorder or another Pervasive 
Developmental Disorder, the additional diagnosis of schizophrenia is made only if prominent delusions or 
hallucinations are also present for at least a month (or less if successfully treated).   
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1.3 Aetiology 
Schizophrenia has a complex aetiology in which genetic-environment interactions are 
likely to be central.  In terms of epidemiology, the twentieth century saw an initially divergent 
approach to schizophrenia with American studies focussing on socio-ecological risk factors 
whilst European studies focussed on genetic risks and population distributions (Jablensky 
2012).  Arguably the first epidemiological study was a Swiss case-control genealogical inquiry 
from records of psychiatric units by Koller (1895) who reported that 'the hereditary loading of 
healthy subjects is much higher than generally assumed', that 'the strongest loading is that of 
psychosis', and that 'the loading in distant relatives is quite low, unless a person at risk is 
exposed to multiple factors’.  It was this ground-breaking study that first highlighted the 
interactions between multiple risk factors, namely hereditary (i.e. genetic) and then unknown 
environmental factors.  Much epidemiological work has been conducted since and the results 
will be summarised below. Based on large systematic reviews, the point prevalence of 
schizophrenia has been estimated at 4.6 per 1,000 people and the lifetime prevalence is 7.2 per 
1,000 (Saha et al. 2005), whilst the annual incidence has been estimated to be 0.24 per 1000 
(McGrath et al. 2003).  Schizophrenia can occur throughout the lifespan, although the majority 
of onsets occur in the 15 to 54 year age range, with peak onset between the ages of 20 and 24 
years (Jablensky 2012), followed by a second peak in later life which is most pronounced in 
women (Hafner et al. 1998).  There is also evidence of a male preponderance for the illness 
(Kirkbride et al. 2006), see  Figure 1.1.   
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Figure 1.1 Age specific incidence rates of schizophrenia by sex from the 3-Center 
AESOP study (Kirkbride et al. 2006)   
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1.4 Risk Factors for Schizophrenia 
 
1.4.1.1 Genetic Risk Factors 
 
At the individual level, having a relative with schizophrenia is the most important risk 
factor for the illness, with lifetime risk of schizophrenia increasing with increasing genetic 
similarity, such that risk is most elevated amongst monozygotic (MZ) twins and in those with 
two parents with the disorder (Gottesman 1991), see figure 1.2. The heritability of a disorder 
can be defined as the proportion of phenotypic variance attributable to genetic variance i.e. the 
extent to which genetic individual differences contribute to phenotypic individual differences. 
 
 
 
Figure 1.2 Lifetime risk of developing schizophrenia in relatives of individuals 
(Gottesman 1991) 
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High familial aggregation has been widely replicated in family studies (e.g. Kendler et 
al. 1993).  Twin studies (Cardno & Gottesman 2000) have estimated high heritability of the 
disorder, approximately 80 to 85%, with probandwise concordance rates (i.e. the proportion of 
twins who have the illness given an affected twin) in MZ twin pairs of 41 to 65 % and up to 28 
% in dizygotic (DZ) pairs.  Other studies have estimated the heritability for the disorder at been 
between 65% and 80% (Lichtenstien et al. 2009; Sullivan et al. 2003). The heritability of 
schizophrenia has been confirmed by adoption studies which are able to separate environmental 
from genetic effects.  Kety et al. (1994) reported that 23.5 % of adoptees who had a biological 
first-degree relative with schizophrenia later developed the illness, compared to 4.7 % of 
control adoptees with no biological parental history of schizophrenia.  Furthermore, a reverse 
adoption study (Wender et al. 1974) found that the grown-up children of individuals without 
schizophrenia who had been adopted by a parent who later developed schizophrenia were not 
at increased risk of the disorder.  Taken together, these findings confirm a high heritability for 
the disorder, suggesting that genetics contribute to altered biology giving rise to the disorder.   
 
Obstacles remain in the genetic investigation of schizophrenia due to non-Mendelian 
inheritance and a likely complex genetic architecture.  The most parsimonious genetic account 
for schizophrenia has been proposed to be a polygenic model in which a number of genes of 
small effect contribute to elevated risk (Iyegbe et al. 2014).  Evidence in favour of this comes 
from family studies in which the risk to an individual increases with the number of affected 
relatives (Gottesman 1991); the concordance rate being higher in MZ twins who have an earlier 
rather than a later onset of the illness (Cardno et al. 1999); and relatives of those with an earlier 
onset of the illness have a higher risk of schizophrenia than those with a later illness onset.  
Taken together these findings also lended support to the idea that susceptibility genes may be 
involved in the control of neurodevelopment (Jones & Murray 1991).   
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1.4.1.2 Pre Genome-Wide Association Study (GWAS) era 
Early genetic work using karyotyping, linkage studies (assessing co-segregation of 
genetic loci with disease within families given that genes which are close together on the 
genome tend to be inherited together) and candidate gene association studies (the identification 
of commonly occurring variants of small effect) in velocardiofacial syndrome led to the 
findings that large deletions on chromosome 22q11.2 are associated with increased risk of 
schizophrenia (Bassett et al. 1998) and higher rates of the 22q11 deletion are found in 
schizophrenia compared to the general population (Karayiorgou et al. 1995).  However, there 
does not appear to be any significant clinical variation in schizophrenia with or without 22q11.2 
deletion (Bassett et al. 2003) affecting the COMT and TBX1 genes 
 
Until recently, although dozens of linkage analyses have been performed in 
schizophrenia, with some reporting genome-wide significant findings (Paunio et al. 2001; 
Maziade et al. 2005; Holliday et al. 2009; Holmans et al. 2009), no locus had been consistently 
replicated across studies, and meta-analyses had failed to identify any locus that surpasses 
genome-wide significance (Ng et al. 2009). This could be explained by multiple genes of small 
effect.  More than one thousand candidate gene association studies have been performed to 
date.  However, the results from earlier studies had been inconsistent and they were limited by 
low power.  Meta-analyses of these studies had identified four out of sixteen candidate genes 
that had “strong” epidemiological credibility (Allen et al. 2008):  DRD1 (dopamine D1 
receptor) on chromosome 5q35.1, DTNBP1 (Dysbindin 1; dystrobrevin binding protein 1) on 
chromosome 6p22.3, MTHFR (methylenetetrahydrofolate reductase) on chromosome 1p 36.3 
and TPH1 (tryptophan hydroxylase 1) on chromosome 11p15.    
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1.4.1.3 Current thinking of the genetic architecture of schizophrenia 
Since these earlier studies, more definitive evidence that genetic risk for schizophrenia 
arises from variation in DNA sequences has come from genome-wide association studies 
(GWAS) studies of single nucleotide polymorphisms (SNPs) and copy number variants 
(CNVs).   A significant strength of GWAS is that it provides a hypothesis-free method.  GWAS 
SNPs in the genome and data from GWAS arrays can also be used to identify rare sub-
microscopic chromosomal deletions and duplications i.e.  CNVs.  These studies were recently 
reviewed by Harrison (2015) and their findings are summarised below.  For illustrative 
purposes, selected loci and genes that confer risk of schizophrenia identified through studying 
SNPs with brief notes on what is known of their neurobiology are given in Table 1.1.  
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Table 1.1 Selected loci and genes showing association to schizophrenia: nomenclature and notes (adapted from 
Harrison 2015) 
Locus Implicated gene Name of gene or product Notes 
12p13.33 CACNA1C L-type calcium a subunit, 
type 1c 
Important in neuronal function.  Mutations 
cause Timothy syndrome and Brugada’s 
syndrome (Bhat et al. 2012) 
12q24.11 DAO D-amino acid oxidase Enzyme which degrades the NMDA receptor 
co-agonist D-serine.  Expression and activity 
increased in schizophrenia. (Verrall et al. 2010) 
1q42.2 DISC1 Disrupted in 
schizophrenia 1 
Identified in a large Scottish pedigree with a 
chromosome 1:11 translocation.  A 
multifunctional scaffolding protein.   (Brandon 
& Sawa 2011) 
11q23.2 DRD2 Dopamine D2 receptor Long known to be the key target of 
antipsychotic drugs, GWAS data now indicate 
that the DRD2 gene may play a role in 
schizophrenia (Beaulieu & Gainetdinov 2011) 
2q33-34 ERBB4 Receptor tyrosine inase 
erbB4 
Receptor for neuregulin 1 and some other 
ligands.  Mutations can cause cancers (Mei & 
Xiong 2008) 
5q33.2 GRIA1 AMPA receptor subunit 
1 (GluA1; GluR1) 
The subunit influences properties of the AMPA 
receptor, and affects synaptic plasticity and 
behaviour (Barkus et al. 2014) 
16p13.2 GRIN2A NMDA receptor subunit 
2A (GluN2A; NR2A) 
The subunit influences properties of the 
NMDA receptor, including synaptic 
localisation and channel conductance (Paoletti 
et al. 2013) 
7q21.11-
12 
GRM3 Metabotropic glutamate 
receptor 3 (mGlu3) 
Group II metabotropic glutamate receptor 
(along with mGlu2), acting primarily as 
inhibitory autoreceptors (Harrison et al. 2008) 
1p21.3 MIR137 MicroRNA 137 Non-protein-coding gene.  A micro RNA, 
which regulates other genes by binding to the 
3’untranslated region of their transcripts 
(Pasquinelli 2012) 
8p12 NRG1 Neuroregulin 1 Growth factor, involved in many aspects of 
nervous system development and plasticity 
(Mei & Nave 2014) 
17p13.3 SRR Serine racemase Enzyme which synthesises D-serine from L-
serine (Balu et al. 2013) 
18q21.2 TCF4 Transcription factor 4 Basic helix-loop-helix transcription factor.  
Haploinsufficiency causes Pitt-Hopkins 
syndrome (Forrest et al. 2014) 
2q32.1 ZNF804A Zinc finger protein 804A Putative transcription factor (Hess & Glatt 
2013) 
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1.4.1.4 Single Nucleotide Polymorphisms 
 
As genome-wide association studies (GWAS) have grown in sample size, there is 
increasing evidence that common SNPs confer increased risk of schizophrenia (Table 1.2).  A 
recent large meta-analysis by the international Psychiatric Genetics Consortium (2014), 
identified over 100 genetic loci that contain SNPs significant for association to schizophrenia 
at the genome-wide level.  Each locus contains one or more genes and one or more variant 
within the gene or genes that contribute to the risk of schizophrenia.  That study, in almost 
37,000 cases and 113,000 controls implicates approximately 600 genes.   
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Table 1.2 Multi-stage GWAS reporting genome-wide significant (<5 × 10−8) findings in schizophrenia, or 
schizophrenia combined with bipolar disorder (adapted from Mowry & Gratten 2013)  
Lead author Locus SNP Odds 
ratio  
P-value Closest gene 
(abbreviation) 
Schizophrenia 
Purcell et al. 2009 6p22.1 rs13194053 .82  9.54 × 10−9 HIST1H2BJ 
Shi et al. 2009 6p22.1 rs13194053 .88  9.54 × 10−9 HIST1H2BJ 
Stefansson et al. 2009 6p21.3-22.1 rs6932590 1.16  1.4 × 10−12 PRSS16 
 11q24.2 rs12807809 1.15  2.4 × 10−9 NRGN 
 18q21.2 rs9960767 1.23  4.1 × 10−9 TCF4 
Rietschel et al. 2012 11p11.2 rs11819869 1.25  3.89 × 10−9 AMBRA1 
Ripke et al. 2011 1p21.3 rs1625579 1.12  1.59 × 10−11 MIR137 
 2q32.3 rs17662626 1.20  4.65 × 10−8 PCGEM1 
 6p21.3-22.1 rs2021722 1.15  2.18 × 10−12 TRIM26 
 8p23.2 rs10503253 1.11  4.14 × 10−8 CSMD1 
 8q21.3 rs7004633 1.16  1.45 × 10−8 MMP16 
 10q24.32 rs7914558 1.10  1.82 × 10−9 CNNM2 
 10q24.33 rs11191580 1.15  1.11 × 10−8 NT5C2 
 11q24.2 rs548181 1.20  2.91 × 10−8 STT3A 
 18q21.2 rs12966547 1.09  2.60 × 10−10 CCDC68 
 18q21.2 rs17512836 1.40  2.35 × 10−8 TCF4 
Shi et al. 2011 1q24.2 rs10489202 1.19  9.50 × 10−9 BRP44 
 8p12 rs16887244 .83  1.27 × 10−10 LSM1 
 8p12 rs1488935 .87  5.06 × 10−9 WHSC1L1 
Steinberg et al. 2011 2p15.1 rs2312147 1.09  1.9 × 10−9 VRK2 
 18q21.2 rs4309482 1.09  7.8 × 10−9 TCF4 
Yue et al. 2011 6p21-22.1 rs1635 .78  6.91 × 10−12 NKAPL 
 11p11.2 rs11038167 1.29  1.09 × 10−11 TSPAN18 
      
Schizophrenia and bipolar disorder 
O’Donovan et al. 2008 2q32.1 rs1344706 1.12  9.96 × 10−9 ZNF804A 
Ripke et al. 2011 3p21.1 rs2239547 1.12  7.83 × 10−9 ITIH3/4 
 10q21.2 rs10994359 1.22  2.5 × 10−8 ANK3 
 12p13.3 rs4765905 1.11  7.0 × 10−9 CACNA1C 
 
 To date, many of the schizophrenia-associated SNPs are in non-coding intronic DNA 
regions or are synonymous exonic polymorphisms.  As there is often no evidence of functional 
difference between the risks and non-risk alleles, identifying the biological basis for the genetic 
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association has been problematic.  A further difficulty has that the identified SNPs are unlikely 
to be themselves the causative SNP but instead are tagging a length of DNA where the causative 
variants lie (Kircher et al. 2014).  One possible explanation for these findings is that the risk 
SNP may alter gene expression.   
 
Schizophrenia risk SNPs typically have odds ratios in the order of 1.1 meaning that 
each has a very small effect on disease risk.  Furthermore, there are a number of SNPs that 
associate with broader phenotypes including bipolar affective disorder, depressive disorder and 
autism (Cross Disorder Group of the Psychiatric Genomics Consortium, 2013; Table 1.2).  This 
emergent genetic pleiotropy suggests that clinical commonality amongst these disorders may, 
to a degree, result from shared genetic predisposition.   
 
There was some initial controversy following the GWAS studies as those studies were 
not able to replicate findings from earlier candidate gene approaches because the first GWAS 
studies initially suggested these genes were not associated with commonly occurring disease-
related genetic variants.  The debate centred around whether genome-wide statistical 
significance was essential in deciding whether or not a particular gene should be considered to 
be a risk factor or if other biological evidence should also be taken into account (Abbott 2008), 
as was the case with scientific arguments around DISC1 (e.g. Porteous 2014).  However, since 
these earlier studies, much progress has been made by combining samples into single 
systematic analyses.   
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However, the most recent meta-analysis (Psychiatric Genetics Consortium, 2014) 
implicates several candidate genes with genome-wide association for several candidate genes 
with high biomechanistic plausibility including the D2 receptor gene and several glutamate 
receptor genes including GRIN2A, GRIA1 and GRM3.   
 
1.4.1.5 Copy Number Variants (CNVs) 
 
In addition to SNPs, genetic risk for schizophrenia is also mediated via CNVs.  These 
are lengths of DNA which are duplicated or deleted, yet were too small to be observed using 
older methods such as karyotyping.  CNVs are a normal feature of the genome, but microarray 
technology has revealed that certain CNVs in particular genomic regions are associated with 
increased risk of schizophrenia.   
 
There is evidence for a small increase in the rate of CNVs in people with schizophrenia 
compared to controls (Walsh et al. 2008; Stone et al. 2008; Levinson et al. 2011) and de novo 
CNVs are associated with a higher risk of schizophrenia (Malhotra et al. 2011; Xu et al. 2008; 
Kirov et al. 2012).  A number of CNVs have been identified that confer an increased risk of 
schizophrenia and these are reported in Table 1.3.  These occur at low frequency in the general 
population and whilst they have higher odds ratios than the SNPs that have been identified to 
date (CNVs with odds ratios over 8) none have yet been identified that are necessary and 
sufficient to cause disease.   
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Table 1.3 Replicated CNVs in schizophrenia (adapted from Mowry & Gratten 2013) 
Lead author Locus CNV Odds ratio  P-value Genes  Other Disorders 
         
Levinson et 
al. 2011 
1q21.1 Del 8.3  2.2 × 10−8 11 Autistic Spectrum Disorder, Mental 
Retardation 
Levinson et 
al. 2011 
2p16.3 Ex 
del 
8.2  5.5 × 10−9 1 
(NRXN1) 
Autistic Spectrum Disorder, Mental 
Retardation 
Mulle et al. 
2010 
3q29 Del 17.0  9.7 × 10−3 19 Autistic Spectrum Disorder, Mental 
Retardation 
Vacic et al. 
2011 
3q29 Dup ∞  1.0 × 10−2 2   
Levinson et 
al. 2011 
7q36.3 Ex 
dup 
4.0  2.0 × 10−3 1 (VIPR2)   
Stefansson et 
al. 2008a 
15q11.2 Del 2.7  6.0 × 10−4 4 Autistic Spectrum Disorder, Prada-
Willi & Angelman syndromes 
Levinson et 
al. 2011 
15q13.3 Del 9.9  2.0 × 10−9 8 Autistic Spectrum Disorder, Mental 
Retardation, Epilepsy 
Ingason et al. 
2011 
15q11.2-
13.1 
Mat 
dup 
7.3  1.0 × 10−2 13–24   
Levinson et 
al. 2011 
16p11.2 Dup 11.6  1.5 × 10−12 26 Autistic Spectrum Disorder, Mental 
Retardation, Developmental Delay 
Stefansson et 
al. 2008b 
16p13.1 Dup 3.3  7.1 × 10−3 11 Autistic Spectrum Disorder, Mental 
Retardation 
Kirov et al. 
2009 
17p12 Del 9.9  5.0 × 10−5 15 Hereditary neuropathy with liability to 
pressure palsies 
Levinson et 
al. 2011 
22q11.2 Del ∞  <1.0 × 10−16 29–43 Velo-cardio-facial syndrome 
         
Abbreviations: Del, deletion; Dup, duplication; Ex del, exonic deletion; Mat dup, maternally-derived duplication 
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CNV regions hitherto identified include those with multiple and single genes.  Each 
CNV is penetrant (Kirov et al. 2014), although with the exception of deletion at 22q11 giving 
rise to velocardiofacial syndrome (Schneider et al. 2014) each CNV is very rare such that it is 
estimated that CNVs may have a causal significance in approximately 5 per cent of cases 
(Costain et al. 2013), although the odds ratios associated with CNVs for these cases are likely 
to be much larger than any other identifiable factors.   
 
In addition to SNPs and CNVs, recent research has also given rise to an association 
between schizophrenia and insertion or deletions affecting a few nucleotides and also single 
nucleotide coding variants (Purcell et al. 2014).  It was estimated that these mutations may 
account for a proportion of risk to similar to CNVs, although CNVs and these newly identified 
mutations appear to contribute approximately 10 per cent of the heritability as common SNPs.  
It is interesting to note this early evidence suggests some shared genetic aetiology with a 
number of neurodevelopmental disorders including autistic spectrum disorder (Malhotra & 
Sebat 2012).  Lately, it has been suggested that these mutations are associated with cognitive 
deficits and are likely to represent de novo changes in the genome (Fromer et al. 2014).   
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1.4.1.6 Linking genes to neurobiology 
There is growing evidence that from genes associated with increased risk of 
schizophrenia converge upon a number of neurobiological pathways that may shed light on the 
underlying pathophysiology of the disorder.  Of particular relevance to this thesis, examples of 
these relevant to the current major aetiological hypotheses of schizophrenia include the 
dopamine D2 receptor (Schizophrenia Working Group 2014), NMDA receptor signalling (e.g. 
Purcell et al. 2014), immune function (Corvin & Morris 2014), calcium signalling (Ripke et al. 
2013), the NRG1-ERBB4-PI3K-AKT1 pathway (Emamian et al. 2004; Harrison & Law, 2006; 
Hatzimanolis et al. 2013; Law et al. 2012; Nicodemus et al. 2010; Norton et al. 2006) which 
is likely involved in plasticity. The AKT1 pathway is of particular interest given its resultant 
inactivation of glycogen synthase kinase 3 (GSK-3), a downstream mediator of the effects of 
D2 receptor activation. Interestingly, using a combined GWAS across three psychiatric 
disorders, the Network and Pathway Analysis Subgroup for the Psychiatric Genomics 
Consortium (2015) found using a pathway approach that there were significant genetic 
associations across epigenetic, immune and neuronal signalling pathways.   
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Whilst the findings summarised above advance the field they account for only a 
minority of the heritability of schizophrenia (Harrison 2015). For example, the common SNPs 
identified in schizophrenia exceeding genome-wide significance explain little of the variance 
in susceptibility to the illness, either individually (<0.1%) or collectively (~2-3%) (Visscher et 
al. 2011).  Yet, attempts to overcome this using polygenic risk scores, which are capable of 
explaining more of the variance, appear to be promising (Iyegbe et al. 2014).   One 
interpretation of the current lack of a robust understanding of the genetics of schizophrenia is 
that the heritability lies in epigenetic factors: “the failure of the search for psychosis genes by 
linkage and association therefore reveals the trans-generational reality of the epigenetic 
phenotype” (Crow 2008).  Indeed it is plausible that epigenetic factors including histone 
modification and DNA methylation contribute to gene-environment interactions (Daxinger & 
Whitelaw 2012; Dempster et al. 2013).  Likewise, it may well be the case that instead of a 
cumulative effect of independent genes, genetic risk for schizophrenia is moderated by epistasis 
i.e. gene-gene interactions (Phillips 2008; Mackay 2014).  Another possibility, as mentioned 
briefly earlier, is that disease prevalence is maintained by de novo mutation across many genes 
in spite of negative selection.  There is some evidence in favour of the latter possibility, as 
increased exonic de novo mutations have been found in people with schizophrenia compared 
to controls (Girard et al. 2011).  Further whole exome sequencing studies, together with GWAS 
and epigenetic studies involving very large sample sizes, will therefore be needed in the future 
to dissect the possible molecular pathways that can lead to this disorder and in particular, how 
these interact with the environmental risk factors described below to result in the phenotypic 
expression of schizophrenia.   
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1.4.1.7 Gene–Environment Interactions 
The first studies of gene x environment interactions in schizophrenia have begun to 
yield interesting results.  These shall be outlined before environmental risk factors are 
considered in more detail below.   
 
Whilst initially a COMT polymorphism was proposed to contribute to the risk of 
schizophrenia in cannabis users (Zammitt et al. 2011), this now seems less pronounced than 
initially thought.  Yet, there is much current interest in AKT1 polymorphisms in cannabis users 
(e.g. Di Forti et al. 2012).  Amongst cannabis users AKT1 c/c carries appear to have a seven-
fold increased risk of schizophrenia compared to t/t  carriers.  Here, the increased risk may be 
occurring via downstream effects in the dopamine signalling cascade.  A Val66Met 
polymorphism in the BDNF gene has been associated with increased risk in positive psychotic 
symptoms in those who have experienced child abuse (Alemany et al. 2011).  This is interesting 
given that the BDNF polymorphism is proposed to impair plasticity, and so may impair how 
the brain processes psychological trauma. The COMT gene has also been investigated in the 
context of stress reactivity in psychosis (e.g. Peerboms et al. 2012) where the Val158Met 
polymorphism  may interact with MTHFR genotype, providing a tentative gene-gene-
environment interaction. Given that there are likely many genes of small of small effect, future 
research on polygenic risk scores may well benefit from specificity to the environments in 
which these genes are expressed.   
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1.4.2.1 Environmental Risk Factors 
 
“Developments in molecular genetics need to go hand in hand with progress in the 
study of environmental factors that interact with genes.  It is easier (and ethically 
preferable) to change the environment than it is to change one’s genes… Even if this 
were possible, it would not be ethically justifiable, especially in Psychiatry” 
Khong 1997 
 
There is consistent epidemiological evidence for significant associations between a 
number of environmental factors and increased risk of schizophrenia.  Whilst a history of 
schizophrenia in a first degree relative is associated with the highest relative risk of having the 
illness at the individual level, environmental risk factors account for many more cases on a 
population basis (Mortensen et al. 1999).  Furthermore, environmental factors appear necessary 
for the manifestation of frank illness in the majority of cases (Van Os & Marcelis, 1998).   There 
is now renewed interest in further understanding the biological mechanisms underlying 
environmental risks for schizophrenia, which are outlined below.   
 
1.4.2.2 Obstetric Factors  
Individuals with schizophrenia are more likely to have a history of prenatal or perinatal 
obstetric complications than healthy subjects from the general population and their own healthy 
siblings (Geddes et al. 1999).  Evidence in favour of this association comes from studies that 
have collected obstetric data from the time of birth (Hultman et al. 1999) and meta-analyses of 
epidemiological studies (Cannon et al. 2002).  The obstetric events that are most associated 
with an increased risk of schizophrenia include low birth weight, prematurity, resuscitation at 
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birth, retarded foetal growth and rhesus incompatibility (Geddes et al. 1999).  One feature that 
most of these adverse events have in common is that of being associated with increased risk of 
hypoxia, which could interfere with foetal and/or neonatal brain development.  An alternative 
possibility is that the increased rate of obstetric complication in schizophrenia may be caused 
by an unknown pre-existing abnormality since women with schizophrenia are more likely to 
have obstetric complications e.g. caesarean sections or instrument-assisted deliveries than 
mothers without schizophrenia (Bennedsen et al. 2001).   
 
Being born in the winter and early spring is associated with an increased risk of 
schizophrenia (Mortensen et al. 1999) (Figure1.3), an effect which remains evident both the 
Northern and Southern hemispheres.  This effect does not interact with familial risk of 
schizophrenia (Hettema et al. 1996).  One explanation for this is that an excess of maternal 
infection in the winter months, such as influenza underlies this association.  Controlling for 
seasonality, it was found that rates of maternal influenza, particularly in the sixth month of 
gestation, were associated with rates of birth of people with schizophrenia (Barr et al. 1990), 
although one study reported an association between schizophrenia and the presence of anti-
influenza antibodies in the first trimester only (Brown et al. 2004).   
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Figure 1.3 The relative risk of schizophrenia according to month of birth (Mortensen et 
al. 1999). The data points and vertical bars show the relative risks and 95 percent confidence 
intervals, respectively, with the month of birth analysed as a categorical variable, and the 
curve shows the relative risk as a fitted sine function of the month of birth.  The reference 
category is December.   
 
There is also evidence that severe prenatal malnutrition, as would occur in a famine for 
example, increases the risk of schizophrenia.  This association has been following in the Nazi-
engendered Dutch Hunger Winter during the Second World War (Susser & Lin 1992) and the 
Chinese Famine (1951-1961) in the wake of the Chinese Communist Party’s “Great Leap 
Forward” resulting in flawed agricultural policies (St Clair et al. 2005).   
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1.4.2.3 Childhood Risk Factors  
 
There is a two-fold increase in the risk of schizophrenia among people with unknown 
fathers compared with people with known fathers, which may be related to the lower 
socioeconomic status of the mothers of these offspring and/or by difficulties in growing up in 
a family without a father (Mortensen et al. 1999).  Individuals who have experienced the death 
of or long-term separation from a parent before the age of 16 years have been shown to have 
an increased risk of psychotic disorder, with the odds ratio in the most robust studies (e.g. 
Morgan et al.  2007, Agid et al. 1999) being in the order of two to three. The largest case-
control evidence comes from the AESOP study, which found the level of risk to be over two 
fold higher in those with a history of separation from or death of a parent before the age of 16, 
after adjusting for potential confounds (Morgan et al. 2007).   
 
Studies have also found associations between childhood abuse/neglect and psychotic 
risk, although this evidence is less consistent and less methodologically robust (Morgan & 
Fisher 2007).  Despite methodological challenges, these studies suggest traumatic events may 
increase the likelihood of experiencing psychotic symptoms (reviewed in van Os et al. 2010) 
and it has been suggested there may be specific associations between different types of trauma 
and specific psychotic phenomena (Bentall & Fernyhough, 2008), with ongoing interest in the 
tentative association between childhood sexual abuse and hallucinosis (e.g. Read et al. 2003; 
Varese et al. 2012).   
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1.4.2.4 Urbanicity  
Schizophrenia is associated with a non-random geographical distribution. That is, urban 
dwelling, or “urbanicity”, is associated with schizophrenia (Faris & Dunham 1939) and there 
is increased risk of psychosis in people who are born or brought up in inner cities compared to 
rural areas (Figure 1.4).  In a study of Swedish conscripts, individuals who developed 
schizophrenia were 1.65 times more likely to have been brought up in urban vs. rural areas 
(Lewis et al. 1992).  Likewise, Marcelis et al. (1998) found that urban birth carried twice the 
risk of later schizophrenia than rural birth.  There is also evidence of a dose-response 
relationship between degree of urbanicity and risk of schizophrenia (Pedersen & Mortensen, 
2001).  
 
A systematic review by Kelly et al. (2010) found that all but one of 18 register-based 
studies examining rates of psychosis according to urbanicity found a positive association.  The 
relative risk was between 1.4 and 4.3, and in most cases was approximately 2.  
 
A number of possible aetiological mechanisms underlying the link between urbanicity 
and schizophrenia have been suggested, including obstetric complications (e.g. Torrey et al. 
2000), perinatal infection, (e.g. McDonald et al. 2001) and perinatal vitamin D deficiency 
(based on McGrath’s hypothesis, 1999).  However research into these specific factors is either 
lacking or has shown that urbanicity continues to make an independent contribution to risk 
(Kelly et al. 2010).   
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A recent population-based study of over 20,000 individuals (Zammit et al. 2010) 
concluded that the association between urbanicity and psychosis appears to be a reflection of 
greater social fragmentation present within cities. Other commentators (e.g. Van Os et al. 2010) 
have identified individual social factors (e.g. being single, living alone), area-level factors such 
as social fragmentation, inequality (see Boydell et al. 2004) and the relationship between 
individual and area-level factors as candidate contributing factors. 
 
 
Figure 1.4 Relative risk of schizophrenia in Denmark according to pace of birth.  In this 
figure the reference category is the rural area (from Mortensen et al. 1999).   
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1.4.2.4 Migration & Ethnicity 
Since Ødegaard (1932) described high rates of Norwegians undergoing a schizophrenic 
breakdown after migration to Minnesota, many studies have replicated the finding that migrants 
are at increased risk of schizophrenia compared to those in the country of origin.  Whilst 
Ødegaard hypothesised that individuals predisposed to schizophrenia are more likely to 
migrate, this has since been refuted (Selten et al. 2002).  Associated with migration are the 
findings that individuals from minority ethnic groups are also at increased risk of 
schizophrenia, and that this showed a dose-dependency, with greatest risk in those who were 
most in the minority (Boydell et al. 2001). 
 
In a meta-analysis (Cantor-Craee & Selton, 2005) the relative risk (RR) of 
schizophrenia was higher in migrants from less economically developed countries and 
particularly for black migrants moving to a white-majority country.  The authors concluded 
this provides evidence for a role of social adversity in schizophrenic aetiology. 
 
The multicentre AESOP study (Fearon et al. 2006) demonstrated a nine-fold and six-
fold increase in the incidence of schizophrenia among African-Caribbeans and Africans 
respectively in three English cities.  This appears very unlikely to be predominantly genetically 
determined as, if this were the case, rates of schizophrenia would be significantly raised in the 
origin countries compared to the native population of the destination, which they are not (e.g. 
Sugarman & Craufurd, 1994).  In a British household survey, Brugha et al. (2004) found that 
African-Caribbeans and Black Africans were more likely than other ethnic minority groups to 
experience indicators of social disadvantage including low socioeconomic class, 
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unemployment, lone parent status, low perceived social support and poverty.  Adjusting for 
these factors modestly reduced the risk of psychosis in these groups.  
 
These findings have also been extended to migrants of other ethnicities to other 
countries (e.g. Selten & Sijben, 1994 and Cantor-Graae et al. 2003).  A more recent meta-
analysis (Bourque et al. 2011) has confirmed an increased risk of psychosis in both first and 
second generation migrants with incidence rate ratios (IRR) of 2.3 and 2.1 respectively, with 
no significant difference between the two generations.  Possible explanations for heterogeneity 
between ethnic groups include perceived discrimination (Veling et al. 2008a) and a replicated 
finding that incidence of psychosis in migrants increases as they form a decreasing proportion 
of the population (e.g. Boydell et al. 2001 & Veling et al. 2008b).  In summary, these studies 
strongly suggest a potential aetiological role for being a member of an ‘outsider’ social 
grouping, either as a migrant, descendant of a migrant or minority.  Other factors such as 
urbanicity (above) do not appear to mediate the risk associated with this (Bourque et al. 2011). 
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1.4.2.5 Cannabis  
Cannabis is the most widely used illicit drug in the world (United Nations 2010).  10% 
of cannabis users will at some point become dependent on the drug and the lifetime prevalence 
of cannabis dependence or abuse (as defined in DSM-III-R, American Psychiatric Association, 
1987) in United States adults was estimated at 4.4% (Anthony et al. 1994).  Until as recently 
as a decade ago many psychiatrists would not have regarded cannabis as dangerous to mental 
health, however this changed following a series of large scale epidemiological studies 
(Morrison & Murray 2007) and wide public debate on the issue.  There is consistent 
epidemiological evidence that the drug is a risk factor for schizophreniform psychotic disorders 
(Moore et al. 2007), exhibiting dose-dependence (Moore et al. 2007) and dose-duration effects 
(Di Forti et al. 2009).  In cannabis users who do not have schizophrenia, there is also evidence 
that use of the drug is associated with increased paranoid ideation (Freeman et al. 2013, 
Freeman et al. 2014), a key symptom of the illness.   
 
The main psychoactive substance in cannabis is 9-tetrahydrocannabinol (THC) 
(Wachtel et al. 2002).  THC was originally described as an agonist of endocannabinoid CB1 
receptors (Felder et al. 1992), however there is growing evidence of partial agonist properties 
from both in vitro (Sim et al. 1996; Petitet et al. 1998; Shen & Thayer 1999; Breivogel & 
Childers 2000; Govaerts et al. 2004; Kelley and Thayer, 2004) and in vivo (Paronis 2012) 
studies.   THC was first isolated from hashish in 1964 by Gaoni & Mechloulam.  Subsequently, 
the effects of THC on dopaminergic function have been widely studied and shall be described 
here.  As THC has a number of double bond and stereo isomers, this discussion will focus on 
the main THC isomer found in cannabis, i.e. (−)-trans-Δ9-tetrahydrocannabinol, which is also 
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referred to in some older studies by its alternative name Δ1-tetrahydrocannabinol and as a 
pharmaceutical preparation using the International Non-Proprietary Name dronabinol. 
 
Cannabis and THC can induce transient positive psychotic symptoms in healthy 
individuals (Moreau 1845, D’Souza et al. 2004, Morrison et al. 2009; Bhattacharyya et al. 
2010; Morrison et al. 2011), and sensitivity to the acute psychotogenic effects of cannabis has 
been shown to be a predictor of subsequent psychotic disorders (Arendt et al. 2005).  There is 
also evidence that THC can elicit schizophrenia-like negative symptoms which are distinct 
from sedation (Morrison & Stone 2011).   It has been proposed that cannabis can precipitate 
psychosis in susceptible individuals (Murray et al. 2007), and therefore represents a potentially 
modifiable risk factor for psychotic disorders. 
 
1.4.2.6 Acute and Chronic Stressors in Adulthood  
 
Sudden changes in an individual’s life (e.g. bereavement, unemployment or moving 
house) are termed life events which have been classified according to the stress they cause an 
individual (Holmes & Rahe, 1967).  In 1968 Brown and Birley reported acute life events to be 
associated with relapse of schizophrenia and Bebbington et al. (1993) found a significant 
relationship between life events and onset or relapse of schizophrenia.   More recently, Myin-
Germeys & van Os (2007) have extended this to show increased stress-reactivity (i.e. 
sensitivity to the small stressors of everyday life) in people with and those at genetic risk of 
schizophrenia.  In a case-control study of the effects of cumulative social disadvantage and 
first-episode psychosis Morgan et al. (2008) found a relationship between social disadvantage 
and odds of psychosis (see table 1.4).  However, there is an intrinsic difficulty in determining 
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causality with this study design and it is well established schizophrenia is accompanied by a 
marked decline in social functioning (Hafner et al. 1999).  Taken together with the evidence 
above there is therefore evidence of causal bidirectionality.  Nonetheless, given the impact of 
similar stressors in childhood on later adult risk of psychosis, it would be reasonable to 
conclude that adult social stressors indeed are contributing to increased schizophrenia risk to a 
degree.   
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Table 1.4 Indicators of social disadvantage and isolation by case-control status 
(adapted from Morgan et al. 2008).  Across all the domains considered, cases were 
more likely to be socially disadvantaged and isolated than were controls.  Data 
presented below are from a restricted sample which yields more conservative 
adjusted odds ratios.   
  
Odds 
Ratio 95 % CI 
Current Employment Unemployed 3.61 2.19-5.96 
 Employed 1 - 
Long-term Employment Unemployed > 1yr 2.44 1.4-4.25 
 Employed 1 - 
Housing Status Self-owned 1 - 
 Family owned 3.15 1.41-7.06 
 Rented 1.93 1.13-3.28 
Housing Stability Moved in past 6 months 2.03 1.02-4.05 
 
Not moved in past 6 
months 1 - 
Current Living 
Arrangements Live alone 2.66 1.62-4.37 
 Live with relatives 5.2 2.63-10.25 
 Live with others 1 - 
Long-term living 
Arrangements Lived alone for > 1 year 2.19 1.26-3.82 
 
Live with others in past 
year 1 - 
Relationship Single 3.36 2.14-5.27 
 In a stable relationship 1 - 
Long-term relationship Never 3.81 2.21-6.59 
 At least 1 1 - 
Networks - Friends Daily 1 - 
 Weekly 3.4 2.01-5.77 
 Less than weekly 5.02 2.73-9.22 
Confidants No 7.74 3.78-15.86 
 Yes 1 - 
Odds ratios presented are adjusted odds ratios, adjusted for age, gender, ethnicity, 
study centre, parental social class, special needs education before the age of 16, and 
pre-morbid IQ.  CI, confidence interval.   
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1.4.3 Summary of Risks  
In summary, at the individual level the most important risk factor for schizophrenia is 
having an affected relative which likely represents the inheritance of multiple genes of small 
effect which together will contribute to a genetic loading for the illness.  This then interacts 
with a number of environmental risk factors occurring through the life-span from conception 
through birth, childhood, adolescence and adulthood.  These are summarised in figure 1.5.   
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Figure 1.5 The developmental risk factor model of schizophrenia to illustrate causality over the life course.   
These risk factors occur throughout the lifespan and have complex interactions with each other.   
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Whilst epidemiological risks are likely crude proxies for more complicated underlying 
variables and interactions, it is possible to conceptualise these across broad categories: 
hereditary and perinatal factors, psychosocial stressors, and cannabis use.  Our current 
understanding of hereditary and perinatal factors has been discussed above, as have the 
psychosocial stressors including childhood and adult psycho-socio-economic adversity.  This 
thesis is concerned with investigating the neurobiology of how psychosocial stressors and 
cannabis use increase psychosis risk, as these represent two of the largest modifiable risk 
factors for the illness.   
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1.5 The Neurobiology of Schizophrenia 
 
1.5.1 Introduction 
 
Much has been learnt regarding the neurobiological basis of schizophrenia with 
progress being catalysed by advances in human in vivo brain imaging over recent decades.  The 
main findings will be summarised below including studies of macroscopic and microscopic 
brain structure, studies of brain function and the major neurochemical theories including 
current conceptualisation of the dopamine hypothesis of schizophrenia. 
 
1.5.2 Macroscopic Brain Structure 
 
The first major study of brain structure in schizophrenia using modern imaging 
technology utilised computed tomography (CT) to find that patients with schizophrenia had 
enlargement of the lateral ventricles (Johnstone et al. 1976).  This finding was replicated in 
further imaging studies (e.g. Andreasen et al. 1986) and subsequent meta-analyses (e.g. 
Wright et al. 2000), with evidence suggesting that the degree of ventricular enlargement is 
related to poorer prognosis (Kolakowska et al. 1985).  Together with the increase in 
ventricular size there have been findings of reduced whole brain weight (Harrison et al. 2003) 
and reduced grey matter volume (Wright et al. 2000).  Subsequent work has identified a 
number of brain regions which show greater volume reductions compared to others including 
a) the left superior temporal gyrus (Honea et al. 2005), which is notable in the context of 
auditory hallucinations which are common in the illness, b) the medial temporal lobe and 
hippocampus (Nelson et al. 1998; Honea et al. 2005), and c) the thalamus (Konick & 
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Friedman 2001).  Other findings include the reversal of the normal asymmetry of planum 
temporale (Petty et al. 1995) with further subsequent evidence of reduced cerebral 
asymmetry (Sommer et al. 2001).  Findings of reduced asymmetry have been hypothesised to 
be related to language and the speciation of Homo sapiens (Crow 2004), although these 
findings may be epiphenomena of abnormal developmental processes which interfere with 
normal brain lateralisation (Harrison 2012).  There is evidence that the major brain changes 
are present in individuals before they develop frank psychosis (Pantelis et al. 2003), that there 
are some volume changes which develop when people who are at high risk of psychosis 
proceed to develop psychosis (Velakoulis et al. 2006), and in patients with a first episode 
psychosis (Steen et al. 2006).  Volume deficits have been observed in unaffected relatives of 
patients with psychosis (Boos et al. 2007), yet there is some evidence of progressive deficits 
with illness duration (Woods et al. 2005), which would suggest that these volumetric changes 
represent a mixture of both state (psychosis) and trait (psychosis-proneness) related effects.  
However, the interpretation of longitudinal studies is complicated by a current incapability to 
adequately tease out the effects of illness vs. antipsychotic treatment on the brain (Lieberman 
et al. 2005).  It should be emphasised here that on an individual basis, these findings remain 
of limited clinical utility, for the time being, as they do not alter clinical management in the 
majority of cases, and are therefore not currently recommended by the United Kingdom’s 
National Institute for Health and Care Excellence (NICE) in the routine management of first-
episode psychosis (NICE 2008).   
 
In addition to volumetric studies, advances in MRI have enabled the measurement of 
white matter connectivity via diffusion tensor imaging (DTI).  A meta-analysis of DTI studies 
in schizophrenia (Ellison-Wright & Bullmore 2009) found significant reductions in 
connectivity in the left frontal deep white matter tracts, interconnecting the frontal lobe, 
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thalamus and cingulate gyrus, and in the left temporal deep white matter tracts, interconnecting 
the frontal lobe, insula, hippocampus, amygdala, temporal and occipital lobes.  These findings 
of structural dysconnectivity are considered with those relating to functional dysconnectivity 
below.   
 
1.5.3 Microscopic Brain Structure  
 
Post-mortem cell counting and microscopic analysis suggested regions of cell loss and 
cortical volumetric reduction associated with schizophrenia (Benes 1993; Bogerts 1993; 
Shapiro 1993; Heckers 1997; Dwork 1997). Following these initial studies, morphometric 
findings in the prefrontal cortex gave rise to the hypothesis that impoverished neuronal 
connectivity was associated with cognitive dysfunction in schizophrenia (Selemon et al. 1995; 
Selemon et al. 1998; Rajkowska et al. 1998). This was conceived by some as the Reduced 
Neuropil Hypothesis (Selemon et al. 1995), whereby atrophy of neuronal processes occurs 
without local neuronal loss, and it was speculated that this was associated with cell loss 
elsewhere in the cortex (Selemon & Goldman-Rakic 2005).  Yet, reductions in the neuropil 
may be due to antipsychotics (e.g. Vernon et al. 2014) or environmental impoverishment 
(Cannon et al. 2003).    
 
Since post-mortem histological studies have yielded a number of controversial findings, 
with some authors suggesting that genetic neuropathology studies hold the key to bridging gaps 
in our current understanding (Kleinman et al. 2011).  There is some evidence to suggest that 
altered synaptic proteins may be associated with reduced plasticity which could manifest itself 
 
76 
 
via decreased numbers of synapses (Eastwood 2003).  There are a number of important 
negative histological findings in schizophrenia suggesting that classically described 
pathological process of neurodegeneration are not in operation.  Specifically, these are the 
absence of neurofibrillary tangles, amyloid plaques, or Lewy bodies (Arnold et al. 1998).  
Whilst it had been suggested that inflammatory processes were unlikely to underlie the illness 
(Roberts & Harrison 2000), there is now renewed interest in inflammatory processes in the 
neuropathology of schizophrenia (Schnieder & Dwork 2011).   
 
1.5.4 Functional Brain Imaging 
 
One of the earliest findings in functional neuroimaging of schizophrenia was that 
patients with schizophrenia had reduced regional cerebral blood flow (rCBF) compared to 
controls in frontal areas, as measured with the xenon-133 technique (Ingvar & Franzen 1974).  
This gave rise to the concept of “hypofrontality” in schizophrenia, which was widely replicated 
using positron emission tomography (PET) (Weinberger & Berman 1996).  However, using 
functional magnetic resonance imaging (fMRI) there have been inconsistencies in results with 
some studies (e.g. Callicott et al. 2003) including reports of increases in blood-oxygen level-
dependent (BOLD) signal associated with lower accuracy on working memory tasks, which 
was interpreted as less efficient recruitment of cortical networks for the task in patients 
compared to controls.  There has been some recent interest in cerebellar involvement in 
schizophrenia, where the illness was hypothesised to be caused by a state of “cognitive 
dysmetria” (Andreasen et al. 1999).  Whilst there is evidence to support a role of the cerebellum 
in the disorder, findings from studies have been heterogeneous (Picard et al. 2008).  As per the 
DTI literature, using resting state fMRI scans there is further evidence of dysconnectivity in 
 
77 
 
the illness, with hyperconnectivity of the default mode network and dysconnectivity between 
the cortex and striatum (Karbasforoushan & Woodward 2012).   
 
1.5.5 The Glutamate System 
 
The glutamatergic system has been implicated in the pathophysiology of the illness 
(Goff & Coyle 2001; Coyle et al. 2003) although more recently attempts have been made to 
combine the glutamate and dopamine models of the disorder (Stone et al. 2007).  One of the 
tenets of the glutamate hypothesis of schizophrenia is that uncompetitive N-methyl-D-aspartate 
(NMDA) receptor antagonists such as ketamine and phencyclidine (PCP) produce psychotic-
like states in humans.  However, it should be emphasised that these states are characterised 
primarily by subjective disembodiment, in addition to dissociation and visual hallucinations 
(Vollenweider et al. 1997), but lacking the auditory hallucinations commonly seen in 
schizophreniform psychosis. In support of glutamatergic involvement in the illness, reductions 
in both NMDA receptor binding (Pilowsky et al 2006) and levels of NMDA receptor mRNA 
(Law & Deakin 2001) in the hippocampus have been reported in schizophrenia.  More recently, 
using single proton magnetic resonance spectroscopy (MRS), individuals at risk of psychosis 
have been found to have elevated glutamine in the anterior cingulate and reduced thalamic 
glutamate, compared to controls (Stone et al. 1999).  There is also some evidence that NMDA 
receptor manipulated animals give rise to a “schizophrenia-like phenotype” (Lipska & 
Weinberger 2000).   
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1.5.6 The Dopamine Hypothesis of Schizophrenia 
 
1.5.6.1 Dopamine in the Brain 
 
Dopamine is a monoamine neuromodulator, although it remains described in many 
texts as a neurotransmitter. It is most abundant in the striatum, limbic system, frontal cortex 
and hypothalamus (see figure1.7; figure 1.8).  The dopamine synthesis pathway involves 
conversion of tyrosine to DOPA via tyrosine hydroxylase, followed by conversion of DOPA 
to dopamine via dopa decarboxylase (figure 1.6)  Dopamine is stored in presynaptic vesicles, 
transported via vesicular monoamine transporter (VMAT) proteins, prior to release into the 
synapse.    
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Figure 1.6 A simplified dopaminergic varicosity and synapse.  Presynaptic and postsynaptic 
neuron membranes and the synaptic cleft are indicated.  D1 and D2-class dopamine receptors 
are positively or negatively coupled to adenylate cyclase (AC) via G proteins (G). Coupling to 
other signalling pathways is not shown. Catechol O-methyltransferase (COMT) and 
monoamine oxidase B (MAO-B) are involved in the metabolism of dopamine (blue circles) to 
products such as homovanillic acid (HVA) and 3-methoxytyramine (3-MT). Dopamine in the 
cleft can bind presynaptically to D2 autoreceptors or the DAT, or postsynaptically to D1- and 
D2-class receptors. Stimulation of D2 autoreceptors inhibits phosphorylation-dependent 
activation of tyrosine hydroxylase (TH), which is rate limiting for the production of dopamine. 
Figure adapted from Blackstone (2009).   
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The striatum projects topographically to the pallidal complex, the ventral tegmental 
area and substantia nigra (Haber, 2012). The outputs from the globus pallidus pars interna and 
substantia nigra (GPi/SN) then projects back to the cortex via the thalamus, completing the 
basic cortico-basal ganglia circuit. This is known as the direct pathway. The side loop, from 
the striatum via the globus pallidus pars externa (GPe) passes through the subthalamic nucleus 
(STN) to the GPi, and is referred to as the indirect pathway (Figure 1.8). In addition, there are 
other projections of the striatum including those to the brainstem (Haber 2012). 
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Figure 1.7 Simplified schematic of dopaminergic neurons and their projections in the rat 
brain. The nigrostriatal fibres project from the substantia nigra to the striatum. The ventral 
tegmental area and the nucleus accumbens represent key structures of the dopaminergic 
mesolimbic reward system. AM, amygdala; MFB, medial forebrain bundle; NA, nucleus 
accumbens; OB, olfactory bulb; PFC, prefrontal cortex; SEP, septum; SN, substantia nigra; 
STR striatum; VTA, ventral tegmental area. (from Aremi 1999).   
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Figure 1.8 Illustration of the major dopaminergic projections in the human CNS:  the 
nigrostriatal pathway (projecting from the substantia nigra to the striatum), the 
mesolimbic pathway (projecting from the ventral tegmental area [VTA] to the nucleus 
accumbens), the mesocortical pathway (projecting from the VTA to the frontal cortex). 
Figure from Malenka et al. (2009). 
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Figure 1.9 Schematic illustrating key structures and pathways of the basal ganglia.  Note: 
brainstem motor connections are not illustrated to simplify the figure. Cd, caudate nucleus; 
ACC, anterior cingulate cortex; dPFC, dorsal prefrontal cortex; GP, globus pallidus; LHb, 
lateral habenula; OFC, orbital frontal cortex; Pu, putamen; RMTg, rostromedial tegmental 
nucleus; SN, substantia nigra; STN, subthalamic n; Thal, thalamus; VP, ventral pallidum; VS, 
ventral striatum; VTA, ventral tegmental area  (from Haber 2014). 
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There are four major dopaminergic projections in the human brain: the nigrostriatal 
pathway (projecting from the substantia nigra to the striatum), the mesolimbic pathway 
(projecting from the ventral tegmental area [VTA] to nucleus accumbens and amygdaloid 
nucleus via the medial forebrain bundle), the mesocortical pathway (projecting from the VTA 
to the frontal cortex via the median forebrain bundle), and the tuberoinfundibular pathway 
(projecting from the hypothalamus to the pituitary gland and median eminence) See figure 1.7.   
 
1.5.6.2 The Role of Dopamine in the Brain: motivation and reward 
Initially it had been thought that the brain’s dopamine system was primarily involved 
in motor function via the extrapyramidal system and basal ganglia, based in part on the clinical 
syndrome and nigral dopaminergic lesions observed in Parkinson’s disease.  However, this 
view was changed by research which found that administration of dopamine receptor 
antagonists reduced an animal’s instrumental response to rewards including food, water and 
sex, as well as intracranial stimulation and drugs (Dews & Morse 1961).  Likewise, a key 
development in our knowledge of the role of dopamine in the brain came with the finding that 
selective damage to dopaminergic fibres gave rise to feeding and drinking deficits (Ungerstedt 
1971). 
 
 Dopaminergic anatomical projections were found to extend beyond the classical motor 
regions of the brain to the limbic system (Ungerstedt 1971) and the prefrontal cortex (e.g. 
Thierry et al. 1973).  These mesolimbic regions included brain areas that were previously and 
serendipitously found to be associated with positive reinforcement upon direct electrical 
stimulation during (Olds & Milner 1954).  Lesions to mesolimbic projections were found to 
reduce the forward locomotion required for reward-seeking behaviour (Smith 1976; Schneirla 
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1959), whilst nigrostriatal lesions disrupt appetitive/preparatory behaviour (Ervin et al. 1977).  
Likewise, dopamine antagonism was found to reduce the rewarding effects of food (Wise et al. 
1978), water (Gerber et al. 1981), cocaine (de Wit & Wise 1977), amphetamine (Yokel & Wise 
1975) and lateral hypothalamic electrical stimulation (Fouriezos & Wise 1976).  Whereas 
dopamine antagonist treated rodents were able to perform operant conditioning tasks (Wise 
1982), they displayed attenuated acquisition for reward-related lever pressing (Wise & 
Schwartz 1981).  Taken together these findings give rise to a number of competing and 
complementary theories of dopaminergic function in behaviour relating to hedonia (Wise et al. 
1978); reward (Wise et al. 1978); reinforcement (Fibiger 1978); and motivational salience 
(Berridge & Robinson 1998). This section will outline some of the important findings in this 
field of research.   
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1.5.6.3 Anatomy  
 Based on connective anatomy and histochemistry, the striatum and related anatomy 
(referred to in some papers as the striatal complex), has been distinguished into three functional 
subdivisions: a limbic subdivision comprising ventral structures including the nucleus 
accumbens (NAc) core and shell (Heimer & Wilson 1975); an intermediate associative 
subdivision and a sensorimotor subdivision comprising dorsolateral structures (Joel & Weiner 
2000; Riedel et al. 2002).   
 
 Studies have found that the nucleus accumbens is a critical site in dopaminergic 
motivation and reward processing.  The accumbens has been divided into three sub-territories: 
the shell, core and rostral pole (Zahm & Brog 1992; Zahm & Heimer 1993).  Some of the key 
anatomical sites related to motivational processing for feeding behaviour provide an example 
of how the functions of these circuits can be related to the underlying anatomy (Kelley 2004).   
 
 The nucleus accumbens receives taste and visceral information from the brainstem via 
direct inputs from the nucleus of the solitary tract to the shell, and indirect inputs from the 
cortex to the shell and core via parabrachial-thalamic projections (Ricardo & Koh 1978; Saper 
1982).  Additional taste information is relayed to the accumbens from the amygdala which 
integrates taste information with multimodal sensory input (McDonald & Jackson 1987).  The 
amygdala also sends information to dopaminergic cells in the ventral tegmental area.  There 
are also projections from the amygdala to other forebrain nuclei which, with the mesolimbic 
and mesocortical dopamine neurons, comprise the forebrain arousal system (Robbins & Everitt 
1987).   
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 The accumbens also has efferent projections to the ventral globus pallidus and lateral 
hypothalamus (Hiemer et al. 1991).  The accumbens shell receives information on the internal 
physiological state of the organism from the hypothalamus (Maldonado-Irizarry & Kelley 
1995).  The accumbens shell integrates sensory, spatial, visceral and memory information 
related to food reward with aminergic modulatory input, to drive hypothalamic and brainstem 
motor centres independently from a motor cortical relay.  The accumbens core integrates 
amygdala inputs related to the affective value of sensory information with frontal inputs in a 
striatocortical loop (Alexander et al. 1990).  Taken together, differences in anatomical 
connectivity suggest the accumbens shell is involved in activational and incentive aspects of 
processing, whilst the accumbens core is involved in directional aspects of motivation (Corbit 
et al. 2001).   
 
 The accumbens shell is greatly interconnected with the medial extended amygdala 
complex (Aheid & Heimer 1988; Heimer et al. 1991) comprising the central amygdala and bed 
nucleus of stria terminalis, which is innervated by dopaminergic projections with a striato-
pallidal organisation (Cassell et al. 1999).  The terminal dopaminergic areas of the extended 
amygdala have been grouped functionally into a parastriatal complex which is distinct from 
the striatum and accumbens shell, on the basis of comparative distribution of calcium binding 
proteins (Riedel et al. 2002).   
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1.5.6.4 Terminology 
 There are inconsistencies in the literature in the precise meanings attributed to the 
constructs used to describe behaviour.  These shall be described as per Di Chiara (2005).   
 
 An underlying principle in the study of behaviour is that life has the goal of self-
perpetuating and organisms reproduce for the survival of their species.  The concept of 
motivation is closely linked to this principle.  Aspects of motivation are thought to be hard-
wired into organisms by evolution such that organisms have an innate ability to encode the 
intrinsic biological value of stimuli and respond accordingly (Glickman & Schiff 1967).  
Therefore, certain stimuli, such as the taste of food or the sound of a predator will result in 
behaviours that will either approach or avoid the stimulus, depending on its motivational 
valence.  These responses are unconditioned primary responses which means that are neither 
based on learnt experiences nor based on imitating the behaviours of others.   
 
 Motivation refers to the thought processes and behaviours that are triggered within an 
organism in response to stimuli that are relevant for the survival of the organism, and are 
therefore termed “motivational stimuli”.  In addition to the unconditioned primary responses, 
an organism must learn the predictive relationships, termed “contingencies”, between stimuli 
that are “salient”, i.e. relevant and biologically meaningful in terms of survival, the organisms 
own response to these stimuli, and the consequences of the organism’s response, termed an 
“outcome”.  The process of an organism learning these contingencies so that it can change its 
behaviour to increase or decrease the occurrence of biologically valuable events is termed 
“instrumental action”.   
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 Motivational stimuli will have a “motivational valence”, which determines the 
direction of the organism’s response in relation to the stimulus whereby a positive motivational 
valence elicits an approach to the stimulus and a negative motivational valence elicits an 
aversion to the stimulus.  The motivational valence can either be learnt by the association of a 
motivational stimulus with a particular outcome, which is referred to as “conditioned”.  This is 
in contrast to valences which are not learnt and are therefore “unconditioned”. 
 
 Behaviour which is motivated (i.e. directed) in response to environmental stimuli can 
be divided into two phases: a preparatory phase, termed “appetitive”, and a “consummatory 
phase”.  These phases can be thought of in terms of patterns of behaviour to two different types 
of motivational stimuli (Woodworth 1918; Konorski 1967): “incentives” and “rewards”.  
Incentive stimuli operate during the appetitive phase, whilst rewarding stimuli operate in the 
consummatory phase of the motivated behaviour.  Incentive stimuli are experienced via sensory 
modalities that can act at a distance, such as smell, sound and vision, and therefore do not 
require direct contact between the organism and the stimulus.  Thus, incentive stimuli can allow 
the organism to achieve it’s a goal, but are not necessarily themselves for the goal in question.  
Rewarding stimuli are experiences via senses requiring direct contact with the stimulus, e.g. 
taste and touch, and unconditionally predict the biological outcome providing the final goal of 
the motivated behaviour.  It must be pointed out that incentives and rewards can co-exist within 
the same object.  For example, the smell of a particular food would be considered the incentive 
stimulus, which motivates the organism to eat it and result in taste, the rewarding stimulus.  A 
stimulus which can strengthen or weaken the responses elicited by it is termed a positive or 
negative reinforcer, respectively.  Rewards, therefore, can act as positive reinforcers.     
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 Incentive stimuli can have two properties: a directional property related to its valence, 
resulting in attraction or repulsion, and an activational property which is associated with a 
particular level of arousal within the organism termed “incentive arousal”.  The incentive 
arousal of a stimulus serves to increase or decrease the incentive properties of other stimuli in 
the particular environment in which it is experienced.  Again these different properties can be 
unconditioned or conditioned.  The process of conditioning in this context is termed “incentive 
conditioning”.   
 
 The learning of stimulus-reward contingencies is termed Pavlovian learning 
(Mackintosh 1983), which is also known as classical conditioning.  In this process, new salient 
stimuli that predict the occurrence of an unconditioned stimulus (US) acquire conditioned 
responses (CR) in line with the valence of the US, thereby becoming conditioned stimuli (CS).  
CS can elicit both conditioned consummatory or conditioned preparatory/incentive responses 
(Konorski 1967).  Preparatory/incentive behavioural responses to the CS are thought of as 
being due to the excitation of the motivational system common to different US (Konorski 
1967).  Therefore, the association with the US results in a representation of the CS which is 
associated with the motivational system through the process of Pavlovian incentive learning 
(Dickson & Balleine 1994) and able to induce preparatory/incentive responses (Konsorski 
1967). Incentive act-outcome instrumental responding is gradually transformed into “habit 
responding” based on stimulus-response associations (Dickinson 1994), meaning that it 
becomes automatic and is learnt.  When a previously conditioned stimulus no longer gives rise 
to a conditioned response, then an “extinction” of that response has occurred. 
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 Early animal studies into the effects of dopamine receptor antagonism on instrumental 
behaviour gave rise to four main hypotheses, which are not mutually exclusive:   
1. The anhedonia hypothesis, which infers a role for dopamine in hedonia, whereby 
dopamine antagonism results in blunting of the rewarding properties of primary 
reinforcers.   
2. The revised anhedonia hypothesis whereby dopamine antagonists result in the loss of 
incentive-motivational and arousal properties of incentives and rewards.   
3. Dopamine antagonism results in impaired performance and sensory-motor functions. 
4. Impairment of Pavlovian incentive learning.   
 
 The roles of dopamine in hedonia, incentive motivation and learning will be described 
in more depth below.  However, owing to discrepancies in experimental findings related to the 
role of dopamine in motivation, which may be related to methodological differences, inferences 
related to the role of dopamine in different anatomical regions regarding particular aspects of 
motivation should be made with caution (Di Chiara 2005).  Furthermore, dopamine plays an 
important role in motor functions.  Given the relationship between response-reinforcement and 
motor performance, this poses a challenge in the study of the role of dopamine in motivation 
and reward processing (Salamone 1992), although approaches to overcome this have included 
measures of the effects of dopamine antagonism on response rates during experimental tasks 
(e.g. Willner et al. 1990).    
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1.5.6.5 Dopamine and Hedonia 
Following the work by Olds & Milner (1954) reporting that direct electric stimulation 
of mesolimbic brain regions was associated with positive reinforcement, further evidence that 
dopamine had a role in hedonia came from the finding that dopamine receptor antagonists 
disrupt instrumental responding in a manner which extends beyond motor impairment as they 
produce a within-session reduction in the rate of lever pressing continuous reinforcement 
schedules (Wise 1982).  This finding was generalised to a number of rewards including water, 
food and psychostimulants (Wise et al. 1978; Wise 1982; Salamone 1987).  Since dopamine 
receptor antagonists had similar effects to extinction, it was hypothesised that dopamine 
antagonists blunted the hedonic impact of rewards (Wise et al. 1978; Wise 1982).   
 
However, Treit & Berridge (1990) found that administration of high dose haloperidol 
does not induce changes in hedonic or aversive taste reactions.  Furthermore, 6-
hydroxydopamine lesions did not alter hedonic taste reactivity (Berridge 1998; Berridge & 
Robinson 1998).  Later, Pecina et al. (1997) concluded that dopamine receptor antagonism 
results in sensorimotor impairment rather than blunting of taste hedonia.   
 
Nonetheless, there is evidence from human in vivo imaging that stimulant-induced 
euphoria is correlated with drug-induced dopamine release (Laruelle et al. 1995; Volkow et al. 
1999; Drevets et al. 2001).   Furthermore, a role for dopamine in euphoria is implicated in some 
hypotheses regarding normal and abnormal mood states including euthymia, dysthymia, 
depression and mania (Papp et al. 1991).  Taken together, these studies suggest that there exist 
both dopamine-independent stimulus-hedonic responses and dopamine dependent state-
hedonic responses.  Yet, it must also be noted here that in addition to processing positively 
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rewarding events, dopamine is also involved in negatively rewarding events, i.e. aversive 
stimuli (Salamone et al. 1997; Salamone 1994).   
 
 
1.5.6.7 Dopamine and aversive stimulation 
 
 Dopamine likely has a role in processing aversive stimuli, in addition to the examples 
of rewarding stimuli outlined above, suggesting a role for dopamine in the stress response.    
Increases in both dopaminergic neuron firing rates, as measured with electrophysiology, and 
extracellular dopamine in response to aversive stimuli and stress have been reported in a 
number (Horvitz et al. 1997; Horvitz 2000; Abercrombie et al. 1989; Imperato et al. 1989; 
McCullough et al. 1993; Kalivas & Duffy 1995; Bassareo et al. 1996) but not all (Mirenowicz 
& Schultz 1996) studies.  Based on these results, it has been suggested that dopamine also plays 
a role in aversive motivation.  Given that different parts of the dopamine system appear to 
respond differently to aversive stimuli, including the accumbens core and shell (Bassareo et al. 
2002; Deutch & Cameron 1992), the responsiveness of dopamine transmission may also be 
dependent on additional properties of the stimulus including novelty and motivational valence.   
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1.5.6.8 Incentive-motivation hypothesis 
 
 
The priming (drive-like) effects of an encounter with an otherwise neutral stimulus that 
has acquired motivational importance through prior association with a reward is termed 
incentive motivation.  Gray & Wise (1980) provided a revision to the anhedonia hypothesis by 
hypothesising that dopamine mediates the incentive-motivational properties of rewards and 
conditioned reinforcers.  This became known as the incentive-motivation hypothesis. 
 
 Whilst dopamine has been proposed to be central for incentive motivation (e.g. Stewart 
et al. 1984), it has been argued by some that the main role of dopamine in incentive motivation 
lies in the “stamping in” of the reward value of a stimulus (Wise 2004).  This is based on the 
finding that dopamine blockade severely impedes Pavlovian conditioning (Spyraki et al. 1982), 
whilst established incentive motivational stimuli can result in conditioned behaviours under 
dopaminergic blockade (McFarland & Ettenberg 1998).  Yet, the capability of incentive stimuli 
to elicit behaviour becomes extinguished over time as the incentive value of the stimulus is 
weakened over time since the pairing of the stimulus with the reinforcer becomes ineffective 
under such conditions over time (Franklin & McCoy 1979).    
 
Studies by Pecina et al. (2003) using dopamine transporter (DAT) knock-down mice 
carrying reduced DAT expression, resulting in increased steady-state extracellular dopamine, 
demonstrated that knockdown mice show faster running for food and increased food intake 
compared to wild-type.  This increased motivation for food was not secondary to increased 
reward from food as estimated from the hedonic reactions to intraoral sucrose infusion.  These 
studies support the hypothesis that that dopamine plays a role in the incentive, rather than the 
rewarding properties of food per se.   
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A number of studies (Berridge 1996; Berridge & Robinson 1998; Robinson & Berridge 
1993) report that dopamine is involved in a process called “incentive salience attribution”.  This 
process refers to stimuli conditioned to a reward by dopamine-independent Pavlovian learning 
being imbued with incentive properties due to conditioned dopamine release.  In other words, 
it was proposed that an incentive stimulus obtains its ability to elicit a response as reward-
predictive stimuli (Schultz 1998) trigger a burst of spikes in dopamine neurons and a 
consequent striatal phasic release of dopamine.  In this model, the stimulus-bound release of 
dopamine was thought of as enabling response-eliciting properties of the stimulus that triggered 
it.  This views the role of phasic dopamine in response expression in a series of events between 
the stimulus and the response i.e. having a stimulus-bound role.   
 
Dopamine neurons have been found to fire with a delay of 100ms after the unpredicted 
presentation of a reward or a reward-conditioned stimulus (Shultz 1998).  In vivo studies in 
rodents and monkeys have found that a behaviourally significant stimulus takes less than 150 
ms to produce a response in the efferent basal ganglia neurons of the substantia nigra pars 
reticulata and the medial globus pallidus (Hikosaka & Wurst 1983).  Thus, by the time a 
stimulus presentation results in activation of dopamine neurons and dopamine starts to elicit its 
post synaptic effects, responsive units along the efferent pathway of the basal ganglia would 
have already initiated their discharge sequences leading to the inhibition of output neurons in 
the substantia nigra and globus pallidus by fast globus pallidus -aminobutyric acid (GABA) 
receptors.  It was therefore proposed that phasic dopamine release is a “teaching signal”, 
strengthening future transmission through striatal synapses activated in coincidence with it.  
This built on earlier work by Beninger & Phillps (1980) who suggested that dopamine receptor 
antagonism impairs Pavlovian incentive learning.  Therefore, reinforcement refers to the 
“stamping-in” of the association between a stimulus and a reward (Wise 1989) and dopamine 
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antagonism results in a progressive decline in reinforced behaviour (Wise 1982).  Likewise, 
place preference for reward in Pavlovian conditioning paradigms is disrupted by dopaminergic 
blockade (Spyraki et al. 1982).   
 
 
 
1.5.6.9 Dopamine and Arousal 
 
 
 Rewarding and reward-associated stimuli result in motivational arousal (Bindra 1968).  
The motivating effect of free reward obtained before a behaviour is known as priming, i.e. the 
precipitation of a learned response habit by administration of an unearned sample of the reward.  
In other words, priming refers to the phenomena by which exposure to a rewarding stimulus 
without (e.g. sugar) without working for it can increase future responses to conditions in which 
that reward (e.g. sugar) or indeed other rewards are obtained.  There is evidence that priming 
is, to some extent, dopamine-dependent (Esposito et al. 1979; Wasserman et al. 1982) and 
dopaminergic potentiation can prime food and drug-seeking behaviour (Roitman et al. 2004; 
de Wit et al. 1981).   
 
Similarly, dopamine plays a role in the facilitation of responding associated with states 
of behavioural arousal induced by reinforcers.  This process is called “incentive arousal” and 
it is thought to facilitate instrumental responding for the reward to witch the incentive has been 
conditioned, in addition to other rewards.  This property acts as a transfer from classical 
conditioning (i.e. Pavlovian) state to an instrumental one, termed “PIT”.  Consistent with this 
role, amphetamine facilitates PIT (Wyvell & Berridge 2000).       
 
As Wise proposed in his paper (1982): 
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“Dopaminergic impairment disrupts first and most strongly the motivational arousal 
function of external rather than internal stimuli…. Reinforcers and their associated 
environmental cues lose their sensory impact in terms of arousal function but not in 
terms of cue function.” 
 
According to this hypothesis, dopamine is a substrate of an arousal state, termed 
“incentive arousal”, which non-specifically increases the ability of incentives to facilitate 
instrumental responding.   This notion is similar to the “incentive state” described by earlier 
theorists (Cofer 1972; Killeen 1975), corresponding to the earlier notion of behavioural 
arousal as being distinct from directional effects of reinforcers.   
 
However, dopaminergic mechanisms are not necessary for pre-reward motivation, but 
rather they amplify this process (Wyvell & Berridge 2000).  In other words, there is 
“enhancement of reward ‘wanting’ without enhanced ‘liking’”, as wanting and liking have 
been proposed to represent two separate dimensions of reward function (Berridge & 
Robinson 1995).   
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1.5.6.10 Dopaminergic transmission 
 
 Dopaminergic neuron activity and dopamine transmission is activated in relation to the 
presentation of motivational stimuli or the expression of specific phases of motivated 
behaviour.  Studies using electrophysiology have shown that dopaminergic neurons respond 
by a burst of spikes to the unpredicted occurrence of primary food stimuli and associated 
conditioned stimuli (Schultz et al. 1993; Schultz 1998).  On the other hand, the unpredicted 
omission of reward leads to the inhibition of dopaminergic activity.  Once a reward occurrence 
or omission becomes predictable, there is a reduction in the activation or inhibition of 
dopaminergic neuron activity.  It was therefore argued that dopamine neurons encode reward 
prediction error signals (Hollerman & Schultz 1998).  Initially unpredictable rewards elicit 
dopamine neuron activations and as the reward becomes predicted by the conditioned stimulus 
with continued experience, the activations elicited by the reward decrease whilst the 
conditioned (reward-predicting) stimulus can induce dopamine neuron activation.  If the 
predicted reward does not occur (e.g. because a test animal makes an incorrect response) then 
a depression in dopamine neuron activity occurs at the same time as an increase in activity 
would have occurred had the reward been obtained (See figure 1.10).  This property is thought 
to be a neural correlate of associative learning.  It is thought that phasic dopamine serves a 
teaching signal in learning process related to the ability to predict reward occurrence in the 
context of motivated behaviour (Schultz 1998) as mentioned previously.  Likewise, studies 
using microdialysis to directly measure extracellular dopamine concentrations, have been used 
to measure the effect of feeding and food-related stimuli in specific brain regions which vary 
depending on a number of experimental conditions (e.g. Gratton & Wise 1994).  The results of 
those studies suggest that dopamine plays different roles in behaviour depending on where in 
the brain it is acting.   
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Figure 1.10 Coding of reward-prediction error during learning by a single dopamine 
neuron.  (Dots) Neuronal impulses, each line showing one trial, with the chronological 
sequence in each panel being from top to bottom. Rewards were small quantities of apple juice 
delivered to the mouth of a monkey. No task: The temporally unpredicted occurrence of reward 
outside of any task induces reliable neuronal activation. Learning: The presentation of a novel 
picture pair in a two-picture discrimination task leads to uncertain behavioural performance 
with unpredictable occurrence of reward and dopamine response. (Top to bottom) Response 
decreases with increasing picture acquisition (only correct trials shown). Familiar: Presentation 
of known pictures in same task leads to predictable occurrence of reward and no dopamine 
response. Error during learning: Error performance with novel pictures leads to omission of 
reward. (From Hollerman & Schultz 1998.) 
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1.5.6.11 The Dopamine Hypothesis of Schizophrenia 
 
The dopamine hypothesis of schizophrenia gained popularity based on the finding that 
the clinical potency of antipsychotics being directly related to their affinity for dopamine 
receptors (e.g. Seeman et al. 1976) (Figure 1.11).  It had first been proposed in an early form 
by van Rossum (1966) who hypothesised that “dopamine receptor blockade is an important 
factor in the mode of action of neuroleptic drugs”.  Van Rossum (1966) subsequently wrote 
that overstimulation of dopamine receptors could be part of the pathophysiology of 
schizophrenia.   
 
Elevated levels of brain dopamine in patients with schizophrenia were initially reported 
in post-mortem studies, which at first reported increases in limbic regions of the forebrain (Bird 
et al. 1979).  Subsequently, increased brain dopamine and dopamine receptors were reported 
in a post-mortem study comparing patients with schizophrenia to controls (Mackay et al. 1982), 
and it was found that increased dopamine in the nucleus accumbens and caudate nucleus were 
unrelated to antipsychotic medication, whereas the reported increase in dopamine receptor 
binding sites was only present for patients in whom antipsychotic medication had been 
continued until death.  The authors interpreted this as reflecting an iatrogenic increase in 
dopamine receptor availability.  However, an earlier post-mortem study (Lee & Seeman 1980), 
which likewise reported increased dopamine receptor availability, also found increased 
availability in antipsychotic-naïve patients in contrast to the results of Mackay et al. (1982).   
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The dopamine hypothesis was later modified by Davis (1991), who attempted to 
incorporate the emergent hypofrontality literature, outlined above.  Davis proposed that 
schizophrenia was caused by subcortical hyperdopaminergia, giving rise to positive symptoms, 
and frontal hypodopaminergia, giving rise to negative symptoms.  Other earlier versions of the 
dopamine hypothesis incorporated the other neurotransmitters, such as the dopamine-serotonin 
hypothesis proposed by Huttunen (1995).   
 
Figure 1.11 The relationship between dopamine receptor half maximal inhibitory 
concentration and the clinical dose of antipsychotics required for treating schizophrenia 
(reproduced from Seeman et al. 1976)   
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The dopamine hypothesis of schizophrenia found further support from studies reporting 
that drugs which increase dopamine release, such as amphetamine, induce transient positive 
psychotic symptoms in healthy volunteers and worsen psychosis in patients with schizophrenia 
(Wallis et al. 1949, Lieberman et al. 1987, Laruelle et al. 2000). Positron Emission 
Tomography (PET) has led to evidence that elevated striatal pre-synaptic dopamine synthesis 
leads to the psychotic symptoms of schizophrenia (Howes et al. 2009).  Using [18F]-DOPA 
uptake to index dopamine synthesis capacity, elevated striatal dopamine synthesis capacity has 
been found in patients with schizophrenia taking antipsychotics and those that were 
medication-naïve (Reith et al. 1994; Hietala et al. 1999; Meyer-Lindenberg et al. 2002; 
McGowan et al. 2004; Howes et al. 2007), people at risk of psychosis (Howes et al. 2009) and 
first-degree relatives of patients with schizophrenia (Huttunen et al. 2008).  However, the 
findings of increased dopamine synthesis in patients with schizophrenia were not replicated in 
all studies (e.g. Dao-Castellano et al. 1997; Elkashef et al. 2000).  Yet, dopamine elevation is 
positively correlated with severity of prodromal psychotic symptoms (Howes et al. 2009). 
Furthermore, striatal [18F]-DOPA uptake is a reliable predictor of striatal dopamine release 
upon amphetamine challenge in non-human primates (Doudet & Holden 2003), but this 
relationship has not been tested in humans.  Subsequently, two separate meta-analyses (Howes 
et al. 2012; Fusar-Poli & Meyer-Lindenberg 2013) have reported that, compared to healthy 
controls, individuals with schizophrenia have increased striatal dopamine synthesis capacity, 
associated with a large effect size of d=.79.  In addition to studies of presynaptic dopamine 
synthesis, other aspects of dopaminergic function have also been investigated.  In a study using 
the D2 receptor SPECT radiotracer [123I]-IBZM following dopamine depletion via -MPT 
administration, patients with schizophrenia exhibited increased D2 receptor availability 
compared to control subjects.  A meta-analysis (Howes et al. 2012) of studies comparing 
baseline D2 receptor availability reported a small increase in patients with schizophrenia 
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compared to controls with an effect size d=.26.   A meta-analysis of studies of dopamine 
transporter availability (Howes et al. 2012) found no significant difference between patients 
and controls.  Elevated dopamine synthesis capacity is therefore the most widely replicated in 
vivo neurochemical finding in psychosis (Howes et al. 2012) and has been found to predict the 
subsequent development of psychosis in at risk individuals (Howes et al. 2009) (Figure1.12). 
However, a meta-analysis of studies of dopamine synthesis capacity using only medication-
naïve patients with schizophrenia has yet to be conducted.  Therefore, the possibility that these 
effects are somehow related to medication effects, possibly via effects on D2 auto-receptors 
which modulate the dopamine synthesis pathway, cannot be completely excluded.   
 
 
Figure 1.12 Studies of presynaptic dopaminergic function: Forrest plot showing the effect 
size and 95% confidence intervals of the difference between patients with schizophrenia 
and controls by study. There was evidence of a significant elevation in schizophrenia with a 
summary effect size of d = .79.  Reproduced from Howes et al. (2012).   
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1.5.6.12 Limitations of the Dopamine Hypothesis 
 
The dopamine hypothesis of schizophrenia is not without criticism (e.g. Moncrieff 
2008).  The main tenets of this relate to cause and effect in terms of dopamine and psychosis, 
and the mode of action of antipsychotics.  Moncrieff argues that the question of whether altered 
dopamine synthesis necessarily causes psychosis still needs to be addressed.  In particular, she 
argues that if patients are more aroused, as would occur in psychosis, then this may account for 
findings of elevated dopamine synthesis capacity.   Moncrieff states that “abnormalities of 
neurotransmitters may be better understood as correlations of psychological states than as 
causes of them.  For example, the surge of adrenalin that accompanies a frightening experience 
does not in itself produce fear… It may be difficult to clarify experimentally whether 
biochemical states qualify as causes of mental experiences or as symptoms. To establish 
causality, longitudinal studies would be needed”.  Indeed, such studies have begun to yield 
results supporting the dopamine hypothesis.  For example, Howes et al. (2009) found that 
elevated dopamine synthesis is found in the prodromal phase of psychosis, and longitudinal 
studies are underway.    
 
Rather than targeting a pathophysiological process, Moncrieff et al. (2005) proposed 
that antipsychotics achieve their desired effects via the inducing a characteristic neurological 
state.  For example, in healthy volunteers antipsychotics produce a state of physical and mental 
slowing, and emotional flattening or detachment (Belmaker & Wald 1977; Healy & Farquhar 
1998; McClelland et al. 1990).  It is argued that these subjective effects may account for the 
ability of antipsychotics to reduce the impact of psychotic phenomena such as hallucinations 
or delusions.   
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Along similar lines, it has also been proposed that there are differences in the clinical 
phenomenology of amphetamine-induced psychosis compared to schizophreniform psychosis 
(Snyder et al. 1972), such as reduced thought disorder and delusions of control.  However, 
others have argued that the two states are indistinguishable (Batki & Harris 2004; Harris & 
Batki 2000).  Amphetamine-induced psychosis results in abnormal stereotyped movements and 
posturing in animals (van Rossum & Hurkmans 1964), and this is likewise observed in 
untreated schizophrenia, albeit without the external motor hyperactivity (Batki & Harris 2004; 
Owens et al. 1982; McCreadie et al. 2002).   
 
Furthermore, studies of dopamine metabolite CSF levels have produced conflicting 
results which may reflect complicated interactions between antipsychotics and dopamine 
metabolite levels (Widerlov 1988).  However, a likely confounding factor in the interpretation 
of these results is that CSF levels provide a marker of whole brain dopamine metabolism and 
therefore lack the spatial specificity of chemical imaging studies.   
 
A further complicating factor in the dopamine hypothesis is that, clozapine, which is 
the treatment of choice for refractory schizophrenia (Taylor et al. 2009), has relatively weak 
affinity for the D2 receptor (Seeman 2002) and it has been hypothesised that its therapeutic 
superiority to the other antipsychotics is due to antagonism of the 5HT2A receptor (Huttunen 
1995).  This is particularly interesting given that 5HT2A agonism results in marked 
hallucinations, albeit predominantly visual, as per the mode of action of the “classic” 
psychedelics such as LSD, psilocybin and mescaline (reviewed in Nichols 2004).   
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Not all patients with schizophrenia appear to exhibit increases in striatal dopamine 
synthesis capacity.  Demjaha et al. (2012) found that patients who do not respond to standard 
antipsychotic treatment have no significant elevation in dopamine synthesis capacity, 
compared to controls, whilst patients who do respond to antipsychotic do exhibit increased 
dopamine synthesis capacity.  The authors concluded that this could be either because of 
differential underlying pathophysiology or differential responsiveness of the dopaminergic 
system to antipsychotic treatment.  The idea that patients who remain symptomatic despite 
antidopaminergic treatment may not have a primary elevation in dopamine synthesis capacity 
gave rise to the hypothesis that schizophrenia as a syndrome may arise from multiple 
neurochemical abnormalities.  This argument was later put forward in a paper by Howes & 
Kapur (2014), which suggested classifying schizophrenia according to the presence or absence 
of hyperdopaminergia (type A and type B schizophrenia, respectively).   
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1.5.6.13 Linking Dopamine Dysfunction to Symptoms: The Aberrant Salience 
Hypothesis 
 
In light of the findings linking dopaminergic dysfunction to schizophrenia it was 
suggested that dopamine is “the wind of the psychotic fire” (Laruelle & Abi-Dargham 1999).  
However, a coherent account of how dopaminergic dysfunction gave rise to psychotic 
symptoms was lacking.  Animal models support the view that striatal dopamine release 
underlies the attribution of motivational salience to stimuli (Berridge & Robinson 
1998).  Based on this and evidence in humans, a mechanism to explain how elevated striatal 
dopamine could lead to psychotic symptoms was proposed (Kapur 2003), where dopamine 
dysregulation leads to the aberrant assignment of salience to internal and external stimuli, and 
psychotic symptoms are secondary to cognitive rationalisation of these experiences.  Kapur’s 
thesis will now be outlined in relation to the role of dopamine in the brain, which was discussed 
earlier in this chapter. 
 
Kapur limits the extent to which reward prediction error electrophysiological findings 
(Schultz et al. 1997; Schultz 1997) account for dopaminergic function, as findings had neither 
been related to aversive stimuli nor the longer-term modulatory role of dopamine (Berridge & 
Robinson 1998; Schultz et al. 1997; Redgrave et al. 1999).  Kapur instead favoured the 
incentive motivational hypothesis of dopaminergic function proposed by Berridge & Robinson 
(1999) and others of a similar theoretical persuasion (Horvitz 2000; Martin-Soelch et al. 2001; 
Di Chiara 1998).  In line with these theories, the mesolimbic dopamine theory attributes 
salience to stimuli which Kapur explained as: 
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“A process whereby events and thoughts come to grab attention, drive action, and 
influence goal-directed behaviour because of their association with reward or 
punishment (Berridge & Robinson, 1998; Berridge 1999). This role of dopamine in 
the attribution of motivational salience does not exclude the roles suggested by 
previous theorists; instead it provides an interface whereby the hedonic subjective 
pleasure, the ability to predict reward, and the learning mechanisms allow the 
organism to focus its efforts on what it deems valuable and allows for the seamless 
conversion of motivation into action (Berridge & Robinson, 1998; Berridge 1999).” 
 
Kapur emphasised some of the phenomenological aspects of delusion formation, 
including the fact that the development of schizophrenic psychosis is slow (Yung & McGorry 
1996) and follows a series of stages in which a period of heightened awareness and anxiety is 
followed by a drive to make sense of the situation and then followed by a sense of relief which 
occurs when a “new awareness” is obtained through the crystallisation of the delusion (Yung 
& McGorry 1996; Bowes & Freedman 1966; Bowers 1968; Roberts 1992).  In parallel, 
dopamine-releasing drugs do not produce psychosis upon single doses in most humans (Yui et 
al. 1999), but do so after chronic administration (Harris & Batki 2000).  This is likely due to 
sensitising effects of these drugs on the dopamine system, whereby initially repeated doses 
result in greater dopamine release.  Furthermore, delusions, Kapur argues, are generally highly 
improbable, vs. impossible beliefs, and are therefore disorders of inferential logic (Roberts 
1992), whilst hallucinations are aberrantly recognised internal percepts (David 1999; Bentall 
1990; Grossberg 2000), i.e. stimuli that are aberrantly recognised as being external when they 
are internal in origin, and/or aberrantly produced internal stimuli.   
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 Kapur proposed that under a hyperdopaminergic state, a stimulus-independent release 
of dopamine could give rise to psychotic symptoms via the “aberrant assignment of salience to 
external objects and internal representations” such that in a psychotic state the dopamine 
system creates salience from otherwise neutral stimuli.  In Kapur’s model, delusions are a top-
down cognitive explanation of aberrantly salient stimuli.  In other words, an individual tries to 
make sense of their experiences by using the explanations that will be influenced by their past 
experiences and culture.  He also explains the mechanism of antipsychotic action in the 
treatment of schizophrenia by dampening salience (Courvoisier 1956), which Kapur argues 
would include aberrant salience, giving rise to the gradual symptomatic relief which is 
observed clinically (Miller 1987).   
 
Using L-DOPA and haloperidol Pessiglione et al. (2006) found that dopaminergic 
agents modulated reward processing so that L-dopa resulted in increased reward-learning 
relative to subjects treated with haloperidol.  Subsequently, tasks have been developed to 
measure aberrant salience including the Salience Attribution Task (SAT) and these have shown 
that psychotic patients exhibit elevated Aberrant Salience (Roiser et al. 2009).  In contrast to 
most other reward-learning tasks, the SAT includes a task-irrelevant stimulus dimension as 
well as a task-relevant stimulus dimension. The subject’s reaction time and subjective rating of 
reinforcement probabilities for relevant and irrelevant stimuli provide measures of the salience 
attached to these dimensions.  Salience attached to the irrelevant dimension is considered 
aberrant. 
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Aberrant salience is directly related to the presence of delusions in medicated patients 
with schizophrenia (Roiser et al. 2009).  In a study using fMRI, Murray et al. (2008) found a 
disruption in reward prediction error among first-episode psychosis patients, as well as 
abnormal activations in dopamine brain regions.  A further fMRI study involving healthy 
volunteers (Roiser et al. 2010) and employing the SAT found that participants who showed 
greater aberrant learning exhibited greater dorsolateral pre-frontal cortex (dlPFC) responses, 
an area targeted by dopamine projections.  Whilst Kapur’s model has heuristic value, its 
predictions are based on animal studies using simple conditioning paradigms and require 
continued investigation in humans.   
 
Using an fMRI version of the SAT in un-medicated individuals at ultra-high risk of 
psychosis compared to healthy controls, Roiser et al. (2012) found that individuals at ultra-
high risk of psychosis were more likely to attribute motivational salience to irrelevant stimulus 
features and this was related to the severity of their delusion-like symptoms.  In addition, it was 
reported that ventral striatal BOLD responses to irrelevant stimulus features were also 
correlated with delusion-like symptoms in the ultra-high risk group. The authors concluded 
that these findings were consistent with and provided support for the Aberrant Salience 
hypothesis. 
 
.   
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1.5.6.13 Dopamine Dysregulation as a Potential Mechanism Linking Risk Factors to 
Psychotic Symptoms 
 
In summary, within schizophrenia, striatal dopamine dysfunction has been proposed to 
underlie the development of psychosis via a process involving ‘Aberrant Salience’ (Kapur 
2003, Kapur 2004, Kapur & Mizrahi 2005, Howes & Kapur 2009).  Two major modifiable 
environmental risk factors for psychosis are cannabis use (Moore et al. 2007) and psychosocial 
stress (Cantor-Graae & Selton, 2005).   This thesis aims to determine the relationships between 
the striatal dopamine system, Aberrant Salience and these environmental risk factors in order 
to further our understanding of the neurobiology of psychosis.   
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1.6 Cannabis & Dopamine  
 
1.6.1.1 Animal Evidence 
 
Several lines of evidence indicate that dopamine dysfunction may mediate the link 
between cannabis exposure and psychosis as has been proposed to occur in schizophrenia.  
Several early animal studies described the interactions of amphetamine, which increases striatal 
dopamine release (Costa et al. 1972), with THC (Garriott et al. 1967; Howes 1973a; Howes 
1973b; Kubena & Barry 1970; Pirch et al. 1973; Zitko et al. 1972), reporting that the 
behavioural effects of amphetamine may be potentiated or antagonised depending on the dose 
of administered THC.  As Howes & Osgood (1974) suggested, “dopamine appears to be a 
prime candidate for consideration in the mode of action of 9-tetrahydrocannabinol”. 
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1.6.1.2 THC & Dopamine Synthesis 
 
Synaptosomes have been used as an in vitro tool to investigate neurotransmitter release, 
uptake and synthesis (DeBelleroche & Bradford 1973).  The use of rodent synaptosomes has 
enabled the measurement of dopamine synthesis from tyrosine (Kuczenski & Segal 1974; 
Thierry et al. 1973; Patrick & Barchas 1974).  Maitre et al. (1970) reported increased [3H]-
dopamine synthesis from [3H]-tyrosine in the brains of rats treated with THC, although this 
may have been related to changes in blood [3H]-tyrosine.  Likewise, Bloom et al. (1978) 
reported THC increased dopamine synthesis.  It was later found that THC caused a 
concentration-dependent decrease in the uptake of [14C]-dopamine into striatal synaptosomal 
preparations from Charles-River mice, along with inducing a small but significant release of 
[14C]-dopamine from pre-incubated synaptosomes (Howes & Osgood 1974).  However, 
Hershkowitz and Szechtman (1979) reported that THC caused an increase in dopamine uptake 
in both cortical and striatal synaptosomes, with greater dopamine uptake in striatal vs. cortical 
preparations.  Bloom (1982) found that in mice synaptosomes, THC produced increases in the 
conversion of tyrosine to dopamine, but high doses of THC resulted in decreased dopamine 
synthesis in both whole brain and striatal synaptosomes (see figure 1.13), in line with previous 
findings (Poddar & Dewey, 1980).  THC also inhibited the active uptake of tyrosine into all 
synaptosome preparations studied. It was suggested that the decrease in precursor uptake may 
be the cause of the decreased dopamine synthesis observed at the higher concentrations of THC 
(Bloom 1982).  This was also seen in previous research (Hershkowitz et al. 1977).   There are 
however differences in the concentrations of dopamine in synaptosomal subfractions which 
preclude direct comparisons between studies (Bloom 1982).  The dose-related THC increase 
in the accumulation of newly synthesised dopamine without producing significant change in 
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the endogenous levels of dopamine was found to be under opioid modulation since pre-
treatment with the -opioid receptor antagonist naloxone reduced dopamine accumulation by 
66% (Bloom & Davey 1978).  This ties in with earlier behavioural experiments with Charles-
River rats that had shown interactions between THC and morphine via dopaminergic 
mechanisms (Hine et al. 1975).   Later microdialysis studies also reported blockade of THC-
induced dopamine efflux via -opioid receptor antagonism (Chen et al. 1990a).   
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Figure 1.13 The effects of THC on the synthesis of [3H]-dopamine in synaptosomes 
prepared from mouse striata.  Values shown are the mean and error bars indicate standard 
error of the mean.  Samples were incubated with 5 x 10-7 M [3H]-tyrosine for 15 minutes.  
Each sample consisted of the tissue from the striatum of approximately one brain. Dopamine 
synthesis was significantly increased by the 3 and 10 M concentrations of THC.  The effect 
was maximal at 10 M with that concentration producing a 97% increase.  Dopamine 
synthesis was decreased by the 30 M concentration.  * p < 0.05 when compared to vehicle 
controls.  (Figure from Bloom [1982]) 
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Since THC induces hypothermia, which in turn can affect dopamine synthesis, the 
increased synaptosomal dopamine synthesis elicited by THC was shown not to be related to 
drug-induced hypothermia (Bloom & Kiernan 1980).  Whilst some studies found no change in 
THC-induced dopamine synthesis (Bracs et al. 1975) or reductions in synthesis (Fenessy & 
Taylor 1977), this may have been related to the reported biphasic dopamine response to THC.  
Interestingly, sleep deprivation was found to result in decreased dopamine turnover in response 
to THC, whilst normal sleep led to no THC-induced dopamine turnover effects (Carlini et al. 
1993).   
 
Agrawal et al. (1985) compared single vs. repeated, over 14 consecutive days of 25, 50, 
or 100 mg/kg, oral dosing of cannabis extract in mice.  Single dose cannabis extract resulted in 
increased in [3H]-spiroperidol binding, indicative of increased dopamine receptor availability.  
Multiple doses at 50 and 100mg/kg, resulted in decreased [3H]-spiroperidol binding.  Scatchard 
analysis indicated this was due to a change in receptor affinity (KD) rather than maximum 
number of binding sites (Bmax) implying a functional change in dopamine receptors associated 
with repeated cannabis exposure.  
 
A study of brain homogenates did not find a significant effect of THC on whole brain 
dopamine (Taylor & Fennessy 1977).  Whilst a later study found that THC did result in 
increased dopamine turnover rates in the cortex and brainstem (including the striatum) 
(Bensemana & Gascon 1978).  However, following a 90 day dosing of THC in Sprague-
Dawley rats, no significant change in dopamine receptor or dopamine levels were observed in 
the caudate nucleus, hypothalamus, septum or hippocampus (Ali et al. 1989).   
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Bhattacharyya et al. (1980) reported a triphasic dopaminergic response to THC in 
which the drug led to an initial decrease in caudate nucleus and midbrain dopamine, followed 
by an increase in dopamine and then a return to baseline.  Aulakh et al. (1980) found a 
complicated temporal relationship between THC and dopamine.  A single dose of THC led to 
a decrease in dopamine levels in the caudate nucleus (CN) and midbrain immediately post 
administration.  However, repeated daily THC administration led to a decrease in dopamine 
levels on day 5, and then gradually returning to normal on day 15 in brains that were studied 
one hour after THC dosing.  When the brains were studied two hours after dosing there was an 
increase in brain dopamine that peaked to a maximum between day 8 and 10 of the regimen 
before reducing.  One potential explanation for the complex temporal course of dopaminergic 
effects is the finding that THC alters monoamine-oxidase activity.  THC has been found to 
inhibit (Schurr & Livne 1976) and increase (Banerjee et al. 1975) the activity of monoamine 
oxidase.   
 
As described earlier, THC is a partial agonist of endocannabinoid CB1 receptors.  More 
recently, CB1 receptor agonism has been found to selectively increase the expression of 
tyrosine hydroxylase, a key enzyme in the dopamine synthesis pathway (Bosier et al. 2012). 
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1.6.1.3 THC & Dopamine Release 
 
THC has been found to increase the release of striatal dopamine (Ng Cheon Ton et al. 
1998) although some findings have been contradictory (Cheer et al. 2004).  One study found 
an increase in THC-induced forebrain dopamine efflux (Chen et al. 1990b) although the same 
research group later reported differences in microdialysis results associated with the strain of 
experimental rat (Chen et al. 1991).  Microdialysis with Sprague-Dawley rats showed that pre-
exposure to THC resulting in behavioural sensitization was associated with reduced stimulation 
dopamine transmission in the nucleus accumbens shell and an increased stimulation in nucleus 
accumbens core in response to THC challenge (Cadoni et al. 2008).  In Long-Evans rats THC 
had no effect on extracellular concentrations of dopamine, DOPAC or homovanilic acid, and 
no effect on amphetamine-induced dopamine release nor fluphenazine-induced transient 
increase in dopamine, DOPAC and homovanilic acid (Castaneda et al. 1991).   
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1.6.1.4 THC & Dopamine Electrophysiology  
 
Electrophysiological studies show acute administration of THC increases ascending 
mesolimbic dopaminergic nerve firing rates via cannabinoid CB1 receptor agonism (French 
1997; Gessa et al. 1998).  This finding was replicated by Diana et al. (1998a) who also showed 
that acute THC withdrawal elicited by both abrupt cessation of chronic THC treatment or 
administration of the cannabinoid CB1 receptor antagonist SR 141716A resulted in decreased 
dopamine nerve activity (Diana et al. 1998b).  However, one study did not find an effect of 
THC on dopaminergic cell activity (Gifford et al. 1997).  Other dopaminergic projections have 
also been studied with THC likewise resulting in increased firing (Melis et al. 2000; Moreno-
Herreras 2008).   
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1.6.2 Human Evidence 
 
Patients with cannabis-induced psychoses have elevated levels of peripheral dopamine 
metabolites (Bowers & Kantowitz  2007) and a case report of a drug-free schizophrenic patient 
who smoked cannabis between single photon emission tomography (SPECT) scans with the 
dopamine D2/3 receptor antagonist radiotracer [123I]iodobenzamide, found evidence of 
dopamine release and an exacerbation of symptoms after cannabis use (Voruganti et al. 2001).  
However, only 1 of 3 subsequent molecular imaging studies of the acute effects of THC in 
healthy volunteers has found evidence of dopamine release (Bossong et al. 2009, Barkus et al. 
2011, Stokes et al. 2009), suggesting that the acute effects of THC on dopaminergic function 
may not be large or consistent in humans.  These studies all administered 10mg or less of THC 
because older pharmacological studies indicated that the “standard joint” (defined by the US 
National Institute of Drug Abuse) delivered an approximate THC dose of 8mg-15mg (Lindgren 
et al. 1981, Smart & Adlaf 1986).  Yet, the THC content of cannabis has increased significantly 
since these studies (Hardwick & King 2008), such that THC doses may be over 40mg per spliff 
(joint; cannabis cigarette) (Hunault et al. 2010), and so the THC doses used in those imaging 
studies may not be sufficient to elicit a consistent dopamine release.  Furthermore, there is 
evidence of sensitisation of the dopamine response to THC in animals (Gorritti et al. 1999); 
repeated THC administration results in a greater post-synaptic response, indicating that 
dopaminergic effects are likely to be greater in regular cannabis users.  
 
Recent studies in ex-cannabis users have found no significant difference in striatal 
dopamine release or post-synaptic dopamine D2/D3 receptor availability  (Urban et al. 2012, 
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Stokes et al. 2012) compared to individuals with no history of chronic cannabis use.  However, 
as these studies were in abstinent ex-cannabis users, it is not clear if this is due to the lack of 
dopaminergic effects of cannabis in humans or the normalisation of dopaminergic function 
with abstinence, as has been reported to be the case with dopamine transporter availability in 
abstinent cocaine users (Volkow et al. 1996) and alcohol users (Volkow et al. 1996).  Therefore 
presynaptic dopaminergic function will be studied in active cannabis users who experienced 
cannabis-induced psychotic-like symptoms because these individuals are most at risk of 
psychosis (Arendt et al. 2005).   
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1.7 Psychosocial Stress & Dopamine 
1.7.1 The Stress Response and Dopamine 
The stress response can be described as the brain and body’s response to a threat or 
potential threat or from internal cues such as memories (Mora et al. 2012).  This requires the 
involvement of multiple brain regions including the prefrontal cortex, amygdala, hippocampus, 
nucleus accumbens, hypothalamus and dynamic feedback processes involving multiple 
neurotransmitters and neuromodulators including dopamine, noradrenaline, acetylcholine and 
GABA (Joels & Baram 2009; Ulrich-Lai & Herman 2009).  The role of fast limbic inputs in 
cortical arousal will be briefly described below, followed by a description of the HPA axis.  
 
Stressors produce a change in extracellular concentrations of multiple neurotransmitters 
resulting in the activation and modulation of behavioural processes to cope with the stressor 
(Robbins 1997; Robbins 2005) and indirect outputs to the hypothalamus modulating the final 
stress responses by increased sympathetic output and the activation of the HPA axis (Ulrich-
Lai and Herman, 2009).   
 
Under normal conditions, the prefrontal cortex (PFC) regulates behaviour, thought and 
emotion in a top-down fashion.  The PFC has direct and indirect connections to monoamine 
cell bodies in the brainstem including the origins of noradrenergic projections in the locus 
coeruleus and dopaminergic projections in the substantia nigra (SN) and ventral tegmental area 
(VTA). The PFC can therefore regulate its own catecholamine levels. The ventromedial 
prefrontal cortex (VMPFC) has extensive connections with subcortical structures including the 
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amygdala, the nucleus accumbens and the hypothalamus that generate emotional responses 
(Price & Amaral 1981; Price et al. 1996; Ghashghaei & Barbas 2002).  Under stress conditions, 
the amygdala activates stress pathways in the hypothalamus and brainstem, resulting in 
increased noradrenaline and dopamine release (see below).  This increased catecholamine 
output during stress strengthens amygdala mediated fear conditioning (Debiec & LeDoux 
2006).  In parallel, acute stress impairs higher-order PFC functions such as working memory 
and attention regulation. Thus, attention regulation switches from 'top-down' control by the 
PFC (Goldman-Rakic 1987) to 'bottom-up' control, whereby salient stimuli capture attention 
(Gazzaley et al. 2007). In addition, the amygdala biases behaviour away from flexible spatial 
navigation towards habitual motor responding (Elliott & Packard 2008). Therefore, during 
stress, the brain's response patterns switches from slower, more thoughtful PFC regulation to 
the reflexive and rapid emotional responses of the amygdala and related subcortical structures. 
   
Processed sensory information enters the limbic system via the amygdala (LeDoux 
2000;  McGaugh 2004) which receives dopaminergic, noradrenergicc, serotonergic, 
cholinergic inputs and afferents releasing glutamate from multiple brain regions (Arnsten 2009; 
Carlsen et al. 1985; Mo et al. 2008; Pérez de la Mora et al. 2010).  Stress results in acute 
amygdalar increases in these neurochemicals, including dopamine (Galvez et al. 1996; Tanaka 
et al. 1991; Kawahara et al. 1993; Mo et al. 2008; Inglis & Moghaddam 1999; Stevenson et al. 
2003; Reznikov et al. 2007; Singewald et al. 2000), with the exception of  acetylcholine (Mark 
et al. 1996).   
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In terms of the dopamine system, the ventral tegmental area projects to and receives 
inputs from a number of regions that are involved in the stress response.  These regions include 
the amygdala, prefrontal and cingulate cortices, hippocampus and nucleus accumbens.    Other 
projections include those from the hypothalamus to the VTA such as those arising from the 
pre-optic area (Simerly & Swanson, 1988; Zahm et al. 2011) which are likely involved in the 
stressors associated with sexual behaviour (Hull & Dominguez 2007; Hull et al. 2007).  
Activation of glutamatergic afferents results in increased VTA activity (Figure 1.14; see also 
figure 1.15 for further circuitry).  On the other hand, the VTA receives inhibitory inputs via the 
tail of the VTA (tVTA), also called the rostromedial tegmental nucleus (RMTg) which is rich 
in GABA neurons (Perotti et al. 2005; Bourdy & Barrott 2012; Jhou et al. 2009).   Since 
wakefulness is also essential to the stress response, the VTA also receives cholinergic input 
from the reticular activating system via nicotinic receptors (Liu et al. 2012).  It is thought that 
tobacco addiction involves this cholinergic-dopaminergic mechanism (Balfour et al. 2000; 
Pidoplichko et al. 1997), through the main addictive compound in tobacco, nicotine (Stolerman 
et al. 1995) 
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Figure 1.14  Mesolimbic dopamine system circuitry.  Simplified schematic of the circuitry 
of the mesolimbic dopamine system in the rat brain highlighting the major inputs to the ventral 
tegmental area (VTA) (glutamatergic projections, blue; dopaminergic projections, red; 
GABAergic projections, orange; orexinergic projections, green). Glutamatergic synapses 
excite postsynaptic neurons and GABAergic synapses inhibit postsynaptic neurons. Dopamine 
release exerts more complex modulatory effects. AMG, amygdala; BNST, bed nucleus of the 
stria terminalis; LDTg, laterodorsal tegmental nucleus; LH, lateral hypothalamus; PFC, 
prefrontal cortex; VP, ventral pallidum.  (Figure from Kauer & Malenka 2007).   
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Figure 1.15 Schematic of tVTA main connectivity. (a) The tVTA receives afferents (in 
green) from a broad range of cerebral structures. The main afferents arise from the frontal 
cortex (Cx), lateral habenula (LHb), hypothalamus (Hyp), superior colliculus (SC), 
periaqueductal gray (PAG), dorsal raphe (DR), laterodorsal tegmentum (LDTg), and 
pedunculopontine tegmental nucleus (PPTg). (b) The tVTA efferents (in red) are more 
restricted and preferentially target midbrain dopamine nuclei: ventral tegmental area (VTA), 
substantia nigra pars compacta (SNc) and the retrorubral field (RR). The tVTA also heavily 
projects to the lateral hypothalamus (LH). (c) The tVTA is well placed to exert control of both 
mesocorticolimbic and nigrostriatal systems. (d) The tVTA may act as a hub, integrating 
converging multimodal signals from widespread structures and channelling them toward 
dopamine systems and their forebrain targets. It is important to note that these tVTA afferents 
(in green) also directly project to the VTA. Abbreviations: NAc, nucleus accumbens; St, dorsal 
striatum (Figure from Bourdy & Barrot 2012).   
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Early theoretical work (Zubin & Spring 1977) formulated a stress-diathesis model of 
schizophrenia suggesting endogenous vulnerability interacted with environmental stressors 
leading to the illness.  Potential interactions between stressors and neurobiological mechanisms 
have been suggested including dopaminergic sensitization whereby exposure to sensitising 
stressors leads to increased neurochemical activation possibly via the hypothalamo-pituitary-
adrenal (HPA) axis (e.g. Yuii et al. 2007).  
 
1.7.2 Preclinical Evidence 
1.7.2.1 The Hypothalamo-Pituitary-Adrenal (HPA) Axis 
In addition to the fast neurotransmission described above, at the whole organism level, 
the acute stress response is mediated via the HPA axis (Armario et al. 2006), which regulates 
the release of corticosteroids.  Perception of a potentially threatening situation, results in 
activation of the hypothalamic paraventricular nucleus (PVN), stimulating corticotrophin-
releasing hormone (CRH) and vasopressin neurons.  This leads to adrenocorticotrophic 
hormone (ACTH) release from the anterior pituitary gland, which in turn causes cortisol, a 
corticosteroid, to be released from the adrenal glands.  A circadian pattern of adrenal 
corticosteroid release has been observed as a release of corticosteroids occurs in hourly pulses 
that are highest in amplitude during the active period (Young 2004).  Background pulsatility 
has been proposed to maintain tissue-responsiveness to stress-induced peaks in corticosteroid 
release (Lightman & Conway-Campbell 2010). 
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1.7.2.2 Corticotrophin-Releasing Hormone Pharmacology 
 
The corticotrophin-releasing factor (CRF) system is a major modulator of the stress 
response.  At the hypothalamic–pituitary level, it is a potent stimulator of adrenocorticotrophic 
hormone (ACTH) (Vale et al. 1981).  Furthermore, CRF is located in various 
corticomesolimbic structures including the amygdala, the bed nucleus of the stria terminalis 
(BNST), and the septum, where it is thought to be involved in the integration of emotional 
responses to stress (Chalmers et al. 1995; Lovenberg et al. 1995), as well as brainstem 
structures, where they regulate the autonomic stress response (Valentino et al. 1991).  Two 
types of CRF receptors, type 1 (CRF1) and type 2 (CRF2), have been identified. CRF1 
receptors are expressed primarily in the medial septum, pituitary, cortex, cerebellum, 
hindbrain, and olfactory bulbs, whereas CRF2 receptors are found in the lateral septum, 
ventromedial hypothalamus (VMH), medial amygdala, paraventricular nucleus (PVN), and 
choroid plexus (Chalmers et al. 1995; Van Pett et al. 2000). 
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1.7.2.3 Corticosteroid Neuropharmacology 
 
Corticosteroids readily enter the brain and bind to the mineralocorticoid receptor (MR) 
and the glucocorticoid receptor (GR) (Reul & de Kloet 1985). Activation of the receptors 
results in waves of gene regulation including transactivation and transrepression (Datson et al. 
2008).  The mineralocorticoid receptor and glucocorticoid receptor result in differential gene 
regulation (Datson et al. 2001) and have different localization patterns in the brain.  The 
mineralocorticoid receptor is mainly expressed in limbic neurons i.e., the PFC, amygdala and 
hippocampus (Reul & de Kloet 1985).  The glucocorticoid receptor is expressed throughout 
the brain on both neurons and glia, with highest expression in the PVN and hippocampus (Reul 
& de Kloet 1985).  The mineralocorticoid receptor is established in maintaining homeostasis 
of limbic circuits (Joëls et al. 2008) whilst glucocorticoid receptor becomes activated only after 
exposure to stress or during the circadian peaks, reacting to the stress response (de Kloet & 
Reul 1987). In cognition, the mineralocorticoid receptor is involved in appraisal of novel 
situations, while activation of the glucocorticoid receptor facilitates the consolidation of stress-
related information (de Kloet et al. 1999).   
 
Adaptation to a stressful situation is a coordinated effort of the limbic system, 
consisting of the hippocampus, amygdala and PFC.  Collectively, these limbic areas also 
facilitate the formation of a memory trace of the event.  Processing of contextual aspects 
depends predominantly on hippocampal function.  The hippocampus is a region with one of 
the highest concentrations of corticosteroid receptors in the mammalian brain (Kim & Diamond 
2002).  One function of the hippocampus is to participate in terminating the stress response 
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through glucocorticoid-mediated negative feedback that inhibits the hypothalamus–pituitary–
adrenal (HPA) axis (Sapolsky et al. 1992; McEwen & Sapolsky 1995).   
 
The primary physiological model of memory storage has been long-term potentiation 
(LTP) whereby a sustained enhancement of synaptic efficacy is produced by stimulation of 
excitatory afferent fibres in line with Hebb's theorem (1949).   Activation of GRs impairs 
hippocampal LTP whereas activation of MRs results in the facilitation of LTP (Pavlides et al. 
1995; Kim & Yoon 1998; Smigra et al. 1998; Pavlides & McEwen 1999).  In addition to 
modulating LTP and therefore hippocampus dependent memory, corticosterone exerts strong 
genomic effects on the activity and plasticity of the hippocampus (McEwen 2001; Kim & 
Diamond 2002; Mirescu & Gould 2006; Joëls 2008).  Low levels of corticosterone, through 
mineralocorticoid receptor activation, facilitate plasticity and hippocampus-dependent memory 
(Diamond et al. 1992).  By contrast, absence or very high levels of corticosterone inhibits 
plasticity; the latter is mediated through the glucocorticoid receptor (Alfarez et al. 2002; Kim 
et al. 2004).   
 
In recent years, corticosteroids have been found to have rapid, non-genomic effects (e.g. 
Groeneweg et al. 2011).  Similar to neurons in the hypothalamus, hippocampal neurons 
spontaneously show miniature excitatory postsynaptic currents (mEPSCs). Corticosteroids 
have been found to rapidly increase the frequency of hippocampal mEPSCs in a manner not 
dependent on gene transcription (Karst et al. 2005).  This mechanism likely interacts with other 
transmitters and hormones, including monoaminergic systems such as dopamine, in the limbic 
system and HPA axis as part of the stress response.  It has been shown for example that the 
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administration of the potent dopamine transport blocker cocaine (benzoylmethylecgonine) and 
stress are both associated with increased strength at excitatory synapses on midbrain dopamine 
neurons, with the synaptic effects of stress but not cocaine being blocked by the glucocorticoid 
receptor antagonist RU486 (Saal et al. 2003).   
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1.7.2.3 The Stress Response & Dopamine 
 
Preclinical studies indicate that both acute and chronic stress alter mesocortical 
dopaminergic function.  Tidey (1996) found that social defeat stress selectively increased 
mesocorticolimbic dopamine release and Hall et al. (1999) found that maternal deprivation of 
neonatal rats produced enduring increases in dopamine release in the nucleus accumbens.  
Likewise, rats who had undergone neonatal isolation were found to have greater cocaine-
induced increased in nucleus accumbens dopamine as measured with microdialysis (Kosten 
2003).  More recently social defeat has been found to result in increased phasic dopamine 
neuron firing in the VTA three weeks after a 10 day exposure to social defeat stress (Razzoli 
et al. 2011).  However, in an experiment using Sprague−Dawley rats, unavoidable stress 
administered over one week and three weeks was associated with a decrease in nucleus 
accumbens dopamine output that remained evident two weeks after administration of stress 
had abated (Mangiavacchi et al. 2001).   Likewise, Long-Evans rats confronted with 30 minutes 
of stress twice daily for 21 days exhibited a reduced cocaine-induced nucleus accumbens 
dopamine response (Shimamoto et al. 2011).  These divergent results may underlie the nature 
of the stress paradigm deployed in different studies.  For example, Miczek et al. (2011) found 
that Long-Evans rats under a ten day episodic defeat paradigm had a sensitised dopamine 
response in the nucleus accumbens, whilst when under a 5 week continuous subordination 
paradigm they exhibited a suppressed dopamine response.   
 
There is evidence that altered dopaminergic function caused by early life persists into 
adulthood.  For example, maternally separated and non-handled Long-Evans rats responded to 
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a mild stressor with greater increases in nucleus accumbens dopamine levels and maternally 
separated rats had reduced nucleus accumbens-core and striatal dopamine transporter sites and 
increased dopamine D3 receptor binding and D3 mRNA levels in the nucleus accumbens-shell 
(Brake et al. 2004).  Likewise, Lister hooded rats that were reared in isolation for six to eight 
weeks post-weaning exhibited increased and prolonged extracellular dopamine responses to 
acute stress compared to group-reared rats (Fulford & Marsden 1998).  In a study of the effects 
of maternal separation on Wistar rats, a transient decrease in substantia nigra pars reticulata 
and ventral tegmental neurons expressing tyrosine hydroxylase was observed at post-natal day 
15 in males and females, followed by an increase at post-natal day 70 in the numbers of ventral 
tegmental tyrosine hydroxylase expressing neurons in females only (Chocyk et al. 2011).  
However, maternal separation in Sprague-Dawley rats was associated with decreased acute 
stress ventral tegmental tyrosine hydroxylase expression and reduced nucleus accumbens and 
midbrain levels, compared to normally housed animals (Jahng et al. 2010).  Yet, repeated 
periods of maternal separation results in decreased dopamine transporter expression and 
increased dopamine response to acute stress, and behavioural responses to stress or cocaine 
(Meaney et al. 2002).  Again, the discrepancy in findings may reflect divergent effects of 
differential stressors on distinct aspects of dopaminergic function, although species effects 
cannot be excluded.  Nonetheless, there is consistent evidence that early life stress results in 
aberrant dopaminergic function later in life.   
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1.7.3 Human Evidence 
 
Elevated urinary dopamine and other catecholamine metabolites has been reported in 
girls with a history of sexual abuse compared to those without (De Bellis et al. 1994).  In an 
fMRI study, left basal ganglia reward pathway dysfunction was observed in adults who were 
abused as children (Dillon et al. 2009).  In a further fMRI study, adolescents who had suffered 
severe early life deprivation exhibited ventral striatal hyporesponsivity during anticipation of 
monetary reward (Mehta et al. 2010).  In an [11C]-raclopride study by Pruessner et al. (2004) 
ventral striatal dopamine release was increased in response to psychosocial stress in humans 
who reported insufficient early life maternal care.  Similarly, a further [11C]-raclopride study 
Wand et al. (2007) found stress-induced cortisol levels were positively associated with 
amphetamine-induced dopamine release in the striatum.  More recently, using the radioligand 
[11C]-PHNO, a D2/3 agonist,  Mizrahi et al. (2011) found increased psychosocial stress-induced 
dopamine release in the associative and sensorimotor functional subdivisions of the striata of 
antipsychotic-naïve subjects with schizophrenia and those at clinical high-risk of the illness 
compared to matched healthy controls, possibly indicative of a sensitised dopaminergic stress 
response (see figure 1.16).  Whilst these findings support acute dopamine release in response 
to stress in humans, it is unknown if long-term psychosocial stress has the same effect.  A 
subsequent study by Oswald et al. (2014) reported positive associations between childhood 
adversity and amphetamine-induced dopamine release.  Elevated dopamine synthesis capacity 
is associated with people at clinical risk of schizophrenia (Howes et al. 2009). People at clinical 
risk of schizophrenia, including those in that sample, report higher rates of long-term 
psychosocial stressors.  However it is not known if this is associated with the altered dopamine 
synthesis capacity, or if they are unconnected and stress acts on cortical regions to cause 
cognitive impairments seen in schizophrenia and at risk individuals. 
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Figure 1.16 [11C]-PHNO positron emission tomography response to stress in the corpus 
striatum and its functional subdivisions.  AST,  associative striatum;  CHR, clinical high 
risk group; LST, limbic striatum; SCZ, schizophrenia group; SMST, sensorimotor striatum.   
 
In summary, the dopaminergic system has complex reciprocal projections with many 
areas involved in the stress response, including afferents from multiple transmitter systems 
and there is evidence from preclinical and clinical research that stress alters dopaminergic 
function.   
 
 
 
 
136 
 
1.8 The Final Common Pathway Theory 
 
As is evidenced above, the hypothesis that dopaminergic mechanisms are central to 
psychosis has become highly influential in our understanding of the neurobiology of 
schizophrenia.  Howes & Kapur (2009) synthesised previous hypotheses, research evidence 
from the literature, and Kapur’s Aberrant Salience hypothesis into a key paper in which various 
risk factors for schizophrenia converge on dopaminergic pathways to cause psychosis through 
creating a state of aberrant salience, which they termed the “Final Common Pathway” theory.  
The authors discuss the main developments of the dopamine hypothesis, namely the discovery 
of the dopaminergic action of antipsychotic drugs (Carlsson & Lindqvit 1963) and the theory 
proposed by Davis et al. (1991) relating positive symptoms to subcortical hyperdopaminergia 
and negative symptoms to frontal hypodopaminergia, which Howes and Kapur refer to as 
versions I and II of the dopamine hypothesis, respectively.  Howes and Kapur conceptualise 
their Final Common Pathway theory as version III of the dopamine hypothesis.  A summary of 
the rationale for the Final Common Pathway follows. 
 
As described previously, a consistent finding in schizophrenia imaging research which 
has been subject to meta-analysis has been that patients with schizophrenia have elevated 
striatal dopamine synthesis capacity (Howes et al. 2012).  Likewise, there is evidence of 
increased striatal dopamine release in schizophrenia (Abi-Dargham et al. 1998; Breier et al. 
1997; Kestler et al. 2001; Laruelle et al. 1996; Laruelle et al. 1999) and a dopamine depletion 
study indicated that baseline occupancy of D2 receptors is increased in schizophrenia (Abi-
Dargham et al. 2000).  Furthermore, in terms of treatment, all currently licensed antipsychotic 
drugs block D2 receptors (as reviewed by Frankle & Laruelle 2002).  The emergent genetic 
evidence is also in keeping with a role for dopaminergic dysfunction in schizophrenia.  Whilst 
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other genes are also significant at the genome-wide level, a significant contributor to the 
polygenic risk of schizophrenia is likely to be the DRD2 gene, as identified by the 
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) genome-wide 
association study.   
 
A variety of environmental psychosocial risk factors, described previously, increase the 
risk of schizophrenia.  Many of these share the common factor of being psychosocial stressors.  
These risk factors include migration, urban upbringing and abuse during childhood, and these 
relate to experiences of social isolation or subordination (van Winkel et al. 2008).  Evidence 
from animal studies indicate that both social isolation and subordination are associated with 
hyperdopaminergia (Hall et al. 1998; Hall et al. 1999; Morgan et al. 2002; Tidey et al. 1996), 
as are models of maternal separation (Kehoe et al. 1996a; Kehoe et al. 1996b).  Other risk 
factors including obstetric complications have also been linked in animal models mesostriatal 
hyperdopaminergia (Boksa & El-Khador 2003).   
 
It is suggested that the multiple genetic and environmental risk factors for schizophrenia 
interact with each other in terms of their effects on the dopamine system, for example social 
isolation rearing potentiates the later effects of simulants (Howes et al. 2000; Jones 1992) or 
of stress (Fulford & Marsden 1998).  Likewise in humans, striatal dopamine release in response 
to stress was elevated in people who reported low maternal care during their early childhood 
(Pruessner et al. 2004).  A further area of the Final Common Pathway hypothesis is that 
research has also extended to the schizophrenic prodrome and the extended, or schizotypal, 
phenotype.  As described above, these groups exhibit hyperdopaminergia (Abi-Dargham et al. 
2004; Howes et al. 2011).   
 
138 
 
 
To encapsulate, in describing their Final Common Pathway (Figure 1.17), Howes and 
Kapur (2009) wrote: 
 
“Firstly we hypothesise that multiple “hits” interact to result in dopamine 
dysregulation – the final common pathway to psychosis in schizophrenia… Second, 
the locus of dopamine dysregulation moves from being primarily at the D2 receptor 
level to being at the presynaptic dopaminergic control level.  Third, dopamine 
dysregulation is linked to “psychosis” rather than schizophrenia, and perhaps in the 
fullness of time it will be about “psychosis proneness”.  The exact diagnosis, 
however, reflects the nature of the hits coupled with sociocultural factors and not the 
dopamine dysfunction per se.  And finally, the dopamine dysregulation is 
hypothesised to alter the appraisal of stimuli, perhaps through a process of aberrant 
salience.”   
 
 
Figure 1.17 Multiple hits interact to result in striatal dopamine dysregulation to alter the 
appraisal of stimuli and resulting in psychosis, whilst current antipsychotic drugs act 
downstream of the primary dopamine dysregulation (adapted from Howes & Kapur 
2009).   
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1.9 Summary 
 
Schizophrenia is a potentially devastating mental illness with a complex aetiology.  
With the exception of 22q11 genetic deletion, the odd ratios for environmental risk factors for 
the disorder are greater than the odds ratios of any single gene hitherto identified.  Within 
schizophrenia, striatal dopamine dysfunction has been proposed to underlie the development 
of psychosis.  Two important epidemiological risk factors for the disorder are chronic cannabis 
use and long-term psychosocial stress, both of which have evidence supporting effects on the 
dopamine system and that the Salience Attribution hypothesis provides an explanatory model 
based on empirical findings to explain how psychotic symptoms may develop.  Thus, elevated 
dopamine synthesis capacity may represent the final common neurobiological pathway (Howes 
& Kapur 2009).  Environmental risk factors are by their very nature modifiable, and so this 
thesis will therefore examine whether these environmental risk factors are associated with the 
same dopaminergic abnormalities that have been observed in schizophrenia.   
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1.10 Hypotheses Relating to this Thesis  
 
1. Regular cannabis users sensitive to cannabis’ psychotogenic effects will exhibit elevated 
dopamine synthesis capacity compared with non-user healthy control participants. 
 
2. There will be a direct relationship between dopamine synthesis capacity and cannabis-
induced psychotic-like symptom severity. 
 
3. Regular cannabis users sensitive to cannabis’ psychotogenic effects will exhibit elevated 
aberrant salience compared with non-user healthy control participants. 
 
4. There will be a direct relationship between aberrant salience attribution and cannabis-
induced psychotic-like symptom severity. 
 
5. Subjects with a high cumulative exposure to psychosocial risk factors for schizophrenia 
will exhibit elevated dopamine synthesis capacity compared to subjects with low 
cumulative exposure to the same environmental stressors.   
 
 
6. Across subjects there will be a direct relationship between dose of psychosocial stress and 
dopamine synthesis capacity.   
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Chapter 2: Materials and Methods 
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Methods are described in this Chapter starting with those used in positron emission 
tomography and followed in a behavioural experiment of salience attribution.   
 
2.1 Ethical Approval 
 
The studies were granted favourable ethical opinions via the National Research Ethics 
Service.  Permission to administer radioligand was provided by the Administration of 
Radioactive Substances Advisory Committee (ARSAC).  The studies were conducted in 
accordance with the Helsinki Declaration (World Medical Association, 2008).  All subjects 
provided informed written consent to participate after an oral and written explanation of the 
studies.   
 
2.2.1 Participant Recruitment 
Inclusion criteria for all participants were: minimum age 18 years, good physical health 
with no history of major medical condition and capacity to give written informed consent.  
Exclusion criteria for all subjects were current or past psychiatric illness (except Cannabis Use 
Disorders in the cannabis user group and Nicotine Use Disorder in all subjects) using the 
Structured Clinical Interview for DSM-IV (SCID) (First et al. 1996), current use of 
psychotropic medication, history of serious mental illness (including psychosis) in a first 
degree relative determined via the Family Interview for Genetic Studies (FIGS) (NIMH 
Genetics Initiative 1992), evidence of an At Risk Mental State for psychosis (Phillips et al. 
2000), DSM-IV TR (American Psychiatric Association 2005) Substance Dependency or Abuse 
(other than cannabis in the cannabis user group and tobacco for all subjects), blood and needle 
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phobia, contra-indications to PET (including pregnancy, breast-feeding, severe obesity, 
previous clinical procedures involving exposure to significant ionizing radiation within the last 
year), contra-indications to MRI (including claustrophobia, the presence of ferromagnetic 
foreign bodies including aneurysm clips, neural stimulators, cardiac pacemakers or 
defibrillators, cochlear implants, ocular foreign bodies [e.g. metal shavings], other implanted 
medical devices [e.g. Swan-Ganz catheter], insulin pump, shrapnel or bullet injuries, patients 
with a history of surgery of uncertain type where the presence of metal clips or wires cannot 
be excluded).   
  
Detailed drug histories were obtained from all subjects using the Cannabis Experience 
Questionnaire (CEQ) (Barkus et al. 2006), structured interview and timeline follow-back.  
Lifetime cannabis use was estimated as the total number of ‘spliffs’ (cannabis cigarettes; 
‘joints’) consumed.  The time taken to smoke an ‘eighth’ of cannabis (1/8 Ounce; approximately 
3.5g, representing the standard unit of sale in Britain) was chosen as the primary index of 
cannabis use as this provides a measure of the amount of current drug consumption (shorter 
time indicating greater consumption).  This is likely to be more accurate than subjective recall 
of the number of ‘spliffs’ consumed because of variability in cannabis dose between ‘spliffs’ 
and inconsistencies in self-reported cannabis use (Akinci et al. 2001).  
 
2.2.2 Cannabis User Group 
Cannabis user cases were recruited from an on-going cohort study in which over 400 
cannabis users were tested when intoxicated with cannabis and when not intoxicated (Morgan 
et al. 2012).  Subjects met the following criteria: current, at least weekly use of cannabis and 
the induction of psychotic-like symptoms in response to smoking cannabis, which was defined 
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as a positive change on the psychotic items score of the Psychotomimetic States Inventory 
(PSI) (Mason et al. 2008) measured 5 minutes after smoking their usual amount of cannabis 
(i.e. when acutely intoxicated) compared to when not intoxicated with the drug.  Cannabis users 
consumed their own cannabis and testing occurred in the presence of a researcher in the 
environment where users habitually consumed cannabis in their usual drug-taking context (e.g. 
at home), as drug effects are typically larger in naturalistic as opposed to laboratory 
environments (Barkus et al. 2006).  Cannabis-induced psychotic-like symptoms abated within 
two hours of consumption and no subject met the DSM-IV TR criteria for a diagnosis of a 
psychotic disorder.  The psychotic items from the PSI covered ‘Delusional Thinking’, 
‘Perceptual Distortions’, ‘Cognitive Disorganization’ (thought disorder) and ‘Paranoia’.  Each 
item is rated on a 4-point scale from “not at all” (score=0) to “strongly” (score=3).  Examples 
of items include “People can put thoughts into your mind” and “You can sense an evil presence 
around you, even though you cannot see it”.  A sample of the cannabis that each participant 
smoked was taken on the day of testing and analysed for levels of THC (Forensic Science 
Service, UK). 
 
2.2.3 Control Group (Cannabis studies) 
Non-user control subjects were recruited from the same geographic area, i.e. London, 
by public advertisement in a newspaper.  Control subjects were required to have no lifetime 
history of cannabis dependence or abuse (DSM-IV), no more than 10 total uses of cannabis in 
their lifetime, no report of the induction of psychotic symptoms by cannabis, and no history of 
cannabis use in the preceding three months.  Community surveys indicate over 30% of young 
adults in England report trying cannabis in their lifetime (Home Office 2011).  Control subjects 
were therefore permitted to have had a minimal exposure to cannabis to ensure the control 
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group was representative of the same general population from which the cannabis users were 
recruited.   
 
2.2.4 High Psychosocial Stress Group (“HPSS”) 
Subjects with a history of high exposure to psychosocial stress were recruited by 
advertisement in a London-wide newspaper.  HPSS “cases” were required to meet at least two 
of the following criteria: 
A)  Inner city upbringing (before age 16) or current dwelling according to the Office for 
National Statistics (ONS) definition of Inner London used by Eurostat i.e. residents of the 
City of London & the following London Boroughs: Camden, City of Westminster, 
Hackney, Hammersmith & Fulham, Haringey, Islington, Kensington & Chelsea, Lambeth, 
Lewisham, Newham, Southwark, Tower Hamlets, and Wandsworth. 
AND/OR  
B) History of Migration from outside the European Union (1st or 2nd generation)  
AND/OR 
C) History of childhood (before age 16 years) adversity and/or psychological trauma - at least 
one of: Parental separation/divorce OR death of a first-degree relative OR physical or 
sexual abuse OR neglect OR going into foster care/adoption OR major disaster OR war OR 
admission to hospital with life-threatening medical problem  
AND/OR 
D) Current adult adversity - At least one of:  living with parents OR living alone for over a 
year OR lack of confidant OR unemployed OR not currently in a relationship.   
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2.2.5 Low Psychosocial Stress Group (“LPSS”) 
LPSS “control” subjects were recruited from the southern United Kingdom by public 
advertisement and were required to meet all of the following criteria:   
A) No personal history of migration from outside the European Union. 
AND 
B) Current rural dwelling  
AND  
C) No history of inner city dwelling (as above) for longer than 6 months. 
AND 
D)  No history of significant childhood difficulty: Both parents still together at subject’s age 
16 and no history of significant childhood psychological trauma (as above) 
AND 
E)  No history of significant life-events in the 6 months prior to the study.   
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2.3 Positron Emission Tomography  
2.3.1 Background to Positron Emission Tomography 
 
 
Figure 2.1 Basic physics of PET. The 18F nucleus (light green) of a radioligand molecule 
decays, emitting a positron that scatters in tissue until it undergoes matter-antimatter 
annihilation with an electron (yellow circle), in which the mass of the positron and the electron 
are converted into two back-to-back 511keV -photons. (Figure reproduced from Cherry et al. 
2006) 
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Positron Emission Tomography (PET) is a molecular imaging technology (Phelps et al. 
1975; Phelphs et al. 1976; Hoffman et al. 1976; Cho et al. 1976; Derenzo et al. 1977) which 
utilises positron emitting radioisotopes labelled to compounds to image and compare 
biochemical processes in vivo.  The commonly used radioisotopes include carbon (11C), oxygen 
(15O) and fluorine (18F).  Radiolabelled compounds, also referred to as radiotracers, are used to 
trace a restricted number of steps in the biochemical process of interest, enabling a kinetic 
analysis to be used to estimate biochemical, and therefore pharmacological, reaction rates.   In 
a standard PET assay the radiotracer is injected intravenously and the PET scan provides a 
measure of the tissue concentration of the radiotracer over time.  These measures are combined 
with a measure of the time course of the radiotracer in a different biological compartment, e.g. 
plasma or a different tissue pharmacological compartment, to model the kinetics of the 
radiotracer.  An overview of PET is outlined below. 
 
PET relies upon the principle that the positron emitted from a radionuclide will travel 
a short distance (less than 3mm) and then undergo matter-antimatter annihilation when it 
encounters an electron.  The maximum resolution of PET is limited to 2-3mm because of the 
distance the positron travels before annihilation.  The energy from this process is equal to the 
combined mass of the positron and electron, and is released in the form of two 511keV-
photons, released at 180o to each other.  This phenomenon enables the positron decay to be 
detected by scintillation detectors arranged around in the ring of the tomograph.  Scintillation 
detectors contain a crystal which emits photons in the visual spectrum upon gamma ray 
absorption, examples of the crystals include bismuth-germanium oxide.  The light signal is 
amplified by a photomultiplier tube which enables its detection reliably.  Two photons detected 
within an ultra-short time interval are assumed to have arisen from the same annihilation event, 
termed a coincidence event.  As the coincidence event releases two photons at 180o from each 
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other, the coincidence event is deemed to have occurred at a point along a straight line between 
the two detectors, termed a coincidence line.  A normal tomograph will contain hundreds of 
detectors, and during the PET scan acquisition millions of coincidence lines are recorded.  The 
coincidence lines from this process are stored as a two-dimensional matrix called a sinogram.  
To enable the formation of a three dimensional image, the sinogram must corrected for irregular 
absorption of photons by the body (attenuation correction) and detector non-uniformity.  The 
images are then reconstructed using a filtered back-projected algorithm.   
 
Post reconstruction data are then presented as a series of three dimensional images 
acquired over a sequence of time frames, known as frames.  The duration of each frame will 
depend upon the decay properties of the radiotracer.  Data collected from a particular region of 
the image enables the formation of time activity curves (TACs), which are then used to 
calculate kinetic variables.   
 
Incorporation of the radionuclide into a pharmaceutical compound enables deductions 
to be made about the biodistribution of binding sites to the radiotracer from the positron 
emission data.  A variety of PET radiotracers exist, thereby permitting the examination of an 
array of biochemical and pharmacological systems.  As an example, much early work in PET 
was concerned with measures of brain metabolism using the radioligand [18F]deoxy-glucose 
(FDG), which is incorporated into the glycolytic pathway after phosphorylation.  Radiotracers 
have also been developed for different aspects of the dopamine system, examples of which 
include [18F]-DOPA for dopamine synthesis, [11C]-Raclopride for dopamine D2/3 receptor 
densities and dopamine release, and [11C]2-carbomethoxy-3--(4-fluorophenyl)tropane 
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([11C]2-CFT) for the dopamine transporter.  A description of the PET measurement of 
dopamine synthesis capacity is given in Box 2.1  
 
Box 2.1 Indexing Dopamine Synthesis Capacity with PET (Adapted from 
supplementary material to Howes et al. 2012) 
Dopamine synthesis capacity can be indexed with PET using two radiolabeled homologues 
of l-3,4-dihydroxy-phenylalanine (L-DOPA): [-11C]L-DOPA ([11C]-DOPA) and 6-
[18F]fluoro-DOPA ([18F]-DOPA) (Kumakura et al. 2009; Garnett et al. 1983). Brain 
metabolism of radiolabeled-DOPA parallels that of endogenous L-DOPA (Cumming et al. 
1987).  In dopamine neurons, these radiotracers are converted by aromatic L-amino acid 
decarboxylase (AADC) into [11C]dopamine and 6-[18F]fluoro-dopamine, respectively, and 
trapped in vesicles in the nerve terminals ready for release (see review by Kumakura et al. 
2009).  AADC is a regulated enzyme and its activity in dopamine neurons is relative to other 
aspects of dopamine metabolism (Cumming et al. 1995). AADC is present in other 
monoaminergic neurons in addition to dopamine neurons (Snow et al. 1993). Nevertheless, 
radiolabeled-DOPA uptake in the striatum is predominantly due to dopaminergic 
innervation, is highly correlated with striatal dopamine levels in post mortem brains, and 
responds to experimental manipulation of brain dopaminergic systems (Cuming et al. 1997; 
Snow et al. 1993; Vernaleken et al. 2006; Gjedde et al. 1991). 
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2.3.2 Theoretical Basis of Ki (Patlak et al. 1983) 
Classical pharmacological studies of solute transfer across membranes have derived one of 
three transfer numbers: the extraction fraction, the influx constant (Ki) and the efflux constant 
(Ke).  Early experimental work typically involved administering the solute of interest into the 
blood stream and taking samples from the two biological compartments e.g. from the blood to 
the brain across the blood-brain barrier.  The calculation of Ki enables reliable quantification 
of solute transfer rates across the blood-brain barrier, except for rapidly transported solutes.  Ki 
had historically been calculated by measurement of the unidirectional flux rate across 
amphibian epithelia from a source solution at constant concentration such that Ki would be 
defined as the steady state flux rate of the solute across the membrane divided by the test solute 
concentration in the source solution.  Using the blood-brain barrier as an example, Ki would be 
defined as the steady state rate of solute flux across the blood-brain barrier from plasma at 
constant concentration divided by the solute plasma concentration.  Patlak et al. (1983) 
proposed a method for the graphical evaluation of Ki from multiple time uptake data when the 
source solution concentration is not constant as would occur in a bolus intravenous 
administration of solute compared to constant infusion, for example.    This model is thus well 
suited to measuring presynaptic dopamine synthesis capacity with [18F]-DOPA because: 
1) It enables the administration of a single bolus injection.  
2) Radiolabelled L-DOPA accumulates in presynaptic terminals where it is converted 
into dopamine, therefore allowing the measurement of the activity of the enzymes 
aromatic acid decarboxylase and DOPA decarboxylase.  
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For the purposes of this calculation, the net transfer of solute across the blood-brain barrier 
is assumed to be unidirectional (i.e. irreversible) throughout the entire experimental period, 
such that this model best fits a solute that is held or bound within the brain compartment by a 
biochemical process.  The equations derived from this model indicated that unidirectional 
influx could be examined by plotting uptake data from multiple measurements within the same 
subject in such a way as to determine whether the resultant curve has a linear phase.  A linear 
phase would therefore indicate that the net transfer process is unidirectional over the time 
period in question, such that the Ki can be calculated (Bradbury & Kleeman 1967).    
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2.3.3 Assumptions of the Patlak Model 
The Patlak model relies on the following assumptions: 
1. There is a single source for the solute, i.e. plasma (denoted by “p”), in the system. 
2. The plasma solute concentration is permitted to vary with time. 
3. Rapid exchange of the solute occurs between plasma and a tissue region comprised of 
n compartments.  The solute can flow freely from plasma into any of these 
compartments and back to plasma.  Therefore, solute transfer between plasma and this 
tissue region is exchangeable or reversible (denoted by “r”).  
4. The solute can enter a further compartment, upon which it cannot leave.  This region is 
the irreversible or bound region (denoted by “b”) that is treated mathematically as a 
single compartment.   
5. The solute within the exchangeable region can leave the region only by entering the 
plasma or the irreversible region.   
6. Solute transfer within the system obeys first-order kinetics, such that the rate constant 
for movement from the jth to the ith compartment denoted as “Kij”.  The validity of this 
assumption being enhanced by the use of trace amounts of radioligand.   
7. The solute does not alter the system. 
8. System metabolism of the solute only occurs in the irreversible region and produces a 
metabolite that is trapped in the irreversible region and is measurable. 
9. The solute is not initially present in the either the exchangeable or irreversible 
compartment.     
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2.3.4 Derivation of Ki 
In addition to the terms defined above, the following will be used in the equations 
detailed below: 
 t = time 
 A = n – 1 vector of the amount of model solute in each exchange compartment. 
 K = (n x n) matrix of the Kij rate constants 
 Q = n vector of rate constants from plasma to the exchangeable compartments (Kip) 
 Cp(t) = plasma tracer concentration. 
݀ܣ
݀ݐ ൌ ܭܣ ൅ ܥܳ௣ሺݐሻ 
Equation 1 Tracer accumulation in the reversible compartment. 
 
If G = (n × n) diagonal matrix of rate constants from the exchangeable to the bound regions 
(Kbi), Kbp is the rate constant for the direct movement of material from the plasma to the trap and U |n 
= (1….1), a(1 × n) vector, then the equation for the amount of material T in the irreversible region  is  
 
݀ܶ
݀ݐ ൌ ܷ
ᇱܩܣ ൅ ܭ௕௣	ܥ௣ 
Equation 2 
 
Cp is measurable from the experimental system, as is the total amount of material in the tissue 
samples (Am).  If Vp is the volume of the plasma in the tissue sampled then:  
ܣ݉ ൌ ܷᇱܣ ൅ ܶ ൅ ௣ܸܥ௣ 
Equation 3 
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Equation 1 can be solved (Hearon, 1963): 
ܣ ൌ ݁௄௧ න ܥ௣݁ି௄௧
௧
଴
݀߬ܳ 
Equation 4 
 
Substituting equation 4 into equation 2 and then solving the resultant equation yields: 
ܶ ൌ ܷ′௡ܩ න ݁௄ఛ න ݁௄ఏ݀ߠ݀߬ܳ ൅ ܭ௕௣ න ܥ௣݀߬
௧
଴
ఛ
଴
௧
௢
 
Equation 5 
 
Integrating equation 5, inserting equations 3 and 4, and the rearranging yields: 
 
ܣ௠ ൌ ൫െܷᇱ௡ܩܭିଵ ൅ ܭ௕௣൯න ܥ௣݀߬ ൅	ܷᇱ௡ሺܩܭିଵ
௧
଴
൅ ܫሻܣ ൅ ௣ܸܥ௣ 
Equation 6 
 
If ܥ௣ is constant, A will approach a finite limit as t  ∞, since the real parts of the 
eigenvalues of K are negative (Hearon, 1963).  So, when t  ∞:  
ܣ௠൫ܥ௣ ൌ constant൯ ൌ 	െܷᇱ௡ܩܭିଵܳ ൅ ܭ௕௣ 
Equation 7 
 
As defined above, the rate of uptake for constant plasma level is given by KiCp.  Therefore, 
equation 7 shows: 
ܭ௜ ൌ 	െܷᇱ௡ܩܭିଵܳ ൅ ܭ௕௣ 
Equation 8 
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Therefore, equation 6 may written as: 
ܣ௠ ൌ 	ܭ௜ න ܥ௣݀߬ ൅	ܷᇱ௡ሺܭ ൅ ܩሻ
௧
଴
ܭିଵܣ ൅ ௣ܸܥ௣ 
Equation 9 
 
As detailed in Patlak et al. (1983), equation 9 can be worked through further such that:  
ܣ௠೟ಭ೟∗ ൌ ܭ௜ න ܥ௣݀߬ ൅ ሺ ଴ܸ ௣ܸሻ
௧
଴
 
Equation 10 
 
Where t* is a sufficient length of time after which the amounts in each of the components of 
the exchangeable region “follow” the plasma concentration and V0 meets the following criteria:  
0≤ V0 ≤ (steady-state space of A) ≤ (space of A) 
The curve produced by plotting 
஺೘
஼೛  vs. ׬ ܥ௣݀߬/ܥ௣
௧
଴  starts at the origin and becomes a straight line with 
slope Ki by t=t*. 
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2.4 Power Calculations 
 
In a recent of test-retest reliability of [18F]-DOPA PET (Egerton et al. 2010) striatal 
Kicer had an intra-class correlation coefficient of approximately 0.9 [mean (SD) Kicer = 
0.01417(0.00127)min-1 (test) and 0.01381(0.00127)min-1 (re-test)].  Previous [18F]-DOPA 
uptake work by Howes et al. found an effect size of 1.25 in patients with schizophrenia (which 
compares well with previous studies: 1.89 [Meyer-Lindenberg et al. 2002]; 1.57 [McGowan et 
al. 2004] and 0.75 in patients exhibiting prodromal symptoms of psychosis [Howes et al. 2009].  
On this basis, it was reasonable to anticipate an effect size of 0.80 in both the Cannabis Group 
vs. Controls and the “HPSS” vs. “LPSS” comparisons (equivalent to 8% ±10 difference in 
[18F]-DOPA uptake between the groups).  Therefore, to achieve a power of 0.8, with an effect 
size of 0.8, p=0.05, using independent t-tests, 21 subjects in each group will be required.   
 
2.5 Blinding 
PET imaging was conducted on the same participant visit to the research institute to 
conduct psychiatric interviews and so it was not possible to conduct image acquisition blind 
to group status.  However, image analysis was conducted blind to group status.   
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2.6 Pre-PET Scan Acquisition (all subjects) 
Subjects were asked to fast and abstain from cannabis for 12 hours, and to refrain from 
smoking tobacco for 2 hours before imaging.  The time period of 12 hours was chosen so that 
cannabis users would not be acutely intoxicated on the day of the PET scan whilst not 
significantly interfering with cannabis users normal pattern of drug use.   
 
On the day of the PET scan, urine drug screen (Monitect HC12, Branan Medical 
Corporation, Irvine, California) confirmed no recent drug use (other than cannabis in the user 
group) and a negative urinary pregnancy test was required in all female subjects.  Subjects 
received carbidopa 150 mg and entacapone 400 mg orally 1 hour before imaging (Sawle et al. 
1994) to reduce the formation of radiolabelled [18F]-DOPA metabolites (Cumming et al. 1993; 
Guttman et al. 1993).   
 
2.7 [18F]-DOPA Production 
For the cannabis study, [18F]-DOPA was produced by GE Imanet using a 17 MeV GE 
PET-trace cyclotron.  The gas target was filled with 18O2 and bombarded at 40 A for 30 
minutes followed by a passivation bombardment of 0.1% F2 in argon at 20 A for 20 minutes.   
This produced [18F]-F by the 18O(p,n) 18F reaction.  An electrophilic fluorination procedure was 
then used to synthesise 6-[18F]fluoro-L-DOPA on a GE tracerlab synthesis platform.  In brief, 
[18F]F was bubbled through a solution of 6-Trimethylstannyl-L-DOPA (60mg) stirring in 
Deutero-chloroform (5ml) over 20mins at 5°C.  6M HCL (2ml) was added and the Chloroform 
evaporated at 70°C (Forsback et al. 2009).  The resulting aqueous mixture was heated at reflux 
for 10 minutes and then allowed to cool.  The cooled crude mixture was purified by semi-
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preparative high pressure liquid chromatography using a polymer X column eluted with 
ammonium acetate buffer.   The peak corresponding to [18F]-L-DOPA eluted at 15 minutes was 
stabilised with 1mg ascorbic acid and sodium phosphate dibasic.  Typical yields were 2.96–
3.33GBq.  For quality assurance, a sample was analysed by reverse phase high-pressure liquid 
chromatography to confirm identity and purity.  To be able to proceed with the injection, a 
radiochemical purity of 95.0% or higher was required.   
 
For the stress study, [18F]-DOPA was produced at Imanova using an 11 MeV Siemens 
RDS Eclipse HP cyclotron.  The gas target was filled with 18O2 and bombarded at 40 µA for 
40 minutes followed by a passivation bombardment of 0.8% F2 in argon at 20 µA for 20 
minutes.   This produced [18F]-F by the 18O(p,n) 18F reaction.  An electrophilic fluorination 
procedure was then used to synthesise 6-[18F]fluoro-L-DOPA on an Eckert & Ziegler 
Pharmtracer synthesis platform.  In brief, [18F]F2 was bubbled through a solution of 6-
Trimethylstannyl-L-DOPA (60mg) stirring in Deutero-chloroform (5ml) over 15mins at 5°C.  
4M HCL (1ml) was added and the Chloroform evaporated at 70°C (Forsback et al. 2009).  A 
further addition of 4M HCl (3ml) was heated at reflux for 15 minutes.  The cooled crude 
mixture was purified by semi-preparative high pressure liquid chromatography using a polymer 
X column eluted with sodium dihydrogen phosphate buffer.   The peak corresponding to [18F]-
L-DOPA eluted at 20 minutes was stabilised with 10mg ascorbic acid and sodium phosphate 
dibasic.  Typical yields were 0.8–1.5GBq.  For quality assurance, a sample was analysed by 
reverse phase high-pressure liquid chromatography to confirm identity and purity.  To be able 
to proceed with the injection, a radiochemical purity of 95.0% or higher was required. 
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2.8 PET Scan Acquisition (Cannabis Study) 
All subjects underwent an [18F]-DOPA scan on an ECAT HR+ 962 PET scanner 
(CTI/Siemens) in 3D mode, with an axial field of view of 15.5cm, performed as previously 
reported (Lieberman et al. 1987).  Psychotic symptoms were assessed using the PANSS at the 
time of scanning.  Head position was marked and monitored via laser crosshairs and a camera, 
and minimized using a head-strap.  A 10-minute transmission scan was performed before 
radiotracer injection for attenuation and scatter correction.  Approximately 180 MBq of [18F]-
DOPA was administered by bolus intravenous injection 30 seconds after the start of PET 
imaging.  Emission data were acquired in list mode for 95 minutes, re-binned into 26 time-
frames (30-second background frame, four 60-second frames, three 120-second frames, three 
180-second frames, and fifteen 300-second frames).   
 
2.9 PET Scan Acquisition (Stress Study) 
All subjects (stress study) underwent an [18F]-DOPA PET scan, acquired on a Siemens 
Biograph HiRez XVI PET scanner (Siemens Healthcare, Erlangen, Germany).  Head position 
was marked and monitored via laser crosshairs and a camera, and minimized using a head-
strap.  A low-dose computed tomography scan (effective dose=0.2 mSv) was acquired for 
attenuation and model-based scatter correction.  Approximately 150 MBq of [18F]-DOPA was 
administered by bolus intravenous injection at the start of PET imaging.  Emission data were 
acquired in list mode for 95 minutes, re-binned into 34 time-frames (eight 15 second frames, 
three 60 second frames, five 120-second frames, and sixteen 300 second frames).   
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2.10 Method for Compensation of Movement Correction  
 
2.10.1 Raw Data 
 
No compensation for subject head movement was applied to the image. 
 
2.10.2 Frame-by-frame realignment  
 
To correct for head movement, non-attenuation-corrected dynamic images were de-
noised using a level 2, order 64 Battle-Lemarie wavelet filter (Turkheimer et al. 1999), and 
individual frames were realigned to a single frame with high signal to noise ratio acquired 10 
minutes after the [18F]-DOPA injection using a mutual information algorithm (Studholme et 
al. 1996).  Transformation parameters were then applied to the corresponding attenuation-
corrected frames, and the realigned frames were combined to create a movement-corrected 
dynamic image (from 6 to 95 minutes following [18F]-DOPA administration) for analysis.  
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2.11 Volume of Interest Definition 
After movement correction standardised volumes-of-interest (VOIs) were defined 
bilaterally in the whole striatum, the limbic (ventral), associative (pre-commisural dorsal 
caudate, precommisural dorsal putamen and postcommisural caudate), and sensorimotor 
(postcommisural putamen) striatal functional subdivisions and the cerebellar reference region 
in Montreal Neurologic Institute space (Martinez et al. 2003; Egerton et al. 2010).   An [18F]-
DOPA template was normalized with the VOI map to each individual PET summation (add) 
image using statistical parametric mapping software (SPM5, http://fil.ion.ucl.ac.uk/spm), 
allowing VOIs to be placed automatically on individual [18F]-DOPA PET images without 
observer bias.   
 
2.12 Kicer Calculation 
[18F]-DOPA uptake was calculated, relative to the cerebellum [Kicer (min-1)], for each 
VOI using the Patlak graphical analysis adapted for a reference tissue input function (Hartvig 
et al. 1991; Hartvig et al. 1997; Hoshi et al. 1993; Patlak et al. 1985).  Good test-retest reliability 
has been demonstrated for striatal [18F]-DOPA Kicer determined this way (Egerton et al. 2010). 
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2.13 Voxelwise Analysis 
For the study in cannabis users, the VOI analysis was complemented by an independent 
voxelwise analysis using a wavelet-based Patlak method (Turkheimer et al. 2006) as previously 
described (Howes et al. 2009). The parametric image for each participant was normalised into 
standard space using the participants PET summation image and the [18F]-DOPA template 
(Howes et al. 2009).  Statistical Parametric Mapping was conducted using SPM5 and a striatal 
mask defined according to previously described criteria (Egerton et al. 2010) to compare 
groups.  Results are presented corrected for multiple comparisons using random field theory as 
applied in SPM5 (p<0.05, corrected at the family-wise error rate).   
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2.14 Behavioural Task: The Salience Attribution Test (SAT) 
 
Figure 2.2 The Salience Attribution Test Subjects are presented with a fixation cross 
followed by a cue.  They then have to respond to the solid square as quickly as possible.  During 
50% of trials, participants are rewarded with money for faster responses, with the probability 
of the reward signaled by the cue. 
 
The SAT is a speeded-response game, with monetary reward, which measures 
responses to task-relevant and task-irrelevant cue features (Roiser et al. 2009; Roiser et al. 
2010).  These measures reflect incentive salience processing, described in Chapter 1, as the 
task-relevant cues are associated with a reward and task-irrelevant cues are not associated with 
reward. The “aberrant salience” measure from the SAT has displayed good face validity in 
previous results, with elevated scores both in high-schizotypy individuals, and in patients with 
schizophrenia suffering from delusions (Roiser et al. 2009).  Furthermore, using a factor 
analysis Schmidt & Roiser (2009) demonstrated the psychometric construct validity of the 
SAT.  In an fMRI study of the SAT, Roiser et al. (2010) found that cues associated with high 
relative to low reward probabilities elicited robust hemodynamic responses in brain networks 
implicated in motivational salience including the midbrain, in the vicinity of the ventral 
tegmental area, and regions targeted by its dopaminergic projections, i.e. medial dorsal 
thalamus, ventral striatum and prefrontal cortex.  Adaptive salience was strongly correlated 
with responses in the medial dorsal thalamus and polar PFC, whilst participants who showed 
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greater aberrant salience exhibited greater dorsolateral PFC responses, and reduced medial 
temporal gyrus (MTG) responses.  Data on the test-retest reliability of the measure are lacking.   
 
As per the description of the task by Roiser et al.: During the task, participants respond 
to a probe (a black square) after seeing 1 of 4 categories of cues (blue animals, red animals, 
blue household objects, and red household objects), which vary along 2 dimensions (colour 
and form); see figure 2.2.  Each cue set comprised 16 different pictures, each of which was 
presented once per block.  Subjects receive monetary reward (£0.05 to £1.00) on 50% of trials, 
with more money available for faster responses.  Feedback was given at the end of each trial.  
The probability of reward varies along one of the cue dimensions (such that if colour was the 
task-relevant dimension if blue stimuli were reward 87.5% of the time, red stimuli would be 
rewarded 12.5% of the time), but not for the other (such that if form was the task-irrelevant 
dimension both animals and household objects would be rewarded 50% of the time).  On 
rewarded trials where participants either made no response or responded after the probe had 
disappeared, the message “Missed: 5 pence” was displayed.  If participants responded 
prematurely (<100ms after the onset of the probe), the message displayed was “Too early: 5 
pence”.  On rewarded trials where participants responded before the probe disappeared, but 
slower than their mean RT from the practice block, the message “Hit – good: 10 pence” was 
displayed.  When participants responded more quickly than their mean practice RT, the 
message “Quick – very good: X pence” was displayed (for responses up to 1.5 standard 
deviations (SDs) faster than their practice mean RT) and “Very quick – excellent: X pence” 
(for responses over 1.5 SDs faster than their practice mean RT). The reward was scaled 
according to X=10+90×(mean RT – trial RT)/(3×SDF), up to a maximum of £1.00. For 
example, a response 1 SDF faster than the mean was reinforced with 40 pence, a response 2 
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SDFs faster was reinforced with 70 pence, and any responses 3 SDFs or faster than the mean 
were reinforced with 100 pence. The money won on each trial was added to the participant's 
running total for that block, Y, which was displayed underneath the feedback: ‘Total – £Y’. On 
reinforced trials, a 0.5 s tone sounded, frequency: (300+(10×X)) Hz. At the end of each block, 
participants indicated, using 10 mm visual analogue scales (VAS), their estimate of the 
reinforcement probabilities for each of the four different CSs. 
 
On the 50% of trials that were not rewarded, the message “Sorry – no money available” 
was displayed, regardless of the speed of response.  Participants were not informed of the 
contingencies between the different pictures and reward.  Participants could earn a maximum 
of £20 on the test (minimum £5).   
 
Category and reward probability contingencies are counterbalanced across participants 
and remained constant throughout the task.  Two experimental sessions (64 trials each) were 
performed each session.  The SAT provides measures of adaptive (relevant) and aberrant 
(irrelevant) motivational salience on the basis of visual analogue scale ratings (VAS; explicit 
salience) and reaction times (RTs; implicit salience).   
 
Before the main task, participants performed a computerised tutorial, with neither 
rewards nor cues, on which they were required to respond as quickly as possible to the onset 
of the probe only. The tutorial featured example displays, written instructions and test trials 
before the main test.  The tutorial was embedded with two practice sessions to familiarize 
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participants with the test and provide a measure of baseline response time (RT).  During 
practice sessions, a fixation cross appeared at the beginning of each trial.  Following a variable 
interval (minimum 0.5 s, maximum 1.5 s) the probe appeared, and participants responded by 
pressing a button as quickly as possible. Participants were instructed to try to respond as 
quickly as they were able to, and before the box disappeared. During the first practice session 
the probe was on the screen for randomized variable periods, with a maximum duration of 1.5 s, 
minimum duration 0.5 s and mean duration 1 s. Feedback was provided after 2 s as ‘Good’ if 
the participant responded before the box disappeared, ‘Try to respond faster’ if they responded 
after the box disappeared, ‘Too early’ if they responded before the box appeared, and ‘No key 
pressed’ if they made no response. On the second practice session, the mean probe duration 
was set to be the mean RT from the first, ensuring participants were responding as quickly as 
possible and to yoke task difficulty to individual performance, such that difficulty in the active 
task was calibrated on a participant-by-participant basis. The standard deviation (s.d.) of the 
fastest half of the trials (SDF) was also calculated, and was used to set the minimum and 
maximum probe durations for the second practice session (mean from first practice 
session±2×SDF). For the main test, the mean, minimum and maximum probe durations were 
calculated from the second practice session in the same way. No monetary reinforcement was 
provided during the practice sessions. 
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2.15 SAT Trial Structure 
A fixation cross was presented at the beginning of each trial. After 1 s, while the 
fixation-cross remained on-screen, one of the four cues was displayed at the left and right of 
the screen and remained on-screen until the end of the trial. After a period of time that varied 
randomly across trials (between 3.5 and 4.5 s) the probe appeared, replacing the fixation-cross, 
and participants attempted to respond before it disappeared using the index finger of their right 
hand on a button-box. The onset of the probe was therefore unpredictable, ensuring that 
participants were unable to anticipate its appearance. The duration of the probe also varied 
randomly across trials, and was calibrated for each participant separately from their own 
practice session data. After 2.25 s feedback was presented for 1.5 s as described above.  On 
rewarded trials, an auditory tone with a frequency proportional to the amount of money won 
on that trial sounded at feedback.  After feedback, a blank screen of variable duration was 
inserted to result in a constant inter-trial interval of 9.25 s. 
 
Four different versions of the SAT were used, each with a different stimulus feature 
(blue, red, animal or household object) reinforced with high probability. Each participant was 
administered the same version for both blocks of the SAT. 
Two measures of motivational salience were calculated for each block. Adaptive salience was 
defined in two ways: behaviourally (implicit measure) and subjectively (explicit measure). RT 
adaptive salience (implicit) was defined as the speeding of responses on high-probability-
reinforcement trials relative to low-probability-reinforcement trials (collapsing across the task-
irrelevant stimulus dimension), and VAS adaptive salience (explicit) was defined as the 
increase in probability rating for high-probability-reinforcement trials relative to low-
probability reinforcement trials (again, collapsing across the task-irrelevant stimulus 
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dimension). The aberrant salience measures were defined as follows: implicit aberrant salience 
is the absolute difference in reaction times between the task-irrelevant cues and task-relevant 
cues; explicit aberrant salience is the difference in visual analogue scale rating, i.e. the 
subjective probability ratings of reward, between the task-irrelevant stimulus dimension.  These 
measures are averaged across the test for each participant. The aberrant salience measures are 
defined as any deviation from equal reaction time or subjective reinforcement probability rating 
of the task-irrelevant stimulus dimension away.  Therefore, it does not make a difference to the 
measure whether the deviation is positive or negative. Therefore aberrant salience was always 
positive, whereas adaptive salience could be positive or negative. The number of premature 
responses and omissions were also recorded for each stimulus type on each block. 
 
2.16 Statistical Analysis 
Data were analysed using the Statistical Package for the Social Sciences, version 21 
(IBM, Armonk, NY, USA).  Statistical significance was defined as p<0.05 (two-tailed) 
throughout.  Normality of distributions was assessed using the one-sample Kolmogorov-
Smirnov test.  Between-group comparisons were made with two-tailed independent t-tests for 
normally distributed data and Mann-Whitney U tests for non-normally distributed data.  
Relationships between Kicer, levels of cannabis use and cannabis-induced psychotic-like 
symptom severity were tested using Pearson’s product-moment correlation coefficient.  
Potential confounders were explored using a single ANCOVA with subject group as the fixed 
factor; Kicer as the dependent variable and confounders as covariates.  Pearson’s product-
moment correlation coefficient to determine if there was a relationship between Kicer and 
cannabis use and stressors.  The primary PET outcome measure was Kicer in the whole striatum.  
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Exploratory analyses were conducted in the striatal sub-divisions (presented uncorrected for 
multiple comparisons).   
 
For the SAT, SAT data were analyzed using repeated-measures analysis of variance.  
Block (1 / 2) was the within-subjects variable and Group (cannabis user / control) was the 
between-subjects variable.  Normality of distributions was assessed using the one sample 
Kolmogorov-Smirnov test.   Salience outcome measures were assessed for statistically 
significant skew.  RT and VAS aberrant salience scores from the SAT were square root 
transformed prior to analysis to reduce skew, though untransformed values are presented in the 
text, figures and tables for clarity. Relationships between data were assessed using Pearson’s r 
product–moment correlation coefficient for normally distributed data and Spearman’s  rank 
correlation was used for non-normally distributed data. To determine whether subjects 
consistently assigned aberrant salience to any particular stimulus feature 2 tests were 
employed. 
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2.17 Summary 
Dopamine synthesis capacity will be compared between cannabis users who experience 
a transient increase in psychotic-like symptoms and non-user controls, and between individuals 
with a high exposure to psychosocial stress and individuals with a low exposure to psychosocial 
stress.  Dopamine synthesis capacity will be indexed as the influx rate constant Kicer, and 
measured with 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine ([18F]-DOPA) positron emission 
tomography.   
 
Adaptive and aberrant motivational salience will be compared between cannabis users 
and non-user controls using the Salience Attribution Test (SAT).  The SAT provides 
behavioural measures of motivational salience during functional magnetic resonance imaging 
to assess neural haemodynamic responses to relevant and irrelevant task features.    
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Chapter 3:  
Dopamine Synthesis Capacity  
and its Relationship to Cannabis-Induced Psychotic Symptoms 
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3.1 Introduction 
 
Cannabis is the most widely used illicit drug in the world and users are at increased risk 
of schizophrenia in a dose-dependent fashion (Moore et al. 2007).  Dopamine dysfunction is 
thought to underlie the development of psychosis (Howes & Kapur 2009).   A recent meta-
analysis has found elevated striatal dopamine synthesis capacity in people with schizophrenia 
(Howes et al. 2012).  It has been proposed, though never directly tested, that cannabis may 
increase the risk of schizophrenia by creating a hyperdopaminergic state in the striatum 
(Voruganti et al. 2001). 
 
3.2 Hypotheses 
 
1) Cannabis users who experience cannabis-induced psychotic-like symptoms have 
increased striatal dopamine synthesis capacity compared to non-user controls.   
 
2) Within the cannabis user group: elevated dopamine synthesis capacity is directly related 
to a higher severity of transient psychotic phenomena. 
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3.3 Materials and Methods 
 
3.3.1 Research Ethics 
The study was conducted according to the research ethics that were described in 
Chapter 2.   
 
3.3.2 Power Calculation 
 
Baseline F-DOPA uptake is the primary measure and the study is powered for this 
variable.  In a study of the test-retest reliability of F-DOPA PET (Egerton et al. 2010) striatal 
F-DOPA uptake had a within group intra-class correlation coefficient of approximately 0.9.  A 
previous study of F-DOPA uptake in patients with schizophrenia by Howes et al. (2009) found 
an effect size of 1.25 in patients with schizophrenia (which compares well with effect sizes 
from other studies, e.g. 1.89 [Meyer-Lindenberg et al. 2002] and 1.57 [McGowan et al. 2004]) 
and 0.75 in patients exhibiting prodromal symptoms of psychosis (Howes et al. 2009).  On this 
basis an effect size of 0.80 in the cannabis user group versus non-user controls was anticipated.  
To achieve a power of 0.8, with an effect size of 0.8 and statistical significance of p=0.05 (two-
tailed) using an independent t-test, it was calculated that 21 subjects would be required in each 
group. 
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3.3.3 Study Population 
The study population including inclusion and exclusion criteria were described in 
Chapter 2.   
 
3.3.6 PET Scans 
 
Subjects were asked to fast and abstain from cannabis for 12 hours and to refrain from 
smoking tobacco for 2 hours before imaging.  On the day of the PET scan, urine drug screen 
(Monitect HC12, Branan Medical Corporation, Irvine, California) confirmed no recent drug 
use (other than cannabis in the user group), and a negative urinary pregnancy test was required 
in all female subjects.  Psychotic symptoms were assessed using the Positive and Negative 
Syndrome Scale at the time of scanning.  No subjects had psychotic symptoms at the time of 
scanning (mean [SD] Positive and Negative Syndrome Scale positive score cannabis users = 
7.3 [0.5]; control subjects = 7.2 [0.4]).  Subjects received carbidopa 150 mg and entacapone 
400 mg orally 1 hour before imaging (Sawle et al. 1994) to reduce the formation of radiolabeled 
[18F]-DOPA metabolites (Cumming et al. 1993;  Guttman et al. 1993).  Head position was 
marked and monitored via laser crosshairs and a camera and minimized using a head-strap.  A 
10-minute transmission scan was performed before radiotracer injection for attenuation and 
scatter correction. Approximately 180 MBq of [18F]-DOPA was administered by bolus 
intravenous injection 30 seconds after the start of PET imaging.  Emission data were acquired 
in three-dimensional mode for 95 minutes, rebinned into 26 timeframes (30-second background 
frame, four 60-second frames, three 120-second frames, three 180-second frames, and fifteen 
300-second frames). 
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3.4 Results 
3.4.1 Subject Characteristics and Scan Parameters 
 
Twenty cannabis users were recruited to the study.  Owing to tomograph malfunction 
during one scan, complete data were available on nineteen users.  All cannabis users consumed 
the drug as a spliff. The mean (SD) age of first cannabis use was 15.5 (1.6) years, and the mean 
(SD) duration of at least weekly use was 4.7 (3.1) years.  The median (interquartile range) time 
taken to smoke an eighth and lifetime exposure to cannabis was 4.0 (13.5) days and 2340 (6240) 
spliffs, respectively.  Within the user group, the median (interquartile range) time between the 
scan and the last cannabis exposure and self-reported cannabis-induced psychotic-like 
symptoms was 14.0 (23.8) hours.  Ten users met DSM-IV criteria for cannabis dependence (n 
= 5) or abuse (n = 5). Mean (SD) time to smoke an eighth was 2.3 (2.2) days in users who met 
dependency/abuse criteria and 6.9 (4.7) days in users who did not meet criteria.  Mean (SD) 
age of first cannabis consumption was 14.8 (1.6) years in users who met dependency/abuse 
criteria, and 16.2 (1.3) years in users who did not meet criteria.  Nineteen control subjects were 
matched to the user group for age (±5 years) and sex.  Subjects’ characteristics are reported in 
Table 3.1. Urine drug screen was positive for THC and negative for all other substances 
(amphetamine, opiates, cocaine, methamphetamine, benzodiazepines) in every cannabis user 
and negative for all drugs (including cannabis) in every control subject. There was a significant 
group difference in current cannabis consumption, as expected, and also in tobacco and ecstasy 
use (Table 3.1). 
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Table 3.1 Sample characteristics and scan parameters 
 Controls (n=19) Cannabis Users (n=19) pa 
Sample characteristic     
Age (years) [mean(SD)] 22.3 (2.8) 20.8 (1.7) 0.07 
Sex (n) 2 female, 17 male 2 female, 17 male 1.00 
Handedness (n) 2 left, 17 right 4 left, 15 right 0.37 
Ethnicity (n) 4AB, 3BB, 1ME, 11WB 4AB, 15WB 0.16b 
Current Drug Usec,d    
 
Cannabis users (n) 
 
0 users, 19 non-users 
 
19 users, 0 non-users 
 
1.00 
Cannabis use (grams  of cannabis/month) 
[median(IQR)] 
0.0 (0.0) 26.3 (90.0) 0.00 
THC content of cannabis (%) [mean(SD)] - 8.7 (3.8) - 
Time since last cannabis exposure (hours) 
[median(IQR) 
- 14.0 (23.8) - 
Time taken to smoke an ‘eighth’ of cannabis (days) 
[median(IQR)] 
- 4.0 (13.5) - 
Age of onset of regular cannabis use (years) 
[mean(SD)] 
- 15.5 (1.6) - 
Tobacco cigarette smokers (n) 8 users, 11 non-users 15 users, 4 non-users 0.02 
Tobacco use in whole sample (cigarettes/day) 
[median(IQR)] 
0.0 (0.0) 4.0 (7.0) 0.01 
Tobacco use in smokers (cigarettes/day) 
[median(IQR)] (tobacco users) 
1.0 (9.0) 7.0 (8.0) - 
Alcohol use in last 3 months (n) 19 users, 0 non-users 19 users, 0 non-users 1.00 
Alcohole use (UK alcohol units/week) 
[median(IQR)] 
9.0 (12.0) 12.0 (21.0) 0.34 
MDMA/ecstasy use in last 3 months (n) 5 users, 14 non-users 11 users, 8 non-users 0.05 
MDMA/ecstasy use in whole sample (grams of 
MDMA/month) [median(IQR)] 
0.0 (0.0) 0.3 (1.0) 0.02 
MDMA/ecstasy use in MDMA/ecstasy users 
(grams of MDMA/month) [median(IQR)] 
0.3 (0.8) 1.0 (1.7) - 
Cocaine use in last 3 months (n) 3 users, 16 non-users 3 users, 16 non-users 1.00 
Cocaine use in whole sample (grams of 
cocaine/month) [median(IQR)] 
0.0 (0.0) 0.0 (0.0) 0.60 
Cocaine use in cocaine users (grams of 
cocaine/month) [median(IQR)] 
<0.1 (<0.1) <0.1 (1.0) - 
Amphetamine use in last 3 months (n) 1 user, 18 non-users 4 users, 15 non-users 0.15 
Amphetamine use in whole sample (grams of 
amphetamine/month) [median(IQR)] 
0.0 (0.0) 0.0 (0.0) 0.27 
Amphetamine use in amphetamine users (grams of 
amphetamine/month) [median(IQR)] 
<0.1 0.5 (0.3) - 
Ketamine use in last 3 months (n) 1 user, 18 non-users 6 users, 13 non-users 0.04 
Ketamine use in whole sample (grams of 
ketamine/month) [median(IQR)] 
0.0 (0.0) <0.1 (0.5) 0.10
Ketamine use in ketamine users (grams of 
ketamine/month) [median(IQR)] 
<0.1 1.5 (2.9) - 
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Psilocybin use in last 3 months (n) 1 user, 18 non-users 1 user, 18 non-users 1.00 
Psilocybin use in whole sample (grams of “magic 
mushrooms”/month) [median(IQR)] 
0.0 (0.0) 0.0 (0.0) 0.80 
Psilocybin use in psilocybin users (grams of 
“magic mushrooms”/month)  
<0.1 2.0 -   
Scan parameter    
Injected dose (MBq) [mean(SD)] 180.6 (7.2) 184.4 (5.2) 0.11 
Specific activity (MBq/µmol) [mean(SD)] 31.1 (17.3) 30.5 (14.0) 0.92 
Whole striatal volume (mm3) [mean(SD)] 17,587.82 (1729.50) 17,942.90 (1286.73) 0.48 
Associative striatal volume (mm3) [mean(SD)] 10,801.19 (1134.46) 10,772.76 (1161.24) 0.94 
Limbic striatal volume (mm3) [mean(SD)] 2,080.30 (234.77) 2,276.51 (977.85) 0.40 
Sensorimotor striatal volume (mm3) [mean(SD)] 4,706 (106.60) 4668.98 (443.16) 0.80 
Abbreviations: AB, Asian British; BB, Black British; MDMA, 3,4-methylenedioxy-N-methylamphetamine (“Ecstasy”); ME, Mixed 
Ethnicity; WB, White British 
a Independent-samples t-tests for variables with normal data distributions; Mann-Whitney U tests for variables with non-normal data 
distributions; 2-tests for dichotomous variables 
b Groups were compared on a dichotomised ethnicity variable (white British vs ethnic minority). 
c Drug use reported in 3 months prior to scan.  Drug user defined as any drug use in the 3 months prior to scan.   
d There was no reported lysergic acid diethylamide, benzodiazepine, opiate or methamphetamine use in the 3 months before scanning. 
e 1 UK alcohol unit = 10mL (~7.88g) alcohol  
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There was no significant group difference in the amount of radioactivity or specific 
activity injected (table 3.1).  There was no significant difference in whole striatal or subdivision 
volumes between the groups.  There was no relationship between age and Kicer in the striatum 
or its subdivisions in the whole sample or in either group (table 3.2). 
 
Table 3.2  The relationship between [18F]-DOPA Kicer and age at PET scan
VOI Whole sample Controls (n=19) Cannabis Users (n=19)  
 r p r p r P  
STR 0.05 0.75 0.00 1.00 -0.17 0.47  
AST 0.06 0.71 0.02 0.92 -0.17 0.48  
LST -0.07 0.69 -0.14 0.56 -0.22 0.36  
SMST 0.07 0.66 0.02 0.93 -0.10 0.68  
Abbreviations: AST, associative striatum; LST, limbic striatum; Kicer , influx rate constant; SMST, 
sensorimotor striatum; STR, whole striatum; VOI, Volume of Interest.   
 
3.4.2 Striatal Dopaminergic Function 
Kicer was significantly reduced in cannabis users relative to controls in the whole 
striatum (figure 3.1).  Secondary analysis in each striatal subdivision showed that this reduction 
reached significance in the limbic and associative subdivisions (table 3.3).  The finding of 
reduced Kicer in cannabis users remained significant after co-varying for other drugs used, with 
the amount of use of each of the drugs listed in table 3.1 included as separate covariates in the 
ANCOVA, in the whole striatum (F1,37=4.65, p=0.040) and its associative F1,37=5.00, p=0.034) 
and limbic (F1,37=7.358, p=0.011)  subdivisions.   
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Figure 3.1 Striatal dopamine synthesis capacity in regular cannabis users (n = 19) and nonuser 
control subjects (n = 19). Dopamine synthesis capacity was significantly reduced in cannabis 
users compared with nonusers (t36 = 2.54, p = 0.016). Error bars indicate standard deviations. 
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Table 3.3  [18F]-DOPA Kicer (min-1) by group
VOI Controls (n=19) Cannabis Users (n=19) Group comparisonsa Effect size 
 Mean (SD) mean (SD) tdf p (Cohen’s d) 
STR 0.0134 (0.0009) 0.0127 (0.0007) 2.5436 0.016 0.85 
AST 0.0127 (0.0009) 0.0121 (0.0007) 5.5436 0.015 0.85 
LST 0.0138 (0.0009) 0.0132 (0.0008) 2.2336 0.032 0.74 
SMST 0.0146 (0.0014) 0.0139 (0.0008) 1.8536 0.070 0.62 
Abbreviations: AST, associative striatum; LST, limbic striatum; Kicer , influx rate constant; SMST, 
sensorimotor striatum; STR, whole striatum; VOI, Volume of Interest  
aIndependent-samples t-tests. 
 
 
Voxel-based analysis confirmed reduced Kicer in the cannabis user group relative to 
non-user controls with peak statistical significance in the right putamen (Figure 3.2).   There 
were no voxels where there was a significant elevation in Kicer in cannabis users relative to 
controls. 
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Figure 3.2 – Reduced striatal dopamine synthesis capacity in regular cannabis users 
relative to non-user controls. The image shows a statistical parametric map of significant 
reductions (p<0.05) in dopamine synthesis capacity, relative to healthy comparison subjects 
(n=19), in regular cannabis users who experienced transient psychotic-like symptoms (n=19).  
The most significant reduction reported by SPM software was in the right putamen (MNI 
coordinates: 28,6,-8) (p=0.048, corrected at the family-wise error rate).  The colour bar 
indicates the t statistic for each voxel. 
 
 
 
183 
 
3.4.3 The Relationship between Striatal Dopamine Synthesis Capacity and Cannabis 
Use  
 
Within the cannabis user group, greater levels of current cannabis use (less time to 
smoke an ‘eighth’ of cannabis) were associated with lower Kicer in the whole striatum (r=-0.77, 
p<0.001; figure 3.3A).  Secondary analysis in each striatal subdivision showed that this pattern 
reached significance in the associative (r=-0.68, p=0.001) and sensorimotor (r=-0.84, p<0.001) 
subdivisions, but not the limbic subdivision (r=-0.26, p=0.290).  In addition, there was a 
significant correlation between age of onset of cannabis use and Kicer in the whole striatum 
(r=0.51, p=0.027; figure 3.3B) and in its associative subdivision (r=0.56, p=0.013), which 
remained significant after controlling for current age (r=0.49, p=0.04[whole striatum]; r=0.54, 
p=0.02 [associative]), with no significant correlation in the sensorimotor (r=0.34, p=0.158) or 
limbic (r=0.36, p=0.126) subdivisions.  There was no significant correlation between age of 
first cannabis use and current cannabis use (r=0.16, p=0.52).   
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Figure 3.3A (top) - The correlation between level of cannabis use (time to smoke an “eighth” 
[~3.5g] of cannabis; days), and striatal dopamine synthesis capacity, indexed as Kicer (min-1), 
in cannabis users (r=-0.77, p<0.001).  
Figure 3.3B (bottom) - The correlation between age of onset of cannabis use and Kicer in the 
whole striatum (r=0.51, p=0.027), which remained significant when controlling for current age 
(r=0.49, p=0.04). 
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Across the whole sample and within the control group there was no significant 
difference between Kicer in tobacco smokers and non-tobacco smokers in any of the regions 
examined (all p-values>0.1).  Within the whole sample and within each group there was no 
relationship between Kicer and daily cigarette use amongst tobacco cigarette smokers in the 
whole striatum (r=0.26, p=0.91 [whole sample], r=0.10, p=0.81 [controls]; r=0.18, p=0.52 
[cannabis users]) and its functional subdivisions (table 3.4).  Within the whole sample and 
within each group there were no significant relationships (all p-values>0.1) between whole 
striatal Kicer and other substances used (listed in table 3.1).   
Table 3.4 The relationship between [18F]-DOPA Kicer and daily cigarette use amongst cigarette smokers 
VOI Whole sample (n=23) Controls (n=8) Cannabis Users (n=15)  
 r P r p r p  
STR 0.03 0.91 0.19 0.65 0.18 0.52  
AST 0.12 0.60 0.15 0.73 0.31 0.26  
LST 0.08 0.73 0.29 0.49 0.22 0.42  
SMST -0.16 0.46 -0.02 0.97 -0.17 0.55  
 
To examine whether cannabis dependency/abuse was associated with reduced Kicer the 
cannabis user group was divided into subjects that met DSM-IV diagnostic criteria for cannabis 
dependency or abuse (n=10), and those who did not meet criteria (n=9).  One-way ANOVA 
found a significant effect of group on whole striatal Kicer (F2,37=4.02, p=0.027, Figure 3.4).  
Post hoc t-tests showed significant differences between the cannabis dependency/abuse and 
non-dependency/non-abuse cannabis user sub-groups (t17=2.80, p=0.012) and between the 
cannabis dependency/abuse sub-group and controls (t27=2.67, p=0.013), but not between the 
non-dependency/non-abuse sub-group and the control group (p=0.60).  When examining the 
striatal subdivisions, significant differences in Kicer between the cannabis dependency/abuse 
and non-dependency/non-abuse cannabis user sub-groups were observed in the associative 
subdivision only (t17=2.89, p=0.010).   
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Figure 3.4 - Striatal dopamine synthesis dopamine synthesis capacity in subjects who met 
DSM-IV criteria for a diagnosis of Cannabis Dependence or Abuse (n=10), regular 
cannabis users who did not meet diagnostic criteria (n=9) and non-user controls (n=19). 
There were significant differences between cannabis dependence/abuse vs. cannabis users who 
did not meet criteria (t17=2.80, p=0.012) and cannabis dependence/abuse vs. control group 
(t27=2.67, p=0.013).  There was no significant difference between controls vs. cannabis users 
who did not meet dependence/abuse criteria (t26=0.54, p=0.60).  Error bars indicate standard 
deviations. 
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3.4.4 The Relationship between Striatal Dopamine Synthesis Capacity and Cannabis-
Induced Psychotic Symptoms 
Within the cannabis user group the mean (SD) increase in PSI psychotic symptom 
subscale score after consuming cannabis was 9.9 (5.1).  There was no significant correlation 
between striatal Kicer and increase in transient psychotic-like symptoms following cannabis use 
[r=0.32, p=0.19] (Figure 3.5).  Within users there was no significant relationship between Kicer 
and both the positive and negative subscales of the PANSS (p>.1).   
 
 
Figure 3.5 - The relationship between striatal Kicer and transient induction of cannabis-
induced psychotic-like symptoms in the cannabis users.  There was no significant 
relationship between the two variables (r=0.32, p=0.19). 
 
 
188 
 
3.4.5 Summary 
These results show that regular long-term cannabis use is associated with a dose-
dependent reduction in dopamine synthesis capacity in the corpus striatum, particularly in those 
meeting diagnostic criteria for cannabis abuse or dependence.  However, no relationship was 
found between dopaminergic function and cannabis-induced psychotic-like symptoms.  
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Chapter 4:  
Salience Attribution and its Relationship to Cannabis-Induced Psychotic Symptoms 
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4.1 Introduction 
 
Cannabis is a widely used recreational drug and users are dose-dependently at increased 
risk of schizophrenia (Moore et al. 2007).  Psychosis has been proposed to reflect a state of 
aberrant salience processing (Kapur 2003) and aberrant salience has been related to the 
presence of delusions in medicated patients with schizophrenia (Roiser et al. 2009).  Likewise, 
individuals at ultra-high risk of psychosis demonstrate aberrant salience processing, the degree 
of which has been related to the severity of delusion-like symptoms (Roiser et al. 2013).  Since 
long-term regular cannabis users are at epidemiological risk of psychosis (Moore et al. 2007), 
salience processing may be disrupted in this group.  However, salience processing has not 
previously been investigated in this group.   
 
In this chapter salience processing is investigated in cannabis users who experience 
transient cannabis-induced psychotic-like symptoms compared to non-user controls using the 
Salience Attribution Task (Roiser et al. 2009).  The SAT is a probabilistic reward learning task 
utilizing cue stimuli that vary along two dimensions, one task-relevant and one task-irrelevant.  
During the task, participants respond to a probe after seeing 1 of 4 categories of cues (blue 
animals, red animals, blue household objects, and red household objects), which vary along 2 
dimensions (colour and form); as described in Chapter 2.    Participants receive monetary 
reward (£0.05 to £1.00) on 50% of trials, with more money available for faster responses.  
Feedback was given at the end of each trial. The probability of reward varies along one of the 
cue dimensions (such that if colour was the task-relevant dimension if blue stimuli were reward 
87.5% of the time, red stimuli would be rewarded 12.5% of the time), but not for the other 
(such that if form was the task-irrelevant dimension both animals and household objects would 
be rewarded 50% of the time).  ‘Adaptive’ reward learning refers to differences in reaction 
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times (the implicit measure of learning) and subjective ratings on a visual analogue scale (the 
explicit measure of learning) along the task-relevant cue dimension, i.e. for high-probability 
reward cue features relative to low-probability reward cue features. ‘Aberrant’ reward learning 
is defined similarly, but along the task-irrelevant dimension, i.e. differences in ratings or 
reaction times between cue features that are both associated with 50% probability of reward 
give rise to aberrant explicit and implicit measures respectively.  
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4.2 Hypotheses 
 
3. Cannabis users who experience cannabis-induced psychotic-like symptoms will show 
elevated levels of aberrant salience compared to non-user controls, indicated by reduced 
implicit adaptive salience and elevated implicit salience measures of the SAT. 
 
4. Within the cannabis user group, aberrant implicit and explicit salience will be directly 
related to a greater severity of transient psychotic phenomena. 
 
Exploratory hypotheses: 
 
A. Cannabis users who meet DSM-IV diagnostic criteria for cannabis dependence or abuse 
will exhibit elevated aberrant implicit salience compared to users who do not meet 
dependence or abuse criteria. 
 
B. There will be a direct relationship between dopamine synthesis capacity and implicit 
aberrant salience processing.   
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4.3 Materials and Methods 
 
4.3.1 Research Ethics 
The study was conducted according to the research ethics that were described in 
Chapter 2.   
 
4.3.2 Power Calculation 
 
Explicit aberrant salience is the primary measure and the study is powered for this 
variable.  In a previous study comparing aberrant salience in people with schizophrenia 
compared to controls (Roiser et al. 2009), explicit aberrant salience was elevated in the patient 
group with a Cohen’s d effect size of 1.6.  Using G*Power software, an a priori power 
calculation was conducted  and it was found that in order to achieve a power of 0.8, with an 
expected effect size of 1.6 and alpha set at p<0.05 (two-tailed), using an independent t-test, it 
was calculated that at least 8 participants would be required in each group. 
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4.3.3 Study Population 
The study population including inclusion and exclusion criteria were described in 
Chapter 2.   
 
 
4.3.4 Salience Attribution Test 
 
The Salience Attribution Test (SAT) was described in Chapter 2.   
 
4.3.5 Statistical Analysis 
 
Data were analyzed using the Statistical Package for the Social Sciences, version 21 
(IBM, Armonk, NY, USA).  Demographic data were analyzed using independent samples t 
tests and 2 tests.  SAT data were analyzed using repeated-measures analysis of variance 
(ANOVA).  Block (1 / 2) was the within-subjects variable and Group (cannabis user / control) 
was the between-subjects variable.  Normality of distributions was assessed using the one 
sample Kolmogorov-Smirnov test.   Salience outcome measures were assessed for statistically 
significant skew.  RT and VAS aberrant salience scores from the SAT were square root 
transformed prior to analysis to reduce skew, though untransformed values are presented in the 
text, figures and tables for clarity. Relationships between data were assessed using Pearson’s r 
product–moment correlation coefficient for normally distributed data and Spearman’s  rank 
correlation was used for non-normally distributed data. To determine whether participants 
consistently assigned aberrant salience to any particular stimulus feature, 2 tests were 
employed.  For all analyses a p value of <0.05 (two-tailed) was considered significant.   
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4.4 Results 
 
4.4.1 Participant Characteristics  
Fifteen cannabis users who experienced a positive change in psychotic-like symptom 
severity in response to cannabis were recruited from the Morgan et al. study.  Owing to data 
storage malfunction for three participants, complete data were available on 12 of these users 
who experienced a positive change in psychotic-like symptom severity in response to cannabis.  
An additional two users who did not experience a positive change in PSI score were recruited 
from the Morgan et al. study and a further three users were recruited by public advertisement.  
Therefore 17, at least weekly cannabis users are included in the present study.  All cannabis 
users consumed the drug as a spliff. 
 
The mean (SD) age of first cannabis use was 15.5 (2.0) years, and the mean (SD) 
duration of at least weekly use was 5.9 (3.1) years.  The mean (SD) time taken to smoke an 
eighth and lifetime exposure to cannabis was 8.3 (7.3) days and 2,850 (2,447) spliffs, 
respectively.  Six users met DSM-IV criteria for cannabis dependence or abuse. Mean (SD) 
time to smoke an eighth was 4.0 (4.3) days in users who met dependency/abuse criteria and 
11.0 (8.4) days in users who did not meet criteria.  Nineteen control participants were matched 
to the user group for age (±5 years) and sex.  Participant characteristics are reported in Table 
4.x. Urine drug screen was positive for THC and negative for all other substances 
(amphetamine, opiates, cocaine, methamphetamine, benzodiazepines) in every cannabis user 
and negative for all drugs (including cannabis) in every control participant. There was a 
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significant group difference in current cannabis consumption, as expected (Table 4.1). There 
was no significant group difference in age or sex. 
 
Table 4.1 Sample characteristics  
 Controls         
(n=17) 
Cannabis Users 
(n=17) 
pa 
Sample characteristic     
Age (years) [mean(SD)] 23.9  (4.2)  22.4 (1.9) 0.19 
Sex (n) 6 female,  11 male  3 female,  14 male 0.44 
Cannabis users (n)  0 17 1.00 
Cannabis use (grams of 
cannabis/month), mean (SD) 
0.0 (0.0) 31.8 (38.5) 0.00 
THC content of cannabis (%), 
mean (SD)  
- 7.5 (2.9) - 
Time to smoke an eighth of 
cannabis (days), mean (SD) 
- 8.3 (7.3) - 
Age of onset of regular cannabis 
use (years), mean (SD) 
- 16.3 (2.0) - 
a Independent-samples t-tests for variables with normal data distributions; Mann-Whitney 
U tests for variables with non-normal data distributions; 2-tests for dichotomous 
variables 
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4.4.2 Salience Attribution Task 
Behavioural data are presented in Table 4.2.   
Table 4.2 Behavioural Data   
Test Measure Controls       
(n=17) 
Cannabis Users 
(n=17) 
pa 
Block 1     
 RT high probability (ms) 300.5 (114.9) 277.5 (111.7) .56 
 RT low probability (ms) 335.8 (51.4) 304.2 (53.2) .10 
 RT adaptive salience (ms) 11.2 (21.9) 3.8 (14.2) .25 
 RT aberrant salience (ms) 12.8 (4.7) 20.8 (19.5) .18 
 VAS high probability (mm) 55.8 (26.9) 63.0 (19.0) .39 
 VAS low probability (mm) 14.1 (8.4) 18.0 (12.1) .41 
 VAS adaptive salience (mm) 41.3 (29.4) 45.7 (25.3) .64 
 VAS aberrant salience (mm) 16.3 (14.5) 10.4 (9.6) .30 
Block 2     
 RT high probability (ms) 312.9 (56.4) 294.8 (57.5) .38 
 RT low probability (ms) 332.7 (58.1) 310.8 (67.0) .33 
 RT adaptive salience (ms) 20.3 (22.4) 14.9 (18.6) .45 
 RT aberrant salience (ms) 13.4 (15.2) 12.4 (7.7) .81 
 VAS high probability (mm) 63.3 (24.7) 66.3 (19.8) .71 
 VAS low probability (mm) 16.3 (9.7) 10.8 (7.6) .09 
 VAS adaptive salience (mm) 46.3 (26.7) 56.0 (23.1) 0.27 
 VAS aberrant salience (mm) 8.7 (6.4) 8.4 (8.6) 0.62 
SPQ  - 19.9 (9.1)  
Abbreviations: RT, reaction time; SPQ; Schizotypal Personality Questionnaire; VAS, visual analogue scale.   
Values given as mean (standard deviation). 
a independent samples t test  
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4.4.2.1 Reaction Time (Implicit Salience) 
All participants responded faster to high relative to low probability reinforced trials 
(F1,31=21.4, p<.001).  There was no group x block interaction (F1,32=0.05, p=0.82) on implicit 
adaptive salience.  Collapsing across blocks, controls exhibited greater implicit adaptive 
salience than cannabis users, but this was not statistically significant (F1,32=1.60 p=0.22, Figure 
4.1).  There was a main effect of block (F1,32=5.28, p = 0.03), as for both groups implicit 
adaptive salience was greater in block 2 than block 1 as determined via post-hoc paired sample 
t test (t= 2.33, p=0.026) (see table 4.2).   
 
 
Figure 4.1 Adaptive Salience (ordinate) based on latency (ms) in cannabis users and 
controls.  Values are means and standard errors. 
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There was no group x block interaction (F1,32 = 1.08, p=0.31) on implicit aberrant 
salience.  Collapsing across blocks, cannabis users exhibited greater implicit aberrant salience 
than controls, but this was not statistically significant (F1,32 = 1.12, p=0.30,  Figure 4.2).  There 
was no effect of block on implicit aberrant salience (F1,32 = 1.30, p = 0.26).  Participants did 
not consistently respond faster in the context of any particular irrelevant stimulus feature 
(p>0.05). 
 
 
 
Figure 4.2 Aberrant Salience (ordinate) based on latency (ms) in cannabis users and 
controls.  Values are means and standard errors. 
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4.4.2.2 Visual Analogue Scales (Explicit Salience)  
Across all participants, high-probability-reinforced trails were rated as being more 
likely to yield reward compared to low-probability-reinforced trials (F1,31=130.0, p<0.001).  
There was no group x block interaction (F1,32=0.38 p=0.54) on explicit adaptive salience.  
Collapsing across blocks, there was no significant effect of group on explicit adaptive salience 
(F1,32=0.80, p=0.38, Figure 4.3).  There was no effect of block (F1,32=3.18, p = 0.08). 
 
 
Figure 4.3 Adaptive Salience (ordinate) calculated from subjective reinforcement 
probability ratings (mm) in cannabis users and controls. Values are means and standard 
errors. 
  
0
10
20
30
40
50
60
Controls Cannabis Users
 
201 
 
There was no group x block interaction (F1,32=0.35 p=0.56) on explicit aberrant 
salience.  Collapsing across blocks, there was no significant effect of group on explicit aberrant 
salience (F1,32=1.09, p=0.30, figure 4).  There was no effect of block (F1,32=2.43, p = 0.13).  
Participants did not consistently rate any particular irrelevant stimulus feature as more likely 
to yield reward relative to the others.   
 
Figure 4.4 Aberrant Salience (ordinate) calculated from subjective reinforcement 
probability ratings (mm) in cannabis users and controls. Values are means and standard 
errors. 
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4.4.3 The Relationship between Salience Processing and Cannabis Use.   
Within the cannabis user group, there were no significant relationships between current 
cannabis use and measures of salience processing (implicit adaptive salience: r = .07, p =.79; 
implicit aberrant salience r = .49, p =.06; explicit adaptive salience r = -.46, p =.07; explicit 
aberrant salience r = .14, p =.61).  There was no significant relationship between age of onset 
of cannabis use and measures of salience processing (implicit adaptive salience: r = 0.32, p = 
0.23; implicit aberrant salience r = -0.18, p = 0.52; explicit adaptive salience r = -0.12, p = 
0.66; explicit aberrant salience r = -0.12, p = 0.65).  There was no significant relationship 
between age of first cannabis use and current cannabis use (r = 0.02, p = 0.95).   
 
As an exploratory analysis, to examine whether cannabis dependency/abuse was 
associated effects of salience processing, the cannabis user group was divided into participants 
that met DSM-IV-TR criteria for cannabis dependency or abuse (n=6) and those who did meet 
criteria (n=11).  Within the cannabis users there was a significant effect of DSM-IV-TR 
dependency/abuse status on implicit aberrant salience (F1,15 = 5.8, p = 0.03), but not on the 
other outcome measures (Figure 4.5).  Across the whole sample, the effect of DSM-IV-TR 
dependency/abuse status on implicit aberrant salience did not reach the threshold for statistical 
significance (F2,32 = 2.9, p = 0.07). 
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Figure 4.5 Implicit Aberrant Salience (ordinate) based in controls and in cannabis users 
who meet DSM-IV Dependency and Abuse (n = 6) and those who do not meet criteria (n 
= 11).  Values (ms) are means and standard errors.  Within the cannabis users there was a 
significant effect of DSM-IV-TR dependency/abuse status on implicit aberrant salience (F1,15 
= 5.8, p = .03), but across the whole sample, this did not reach the threshold for statistical 
significance (F2,32 = 2.9, p = .07). 
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4.4.4 The Relationship between Aberrant Salience Processing and Cannabis-Induced 
Psychotic-Like Symptoms 
Within the cannabis users who experienced cannabis-induced psychotic-like symptoms 
(n = 12) there was a significant relationship between cannabis-induced psychotic-like symptom 
severity and explicit aberrant salience (r = 0.61, p = 0.04).  See figure 4.6.  There were no 
significant relationships between cannabis-induced psychotic-like symptoms and the other 
salience measures (p>0.05), or between SPQ score and all salience measures (p>0.05). 
 
 
Figure 4.6 The relationship between Explicit Aberrant Salience (mm) and cannabis-
induced psychotic-like symptom severity (change in Psychotomimetic States Inventory 
Score)  
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4.4.5 The Relationship between Salience Processing and Dopaminergic Function  
As an exploratory analysis, data are also presented on salience processing and 
dopaminergic functioning.  Six controls in the present study had participated in the study of 
dopaminergic function in cannabis users.  Both implicit and explicit adaptive salience were 
positively correlated with whole striatal dopamine synthesis capacity, whilst implicit aberrant 
salience was inversely correlated with whole striatal dopamine synthesis capacity (Figure 4.7 
Table 4.3).  
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Figure 4.7 The relationships between dopamine synthesis capacity (indexed as Kicer) in the 
whole striatum and implicit adaptive salience (top) and implicit aberrant salience 
(bottom) in controls.   
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Table 4.3 The relationships between salience attribution and dopamine synthesis 
capacity (indexed as Kicer) in the striatum and each of its functional subdivisions in 
controls who had previously undergone PET scans (n=6).   
 Kicer (min-1) RT 
Adaptive 
Salience 
RT 
Aberrant 
Salience 
VAS 
Adaptive 
Salience 
VAS Aberrant 
Salience 
ROI Mean (SD) r p r p r p r p 
STR .0132 .0014 .94 .006 -.91 .01 .82 .05 -.15 .78 
 
Ten cannabis users in the present study had participated in the study of dopaminergic 
function in cannabis users.  There were no significant relationships between the SAT outcome 
measures and dopamine synthesis capacity in the whole striatum (Table 4.3).  There were no 
other significant relationships between salience measures and dopamine synthesis in the other 
striatal functional subdivisions. 
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Table 4.4 The relationships between salience attribution and dopamine synthesis 
capacity (indexed as Kicer) in the striatum and each of its functional subdivisions in 
cannabis users who had previously undergone PET scans (n=10).   
 Kicer (min-1) RT Adaptive 
Salience 
RT Aberrant 
Salience 
VAS Adaptive 
Salience 
VAS 
Aberrant 
Salience 
ROI Mean (SD) r p r p r p r p 
STR .0128 .0008 .27 .45 -.11 .77 .55 .10 .22 .55 
 
 
 
Fisher’s r-to-z transformation was applied to examine for significant differences in the 
relationships between dopaminergic functioning and salience processing in users and controls.  
Significant differences were found in the relationships between both implicit adaptive and 
aberrant salience processing and dopamine synthesis capacity in the whole striatum. 
Specifically, cannabis use was associated with the loss of a positive relationship between 
implicit adaptive salience and dopamine synthesis capacity, and the loss of an inverse 
relationship between implicit aberrant salience and dopamine synthesis capacity.   
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Table 4.5 Fisher’s r-to-z transformation to examine significant differences in the 
relationships between salience processing and striatal dopamine synthesis capacity in 
cannabis users and controls.   
 RT Adaptive 
Salience 
RT Aberrant 
Salience 
VAS Adaptive 
Salience 
VAS Aberrant 
Salience 
ROI z p z p z p z p 
STR 2.12 .03 -2.05 .04 .78 .44 -.54 .59 
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4.5 Summary 
These results demonstrate that regular long-term cannabis use is not associated with 
statistically significant differences in behavioural measurements of salience processing.  
However, these results show preliminary evidence for a difference in implicit aberrant salience 
between cannabis who do and do not meet DSM-IV criteria for cannabis abuse or dependence. 
The results above also indicate a loss of relationship between implicit salience processing and 
dopamine synthesis capacity in the whole striatum associated with long-term cannabis use.   
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Chapter 5: 
The Relationship Between Apathy and 
Dopamine Synthesis Capacity in Cannabis Users 
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5.1 Introduction 
Over 100 years ago, the Indian Hemp Commission reported that heavy cannabis use 
was associated with apathy (Indian Hemp Drugs Commission 1893).  This is particularly of 
interest to schizophrenia research as apathy has also long been recognised as being an important 
and common negative symptom of schizophrenia.  Bleuler (1911) described the apathy he saw 
in his patients:   
 
“an indifference to everything—to friends and relations, to vocation or enjoyment, to 
duties or rights, to good fortune or to bad.” 
 
Likewise, Kraeplin (1919) wrote: 
 
“(my) patients have lost every independent inclination for work and action; they sit 
about idle, trouble themselves about nothing, do not go to their work, neglect their most 
pressing obligations, although they are perhaps still capable of employing themselves 
in a reasonable way if stimulated from outside.” 
 
Heavy cannabis use has been associated with educational and occupational under-
achievement in several (Brook et al. 2002; Fergusson et al. 2003; Gruber et al. 2003; Kandel 
et al. 1986; Macleod et al. 2004; Horwood et al. 2010) but not all studies (Reilly et al. 1998).  
Since then, there is evidence that regular use of the drug is associated with apathy (Looby and 
Earleywine 2007; McGlothin & West 1968; Tennant & Groesbeck 1972; Verdejo-Garcia et al. 
2006), defined as reduced motivation for goal-directed behaviour (Levy & Dubois 2006; Marin 
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1991).  Thus, reduced motivation, i.e. apathy, had been proposed to be one factor potentially 
involved in impaired educational and occupational outcomes associated with heavy cannabis 
use (Fergusson et al. 2003).  In support of this, heavy chronic cannabis use has been found to 
produce apathetic behaviours in rhesus monkeys (Paule et al. 1992).  However, there is limited 
evidence of amotivational effects of cannabis from laboratory studies in humans using operant 
conditioning paradigms (Cherek et al. 2002) and that this may be related to heavy use of the 
drug (Mendelson et al. 1976; Lane et al. 2005).  There is evidence both from studies in animal 
models and humans that THC administration disrupts reinforced behaviour (Stiglick and 
Kalant 1983; Kamien et al. 1994; Lane & Cherek 2002; Lane et al. 2004; Foltin et al. 1989).  
As described in Chapter 1, a key proposed function of the mesolimbic dopaminergic system is 
to mediate the processing of incentive stimuli by modifying their motivational value (Berridge 
and Robinson 1998).  Under this model, the dopamine system encodes the salience, i.e. 
biological importance, of sensory stimuli.  Since there is evidence that this process is in turn 
modulated by the brain’s own “cannabis”, the endocannabinoid system (Fernandez-Ruiz et al. 
2010; Melis et al. 2012; Melis and Pistis 2012), disturbance of endocannabinoid signalling via 
the actions of exogenous cannabinoids (i.e. THC) will therefore likely alter dopamine-mediated 
reward processing.   
 
A functional magnetic resonance imaging (fMRI) study has reported attenuated striatal 
reward processing in chronic cannabis users (van Hell et al. 2010).  It was therefore proposed 
that attenuated mesolimbic dopaminergic transmission due to long-term cannabis use results in 
a mesolimbic reward system that is hyporesponsive to non-drug stimuli (van Hell et al. 2010), 
in line with the reward deficiency hypothesis (Blum et al. 2000; Koob and Le Moal 2005). 
Whilst only a limited number of studies have examined processing of drug and non-drug 
stimuli within the same model, there is evidence to support the hypothesis that complementary 
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processes co-occur within an individual to give rise to both hypersensitivity to drug reward and 
hyposensitivity to non-drug rewards (Garavan et al. 2000; Wrase et al. 2007; Zijlstra et al. 
2009). However, it has also been proposed that amotivational symptoms in cannabis users 
could be attributed to coexisting depressive symptoms (Musty and Kaback 1995).  
 
Treatment with the dopamine precursor levodopa and pramipexole, a dopamine D2 
agonist, has both been found to improve apathy in patients with Parkinson’s disease (Czernecki 
et al. 2002; Lemke et al. 2006), where striatal hypodopaminergia has been found to be related 
with apathy in depressed patients with Parkinson’s disease (Remy et al. 2005).   
 
Studies of macaque monkeys have found that mesolimbic dopamine pathway loss, 
induced via 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesions, predicted apathetic 
behaviour (Brown et al. 2012; Schneider et al. 1988) and that apathy was inversely correlated 
to [18F]-DOPA uptake in the nucleus accumbens and dorsal striatum (Brown et al. 2012).  In 
the context of the findings from Chapter 3, a supplementary hypothesis was made that that 
apathy in cannabis users would be inversely correlated with striatal dopaminergic function. 
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5.2 Materials and Methods 
 
5.2.1 Research Ethics & Governance  
 
The research ethics and governance are described in Chapter 2.  
 
5.2.2 Study Population  
 
14 regular cannabis users (defined as at least weekly cannabis use for >1 year; mean 
[SD] age 20.4 [1.3] years, 13 males, one female) recruited from an ongoing cohort study 
(Morgan et al. 2011) who participated in the study described in Chapter 3.  The median 
(interquartile range, IQR) time to smoke an ‘eighth’ was 3.8 (6.0) days, and the mean (SD) age 
of onset of regular cannabis use was 16.3 (2.2) years. 
 
5.2.3 Study Measures 
 
In addition to the procedures described in Chapter 3 including structured psychiatric 
history, detailed drug history and positron emission tomography, participants completed the 
Apathy Evaluation Scale (self-rated) (AES-S) (Marin et al. 1991). 
 
5.2.4 Statistical analysis 
 
Normality of distributions was assessed using the one-sample Kolmogorov–Smirnov 
test. Relationships between Kicer, levels of cannabis use and apathy severity were tested using 
Pearson’s correlation coefficient for normally distributed data and Spearman’s rank correlation 
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coefficient for non-normally distributed data. Statistical significance was defined as p < 0.05 
(two-tailed). The primary outcome measure was Kicer in the whole striatum. Exploratory 
analyses in the striatal sub-divisions (presented uncorrected for multiple comparisons) were 
conducted. Exploratory analyses between sub-groups were conducted using independent 
samples t-tests for normally distributed data and Mann–Witney U tests for non-normally 
distributed data. 
 
 
5.3 Results 
 
It was found that all cannabis users scored in excess of 34 points on the AES-S (median 
[IQR] 59.5 [7.5]), indicative of significant ‘apathy’ based on normative data from a healthy 
population non-cannabis using sample (mean [SD] = 24.4 [4.5]) (Kant et al. 1998).  There was 
no significant difference in apathy scores between subjects who met DSM-IV(TR) criteria for 
abuse or dependence and users who did not meet criteria (p = .71), and there was no significant 
difference in Kicer between those subgroups in the whole striatum (t12 = 1.96, p = .07).  There 
were no significant relationships between apathy and the volumes of any of the ROIs examined 
(all p > .1). 
 
Kicer was inversely correlated to AES-S score in the whole striatum and its associative 
subdivision (Spearman’s rho = −.64, p = .015 [whole striatum]; rho = −.69, p = .006 
[associative]) but not in the limbic or sensorimotor subdivisions (Fig. 6.1).  Cook’s D and 
leverage analysis indicated that these correlations were not driven by outlying data points. Our 
findings of an inverse relationship between apathy and Kicer  in the whole striatum and its 
associative subdivision remained significant when co-varying for the respective striatal volume 
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(rdf  = −.6111, p = .03 [whole striatum]; rdf  = −.6211, p = .03 [associative]) and for recent tobacco 
and alcohol use (rdf  = −.6310, p = .03 [whole striatum]; rdf   = −.6510, p = .02 [associative]).  
 
 
 
 
 
 
 
Figure 5.1 The relationship between whole striatal dopamine synthesis capacity (Kicer) and 
apathy (AES-S score) (rho = −.64, p = .015) 
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There were no significant relationships between AES-S and current cannabis 
consumption (rho = .28, p = .34) or age of first cannabis use (rho = .25, p = .40), suggesting that 
it is not related to recent use or age of first use of cannabis per se. In addition, there were no 
significant relationships between the time since last cannabis exposure and apathy (rho = −.39, 
p = .17) or  Kicer (rho = −.24, p = .41).  Furthermore, there was no relationship between apathy 
and psychotogenic response to cannabis (rho = .11, p = .70). However, there was no significant 
relationship between Apathy and the CEQ After Effects scale (rho = −.06, p = .83), and there 
was no significant relationship between the CEQ After Effects scale and whole striatal Kicer 
(r = −.46, p = .88). Four subjects reported a family history of depression in a first degree 
relative. There was no significant difference in Kicer between subjects with and without a family 
history of depression (tdf = .3412, p = .74). 
 
 
5.4 Summary  
 
14 of the cannabis users who participated in the experiment described in Chapter 3 
completed the AES-S.  Of these, all subjects scored in excess of 34 points on the AES-S 
(median [interquartile range] 59.5 [7.5]), indicative of significant apathy based on normative 
data. Kicer was inversely correlated to AES-S score in the whole striatum and its associative 
functional subdivision (Spearman’s rho = −0.64, p = 0.015 [whole striatum]; rho = −0.69, p  
= 0.006 [associative]) but not in the limbic or sensorimotor striatal subdivisions. There were 
no significant relationships between AES-S and current cannabis consumption (rho = 0.28, 
p = 0.34) or age of first cannabis use (rho = 0.25, p = 0.40). 
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Chapter 6:  
Dopamine synthesis capacity  
and its Relationship to Psychosocial Risk Factors for Schizophrenia 
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6.1 Introduction 
 
Whilst a history of schizophrenia in a first degree relative is associated with the highest 
relative risk of having the illness at the individual level, environmental risk factors account for 
many more cases on a population basis (Mortensen 1999).  Furthermore, environmental factors 
appear necessary for the manifestation of frank illness in the majority of cases (Van Os & 
Marcelis, 1998).  Epidemiological studies have found that a number of psychosocial stressors 
increase the risk of schizophrenia.  As discussed in chapter 1, the main identified psychosocial 
stressors relate to inner city dwelling, migration, childhood adversity and/or trauma, and adult 
adversity.  These will be revisited below. 
 
Inner city dwelling, or “urbanicity”, was first associated with schizophrenia in a 
landmark epidemiological study where Faris and Dunham (1939) recorded the pre-admission 
geographical location of over 30,000 patients treated in Chicago’s psychiatric hospitals and 
they found high rates of schizophrenia ‘‘in the deteriorated regions in and surrounding the 
centre of the city, no matter what race or nationality inhabited that region.’’ Subsequently, in a 
study of 49,191 male Swedish conscripts linked to the Swedish National Register of Psychiatric 
Care, Lewis et al. (1992) found that the incidence of schizophrenia was 1.65 times higher 
among men brought up in cities than in those who had had a rural upbringing. Likewise, 
Marcelis et al. (1998) followed up all live births recorded between 1942 and 1978 in the 
Netherlands through the National Psychiatric Case Register for first psychiatric admission for 
psychosis between 1970 and 1992 (n=42,115) and found that urban birth carried twice the risk 
of later schizophrenia than rural birth. A systematic review by Kelly et al. (2010) found that 
all but one of 18 register-based studies examining rates of psychosis according to urbanicity 
found a positive association. The relative risk was between 1.4 and 4.3, and in most cases was 
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approximately 2. There is also evidence of a dose-response relationship between degree of 
urbanicity and risk of schizophrenia (Pedersen & Mortensen, 2001). 
 
Many studies have replicated the finding that migration is a risk factor for schizophrenia 
since Ødegaard (1932) described high rates of Norwegians undergoing a schizophrenic 
breakdown after migration to Minnesota.  In a meta-analysis (Cantor-Craee & Selton, 2005) 
the relative risk (RR) of schizophrenia was higher in migrants from less economically 
developed countries and particularly for black migrants moving to a white-majority country.    
A recent meta-analysis (Bourque et al. 2011) has confirmed an increased risk of psychosis in 
both first and second generation migrants with incidence rate ratios (IRR) of 2.3 and 2.1 
respectively with no significant difference between the two generations.  The effect of 
migration may also be related to ethnic minority status as a replicated finding is that the 
incidence of psychosis in migrants increases as they form a decreasing proportion of the 
population (e.g. Boydell et al. 2001 & Veling et al. 2008b).  Other factors such as urbanicity 
do not appear to mediate the risk associated with this (Bourque et al. 2011). 
 
There is evidence that a variety of childhood stressors increase the risk of psychosis.  
There is an approximate two-fold increase in the risk of schizophrenia among people with 
unknown fathers compared with people with known fathers (Mortensen et al. 1999) and in 
individuals who have experienced the death or long-term separation from a parent before the 
age of 16 years (e.g. Morgan et al.  2007, Agid et al. 1999).  Studies have also found 
associations between childhood abuse and/or neglect and psychotic risk although this evidence 
is less consistent (Morgan & Fisher 2007).  Despite methodological challenges, these studies 
suggest traumatic events may increase the likelihood of experiencing psychotic symptoms 
(reviewed in Read et al. 2008 and van Os et al. 2010) and it has been suggested there may be 
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specific associations between different types of trauma and specific psychotic phenomena 
(Bentall & Fernyhough, 2008), with ongoing interest in the tentative association between 
childhood sexual abuse and hallucinosis (e.g. Read et al. 2003; Varese et al. 2012).   
 
Sudden changes in an individual’s life, e.g. bereavement, unemployment or moving 
house, are termed life events.  In 1968, Brown and Birley reported acute life events to be 
associated with relapse of schizophrenia and Bebbington et al. (1993) found a significant 
relationship between life events and onset or relapse of schizophrenia.   More recently, Myin-
Germeys & van Os (2007) have extended this to show increased stress-reactivity, i.e. sensitivity 
to the small stressors of everyday life, in people with and those at genetic risk of schizophrenia.  
In a case-control study of the effects of cumulative social disadvantage and first-episode 
psychosis Morgan et al. (2008) found a relationship between social disadvantage and the odds 
of psychosis, these factors included living with relatives (OR 5.2), living alone for over a year 
(2.19), lacking a confidant (OR 7.74), being unemployed (3.61) and currently not being in a 
stable relationship (3.36).   
 
Dopamine dysfunction is thought to underlie the development of psychosis (Howes & 
Kapur 2009).   As described in chapter 1, there is evidence from preclinical and clinical studies 
that both acute and chronic stress alter mesocortical dopaminergic function.  Briefly, in animals 
social defeat stress was found to selectively increase mesocorticolimbic dopamine release 
(Tidey 1996) and increase phasic dopamine neuron firing in the ventral tegmental area (Razzoli 
et al. 2011).   Maternal deprivation and neonatal isolation have been associated with enduring 
increases in dopamine release in the nucleus accumbens (Hall et al. 1999) and greater cocaine-
induced nucleus accumbens dopamine (Kosten 2003).  However, there have been 
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inconsistencies in findings as separate studies found that unavoidable stress administered over 
one week and three weeks was associated with a decrease in nucleus accumbens dopamine 
output that remained evident two weeks after administration of stress had abated 
(Mangiavacchi et al. 2001) and 30 minutes of stress administered twice daily for 21 days was 
associated with a reduction cocaine-induced nucleus accumbens dopamine response 
(Shimamoto et al. 2011).   
 
In terms of evidence of dopaminergic effects of psychosocial stress from human studies, 
elevated urinary dopamine and other catecholamine metabolites have been reported in girls 
with a history of sexual abuse compared to those without (De Bellis et al. 1994).  There is fMRI 
evidence of striatal reward pathway dysfunction in adults who were abused as children (Dillon 
et al. 2009) and adolescents who had suffered severe early life deprivation.  In PET studies, 
Pruessner et al. (2004) reported ventral striatal dopamine release was increased in response to 
psychosocial stress in humans who reported insufficient early life maternal care; Wand et al. 
(2007) found stress-induced cortisol levels were positively associated with amphetamine-
induced dopamine release in the striatum; Mizrahi et al. (2011) found increased psychosocial 
stress-induced striatal dopamine release in antipsychotic-naïve subjects with schizophrenia and 
those at clinical high-risk of the illness compared to matched healthy controls; and Oswald et 
al. (2014) reported positive associations between childhood adversity and amphetamine-
induced dopamine release.   
 
To summarize, it has been proposed, though never directly tested, that psychosocial 
stressors may increase the risk of schizophrenia by creating a hyperdopaminergic state in the 
striatum (Thompson et al. 2004; Howes et al. 2004; Selten et al. 2013). 
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6.2 Hypotheses 
 
1. Subjects with a high cumulative exposure to psychosocial risk factors for schizophrenia 
will exhibit elevated dopamine synthesis capacity compared to subjects with low 
cumulative exposure to the same environmental stressors.   
2. Within subjects with a high cumulative exposure to psychosocial risk factors for 
schizophrenia there will be a direct relationship between dose of psychosocial stress 
and dopamine synthesis capacity.   
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6.3 Materials and Methods 
 
6.3.1 Research Ethics 
The study was approved by the National Research Ethics Service and the 
Administration of Radioactive Substances Advisory Committee (ARSAC).  The study was 
conducted in accordance with the Helsinki Declaration and all subjects provided informed 
written consent to participate. 
 
6.3.2 Power Calculation 
 
The power calculation is described in Chapter 2.   
 
 
6.3.3 Study Population 
The study population including inclusion and exclusion criteria are described in 
Chapter 2.   
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6.3.6 Psychosocial measures 
 
The following measures of urbanicity were taken: childhood urbanicity score, current 
urbanicity score, current dwelling population and population density.  The urbanicity score was 
based on the Mortensen et al. (1999) categorization of urbanicity, i.e. rural area (with a 
population less than 10,000) = 1 point; provincial town (with a population less than 100,000) 
= 2 points; provincial city (with a population less than 100,000) = 3 points; the suburbs of a 
capital = 4 points; capital city = 5 points.  Only the boroughs of Inner London (as defined by 
the ONS and Eurostat), listed above, were designated “capital city”.  Detailed histories of the 
location of each subject’s residence were recorded throughout their lives.  The childhood 
urbanicity score was then calculated for each subject based on the urbanicity score for each 
year of the subject’s life from birth to age 16 years.  The lowest possible score is therefore 16, 
and the highest possible score is 80.  Where a subject had lived at more than one address during 
their childhood, a score was allocated based on where they had spent the majority of that year 
living.  Current and historical populations were based on data obtained from the Office of 
National Statistics, for United Kingdom data, and from census data publicly available on the 
internet for non-United Kingdom data.  Current population density was obtained from the 
Office of National Statistics.   
 
The following childhood adversity measures were taken:  the Childhood Trauma 
Questionnaire (CTQ) (Bernstein & Fink 1998), childhood experiences of care and abuse 
(CECA) (Bifalco et al. 2006), a questionnaire of bullying, and subjects were asked whether 
their parents had separated or died before their 17th birthday.  The CTQ is a validated 28 item 
self-report inventory measuring physical abuse, sexual abuse, emotional abuse, physical 
neglect and emotional neglect.  The CECA is a validated structured interview that measures 
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parental care (neglect and antipathy), parental physical abuse, and sexual abuse from any adult 
before age 17.  The questionnaire of bullying was adapted from the Olweus Bullying 
Questionnaire (Olweus 1996) and includes five items measuring frequency and severity of 
physical and emotional abuse from peers during childhood.   
 
The following demographics of adult adversity were taken: current living 
arrangements, relationship status, and personal and parental history of migration.  Detailed 
histories of life events over the preceding six months were obtained via the List of Threatening 
Events (Brugha & Cragg 1990), and a life events score then calculated from these events based 
on the Holmes & Rahe life events stress scale.   
 
The following clinical measures were taken: Brief Impact of Events Scale (IES-6) 
(Thoresen et al. 2010), Beck Depression Inventory (BDI); Beck Anxiety Inventory (BAI); The 
Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE), which measures 
schizotypy, and the Aberrant Salience Inventory (ASI).   
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6.3.7 PET Scans 
 
Subjects were asked to fast 5 hours and to refrain from smoking tobacco for 2 hours 
before imaging.  On the day of the PET scan, urine drug screen (Monitect HC12, Branan 
Medical Corporation, Irvine, California) confirmed no recent drug use, and a negative urinary 
pregnancy test was required in all female subjects.  Head position was marked and monitored 
via laser crosshairs and a camera and minimized using a head-strap.   
 
A Siemens Biograph 6 TruePoint PET-CT scanner (Siemens Healthcare, Erlangen, 
Germany) was used.  A computed tomography (CT) scan (effective dose=0.36 mSv) was 
acquired for attenuation and model-based scatter correction prior to each PET scan. A target 
dose of approximately 150 MBq of [18F]-DOPA was administered by bolus intravenous 
injection at the start of PET imaging.  Emission data were acquired in list mode for 95 minutes, 
reconstructed in a 128 x 128 matrix with 2.6x zoom via filter back projection with a three 
dimensional 5mm full-width half-maximum Gaussian image filter and re-binned into 32 
timeframes (comprising eight 15-second frames, three 60-second frames, five 120-second 
frames, and sixteen 300-second frames). 
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6.3.8 Image analysis 
 
The image analysis methods are details in chapter 2 and summarized below.  To correct 
for head movement in the scanner, non-attenuation-corrected dynamic images were de-noised 
using a level 2, order 64 Battle-Lemarie wavelet filter.  Non-attenuation-corrected images were 
used for the realignment algorithm as they include greater scalp signal, improving re-alignment 
compared with attenuated-corrected images (Turkheimer et al. 1999).  Frames were realigned 
to a single ‘reference’ frame, acquired 10 min post-injection, employing a mutual information 
algorithm (Studholme et al. 1996). The transformation parameters were then applied to the 
corresponding attenuated-corrected dynamic images. The realigned frames were then 
summated, creating a movement-corrected dynamic image, which was used in the analysis. 
The cerebellar reference region (Kumakura & Cumming 2009) was defined using a 
probabilistic atlas (Martinez et al. 2003), and as previously described, regions of interest (ROI) 
in the whole striatum and its functional sub-divisions were delineated to create an ROI map 
(Egerton et al. 2010).  The functional subdivisions of the striatum reflect the topographical 
arrangement of corticostriatal projections.  Projections to the sensorimotor striatum come from 
the motor cortex and related areas for instance the premotor cortex, primary motor cortex, and 
supplementary motor cortex; projections to the associative striatum start in associative regions 
such as dorsolateral prefrontal cortex; and projections to the limbic striatum are from limbic 
areas such as the amygdala and hippocampus (Haber, 2003). SPM8 
(http://www.fil.ion.ucl.ac.uk/spm) was then used to normalize the ROI map together with the 
tracer-specific ([18F]-DOPA) template (Egerton et al. 2010, Howes et al. 2009) to each 
individual PET summation image.  This nonlinear transformation procedure allowed ROIs to 
be automatically placed on individual [18F]-DOPA PET dynamic images. The influx constant 
(Kicer, written as Ki in some previous publications (Howes et al. 2009)) for the entire striatal 
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ROI and the functional subdivisions bilaterally were calculated compared with uptake in the 
reference region using a graphical approach adapted for a reference tissue input function 
(Egerton et al. 2010). 
  
6.3.9 Statistical analysis 
Normality of distribution and homogeneity of variance were assessed using 
Kolmogorov–Smirnov and Levene’s tests, respectively. The primary analysis was for Group 
(HPSS vs. LPSS) differences in demographic and imaging variables were determined using 
independent samples t-tests for normally distributed data, Mann–Whitney U-tests for non-
normally distributed data, and the χ2 test for dichotomous variables. The primary region of 
interest was the whole striatum.  Exploratory analyses were performed in the functional 
subdivisions of the striatum.  Potential confounds were explored post hoc using analysis of 
covariance (ANCOVA).  To examine the effects of childhood and recent psychosocial stressors 
a combined psychosocial stress score was derived from the CECA and recent life events score 
(LES).  For the combined psychosocial stress score (CPSS), the CECA and recent life events 
score were combined with equal weight to both on a total scale from 0 to 100, such that half 
the score was from the CECA (maximum 32 points) and half the score from the life events 
score (maximum 250 points).  The formula applied was:  
ܥ݋ܾ݉݅݊݁݀	݌ݏݕ݄ܿ݋ݏ݋݈ܿ݅ܽ	ݏݐݎ݁ݏݏ	ݏܿ݋ݎ݁ ൌ ൬50 ቀ஼ா஼஺ଷଶ ቁ൰ ൅ ൬50 ቀ
௅ாௌ
ଶହ଴ቁ൰  
Within HPSS, the relationship between Kicer and combined psychosocial stress score 
was tested using Pearson’s product-moment correlation coefficient.  A two-tailed significance 
level of p=0.05 was employed throughout.   
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6.4 Results 
6.4.1 Subject Characteristics and Scan Parameters 
13 HPSS ‘cases’ were recruited to the study by public advertisement.  All HPSS were 
current London residents and had spent most of their childhood, up to age 16, in London or the 
capital city of their country of birth. All HPSS were either first or second generation migrants 
to both the United Kingdom and the European Union.  Nine HPSS had a history of parental 
separation or death during childhood.  Five HPSS lived alone, two lived with their children but 
with no other adult, two lived with their parents, one lived with a long-term partner and three 
lived with others.  Eight HPSS were single, one was married and four were in a stable non-
cohabiting relationship.   
13 LPSS ‘controls’ were matched to the HPSS group on the basis of age (+/- 5 years) 
and sex.  None of LPSS were current residents of Greater London.  All LPSS were born and 
had spent most of their childhood outside London.  11 LPSS had no history of first or second 
migration to the United Kingdom and the European Union.  1 LPSS was born in Sweden to 
British parents and moved to the United Kingdom during infancy and 1 further LPSS had a 
South African parent of British descent.  2 LPSS had a history of parental divorce. Seven LPSS 
lived with their partner, one LPSS was in a stable non-cohabiting relationship but lived with 
friends, and five LPSS were single and living with their family.   
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Table 6.1 Sample characteristics and scan parameters 
 LPSS (n=13) HPSS (n=13) pa 
Sample characteristic     
Age (years) [mean(SD)] 27.8 (7.0) 30.3 (7.7) .39 
Sex (n) 6 female, 7 male 6 female, 7 male 1.00 
Ethnicity (n) 13 WB 3 BA, 3BB, 3 BC, 3 ME, 1 OE .00 
Migration (n) 1 FGM, 11 N, 1 SGM 4 FGM, 9 SGM <.001 
Urbanicity    
Childhood urbanicity Score [mean(SD)] 26.1 (12.0) 69.1 (13.0) .00 
Current urbanicity [mean(SD)] 7 R, 6 PC 9 ICC, 4 OCC .00 
Current dwelling population [mean(SD)] 67,012 (73,231) 8,174,000 (0) .00 
Current dwelling population density (km-2) 
[mean(SD)] 
3,891 (4,500) 9,251 (4,237) .01 
Childhood Adversity      
CTQ [mean(SD)] 2.6 (2.6) 18.4 (17.3) .01 
CECA [mean(SD)] .8 (1.3) 6.2 (5.9) <.01 
Childhood bullying [mean(SD)]  5.0 (5.5) 8.7 (4.4) .08 
Parental Separation or death during childhood (n) 2   9 .02 
Adult Adversity    
Current living arrangement 3 F, 5 CHP, 5 P,  5 A, 2 AWC, 1 CHP, 2 P, 1 OF, 
1 F, 1 OLA 
.01 
Relationship status  5 S, 7MCL 8 S, 1 MCL, 4 NCS  
Adverse life events (last 6 months) 0.4 (0.8) 3.2 (1.6) .00 
Life events score (last 6 months) 8.9 (30.9) 89 (47.7) .00 
Clinical Scores    
BDI  [mean(SD)] 1.8 (2.8) 7.8 (5.6) <.001 
BAI  [mean(SD)] 2.5 (3.7) 11.5 (10.7) .01 
IES-6  [mean(SD)] 2.0 (2.6) 8.8 (7.9) .01 
O-LIFE  [mean(SD)] 7.7 (6.8) 14.1 (9.8) .07 
ASI  [mean(SD)] 4.8 (4.9) 12.4 (7.9) .01 
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Table 6.1 (continued)  
   
 LPSS (n=13) HPSS (n=13) pa 
Current Drug Usec,d    
Tobacco cigarette smokers in last 3 months (n) 1 user, 12 non-users 4 users, 9 non-users .32 
Tobacco use in whole sample (cigarettes/day) 
[mean(SD)] 
.1 (.3) 2.3 (4.0) .07 
Tobacco use in smokers (cigarettes/day) 
[median(IQR)] (tobacco users) 
1.0 (-) 7.4 (3.8) - 
Alcohol use in last 3 months (n) 10 users, 3 non-users 13 users, 0 non-users .22 
Alcoholc use (UK alcohol units/week) [mean(SD)] 9.3 (10.0) 8.0 (9.6) .73 
Scan parameter    
Injected dose (MBq) [mean(SD)] 141.3 (9.3) 143.6 (7.2) .48 
Specific activity (MBq/µmol) [mean(SD)] 35.3 (6.0) 44.6 (15.3) .06 
Whole striatal volume (mm3) [mean(SD)] 17,665 (2,143) 16,982 (1,538) .36 
Associative striatal volume (mm3) [mean(SD)] 10,902 (1,386) 10,552 (1,042) .47 
Limbic striatal volume (mm3) [mean(SD)] 2,138 (279) 2,050 (152) .33 
Sensorimotor striatal volume (mm3) [mean(SD)] 4,624 (533) 4,380 (406) .20 
Abbreviations: A, alone; ASI, Aberrant Salience Inventory; AWC, alone with children; BA, black African; BAI; Beck Anxiety 
Inventory; BB, black British; BC, black Caribbean; BDI, Beck Depression Inventory;; CECA, Childhood experiences of care and 
abuse; CHP, co-habiting partner; CTQ, Childhood Trauma Questionnaire; F, friends; FGM, first generation migrant; ICC, inner capital 
city; IES-6, Brief Impact of Events Scale; MCL, married, in a civil partnership or living with long-term partner; ME, mixed ethnicity; 
N, native; NCS, non-cohabiting stable relationship; OCC, outer capital city; OE, other ethnicity; OF, other family; OLA, other living 
arrangement; O-LIFE, Oxford-Liverpool Inventory of Feelings and Experiences; P, parents; PC, provincial city; R, rural; S, single; 
SEAT, Social Environment Assessment Tool; SGM, second generation migrant; WB, White British 
a Independent-samples t-tests for variables with normal data distributions; Mann-Whitney U tests for variables with non-normal data 
distributions; 2-tests for dichotomous variables 
b Groups were compared on a dichotomised ethnicity variable (white British vs ethnic minority). 
Groups were compared on a dichotomised living arrange variable (living without other adults vs living with other adults) 
Groups were compared on a dichotomised relationship variable (co-habiting partner vs other status) 
c 1 UK alcohol unit = 10mL (~7.88g) alcohol  
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There was no significant group difference in the amount of radioactivity injected (table 
6.1).  The specific activity was higher in HPSS vs. LPSS, although this did not reach the 
threshold for statistical significance. There was no significant difference in whole striatal or 
subdivision volumes between the groups.  The groups did not differ in terms of substance use 
including alcohol, tobacco, cannabis, ecstasy (MDMA), cocaine (p>.1).   
 
6.4.2 Striatal Dopaminergic Function 
Kicer was significantly reduced in HPSS relative to LPSS in the whole striatum (figure 
6.1).  The group difference in whole striatal Kicer remained significant when co-varying for 
specific activity (F2,25 = 4.6, p = .02).  Secondary analysis in each striatal subdivision showed 
that this reduction reached significance in the limbic and associative subdivisions (table 6.3).   
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Figure 6.1 Striatal dopamine synthesis capacity in LPPS (n = 13) and HPSS subjects (n = 
13). Dopamine synthesis capacity was significantly reduced in HPSS compared with LPSS 
(t24 = 2.32, p = .029). Error bars indicate standard deviations. 
 
  
 
236 
 
 
 
Table 6.2  [18F]-DOPA Kicer (min-1) by group
VOI LPSS (n=13) HPSS (n=13) Group comparisonsa Effect size 
 Mean (SD) mean (SD) tdf p (Cohen’s d) 
STR .0131 (.0010) .0123 (.0005) 2.3224 .029 .91 
AST .0131 (.0011) .0122 (.0005) 2.4524 .022 .96 
LST .0137 (.0010) .0125 (.0009) 3.1724 .004 1.24 
SMST .0129 (.0012) .0125 (.0009) 1.1524 .263 .45 
Abbreviations: AST, associative striatum; LST, limbic striatum; Kicer , influx rate constant; SMST, 
sensorimotor striatum; STR, whole striatum; VOI, Volume of Interest  
a Independent-samples t-tests. 
 
6.4.3 Smoking and Dopamine Synthesis Capacity 
There were higher rates of smoking in HPSS vs. LPSS, although these did not reach the 
threshold for statistical significance.    When co-varying for the number of cigarettes smoked 
per day, the finding of reduced dopamine synthesis capacity in HPSS vs. LPSS did not remain 
significant in the whole striatum (F2,24 = 2.0, p = .16), but did remain significant in the limbic 
striatal subdivision only (F2,24 = 4.2, p = .03).  Removing cigarette smokers from the analysis 
yielded n=11 LPSS and n=9 HPSS.  As per the ANCOVA, the finding of reduced dopamine 
synthesis capacity in HPSS vs. LPSS did not remain significant in the whole striatum (t18 = 1.3, 
p = .22), but did remain significant in the limbic striatal subdivision only (t18 = 2.1, p = .05). 
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6.4.4 The relationship between dopamine synthesis capacity and symptoms of anxiety and 
depression  
 
Clinical rating scales are reported in table 6.1.  HPSS scored significantly higher than 
LPSS on measures of depressive and anxiety symptoms (BDI and BAI respectively), the degree 
to which previous stressors were having an impact on their lives in the week prior to scanning 
(BIE), schizotypy (O-LIFE) and aberrant salience (ASI).   
 
Across all subjects, there was no significant relationship between dopamine synthesis 
capacity in the whole striatum and the BDI (r=-.28, p=.17) and BAI (r=-.24, p=.14).  When co-
varying for depressive and anxiety symptoms, the finding of reduced dopamine synthesis 
capacity in HPSS vs. LPSS did not remain significant in the whole striatum (F3,24 = 1.3, p = 
.29), but did remain significant in the limbic striatal subdivision only (F3,24 = 3.0, p = .05).   
 
6.4.5 The relationship between dopamine synthesis capacity and combined childhood and 
adult psychosocial stressors   
 
The relationships between dopamine synthesis capacity and combined psychosocial 
stress score are given in table 6.3.  A significant relationship between psychosocial stress and 
dopamine synthesis capacity was observed in the associative striatal subdivision only (figure 
6.2).   
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Table 6.3  The relationship between [18F]-DOPA Kicer and combined psychosocial stress 
score in HPSS 
VOI STR AST LST SMST 
 r p R P r p r P 
CPSS .49 .09 .68 .01 .22 .47 .03 .92 
Abbreviations: AST, associative striatum; LST, limbic striatum; Kicer , influx rate constant; SMST, 
sensorimotor striatum; STR, whole striatum; VOI, Volume of Interest.  
 
 
 
Figure 6.2 The relationship between a combined childhood and recent psychological 
stress and dopamine synthesis capacity in the associative subdivision of the striatum in 
HPSS (r = .68, p = .01).  
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6.5 Summary 
These results show that long-term psychosocial stress is associated with a reduction in 
dopamine synthesis capacity in the corpus striatum and its associative and limbic subdivisions. 
However, the finding of reduced dopamine synthesis in the whole striatum may be related to 
the confounding factors of increased cigarette smoking and affective symptoms in those with 
high exposure to long-term psychosocial stress.  The finding of reduced dopamine synthesis 
capacity in the limbic subdivision of the striatum remained significant when co-varying for 
these factors.  Within individuals with a high cumulative exposure to psychosocial stress, there 
was a significant positive correlation between a combined score of childhood and recent 
stressors and dopamine synthesis in the associative subdivision of the striatum.   
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Chapter 7: Discussion 
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7.1 Introduction  
 
The two PET studies and one behavioural study detailed herein have investigated 
dopaminergic mechanisms for the major environmental risk factors of psychosis.  The results 
obtained are discussed below, beginning with the PET study in cannabis users and followed by 
the behavioural study of cannabis users.  The next section discusses the findings of the PET 
study in individuals exposed to high and low cumulative psychosocial stressors.  This is 
followed by a section discussing the effects of tobacco on the dopamine system, since this has 
implications for interpreting the results of the two PET studies.  Finally, general conclusions 
and future directions are discussed.   
 
7.2.1 Dopamine synthesis capacity and its relationship to cannabis induced psychotic 
symptoms 
 
The main finding from this study is that striatal dopamine synthesis capacity is lower 
in current cannabis users than matched non-user controls (effect size: Cohen’s d = .85; t36 = 
2.54, p = .016).  In users, lower dopamine synthesis capacity was associated with greater 
current cannabis use (r = −.77, p < .001) - explaining 59% of variance in striatal dopamine 
synthesis capacity - and earlier age of onset of use (r = .51, p = .027), but not with cannabis-
induced psychotic-like symptoms (r = .32, p = .19).   Importantly, it was also found that 
the lower levels of dopamine synthesis capacity in cannabis users compared to non-users were 
driven by users who met diagnostic criteria for abuse and dependence (F2,37 = 4.02, p = .027).    
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7.2.2 Hypothesis 1: Regular cannabis users sensitive to cannabis’ psychotogenic effects 
exhibit elevated dopamine synthesis capacity compared with nonuser control subjects 
 
The findings that regular cannabis users sensitive to cannabis’ psychotogenic effects 
exhibit reduced dopamine synthesis capacity compared with nonuser control subjects are 
inconsistent with the hypothesis that regular cannabis users sensitive to cannabis’ 
psychotogenic effects exhibit elevated dopamine synthesis capacity compared with nonuser 
control subjects. 
 
 
7.2.3 Hypothesis 2: There will be a direct relationship between dopamine synthesis 
capacity and cannabis-induced psychotic-like symptom severity. 
 
The findings of no significant relationship between dopamine synthesis capacity and 
cannabis-induced psychotic-like symptom severity are inconsistent with the hypothesis that 
there is a direct relationship between dopamine synthesis capacity and cannabis-induced 
psychotic-like symptom severity. 
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7.2.4 Interpretation of findings 
These results extend previous findings in current (Albrecht et al. 2012) and recently 
abstinent cannabis users (Urban et al. 2012), which found reduced dopamine receptor density 
was associated with higher current cannabis use and lower dopamine release in the associative 
striatum was associated with earlier age of onset of cannabis.  Whilst these studies (Urban et 
al. 2012, Sevy et al. 2008, Albrecht et al. 2012) and a further study in ex-users (Stokes et al. 
2012) have reported estimates of the number of lifetime uses of cannabis, and the current 
sample is comparable to these, measures of the amount or type of cannabis consumed have not 
been reported, such that direct comparisons of cannabis use across the studies cannot be made.  
The findings of reduced dopamine synthesis capacity in dependent subjects may reflect a 
“blunted” dopamine system, as observed with other drugs of addiction (Volkow et al. 2011).  
Taken with findings from these and other studies (Heinz et al. 2005; Wu et al. 1997; Martinez 
et al. 2011; Wang et al. 2012), there is mounting evidence that dopaminergic dysfunction 
provides a biomarker of addiction severity.   
 
Whilst the case-control design of this study is not able to detect a causative relationship 
between cannabis use and dopamine dysfunction, the findings suggestive of dose-effects 
warrant further research into potential causative mechanisms.  Animal studies indicate 
increased dopaminergic function in response to acute THC treatment.  However, there is 
evidence of a biphasic dose-dependent dopamine response to THC (Bloom 1982), suggesting 
higher cannabis exposures may reduce dopamine synthesis capacity, in line with these findings.  
Furthermore, with the exception of perinatal studies (Walters & Carr 1988), animal data on 
dopaminergic effects of long-term and high dose cannabis exposures are sparse and the longest 
duration of THC administration has been twenty-one days (Gorriti et al. 1999; Wu & French 
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2000; Ginovart et al. 2012; Behan et al. 2012).  Of these, one study (Ginovart et al. 2012) in 
Sprague-Dawley rats reported that long-term treatment with THC was associated with reduced 
striatal tyrosine hydroxylase gene expression and concurrent supersensitivity of D2/3 receptors 
and a separate study (Behan et al. 2012) in catechol-0-methyltransferase mutant mice found 
chronic treatment with THC in adolescence was associated with reduced dopaminergic cell 
size in the ventral tegmental area.   
 
One explanation for these findings is that chronic cannabis use is associated with 
dopaminergic down-regulation of dopamine synthesis enzyme activity in response to repeated 
dopamine drug-induced release.  This might underlie amotivation and reduced reward 
sensitivity in chronic cannabis users (van Hell et al. 2010) (see below).  Alternatively, 
preclinical evidence suggests that low dopamine neurotransmission may predispose an 
individual to substance use (Nader et al. 2006).  However, this is inconsistent with findings 
that recently abstinent and former cannabis users show neither altered dopamine receptor 
availability (Sevy et al. 2008; Stokes et al. 2012; Albrecht et al. 2012) nor altered dopamine 
release (Urban et al. 2012), suggesting that altered dopaminergic function during chronic 
cannabis use is normalised by abstinence, as is observed with amphetamine in vervet monkeys 
(Melega et al. 1997). 
 
In the present study dopaminergic function was investigated in cannabis users who 
experience a transient increase in psychotic-like experiences when acutely intoxicated with 
cannabis.  The increase in psychotic-like experience severity was of the same order of 
magnitude as observed in studies on the effects of cannabis and ketamine (Mason et al. 2009) 
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and the dream state (Mason & Wakerley 2012), given that dreaming has long been proposed 
to model psychosis (e.g. Hobson 2004).  The lack of relationship between the induction of 
psychotic-like experiences and dopaminergic function suggests that these findings would 
generalise to cannabis-users in general but this requires confirmation in further studies.  
 
These findings suggest that elevated striatal dopamine synthesis capacity is unlikely to 
be the mechanism underlying the link between cannabis and psychosis.   This study focussed 
on the striatum as dopaminergic changes here have been reliably linked to psychosis (Howes 
et al. 2012) but the possibility cannot excluded that dopaminergic changes in extra-striatal 
regions underlie cannabis-induced psychotic symptoms.  A previous study (Glenthoj et al. 
2006) using SPECT reported a significant increase in temporal cortex D2/3 receptor availability 
in antipsychotic-naïve first-episode psychosis patients who tested positive for cannabis 
compared to those who did not.  Alternatively, the mechanism may be mediated via non-
dopaminergic systems, such as direct effects on cannabinoid receptors (Hirvonen et al. 2012).   
 
Whilst the results of this study find reduced dopamine synthesis in long-term heavy 
cannabis users, the animal data available find complex effects of cannabis/THC on the 
dopamine system where increases or decreases in dopaminergic function are dependent on 
other environmental factors – such as stress (Littleton et al. 1976).  Nevertheless, findings that 
striatal dopamine release in patients with co-morbid schizophrenia and substance dependence 
is blunted but still associated with amphetamine-induced psychotic symptoms (Thompson et 
al. 2012) supports the possibility that other aspects of striatal dopaminergic function are altered 
by cannabis, for example super-sensitivity at D2 receptors (Seeman & Seeman 2014),  or that 
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cannabis use interacts with other risk factors for schizophrenia to induce a downstream relative 
hyperdopaminergia in the dopamine pathway.   In parallel, early work in Wistar rats (Littleton 
et al. 1976) found THC decreased striatal dopamine uptake compared to vehicle, but increases 
in striatal dopamine uptake were observed when THC-treated rats were housed under 
“stressful” vs. “normal” conditions.  Earlier age of onset of cannabis use increases psychosis 
risk and may interfere with normal brain development (Ashtari et al. 2009).  Another possibility 
is thus that cannabis use during key developmental periods alters the regulation of 
dopaminergic function to make it more susceptible to subsequent stressors which could 
underlie an increased risk of psychosis.  Further prospective studies on the effects of chronic 
cannabis exposure are therefore warranted.   
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7.2.5 The relationship between subjective apathy and dopamine synthesis capacity in 
cannabis users  
 
The main finding from this study was that within chronic cannabis users, there was 
inverse relationship between striatal dopamine synthesis capacity and apathy.  This was the 
first study to investigate the relationship between apathy and striatal dopamine synthesis 
capacity in regular active cannabis users. The results suggest that the reduction in striatal 
dopamine synthesis capacity associated with regular cannabis use may indeed underlie the 
reduced reward sensitivity and amotivation associated with chronic cannabis use (van Hell et 
al. 2010), accounting for 40 % of the variance in apathy. Whilst the study was cross-sectional 
so that causality cannot be inferred, this interpretation is supported by preclinical lesion studies 
(Schneider et al. 1988) that show lowering dopamine results in apathy and that apathy is 
inversely related to reduced dopamine function in both patients with Parkinson’s disease 
(Remy et al. 2005) and lesioned animals (Brown et al. 2012).  A further possibility could be 
that the cannabis users were in a state of withdrawal; however, THC and its metabolites have 
an elimination half-life of about 7 days (Maykut 1985), and all our cannabis users were regular, 
long-term users who had consumed cannabis within the past 7 days (median time since last 
consumption = 14.1 h) and so this would be unlikely.  The results extend previous findings of 
attenuated striatal response to reward anticipation activity in cannabis users (van Hell et al. 
2010).  Long-term cannabis use has been associated with apathy (Looby and Earleywine 2007; 
McGlothin & West 1968; Tennant & Groesbeck 1972). The very high apathy scores in this 
sample are striking, the scale we used has not previously been administered in cannabis users.  
One study has, however, attributed amotivational symptoms to coexisting depressive 
symptoms (Musty and Kaback 1995).  Yet, none of the subjects in that study met the threshold 
for a DSM-IV (TR) diagnosis of major depressive episode or disorder, or indeed any DSM-IV 
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(TR) diagnosis except for Cannabis Use Disorders. However, as depressive symptom scales 
were not included, the possibility that sub-clinical depressive symptoms have contributed to 
the findings cannot be excluded.  Since apathy is also a symptom of depression, further studies 
to disentangle the relationship between apathy and depressive symptoms and their possible 
effects on the day-to-day lives of heavy chronic cannabis users are therefore warranted.  The 
striatum has been conceptualised as the interface between motivation and action (Mogenson & 
Yang 1991).  Whilst no relationship was found between apathy and dopamine synthesis 
capacity in the limbic striatal subdivision which has been described as being involved in 
motivation (Martinez et al. 2003), the findings of a significant relationship between apathy and 
dopamine synthesis capacity in the dorsal (associative) striatum fit with findings from the 
Brown et al. (2012) study.  The associative subdivision of the striatum is part of the 
corticostriatal–thalamo-cortical loop projecting to and from associative areas of cortex 
including the dorsolateral prefrontal cortex (Joel and Weiner 2000) which has dense 
interconnections with premotor areas involved in motor planning (Barbas 2000) and therefore 
goal-directed behaviour.   
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7.2.6 Limitations of the study of Dopamine synthesis capacity and its relationship to 
cannabis induced psychotic symptoms 
 
One potential limitation of this study is that subjects consumed their own cannabis, 
rather than a standard preparation.  However, individuals were tested whilst intoxicated and 
the levels of THC in samples of the cannabis subjects were using were measured and it was 
confirmed that the cannabis contained high levels of THC in all subjects (mean THC content 
= 8.7%).  There was no fixed interval between cannabis exposure and PET, meaning that 
heavier cannabis users may have had a shorter interval between exposure and scan.  It therefore 
remains possible that differences in the time since last cannabis use contribute to the differences 
between the dependent/abuser and non-dependent groups, rather than dependency or abuse per 
se.   In addition, the lack of association between cannabis-induced psychotic symptoms may 
be due to variable interval between cannabis exposure and PET.  However, in terms of acute 
effects of cannabis, only 1 of 3 PET studies of the acute effects of THC in healthy volunteers 
has found evidence of dopamine release (Bossong et al. 2009; Stokes et al. 2009; Barkus et al. 
2012), suggesting that the acute effects of THC on dopaminergic function may not be large or 
consistent in humans.     As a challenge in these earlier studies is one of relatively low sample 
size,  Bossong et al. (2015) have recently combined data from their 2009 study with those from 
the Stokes et al. (2009) study so that data are available on n=20 participants.  In this new 
analysis, [11C]raclopride binding in the limbic striatum is reduced by -3.65 %, consistent with 
THC-induced dopamine release.  However, Nutt et al. (2015) are of the opinion that this is 
relatively smaller than the drug-induced dopamine release caused by other recreational agents, 
particularly the stimulants. Given that THC and its metabolites have an elimination half-life of 
about 7 days (Maykut et al. 1985), and all the cannabis users were regular, long-term users 
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who had consumed cannabis within the last 7 days (median time since last consumption = 14 
hours), subjects were unlikely to be acutely withdrawing.  
 
The measures of substance use rely on self-report and it was not possible to 
independently verify substance use histories beyond on-going cannabis use in the user group 
and no recent use of other drugs in all participants.  As would be expected, higher rates of other 
substance use were reported in cannabis users, although, with the exception of tobacco, the use 
of other substances was low in both groups.  The findings remained significant after co-varying 
for all other drug use suggesting that use of other substances does not underlie the findings, 
although it should be noted that the analysis of co-variance may be less able to adjust for factors 
when groups differ significantly in covariates (Miller et al. 2001) and should be considered 
exploratory.  It is therefore impossible to exclude the possibility that group differences in other 
drug use contributed to the results observed.   
 
Whilst cannabis users in the sample reported higher levels of ecstasy use than controls, 
ecstasy has been associated with increased dopamine synthesis capacity (Tai et al. 2011), so 
this is unlikely to explain the findings.  More of the cannabis users smoked cigarettes than 
controls.  The effects of cigarette smoking on presynaptic dopamine function are unclear - 
tobacco use has been associated with reduced amphetamine-induced dopamine release (Busto 
et al. 2009), but increased dopamine synthesis capacity (Salokangas et al. 2000).  In addition, 
tobacco smoking may influence [18F]-DOPA kinetics via cerebral blood flow effects (Domino 
et al. 2004), which, if regionally selective could affect the outcome measure (Kicer).  However, 
a relationship was not found between levels of cigarette consumption and dopamine synthesis 
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capacity, suggesting this does not influence the results, although further research is needed to 
determine the effect of tobacco smoking on dopaminergic function. 
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7.2.7 Summary of Findings from the Study of Dopamine Synthesis Capacity and its 
Relationship to Cannabis-Induced Psychotic Symptoms 
 
These results show that regular long-term cannabis use is associated with a dose-
dependent reduction in dopamine synthesis capacity in the corpus striatum, particularly in those 
meeting diagnostic criteria for cannabis abuse or dependence.  However, no relationship was 
found between dopaminergic function and cannabis-induced psychotic-like symptoms. These 
findings question the prevailing assumption that cannabis increases the risk of schizophrenia 
by inducing the same dopaminergic alterations seen in schizophrenia (Bowers & Kantrowitz 
2007). 
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7.3 Salience Attribution and its Relationship to Cannabis-Induced Psychotic Symptoms 
 
7.3.1 Key Results 
 
The main finding from this study is that regular long-term cannabis use is not associated 
with statistically significant differences in behavioural measurements of salience processing.  
However, these results show preliminary evidence for a difference in implicit aberrant salience 
between cannabis who do and do not meet DSM-IV criteria for cannabis abuse or dependence 
(F1,15 = 5.8, p = .03, effect size: Cohen’s d = 1.2). The relationships between current cannabis 
use and salience processing approached the threshold for statistical significance (r =.49, p = .06 
[implicit aberrant]; r = -.46, p = .07[explicit adaptive]) suggesting that increased use of the drug 
may be associated with increased aberrant and concomitant decreased adaptive salience.  
Within cannabis users who experienced a cannabis-induced psychotic-like symptoms, there 
was a significant relationship between cannabis-induced psychotic-like symptom severity and 
explicit aberrant salience processing (r = .61, p = .01).  In an exploratory analysis, within 
controls there were positive relationships between both measures of adaptive salience and 
whole striatal dopamine synthesis capacity (r = .94, p = .006[implicit]; r = .82, p = .05 
[explicit]), whilst there was inverse relationship between implicit aberrant salience and whole 
striatal dopamine synthesis capacity (r = -.91, p = .01).  However, no significant relationships 
between whole striatal dopamine synthesis capacity and salience processing were observed in 
cannabis users.  The results also indicate a loss of relationship between implicit salience 
processing and dopamine synthesis capacity in the whole striatum associated with long-term 
cannabis use (z = 2.12, p = .03 [adaptive], z = -2.12, p = .04[aberrant]).  
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7.3.2 Hypothesis 3: Regular cannabis users sensitive to cannabis’ psychotogenic effects 
exhibit elevated aberrant salience compared with nonuser control subjects 
 
The findings that regular cannabis users sensitive to cannabis’ psychotogenic effects 
exhibit no significant difference in aberrant salience compared with non-user control subjects 
is inconsistent with the hypothesis that regular cannabis users sensitive to cannabis’ 
psychotogenic effects exhibit elevated aberrant salience compared with nonuser control 
subjects.    
 
7.3.3 Hypothesis 4: There will be a direct relationship between aberrant salience 
attribution and cannabis-induced psychotic-like symptom severity. 
 
The finding of a significant correlation between cannabis-induced psychotic-like 
symptom severity and explicit aberrant salience provides evidence to support the hypothesis 
that there will be a direct relationship between aberrant salience attribution and cannabis-
induced psychotic-like symptom severity. 
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7.3.4 Exploratory hypothesis A.  Cannabis users who meet DSM-IV diagnostic criteria 
for cannabis dependence or abuse will exhibit elevated aberrant salience compared to 
users who do not meet dependence or abuse criteria. 
 
The finding of elevated implicit aberrant salience in cannabis users who met DSM-
IV(TR) criteria for cannabis dependence or abuse compared to users who do not meet criteria 
supports this hypothesis.   
 
7.3.5 Exploratory hypothesis B. There will be a direct relationship between dopamine 
synthesis capacity and aberrant salience processing.   
 
The findings of an inverse relationship between dopamine synthesis capacity and 
implicit aberrant salience in healthy controls and no significant relationship between the two 
measures in cannabis users is inconsistent with this hypothesis.   
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7.3.6 Interpretation of Findings from the Study of Salience Attribution and its 
Relationship to Cannabis-Induced Psychotic Symptoms 
 
This is the first study to examine aberrant salience processing in cannabis users.  Whilst 
there was no significant difference in aberrant salience between the cannabis users and controls, 
findings of increased implicit aberrant salience in cannabis users who meet DSM-IV(TR) 
criteria for abuse or dependence compared to those who do not, together with the trends toward 
a positive and negative relationship between current cannabis use and measures of aberrant and 
adaptive salience, respectively are consistent with the prediction that heavy cannabis use is 
associated with a state of aberrant salience (i.e. as described by Kapur [2003]) and this may 
account for the association between cannabis use and increased psychosis-proneness (Nunn et 
al. 2001).  This is further supported by the finding that cannabis-induced psychotic-like 
symptom severity and explicit aberrant salience are significantly positively correlated, in line 
with findings of a positive relationship between explicit aberrant salience and delusion-like 
symptoms in people at ultra-high risk of psychosis (Roiser et al. 2013) (Figure 7.1) and 
delusional symptoms in people with schizophrenia (Roiser et al. 2009), which in turn provide 
evidence supporting the face validity of the SAT.  Since pre-existing high schizotypy 
(psychosis-proneness) increases the likelihood of a psychotogenic response to cannabis (e.g. 
Nunn et al. 2001), increased explicit aberrant salience may underlie this process.   
 
In addition, there were some novel findings not predicted by the aberrant salience 
hypothesis.  These were that in healthy controls, whole striatal dopamine synthesis capacity 
was positively correlated with both measures of adaptive salience processing and negatively 
correlated with implicit aberrant salience.   
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Figure 7.1 Explicit aberrant salience was positively correlated with delusion-like 
symptoms in individuals at ultra-high risk of risk psychosis.  (Abbreviations: VAS, visual 
analogue scale; CAARMS, Comprehensive Assessment for the At Risk Mental State)    
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The finding of opposite relationships between dopamine synthesis capacity and salience 
processing in healthy controls is not predicted by the aberrant salience hypothesis, where 
increased dopamine synthesis capacity is predicted to be related to increased aberrant salience 
and not vice versa.  The only study to have previously assessed dopamine synthesis and 
aberrant salience processing did not find significant relationships between the measures (Roiser 
et al. 2013).  However, that study did report that higher dopamine synthesis capacity predicted 
greater adaptive reward prediction haemodynamic responses in controls, whereas the opposite 
relationship applied in the individuals at ultra-high risk of psychosis, in line with the findings 
in control subjects in the current study.  Roiser et al. (2013) speculated that the positive impact 
of high dopamine synthesis capacity on motivational salience signalling may depend on the 
baseline state of the dopamine system, such that in healthy volunteers, high dopamine synthesis 
capacity may facilitate the transmission of motivational salience, potentiating appropriate 
phasic signals against a background of relatively low gain or tonic dopamine release.  Taken 
together with findings that there is a loss of relationship between implicit salience processing 
and dopamine synthesis capacity in the whole striatum associated with long-term cannabis use, 
and given that the mesolimbic dopamine system plays a central role in normal salience 
processing (Zink et al. 2003) which is modulated by the endocannabinoid signalling 
(Fernandez-Ruiz et al. 2010; Melis et al. 2012; Melis & Pistis 2012), this would suggest that 
long-term cannabis use may give rise to aberrant salience by disrupting dopaminergic salience 
processing.  Whilst the effects of acute THC on aberrant salience processing using the SAT 
have yet to be reported in the literature, and the case-control design of this study is not able to 
infer causality, there is evidence from a study using the oddball task (Bhattacharyya et al. 2012) 
that THC reduces latency to non-salient vs. salient stimuli in healthy volunteers, consistent with 
this interpretation.  However, this phenomena may not be restricted to reward-based learning 
only, as increased speed and error rates observed were observed with THC challenge in a 
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learning and episodic memory task (Curran et al. 2002).  Nonetheless, long-term cannabis use 
has been associated with impairments in filtering out non-salient information during a selective 
attention task (Solowij et al. 1991) and THC resulted in irrelevant background visual and 
auditory stimuli becoming more salient during the performance of a visual processing task 
(D’Souza et al. 2004).    
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7.3.7 Cannabis, Cognition and Schizophrenia 
 
Impaired cognition is a key feature of schizophrenia and this is more predictive of 
functional outcome than any other symptomatic measure (Green 1996).  Endophenotypes are 
internal markers of a disorder and can be present across multiple domains e.g. biochemical, 
anatomical, or cognitive markers of functional capacity.  In complex disorders, such as 
schizophrenia, endophenotypes have been thought of as quantitative traits intermediate 
between the predisposing causative mechanisms (e.g. genotype) and overt clinical signs and 
expressed symptoms, i.e. the phenotype (Gottesman & Gould 2003, Gottesman & Hanson 
2005).  Adolescence is a period of vulnerability to the development of neurocognitive effects 
associated with cannabis use and there is also growing evidence that cannabis use is associated 
with multiple cognitive endophenotypes that are in common with schizophrenia such as 
response inhibition (i.e. more effortful response inhibition on Go/No-Go, stop-signal and 
stroop tasks, suggestive of impaired anterior cingulate and inhibitory control prefrontal 
networks[Kiehl et al. 2000; Weisbrod et al. 2000; Badcock et al. 2002; Braff et al. 2004; Kerns 
et al. 2005]);  sustained attention (i.e. poor performance on continuous performance tasks 
[Cornblatt et al. 1994; Michie et al. 2000]), working memory (i.e. impaired active maintenance 
and manipulation of stored information critical for planning and guiding behaviour, suggestive 
of deficits in prefrontal, parietal and subcortical networks) and executive function (as measured 
with tasks of frontal lobe functions such as verbal fluency, Tower of London task and 
Wisconsin Card Sorting Test [Heinrichs et al. 2005; Pantelis et al. 1997]) (Solowij & Michie 
2007).   
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Yet, behavioural studies have demonstrated that acute THC challenge produces 
transient, acute psychotic reactions, the extent of which are unrelated to the degree of cognitive 
impairment or anxiety.  There is a large body of evidence describing the vulnerability of 
adolescents to impaired cognition, across a range of domains, associated with cannabis use 
(reviewed by Jager & Ramsey 2008).  Animal studies indicate that brain CB1 receptor levels 
peak in early adolescence (Belue et al. 1995) and humans exposed to cannabis in adolescence 
are more likely to have impaired neurocognitive function than individuals exposed in adult life 
(Fontes et al. 2011).  Furthermore, there is evidence that neurocognitive deficits (such as 
impaired reaction times, attention and memory) associated with adolescent cannabis use can 
persist after abstinence (Medina et al. 2007).   As described by Schmidt & Roiser (2009) in 
order to perform the SAT, participants must be able to attend continuously for an extended 
period, use working memory, learn probabilistic associations and guide responses on the basis 
of such associations, all of which may be impaired with cannabis use (Scholes & Martin-
Iverson 2009; Pope et al. 2001), therefore potentially explaining poorer measures in the 
cannabis-dependent group because learning and memory are impaired.  In a study assessing 
the construct validity of the SAT, in order to examine whether other cognitive processes 
(including working memory, sustained attention, probabilistic reversal learning) were 
influencing measures on the SAT, Schmidt & Roiser (2009) performed a factor analysis using 
the SAT with a battery of cognitive tasks.  They found that the SAT could dissociate aberrant 
salience processing from other aspects of reward learning and attention (including 
operant/explicit learning, general cognitive ability, contingency-based speeding and attentional 
vigilance), although adaptive salience and learned irrelevance were associated with each other.  
It is therefore unlikely that other aspects of cognitive function that are affected by cannabis use 
are influencing the current results.  Although, these were not verified in the current study, and 
so the findings may be due to impaired learning and memory in the cannabis group.  Likewise, 
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findings of increased implicit aberrant salience in cannabis users who were dependent on the 
drug may be related to THC effects on memory and motivation.  However, the cannabis users 
in this study had faster reaction times than non-users on both high and low probability items in 
both blocks of the SAT, suggesting that general psychomotor slowing in cannabis users is 
unlikely to account for the current results.   
 
7.3.8 Limitations of the Study of Salience Attribution and its Relationship to Cannabis-
Induced Psychotic Symptoms 
 
A potential limitation of the current study is that subjects consumed their own cannabis, 
rather than a standard preparation.  However, individuals were tested whilst intoxicated and 
the levels of THC in samples of the cannabis subjects were using were measured and it was 
confirmed that the cannabis contained high levels of THC.  There was no fixed interval between 
cannabis exposure and SAT session, meaning that heavier cannabis users may have had a 
shorter interval between exposure and scan.  It therefore remains possible that differences in 
the time since last cannabis exposure, and therefore acute vs. chronic effects of cannabis, 
contribute to the differences between the dependent/abuser and non-dependent groups, rather 
than dependency or abuse per se.  The measures of substance use rely on self-report and it was 
not possible to independently verify substance use histories beyond on-going cannabis use in 
the user group and no recent use of other drugs in all participants.   
    
Given that a relatively small sample of cannabis users was tested and multiple statistical 
comparisons were performed, there is a raised possibility of type I errors.  It is also important 
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to consider the possibility of type II error in these findings.  The sample had 99% power to 
detect the effect size (Cohen’s d = 1.6) seen in a previous study of salience processing in 
patients with schizophrenia, which is above the 80% power threshold conventionally 
considered adequate.  Whilst at this power there is a 1% chance that a true effect at this 
magnitude has been missed, consideration should be given to the possibility that a weaker effect 
has been missed.  Sensitivity analysis indicates that this study would be able to detect an effect 
side of Cohen’s d = .99 with 80 % power.  Furthermore, since the SAT continues four measures 
of salience processes, in order for these to survive Bonferroni correction, applying an alpha 
= .0125 would decrease the sensitivity of this study to detect an effect size of d = 1.2 with 80 % 
power.  Therefore, a larger sample size would be required to detect less pronounced effects of 
cannabis use on salience processing, which may indeed be the case given that none of the 
cannabis users experienced psychotic symptoms when not intoxicated with the drug and 
therefore at the time of undertaking the SAT.   
 
A recently published large randomized, placebo-controlled study found that THC 
increased paranoia by increasing negative affect (i.e. depression and anxiety).  A further 
limitation of this study would therefore be that measures of depression and anxiety, such as the 
Beck Depression Inventory and the Beck Anxiety Inventory, were not recorded.  Future work 
should therefore assess the relationships between both long-term cannabis use and acute THC 
on salience processing, psychotic symptoms, paranoia and negative affect.   
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7.3.9 Summary of the Findings of the Study of Salience Attribution and its Relationship 
to Cannabis-Induced Psychotic Symptoms 
 
These results suggest that cannabis dependence and abuse is associated with increased 
implicit aberrant salience processing, and that within cannabis users there is a positive 
relationship between explicit aberrant salience and cannabis-induced psychotic-like symptom 
severity.  There is also evidence that long-term cannabis use was associated with altered 
relationships between striatal dopamine synthesis capacity and salience processing.  Long-term 
cannabis use may therefore be increase the risk of psychotic like symptoms by increasing 
aberrant salience via non-dopaminergic mechanisms of reward-processing.  
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7.4 Dopamine Synthesis Capacity and its Relationship to Psychosocial Risk Factors for 
Schizophrenia 
 
7.4.1 Key Results 
 
The main finding from this study is that striatal dopamine synthesis capacity is lower 
in individuals with a high cumulative exposure to psychosocial stress than those with a low 
cumulative exposure to psychosocial stress (effect size: Cohen’s d = .91; t24 = 2.32, p = .029).  
Within individuals with a high cumulative exposure to psychosocial stress, the combination of 
childhood stressors and recent adult stressors was positively correlated with dopamine 
synthesis capacity in the associative subdivision of the striatum (r = .68, p = .01), explaining 
46 % of the variance in dopamine synthesis capacity.   
 
7.4.2 Hypothesis 5: Participants with a high cumulative exposure to psychosocial risk 
factors for schizophrenia will exhibit elevated dopamine synthesis capacity compared to 
participants with low cumulative exposure to the same environmental stressors.   
 
The finding that participants with a high cumulative exposure to psychosocial stressors 
exhibit reduced dopamine synthesis capacity compared to participants with low cumulative 
exposure is inconsistent with this hypothesis.   
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7.4.3 Hypothesis 6: Within participants with a high cumulative exposure to psychosocial 
stressors, there will be a direct relationship between dose of psychosocial stress and 
dopamine synthesis capacity.   
 
The findings of a significant correlation between dopamine synthesis capacity and a 
combined score of childhood and recent stressors is consistent with this hypothesis. 
 
7.4.4 Interpretation of the Study of Dopamine Synthesis Capacity and its Relationship to 
Psychosocial Risk Factors for Schizophrenia 
 
This is the first study to directly compare dopamine synthesis capacity in healthy 
participants with and without long-term exposure to psychosocial stress.  Childhood adversity 
increases the risk of adult mental illness and psychosis in particular, accounting for up to 33 % 
of cases (Varese et al. 2012).  Although the case–control design of this study is not able to 
detect a causative relationship between psychosocial stress and dopamine dysfunction, the 
findings suggestive of a potential dose relationship between psychosocial stress and dopamine 
synthesis capacity warrant further research into potential causative mechanisms.   
 
One explanation for the group difference is that long-term exposure to psychosocial 
stress is associated with dopaminergic down-regulation, particularly in the limbic striatum.  
This would be consistent with an fMRI study with found that adolescents who had suffered 
severe early life deprivation exhibited ventral striatal hyporesponsivity during anticipation of 
monetary reward (Mehta et al. 2010).  However, this would not be consistent with the finding 
of a relationship between dopamine synthesis capacity in the associative striatum and combined 
childhood and recent adult stress.  Yet, a finding in a [11C]-raclopride study (Pruessner et al. 
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2004) in which ventral striatal dopamine release was increased in response to psychosocial 
stress in humans who reported insufficient early life maternal care would suggest that dopamine 
system can become sensitised to psychosocial stressors.  Likewise, Oswald et al. (2014) 
reported positive associations between childhood adversity and amphetamine-induced 
dopamine release.  Furthermore, in a subsequent [11C]-raclopride study Wand et al. (2007), 
stress-induced cortisol levels were positively associated with amphetamine-induced dopamine 
release in the striatum.  The current findings of a relationship between childhood stressors and 
recent adult life events and associative striatal dopamine synthesis capacity is consistent with 
the a [11C]-PHNO study in which  Mizrahi et al. (2011) found increased psychosocial stress-
induced dopamine release in the associative and sensorimotor functional subdivisions of the 
striata of antipsychotic-naïve subjects with schizophrenia and those at clinical high-risk of the 
illness compared to matched healthy controls, possibly indicative of a sensitised dopaminergic 
stress response.  Furthermore, the finding of a positive relationship between childhood and 
adult recent psychosocial stressors in the associative (dorsal) subdivision of the striatum is 
pertinent, the region in which dopamine dysfunction has been observed most frequently in 
psychosis (Howes et al. 2009).  However, this interpretation should be considered highly 
speculative given the overall group reduction in dopamine synthesis capacity in the high stress 
group compared to low stress group.   
 
The study examined a variety of known psychosocial stressors and was not powered to 
perform multiple analyses to examine any potential differential effects.  One possibility is that 
continual low level stressors, as would be encountered by urbanicity for example, have a 
dampening effect on the dopamine system, whilst repeated sudden traumatic stressors, as 
would be the case with child abuse or adult life events potentiate the dopamine system.  In 
support of this interpretation is animal evidence that finds both increases and decreases in 
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dopaminergic response depending on the type of stressor, its duration and the age of the animal 
at the time of stressor.  For example, maternal deprivation and isolation of neonatal rats was 
associated with increased dopamine release (Hall et al. 1999; Kosten 2003), whilst unavoidable 
stress administered over one week and three weeks was associated with a decrease in nucleus 
accumbens dopamine output (Mangiavacchi et al. 2001). Furthermore, rats under a ten day 
episodic defeat paradigm had a sensitised dopamine response in the nucleus accumbens, whilst 
when under a 5 week continuous subordination paradigm they exhibited a suppressed 
dopamine response (Miczek et al. 2011).   
 
7.4.5 Limitations of the Study of Dopamine Synthesis Capacity and its Relationship to 
Psychosocial Risk Factors for Schizophrenia 
 
The measures of psychosocial stress rely on self-report and it was therefore not possible 
to independently verify the histories of psychosocial stressors.  Furthermore, the assessment of 
childhood trauma may be liable to recall bias in depressed patients (Lewinsohn & Rosenbaum, 
1987).  However, measures of childhood trauma have also been demonstrated to remain stable 
over time and to be independent of the current degree of abuse-related psychopathology (Paivio 
2001).  Despite ongoing concerns that retrospective reporting overestimates associations 
between abuse and adult psychopathology (Gilbert et al. 2009), there is evidence that 
prospective and retrospective measures of abuse predict similar rates of mental illness (Scott 
et al. 2012) and recall bias accounts for less than 1% of variance in measures of child abuse 
(Fergusson et al. 2011).  Yet, difficulties remain in measuring and quantifying emotional 
neglect due in part to its highly subjective nature (Watson et al. 2014).  As this was the first 
study to mention brain dopamine synthesis capacity in human participants exposed to a range 
of psychosocial risk factors for the disorder, the categorisation is arguably a catch-all, 
 
269 
 
containing a range of experiences from the most serious psychological trauma to demographic 
factors alone.  Along these lines there is no single measure that is used in the literature to index 
both historical and current psycho-social risk factors in the same scale.  Furthermore, 
relationships and interactions between these risk factors are likely to be complex.  As such the 
use of the combined psychosocial stress score in this study should be considered exploratory.  
Given the performance of multiple correlations, a further limitation of this study is that a 
regression model was not conducted.   
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7.4.6 Potential Confounders  
 
There was a trend for the groups to differ in terms of the specific activity of the injected 
radiotracer (p = .06), with higher specific activity in the high stress group.  The group difference 
in whole striatal Kicer remained significant when co-varying for specific activity (F2,25 = 4.6, p 
= .02).  However, across all participants, there was a negative correlation between specific 
activity and dopamine synthesis capacity, suggesting that this could be having an effect on the 
main result.  The specific activity is the physical decay-corrected proportion of radioactive vs. 
non-radioactive tracer concentration.  Yet, a higher specific activity would in theory result in 
greater signal in the striatum vs. the cerebellar reference region, thereby increasing the Kicer, 
which suggests that this potential confound could be spurious.  In other words, a higher specific 
activity in the high stress group would result in an over-estimation of Kicer, thereby increasing 
the magnitude of the observed effect, but not changing the overall finding of this study.   
 
As would be expected, higher rates of smoking were reported in the high psychosocial stress 
group.  The findings did not remain significant in the whole striatum when co-varying for 
cigarette use or removing smokers from the analysis, however the findings did remain 
significant in the limbic striatal subdivision.  Likewise, higher rates of depressive and anxiety 
symptoms were reported in the high psychosocial stress group.  Similarly, the findings did not 
remain significant in the whole striatum when co-varying for depression and anxiety 
symptoms, but did remain significant in the limbic striatal subdivision only.  Whilst the finding 
of reduced limbic striatal dopamine synthesis capacity appears consistent when attempting to 
adjust for confounds, it must be noted again that analysis of covariance may be less able to 
adjust for factors when groups differ significantly in their covariates (Miller & Chapman 2001) 
and should therefore be considered exploratory.   
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As per the above study in cannabis users, the precise effects of tobacco smoking on 
striatal dopamine function remain to be fully elucidated (see below).  Tobacco has been 
associated with increased dopamine synthesis capacity in a study of heavy smokers 
(Salokangas et al. 2000) with no effect seen in a subsequent study of moderate smokers 
(Bloomfield et al. 2014), as well as reduced amphetamine-induced dopamine release (Busto et 
al. 2009). 
 
The dopamine system has been implicated in both the pathophysiology of depression 
and in its treatment (e.g. Nutt 2006).  Higher rates of depression are seen in Parkinson’s disease 
(Cummings & Masterman 1999), which is characterized by reduced dopaminergic 
transmission and both reduced striatal dopamine synthesis capacity and DAT availability have 
been associated with depressive symptoms in Parkinson’s (Koerts et al. 2007; Weintraub et al. 
2005).  Reduced dopamine synthesis capacity has also been found in depressed patients without 
Parkinson’s (Martinot et al. 2001).  One study did find a relationship between trait depression 
severity and D2 receptor availability (Kestler et al. 2000) but in a subsequent study, patients 
with major depressive disorder did not exhibit altered striatal D2 availability and there was no 
relationship between depressive symptoms and D2 receptor availability (Hirvonen et al. 2008).  
However, reduced striatal DAT availability has been observed in depression (Meyer et al. 
2001) and has been found to be associated with the duration of dysthymia (Lehto et al. 2008).  
Although some studies have not found altered DAT availability in depression (Moresco et al. 
2000).  There is also evidence that patients with depression exhibit greater monoamine oxidase 
activity (Meyer et al. 2006).  Given the evidence that dopaminergic function may be reduced 
in depression together with the finding that negative affect may be influencing the result from 
the present study, further work is therefore warranted to investigate causative mechanisms, 
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given that both childhood adversity and recent life events are risk factors for depression 
(Kendler et al. 2004; Biondi & Picardi 1999).   
 
Lastly, the groups in this study differed significantly in their ethnicity.   It is not known 
if ethnicity has an effect on dopamine synthesis capacity.  However, even though there is no 
available evidence to suggest that this may be the case, a further study assessing dopaminergic 
function in people of different ethnicities would be needed in order to exclude this possibility.   
 
7.4.7 Summary of Findings of the Study of Dopamine Synthesis Capacity and its 
Relationship to Psychosocial Risk Factors for Schizophrenia 
 
These findings show that long-term exposure to psychosocial stressors may be 
associated with reduced striatal dopamine synthesis capacity, particularly in the limbic 
subdivision of the striatum, although this may be associated with affective symptoms and 
tobacco.  However, seemingly contradictorily, these findings also indicate that there is a 
positive relationship between childhood and adult recent psychosocial stressors in the 
associative (dorsal) subdivision of the striatum, the region in which dopamine dysfunction has 
been observed most frequently in psychosis.  The disparity in these findings may reflect a 
differential effects of psychosocial stressors on the striatal dopamine system.   
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7.5. Cigarette Smoking and Dopamine Synthesis Capacity  
 
The potential confounding effects of cigarette smoking on dopamine synthesis capacity 
have been outlined above and will be given detailed consideration here.   
 
Tobacco addiction has been proposed to involve the effects of nicotine on the 
dopaminergic system (Balfour et al. 2000; Pidoplichko et al. 1997) since nicotinic receptors 
have been identified on nigrostriatal and mesolimbic dopaminergic neurons (Clarke & Pert 
1985).  Studies in rodents and non-human primates show that tobacco or nicotine increase 
dopamine neuron firing (Grenhoff et al. 1986; Zhang & Sulzer 2004), increase dopamine 
release (Di Chiara & Imperato 1988; Dewey et al. 1999; Gallezot et al. 2013; Marenco et al. 
2004; Pontieri et al. 1996; Cumming et al. 2003), and increase dopamine synthesis (Tsukada 
et al. 2005) in the mesolimbic system.  There is also evidence that nicotine alters the ratio of 
phasic bursts relative to tonic firing in the nucleus accumbens, thereby increasing the signal-
to-noise relationship of dopamine system (Zhang et al. 2009). 
 
In humans, tobacco use has been associated with both increased striatal dopamine 
synthesis capacity (Salokangas et al. 2000) and dopamine release in response to acute cigarette 
use in smokers (Brody et al. 2004; Le Foll et al. 2013).  However, two studies found that acute 
nicotine use did not elicit a significant dopamine release in smokers (Barrett et al. 2004; 
Montgomery et al. 2007), although these did find that the subjective hedonic response to acute 
nicotine was related to dopamine release.  Yet, a subsequent study found that nicotine did result 
in dopamine release in smokers, but not in non-smokers (Takahashi et al. 2008).  Smoking-
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induced dopamine release has been associated with a reduction in craving and the severity of 
tobacco dependence (Brody et al. 2004).  Yet, unlike other drugs of addiction, drug-related (i.e. 
smoking-related) cues did not result in significant dopamine release in smokers when compared 
with neutral images (Chiuccariello et al. 2013).  However, since the plasma half-life of nicotine 
is approximately two hours (Hukkanen et al. 2005) and that PET study was conducted one hour 
after nicotine exposure, it likely that the findings could be explained by the persistence of 
nicotine resulting in minimized craving and the ability to detect cue-induced dopamine release.  
This is especially relevant given that images of tobacco and tobacco advertising are highly 
salient to cigarette smokers.  An alternative possibility would therefore be that nicotine disrupts 
reward processing via non-dopaminergic mechanisms.   
 
Interestingly, one study (Busto et al. 2009) found that tobacco dependence was 
associated with reduced amphetamine-induced striatal dopamine release, although this is likely 
exacerbated by comorbid depression.  Also of interest, are findings from one study using 
decotinised cigarettes which suggest that there may be lateralisation effects of the 
dopaminergic system relating to nicotine addiction, such that the left striatum has been 
associated with nicotine-induced striatal dopamine release, whilst the right striatum was not 
(Domino et al. 2013). 
 
In terms of receptor availability, one study found that there were differences in D2 
receptor availability between male smokers vs. non-smokers, whilst no differences were 
observed between female smokers vs. non-smokers (Brown et al. 2012).  This study also found 
that there were differences in caudate and putamen D2 receptor availability between male and 
female smokers, but not between male and female non-smokers.  In a separate study (Fehr et 
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al. 2008), reduced striatal D2 receptor availability was reported in smokers compared to non-
smokers, with a positive correlation between nicotine craving and ventral striatal D2 
availability.   Reduced ventral striatal D1 receptor availability has likewise been reported in 
smokers vs. non-smokers (Dagher et al. 2001; Yasuno et al. 2007).  Although other studies 
reported no significant difference in D2 availability between smokers and non-smokers (Yang 
et al. 2006; Yang et al. 2008). 
 
 
These findings may reflect differences in the study design (Gallezot et al. 2013), the 
influence of other factors, such as sex effects, co-morbidity, or genetic variants (Dierker et al. 
2002; Kendler et al. 1993; Lerman et al. 1998; Zhang et al. 2006), or the difficulty of imaging 
dopamine changes that are comparatively small (Egerton et al. 2010).  In terms of other aspects 
of dopaminergic function, whilst three studies did report reduced dopamine transporter 
availability in smokers vs. non-smokers (Yang et al. 2008; Newberg 2007; Leroy et al. 2012), 
a large study on the dopamine transporter did not find an association between cigarette smoking 
and dopamine transporter availability (Thomsen et al. 2013), in line with earlier findings 
(Staley et al. 2001). 
 
These studies indicate that striatal dopamine synthesis may be altered by nicotine 
exposure.  Only one study had previously investigated dopamine synthesis capacity in cigarette 
smokers. This study, exclusively in male volunteers, found that striatal uptake of [18F]-DOPA 
was 16–29% higher in smokers than non-smokers (Salokangas et al. 2000).  However, as this 
sample was exclusively of males and there is evidence of sex differences in the release of 
dopamine in response to nicotine (Dluzen and Anderson, 1997), dopamine synthesis capacity 
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was examined in a larger sample of cigarette smokers that included females and did not have a 
history of psychiatric co-morbidity including depression and alcohol use disorders, compared 
to controls, to further examine whether tobacco smoking was influencing the findings of 
reduced dopamine synthesis capacity in cannabis users (Chapter 3) and individuals exposed to 
long-term psychosocial stressors (Chapter 5).     
 
Dopamine synthesis capacity was measured in 15 cigarette smokers compared to 15 
non-smoker controls (Bloomfield et al. 2014) using the same methods employed for the 
measurement of Kicer as described in Chapter 3.  This study found no evidence for altered 
striatal dopamine synthesis in tobacco smokers compared with non-smokers (figure 7.2), or 
relationship between the levels of daily cigarette smoking and dopamine synthesis capacity (r 
= −.23, p = .41).  Furthermore, an effect of nicotine dependence on dopamine synthesis capacity 
was not observed.   
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Figure 7.2 Whole striatal dopamine synthesis capacity (indexed Kicer) in smokers 
compared to non-smokers (tdf = .6428, p = .53).  
 
These negative findings are in contrast to a previous report of elevated dopamine 
synthesis capacity in 9 male smokers compared with 10 non-smokers (Salokangas et al. 2000). 
Although striatal dopamine synthesis capacity may be higher in females (Laakso et al. 2002), 
this was not evident in this sample. The subjects in the study by Salokangas et al. were heavy 
smokers (at least 15 cigarettes/day, mean 19.8 cigarettes/day compared with mean 8.1 
cigarettes/day in this study), which could explain the difference with these findings.  Although 
there was no evidence of a relationship between Kicer and the level of daily cigarette 
consumption, this may indicate that elevations in presynaptic dopamine synthesis capacity are 
only apparent in heavy smokers. 
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The study by Salokangas et al. (2000) used the same methodology as a previous study 
by Hietala et al. (1999), i.e. Carbidopa 100 mg only was administered 90 min before PET scan 
(Personal Communication from Professor Salokangas), followed by measurement of 
radiolabeled metabolites in the arterial input function.  This is in comparison to the carbidopa 
150 mg and entacapone 400 mg administered one hour before PET scan followed by a 
cerebellar reference region approach in this study.  Data on the effects of smoking on the 
pharmacodynamics of entacapone are lacking. Entacapone undergoes rapid hepatic metabolism 
via the uridine 5'-diphospho-glucuronosyltransferase pathway (Lautala et al. 2000).  Data from 
studies in humans (Bock & Köhle 2004) and mice models (Villard et al. 1998) indicate that 
cigarette smoke is a potent inducer of uridine 5'-diphospho-glucuronosyltransferase, which 
would thus lead to a faster elimination of entacapone and therefore a potential reduction in 
plasma [18F]-DOPA in smokers vs controls whom have had entacapone administered. As the 
reference region approach theoretically eliminates the plasma input function, it would be 
predicted that the main effect of any potential reduction in plasma [18F]-DOPA would result in 
increased variability of Kicer without altering mean Kicer. However, there are limited data 
directly comparing Ki values obtained via a tissue reference region and arterial plasma input 
function method, as was the case in the study by Salokangas et al. (2000). Sossi et al. (2003) 
reported a comparison between a reference region and arterial input function approach.  In that 
study, Sossi et al. used the occipital lobe as the reference region, rather than the cerebellum 
used in this study.  Therefore, it remains possible that a difference in entacapone metabolism 
in smokers may be underlying the disparity in results between this study and that of Salokangas 
et al. (2000). Nevertheless, the entry into and exit from the brain of radiolabeled plasma 
metabolites may affect graphical analysis (Boyes et al. 1986; Cumming et al. 1987) and could 
bias results if metabolism is selectively altered in one group. Compared with non-smokers, 
smokers have reduced cerebrospinal levels of the dopamine metabolite homovanillic acid 
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(Geracioti et al. 1999) and there is evidence of reduced MAO-A and MAO-B activity in 
smokers (Fowler et al. 1996a, 1996b).  However, as these differences would, if anything, 
reduce the production of radiolabeled metabolites in smokers, they are unlikely to explain the 
failure to detect an elevation in smokers. In summary, even if entacapone clearance is higher 
in this smoker group, it cannot be concluded that it would be sufficient to impact metabolite 
production within the experimental window. Furthermore, even if there was a sufficient impact 
on metabolite production, the use of a reference region approach would be expected to be 
sufficiently robust to overcome this problem. 
 
Survey data in Great Britain indicate that over the last few decades there has been a 
gradual decline in the number of cigarettes consumed per day among smokers, such that the 
average number of cigarettes smoked per day is now 12 for men and 11 for women (Office for 
National Statistics, 2013).  The sample of moderate smokers is therefore in the same range as 
that of the general population. Overall the findings and those of Salokangas et al. thus indicate 
that there is no markedly altered dopamine function in moderate smokers, but alterations are 
apparent in heavy smokers.  
 
The role of the dopamine system in drug reinforcement has long been accepted from 
animal studies (e.g. Koob 1992) and there is mounting evidence that dysregulated dopamine 
function is central to addiction behaviours in humans (as reviewed by Volkow et al. 2011), 
although there is emergent evidence of parallel opioid-dopaminergic abnormalities in addiction 
(e.g. Scott et al. 2007).  There is growing evidence that chronic drug abuse is associated with 
abnormal striatal dopaminergic functioning in humans, as has been found with alcohol (Heinz 
et al. 2005), cannabis (Chapter 3), cocaine (Wu et al. 1997), methamphetamine (Wang et al. 
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2012), and ecstasy (Tai et al. 2011).  However, the study suggests that dopamine dysregulation 
may only become apparent at higher levels of use, either because it is below the level of 
detection with more moderate use, or because it is a cumulative consequence of heavy use.  It 
must be emphasised that like all of the cross-sectional studies on dopamine transmission, that 
the presence or absence of dopaminergic abnormalities may be due to interactions between a 
trait (i.e. addiction proneness) and a state (e.g. addiction, withdrawal or abstinence).   
 
Therefore, as dopamine synthesis capacity has been found to be elevated in heavy 
smokers vs. controls, and found to be the same in moderate smokers vs. controls, it is extremely 
unlikely that smoking is contributing to the findings of reduced dopamine synthesis in both 
cannabis users vs. controls (Chapter 3) and individuals with high exposure to long-term 
psychosocial stressors vs. individuals with low exposure (Chapter 6).   
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7.6 General conclusions and future directions  
 
The studies detailed above indicate that there was a relationship between cannabis-
induced psychotic-like symptoms and aberrant salience processing and long-term cannabis use 
is associated with an altered relationship between salience processing and dopamine synthesis 
capacity.  However,  the lack of a significant relationship between dopamine synthesis capacity 
and cannabis-induced psychotic-like symptoms and the finding that cannabis use was 
associated with reduced, rather than increased, striatal dopamine synthesis capacity is not 
consistent with the model that cannabis increases the risk of psychosis by creating a state of 
aberrant salience via increased dopamine synthesis capacity.   
 
In line with these findings, Thompson et al. (2013) found that patients with comorbid 
schizophrenia and substance dependence, including cannabis, had reduced amphetamine-
induced dopamine release.  Yet, despite a blunted dopamine response, this study found the 
previously described relationship between dopamine release and increase in psychotic 
symptoms (as per Laruelle et al. 1999), which they suggested may be due to super-sensitivity 
of the D2 receptor in line with a recent hypothesis advanced by Seeman & Seeman (2014), 
findings from animal studies that chronic THC sensitises the D2 receptor (Ginovart et al. 2012) 
and that genetic variation of AKT1 genotype may alter D2 receptor signalling to increase the 
risk of cannabis-induced psychosis (Di Forti et al. 2012).  This therefore calls into question the 
final common pathway hypothesis, which has gained traction since its publication.  As Murray 
et al. (2014) commented : 
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“… it is becoming clear is that there are different pathways to schizophrenia-like 
psychosis (Howes & Murray 2013). These pathways include neurodevelopmental 
impairment, affective disturbance, and abuse of drugs. Furthermore, it seems that 
excess striatal dopamine synthesis is not the final common pathway in all psychotic 
individuals.”  
 
 
Whilst the Aberrant Salience hypothesis has heuristic value, one key phenomenological 
aspect of schizophrenic psychosis that is not accounted for by the Final Common Pathway 
model is paranoia.  Paranoia is both central to a diagnosis of paranoid schizophrenia, although 
it exists on a continuum of severity in the general population (Bebbington et al. 2013), and has 
been identified by factor analysis to be independent of other psychotic experiences (Ronald et 
al. 2013).     In simple terms, paranoia is about reading threat in neutral settings.  Whereas this 
is entirely compatible with the aberrant salience hypothesis in terms of increased threat-related 
aberrant salience, it does not take into account reward-based aberrant salience.  To put this 
another way – why would increased dopamine synthesis only result in paranoia and not positive 
incentive motivation?  If this alternative mechanism (i.e. increased positive incentive salience) 
occurs, might this explain manic episodes in bipolar affective disorder?  Whilst dopamine 
antagonism is used clinically in the treatment of manic episodes and some antipsychotic agents 
have mood stabilizing properties, the initial hypothesis as advanced by Kapur does not take 
these issues into account and further research is needed to explore these possibilities.   
 
In addition to the link between cannabis-induced psychotic symptoms and aberrant 
salience, THC has also been proposed to increase anxiety via amygdala endocannabinoid 
receptors (Bhattacharyya et al. 2010).  In a large randomized, placebo-controlled, study of 
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THC, Freeman et al. (2014) found that increases in paranoia caused by THC were accounted 
for by increases in negative emotions such as anxiety.  There is novel evidence that 
dopaminergic mechanisms may be underlying this process too as a recent study by Volkow et 
al. (2014) found that, compared to controls, cannabis users had a blunted methylphenidate-
induced dopamine release and that within cannabis uses, dopamine release was inversely with 
negative emotions and addiction severity.   
 
Furthermore, the finding of an inverse relationship between apathy and dopamine 
synthesis capacity in cannabis users could provide an indirect route to increase psychosis risk, 
by increasing social withdrawal resulting in reduced data gathering (i.e. jumping to 
conclusions) (Garety & Freeman 1999) and reducing motivation to generate or considerate 
alternative explanations for experiences (Freeman et al. 2004), in line with the threat 
anticipation model of persecutory delusions (Freeman 2007).   However, this is speculative and 
requires further investigation.   
 
 It must of course be held in mind that outside the association of cannabis and frank 
schizophreniform psychosis, long-term heavy use cannabis is associated with a number of 
adverse outcomes that themselves resemble the different phenotypic domains of the illness.  
These are increased positive psychotic symptoms (as reviewed in chapter 1), cognitive 
impairment (Crane et al. 2013; Fried et al. 2005; Meier et al. 2012) and negative symptoms 
such as reduced motivation (as described above).  One possible explanation is that heavy 
cannabis use increases the risk of each of those domains to varying degrees and it is the 
relationships between the effects in these domains that accounts for some of the risk of 
developing a frank schizophrenia phenotype.  However, this hypothesis needs testing in large 
studies.   
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It must also be recalled that in view of the complex effects of THC on the dopamine 
system, as reviewed earlier, cannabis may well have differential effects on different parts of 
the mesolimbic dopamine pathway.  Therefore, it is not beyond the realms of possibility that 
long-term cannabis exposure results in pre-synaptic hypodopaminergia (i.e. decreased 
dopamine synthesis capacity) and at the same time is associated with a post-synaptic 
hyperdopaminergia (i.e. increased D2 receptor sensitivity).  Taken together, an albeit 
paradoxical possibility could therefore be: the increased risk of psychosis associated with 
cannabis may be occurring at various levels, such that dopaminergic mechanisms of salience 
attribution are disrupted whilst D2 sensitivity is increased, a reduction in dopamine synthesis 
capacity may contribute to negative affect which increases the risk of paranoia, and reduced 
motivation associated with hypodopaminergia increases the likelihood that cognitive 
distortions arise which contribute to the development of persecutory beliefs.   
 
To complicate the picture, there has also recently been evidence to suggest that part of 
the association between schizophrenia and cannabis is due to a shared genetic aetiology (Power 
et al. 2014), suggestive of potential bi-directionality.  Future understanding of how cannabis 
increases the risk of psychosis therefore would benefit from studies that are able to assess the 
relationships between acute and chronic cannabis and cannabinoid effects on the dopamine 
system, and how these relate to salience processing, negative affect and paranoia, and how 
these interact with genetic risk.   
 
 
In terms of understanding psychosocial risk, whilst dopamine synthesis capacity was 
not elevated in a relatively small sample size, a finding of interest from the above study is that 
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there is a relationship between childhood adversity and recent adult stress in the associative 
striatum, in line with the schizophrenia literature.  Furthermore, findings of increased negative 
emotions and schizotypy require further investigation.  Likewise, further work is necessary to 
disentangle which psychosocial stressors are driving these presumptive effects.  In particular, 
the relationships between these stressors and aberrant salience, the development of psychotic-
like symptoms, stress reactivity and other aspects of dopaminergic function including 
dopamine release and dopamine receptor availability are needed.   
 
The dopaminergic mechanisms underlying the association between psychosocial 
stressors and psychosis perhaps share similarities with above proposed model of dopaminergic 
mechanisms of psychosis in cannabis use.  These have already been proposed by Howes & 
Murray (2013) in an integrated sociodevelopmental-cognitive model of schizophrenia.  This 
suggests that childhood psychosocial stressors sensitise, and indeed cross-sensitize, the 
dopamine system (Jezierski et al. 2007; Prasad et al. 1995; de Jong et al. 2005).  Psychosocial 
stressors also increase the risk of developing cognitive schemas that perceive the world as 
threatening (Bentall et al. 2009), and this is likely compounded by negative affects which 
would increase the risk of paranoia, as above.  In support of this are well replicated associations 
between childhood maltreatment and negative emotion (Bifulco et al. 1991; Kendler et al. 
2004), findings that urbanicity alters neural stress response and increases negative affect 
(Lederbogen et al. 2011), and adverse life events being risk factors for depression (Biondi & 
Picardi 1999).  The potential effect of psychosocial stress on dopaminergic function may only 
increase risk if there are interactions with other risk factors, in particular genetic risks (Modinos 
et al. 2013), consistent with current models of gene-environment interactions in psychosis (van 
Winkel et al.)   
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Despite the above, a key answered question remains.  Given that increased striatal 
dopamine synthesis capacity is such a well replicated finding in psychosis (and at least the 
hypothesised type A schizophrenia [Howes & Kapur 2014]), and that the main environmental 
risk factors addressed in this thesis are not associated with elevated dopamine synthesis 
capacity in the absence of psychotic symptoms, does the key to understanding the neurobiology 
of these risks and future preventative interventions for psychosis lie in answering the question 
“What are the adaptive neurochemical mechanisms that prevent individuals exposed to these 
risks from developing psychosis?”  For now, the answers lie outside this thesis.   
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7.7 Final conclusion 
 
This thesis investigated the dopaminergic mechanisms underlying the relationship 
between chronic cannabis use and long-term psychosocial stress, two important 
epidemiological risk factors for schizophrenia, in line with the Aberrant Salience and Final 
Common Pathway hypotheses.  Environmental risk factors are by their very nature modifiable, 
and so this thesis examined whether these environmental risk factors are associated with the 
same dopaminergic abnormalities that have been observed in schizophrenia.  Contrary to the 
hypotheses, both long-term cannabis use and exposure to psychosocial stressors were not 
associated with increased dopamine synthesis capacity.  Furthermore, cannabis-induced 
psychotic-like symptoms were not related to dopamine synthesis capacity, yet they were related 
to a behavioural measure of aberrant salience processing.  Although, compared to controls, 
cannabis users did not exhibit altered aberrant salience processing, there was preliminary 
evidence to suggest that dopaminergic mechanisms of salience processing may indeed be 
altered by long-term cannabis use.  There was, however, evidence to suggest a similar 
relationship between certain psychosocial risk factors for schizophrenia and dopaminergic 
function to that which has been observed in the illness.  Future research should investigate how 
these findings relate to other aspects of dopaminergic function, cognitive models of psychosis 
and genetic risks for schizophrenia.   
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ARCHIVAL REPORTDopaminergic Function in Cannabis Users
and Its Relationship to Cannabis-Induced
Psychotic Symptoms
Michael A.P. Bloomﬁeld, Celia J.A. Morgan, Alice Egerton, Shitij Kapur,
H. Valerie Curran, and Oliver D. HowesBackground: Cannabis is the most widely used illicit drug globally, and users are at increased risk of mental illnesses including
psychotic disorders such as schizophrenia. Substance dependence and schizophrenia are both associated with dopaminergic
dysfunction. It has been proposed, although never directly tested, that the link between cannabis use and schizophrenia is mediated
by altered dopaminergic function.
Methods: We compared dopamine synthesis capacity in 19 regular cannabis users who experienced psychotic-like symptoms when
they consumed cannabis with 19 nonuser sex- and age-matched control subjects. Dopamine synthesis capacity (indexed as the inﬂux
rate constant Ki cer ) was measured with positron emission tomography and 3,4-dihydroxy-6-[
18F]-ﬂuoro-l-phenylalanine ([18F]-DOPA).
Results: Cannabis users had reduced dopamine synthesis capacity in the striatum (effect size: .85; t36 ¼ 2.54, p ¼ .016) and its
associative (effect size: .85; t36 ¼ 2.54, p ¼ .015) and limbic subdivisions (effect size: .74; t36 ¼ 2.23, p ¼ .032) compared with control
subjects. The group difference in dopamine synthesis capacity in cannabis users compared with control subjects was driven by those
users meeting cannabis abuse or dependence criteria. Dopamine synthesis capacity was negatively associated with higher levels of
cannabis use (r ¼ .77, p  .001) and positively associated with age of onset of cannabis use (r ¼ .51, p ¼ .027) but was not associated
with cannabis-induced psychotic-like symptoms (r ¼ .32, p ¼ .19).
Conclusions: These ﬁndings indicate that chronic cannabis use is associated with reduced dopamine synthesis capacity and question
the hypothesis that cannabis increases the risk of psychotic disorders by inducing the same dopaminergic alterations seen in
schizophrenia.Key Words: Addiction, dependence, dopamine, drugs, imaging,
psychosis
Cannabis is the most widely used illicit drug globally (1), andthe prevalence of cannabis abuse or dependence in theUnited States is 4.4% (2). Cannabis can induce transient
psychotic symptoms in healthy individuals (3,4), and there is
consistent epidemiologic evidence that cannabis dose-
dependently increases the risk of psychotic disorders (5,6).
Dopaminergic dysfunction is linked to drug dependence (7–11)
and psychosis (12–17). Increased dopamine synthesis capacity and
release have been reported in psychotic patients (18–26), drugs that
increase dopamine release can induce or worsen psychosis (15,27,28),
and elevated dopamine synthesis capacity has been reported in
people who subsequently develop a frank psychotic disorder (29–32).
Patients with cannabis-induced psychosis have elevated peripheral
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http://dx.doi.org/10.1016/j.biopsych.2013.05.027dopamine release and symptom exacerbation in a schizophrenic
patient following cannabis use (34). Thus, cannabis has been
proposed to increase psychosis risk by causing striatal hyperdopa-
minergia (32).
Supporting this, preclinical studies indicate acute administra-
tion of Δ9-tetrahydrocannabinol (THC), the main psychoactive
ingredient of cannabis (35), increases mesolimbic dopaminergic
neuron ﬁring rates via endocannabinoid CB1 receptor agonism
(36). CB1 agonists inhibit striatal dopamine reuptake (37), selec-
tively increase tyrosine hydroxylase expression (38), and increase
dopamine release (39) and synthesis (40) in the majority of,
although not all, studies (41).
Dopaminergic sensitisation to THC occurs in animals (42),
suggesting that dopaminergic effects are greater with regular
cannabis exposures. Studies in recently abstinent and ex-cannabis
users have not found abnormal striatal dopamine release (43) or D2/3
receptor availability (44,45), but this may be due to normalization of
dopaminergic function with abstinence, as has been observed with
alcohol (46). One study reported reduced dopamine transporter
availability in cannabis users (47), although this was related to
concurrent tobacco use, rather than cannabis. However, to our
knowledge, no study has examined dopamine synthesis capacity in
cannabis users or whether acute psychotic response to cannabis is
related to dopaminergic function.
We therefore sought to study presynaptic dopaminergic
function in active cannabis users who experienced cannabis-
induced psychotic-like symptoms because these individuals are
most at risk of psychosis (48). We hypothesized that regular
cannabis users sensitive to cannabis’ psychotogenic effects would
exhibit elevated dopamine synthesis capacity compared with
nonuser control subjects, and this would be directly related to
cannabis-induced psychotic-like symptom severity.BIOL PSYCHIATRY 2014;75:470–478
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The study was approved by the National Research Ethics
Service and the Administration of Radioactive Substances Advi-
sory Committee. The study was conducted in accordance with the
Declaration of Helsinki. All subjects provided informed written
consent to participate.
Study Population
Inclusion criteria for all subjects were as follows: minimum age
18 years, good physical health with no history of major medical
condition, and capacity to give written informed consent.
Exclusion criteria for all subjects were current or past psychiatric
illness (except cannabis use disorders in the cannabis user group
and nicotine use disorder in all subjects) using the Structured
Clinical Interview for DSM-IV (49), history of serious mental illness
(including psychosis) in a ﬁrst-degree relative determined via the
Family Interview for Genetic Studies (50), evidence of an At Risk
Mental State for psychosis (51), DSM-IV-TR (52) substance
dependency or abuse (other than cannabis in the cannabis user
group and tobacco for all subjects), and contraindications to
positron emission tomography (PET; including pregnancy and
breast-feeding). None of the subjects were taking psychotropic
medication at the time of study participation.
Detailed drug histories were obtained from all subjects using
the Cannabis Experience Questionnaire (53), structured interview
and timeline follow-back. Lifetime cannabis use was estimated as
the total number of “spliffs” (cannabis cigarettes; “joints”) con-
sumed. The time taken to smoke an “eighth” of cannabis (one-
eighth ounce; approximately 3.5 g, representing the standard unit
of sale in Britain) was chosen as the primary index of cannabis use
because this provides a measure of the amount of current drug
consumption (shorter time indicating greater consumption). This
is likely to be more accurate than subjective recall of the number
of spliffs consumed because of variability in cannabis dose
between spliffs and inconsistencies in self-reported cannabis
use (54).
Cannabis User Group
We recruited cases from an ongoing cohort study in which
more than 400 cannabis users were tested when intoxicated with
cannabis and when not intoxicated (55). Subjects met the
following criteria: current, at least weekly use of cannabis and
the induction of psychotic-like symptoms in response to smoking
cannabis, which was deﬁned as a positive change on the
psychotic items score of the Psychotomimetic States Inventory
(PSI) (56) measured 5 minutes after smoking their usual amount
of cannabis (i.e., when acutely intoxicated) compared with when
not intoxicated with the drug. Cannabis users consumed their
own cannabis, and testing occurred in the presence of a
researcher in the environment where users habitually consumed
cannabis in their usual drug-taking context (e.g., at home)
because drug effects are typically larger in naturalistic as opposed
to laboratory environments (53). Cannabis-induced psychotic-like
symptoms abated within 2 hours of consumption, and no subject
met the DSM-IV TR criteria for a diagnosis of a psychotic disorder.
The psychotic items from the PSI covered “Delusional Thinking,”
“Perceptual Distortions,” “Cognitive Disorganization” (thought
disorder), and “Paranoia.” Each item is rated on a 4-point scale
from “not at all” (score ¼ 0) to “strongly” (score ¼ 3). Examples of
items include “People can put thoughts into your mind” and “You
can sense an evil presence around you, even though you cannot
see it.” A sample of the cannabis that each participant smokedwas taken on the day of testing and analyzed for levels of THC
(Forensic Science Service, Birmingham, United Kingdom).
Control Group
Nonuser control subjects were recruited from the same geo-
graphic area by public advertisement. Controls were required to
have no lifetime history of cannabis dependence or abuse (DSM-IV),
no more than 10 total uses of cannabis in their lifetime, no report of
the induction of psychotic symptoms by cannabis, and no history of
cannabis use in the preceding 3 months. Community surveys
indicate that more than 30% of young adults in England report
trying cannabis in their lifetime (57). We therefore permitted control
subjects to have had a minimal exposure to cannabis to ensure the
control group was representative of the same general population
from which we recruited the cannabis users.
PET Data Acquisition
All subjects underwent a 3,4-dihydroxy-6-[18F]-ﬂuoro-/-phenyl-
alanine ([18F]-DOPA) scan on an ECAT HR 962 PET scanner (CTI/
Siemens, Knocksville, Tennessee) in three-dimensional mode, with
an axial ﬁeld of view of 15.5 cm, performed as previously reported
(28). Subjects were asked to fast and abstain from cannabis for 12
hours and to refrain from smoking tobacco for 2 hours before
imaging. On the day of the PET scan, urine drug screen (Monitect
HC12, Branan Medical Corporation, Irvine, California) conﬁrmed
no recent drug use (other than cannabis in the user group), and a
negative urinary pregnancy test was required in all female
subjects. A research clinician assessed psychotic symptoms using
the Positive and Negative Syndrome Scale at the time of
scanning. No subjects had psychotic symptoms at the time of
scanning (mean [SD] Positive and Negative Syndrome Scale
positive score cannabis users ¼ 7.3 [.5]; control subjects ¼ 7.2
[.4]). Subjects received carbidopa 150 mg and entacapone 400
mg orally 1 hour before imaging (58) to reduce the formation of
radiolabeled [18F]-DOPA metabolites (59,60). Head position was
marked and monitored via laser crosshairs and a camera and
minimized using a head-strap. A 10-minute transmission scan was
performed before radiotracer injection for attenuation and scatter
correction. Approximately 180 MBq of [18F]-DOPA was adminis-
tered by bolus intravenous injection 30 seconds after the start of
PET imaging. We acquired emission data in list mode for 95
minutes, rebinned into 26 timeframes (30-second background
frame, four 60-second frames, three 120-second frames, three
180-second frames, and ﬁfteen 300-second frames).
Volume of Interest Analysis
To correct for head movement, nonattenuation-corrected
dynamic images were denoised using a level 2, order 64 Battle-
Lemarie wavelet ﬁlter (61), and individual frames were realigned
to a single frame acquired 10 minutes after the [18F]-DOPA
injection using a mutual information algorithm (62). Transforma-
tion parameters were then applied to the corresponding
attenuation-corrected frames, and the realigned frames were
combined to create a movement-corrected dynamic image (from
6 to 95 minutes following [18F]-DOPA administration) for analysis.
After movement correction, we deﬁned standardized volumes
of interest (VOIs) bilaterally in the whole striatum, the limbic
(ventral), associative (precommisural dorsal caudate, precom-
misural dorsal putamen, and postcommisural caudate), and
sensorimotor (postcommisural putamen) striatal functional sub-
divisions and the cerebellar reference region in Montreal Neuro-
logic Institute space (63,64). An [18F]-DOPA template was
normalized with the VOI map to each individual PET summationwww.sobp.org/journal
Table 1. Sample Characteristics and Scan Parameters
Controls (n ¼ 19) Cannabis Users (n ¼ 19) pa
Sample Characteristic
Age (years), mean (SD) 22.3 (2.8) 20.8 (1.7) .07
Sex (n) 2 female, 17 male 2 female, 17 male 1.00
Handedness (n) 2 left, 17 right 4 left, 15 right .37
Ethnicity (n) 4 AB, 3 BB, 1 ME, 11 WB 4 AB, 15 WB .16b
Current Drug Usec,d
Cannabis users (n) 0 users, 19 nonusers 19 users, 0 nonusers 1.00
Cannabis use (grams of cannabis/month), median (IQR) .0 (.0) 26.3 (90.0) .00
THC content of cannabis (%), mean (SD) — 8.7 (3.8) —
Time since last cannabis exposure (hours), median (IQR) — 14.0 (23.8) —
Time taken to smoke an “eighth” of cannabis (days), median (IQR) — 4.0 (13.5) —
Age of onset of regular cannabis use (years), mean (SD) — 15.5 (1.6) —
Tobacco cigarette smokers (n) 8 users, 11 nonusers 15 users, 4 nonusers .02
Tobacco use in whole sample (cigarettes/day), median (IQR) .0 (.0) 4.0 (7.0) .01
Tobacco use in smokers (cigarettes/day), median (IQR) (tobacco users) 1.0 (9.0) 7.0 (8.0) —
Alcohol use in past 3 months (n) 19 users, 0 nonusers 19 users, 0 nonusers 1.00
Alcohole use (United Kingdom alcohol units/week), median (IQR) 9.0 (12.0) 12.0 (21.0) .34
MDMA use in past 3 months (n) 5 users, 14 nonusers 11 users, 8 nonusers .05
MDMA use in whole sample (grams of MDMA/month), median (IQR) .0 (.0) .3 (1.0) .02
MDMA use in MDMA users (grams of MDMA/month), median (IQR) .3 (.8) 1.0 (1.7) —
Cocaine use in past 3 months (n) 3 users, 16 nonusers 3 users, 16 nonusers 1.00
Cocaine use in whole sample (grams of cocaine/month), median (IQR) .0 (.0) .0 (.0) .60
Cocaine use in cocaine users (grams of cocaine/month), median (IQR) .1 (.1) .1 (1.0) —
Amphetamine use in past 3 months (n) 1 user, 18 nonusers 4 users, 15 nonusers .15
Amphetamine use in whole sample (grams of amphetamine/month), median (IQR) .0 (.0) .0 (.0) .27
Amphetamine use in amphetamine users (grams of amphetamine/month), median (IQR) .1 .5 (.3) —
Ketamine use in past 3 months (n) 1 user, 18 nonusers 6 users, 13 nonusers .04
Ketamine use in whole sample (grams of ketamine/month), median (IQR) .0 (.0) .1 (.5) .10
Ketamine use in ketamine users (grams of ketamine/month), median (IQR) .1 1.5 (2.9) —
Psilocybin use in past 3 months (n) 1 user, 18 nonusers 1 user, 18 nonusers 1.00
Psilocybin use in whole sample (grams of “magic mushrooms”/month), median (IQR) .0 (.0) .0 (.0) .80
Psilocybin use in psilocybin users (grams of “magic mushrooms”/month) .1 2.0 —
Scan Parameter
Injected dose (MBq), mean (SD) 180.6 (7.2) 184.4 (5.2) .11
Speciﬁc activity (MBq/mmol), mean (SD) 31.1 (17.3) 30.5 (14.0) .92
Whole striatal volume (mm3), mean (SD) 17,587.82 (1729.50) 17,942.90 (1286.73) .48
Associative striatal volume (mm3), mean (SD) 10,801.19 (1134.46) 10,772.76 (1161.24) .94
Limbic striatal volume (mm3), mean (SD) 2080.30 (234.77) 2276.51 (977.85) .40
Sensorimotor striatal volume (mm3), mean (SD) 4706 (106.60) 4668.98 (443.16) .80
AB, Asian British; BB, black British; IQR, interquartile range; MDMA, 3,4-methylenedioxy-N-methylamphetamine (“Ecstasy”); ME, mixed ethnicity; WB,
white British.
aIndependent-samples t tests for variables with normal data distributions; Mann-Whitney U tests for variables with nonnormal data distributions;
χ2 tests for dichotomous variables.
bGroups were compared on a dichotomized ethnicity variable (white British vs. ethnic minority).
cDrug use reported in 3 months before scan. Drug user deﬁned as any drug use in the 3 months before scan.
dThere was no reported lysergic acid diethylamide, benzodiazepine, opiate, or methamphetamine use in the 3 months before scanning.
e1 UK alcohol unit ¼ 10 mL (7.88 g) alcohol.
472 BIOL PSYCHIATRY 2014;75:470–478 M.A.P. Bloomﬁeld et al.(add) image using statistical parametric mapping software (SPM5,
http://ﬁl.ion.ucl.ac.uk/spm), allowing VOIs to be placed automati-
cally on individual [18F]-DOPA PET images without observer bias.
We calculated [18F]-DOPA uptake, relative to the cerebellum
[Ki cer (min
–1)], for each VOI using the Patlak graphic analysis
adapted for a reference tissue input function (65–68). We have
previously demonstrated good test–retest reliability for striatal
Ki cer determined this way (64).
Voxelwise Analysis
We complemented the VOI analysis with an independent
voxelwise analysis using a wavelet-based Patlak method (69) as
previously described (29). The parametric image for eachwww.sobp.org/journalparticipant was then normalized into standard space using the
participants PET summation image and the [18F]-DOPA template
(29). Statistical parametric mapping was conducted using SPM5
and a striatal mask deﬁned according to previously described
criteria (64) to compare groups. Results are presented corrected
for multiple comparisons using random ﬁeld theory as applied in
SPM5 (p  .05, corrected at the family-wise error rate).
Statistical Analysis
We assessed normality of distributions using the one-sample
Kolmogorov-Smirnov test. Between-group comparisons were
made with two-tailed independent t tests for normally distributed
data and Mann-Whitney U tests for nonnormally distributed data.
Figure 1. Striatal dopamine synthesis capacity in regular cannabis users
(n ¼ 19) and nonuser control subjects (n ¼ 19). Dopamine synthesis
capacity was signiﬁcantly reduced in cannabis users compared with
nonusers (t36 ¼ 2.54, p ¼ .016). Error bars indicate standard deviations.
Table 2. [18F]-DOPA Kicer (min
–1) by Group
Control Subjects
(n ¼ 19)
Cannabis Users
(n ¼ 19)
Group
Comparisonsa Effect Size
VOI Mean SD Mean SD tdf p (Cohen’s d)
STR .0134 .0009 .0127 .0007 2.5436 .016 .85
AST .0127 .0009 .0121 .0007 5.5436 .015 .85
LST .0138 .0009 .0132 .0008 2.2336 .032 .74
SMST .0146 .0014 .0139 .0008 1.8536 .070 .62
AST, associative striatum; Kicer , inﬂux rate constant; LST, limbic
striatum; SMST, sensorimotor striatum; STR, whole striatum; VOI, volume
of interest.
aIndependent-samples t tests.
M.A.P. Bloomﬁeld et al. BIOL PSYCHIATRY 2014;75:470–478 473Relationships among Ki cer , levels of cannabis use, and cannabis-
induced psychotic-like symptom severity were tested using
Pearson’s product–moment correlation coefﬁcient. Potential con-
founding effects of other substance use were explored using a
single analysis of covariance (ANCOVA) with subject group as the
ﬁxed factor; Ki cer as the dependent variable and levels of use of
each substance other than cannabis as separate covariates, and
using Pearson’s product–moment correlation coefﬁcient to deter-
mine if there was a relationship between Ki cer and levels of
tobacco smoking. Statistical signiﬁcance was deﬁned as p  .05
(two-tailed). Our primary outcome measure was Ki cer in the whole
striatum. Exploratory analyses were conducted in the striatal
subdivisions (presented uncorrected for multiple comparisons).
Results
Subject Characteristics and Scan Parameters
Twenty cannabis users were recruited to the study. Owing to
tomograph malfunction during one scan, complete data were
available on nineteen users. All cannabis users consumed the drug
as a spliff. The mean (SD) age of ﬁrst cannabis use was 15.5 (1.6)
years, and the mean (SD) duration of at least weekly use was 4.7
(3.1) years. The median (interquartile range) time taken to smoke
an eighth and lifetime exposure to cannabis was 4.0 (13.5) days
and 2340 (6240) spliffs, respectively. Within the user group, the
median (interquartile range) time between the scan and the last
cannabis exposure and self-reported cannabis-induced psychotic-
like symptoms was 14.0 (23.8) hours. Ten users met DSM-IV criteria
for cannabis dependence (n ¼ 5) or abuse (n ¼ 5). Mean (SD) time
to smoke an eighth was 2.3 (2.2) days in users who met depend-
ency/abuse criteria and 6.9 (4.7) days in users who did not meet
criteria. Mean (SD) age of ﬁrst cannabis consumption was 14.8 (1.6)
years in users who met dependency/abuse criteria, and 16.2 (1.3)
years in users who did not meet criteria. Nineteen control subjects
were matched to the user group for age (5 years) and sex.
Subjects’ characteristics are reported in Table 1. Urine drug screen
was positive for THC and negative for all other substances(amphetamine, opiates, cocaine, methamphetamine, benzodiaze-
pines) in every cannabis user and negative for all drugs (including
cannabis) in every control subject. There was a signiﬁcant group
difference in current cannabis consumption, as expected, and also
in tobacco and ecstasy use (Table 1).
There was no signiﬁcant group difference in the amount of
radioactivity or speciﬁc activity injected (Table 1). There was no
signiﬁcant difference in whole striatal or subdivision volumes
between the groups. There was no relationship between age and
Ki cer in the striatum or its subdivisions in the whole sample or in
either group (data available on request).
Striatal Dopaminergic Function
Ki cer was signiﬁcantly reduced in cannabis users relative to
controls in the whole striatum (Figure 1). Secondary analysis in
each striatal subdivision showed that this reduction reached
signiﬁcance in the limbic and associative subdivisions (Table 2).
The ﬁnding of reduced Ki cer in cannabis users remained signiﬁ-
cant after covarying for other drugs used, with the amount of use
of each of the drugs listed in Table 1 included as separate
covariates in the ANCOVA, in the whole striatum (F1,37 ¼ 4.65, p ¼
.040) and its associative (F1,37 ¼ 5.00, p ¼ .034) and limbic (F1,37 ¼
7.358, p ¼ .011) subdivisions.
Voxel-based analysis conﬁrmed reduced Ki cer in the cannabis
user group relative to nonuser control subjects with peak statistical
signiﬁcance in the right putamen (Montreal Neurological Institute
coordinates: 28, 6, −8; p ¼ .048 [corrected for familywise error];
Figure 2). There were no voxels where there was a signiﬁcant
elevation in Ki cer in cannabis users relative to control subjects.
The Relationship Between Striatal Dopamine Synthesis
Capacity and Cannabis Use
Within the cannabis user group, greater levels of current
cannabis use (less time to smoke an eighth of cannabis) were
associated with lower Ki cer in the whole striatum (r ¼ .77, p 
.001; Figure 3A). Secondary analysis in each striatal subdivision
showed that this pattern reached signiﬁcance in the associative
(r ¼ –.68, p ¼ .001) and sensorimotor (r ¼ –.84, p  .001)
subdivisions but not the limbic subdivision (r ¼ –.26, p ¼ .290).
In addition, there was a signiﬁcant correlation between age of
onset of cannabis use and Ki cer in the whole striatum (r ¼ .51, p ¼
.027; Figure 3B) and in its associative subdivision (r ¼ .56, p ¼
.013), which remained signiﬁcant after controlling for current age
(r ¼ .49, p ¼ .04 [whole striatum]; r ¼ .54, p ¼ .02 [associative]),
with no signiﬁcant correlation in the sensorimotor (r ¼ .34, p ¼
.158) or limbic (r ¼ .36, p ¼ .126) subdivisions. There was no
signiﬁcant correlation between age of ﬁrst cannabis use and
current cannabis use (r ¼ .16, p ¼ .52).www.sobp.org/journal
Figure 2. Reduced striatal dopamine synthesis capacity in regular
cannabis users relative to nonuser controls. The image shows a statistical
parametric map of signiﬁcant reductions (p  .05) in dopamine synthesis
capacity, relative to healthy comparison subjects (n ¼ 19), in regular
cannabis users who experienced transient psychotic-like symptoms (n ¼
19). The most signiﬁcant reduction was in the right putamen (Montreal
Neurological Institute coordinates: 28, 6, 8; p ¼ .048, corrected at the
family-wise error rate). The color bar indicates the t statistic for each voxel.
Figure 3. (A) The correlation between level of cannabis use (time to
smoke an “eighth” [3.5 g] of cannabis; days) and striatal dopamine
synthesis capacity, indexed as Ki cer (min
–1), in cannabis users (r ¼ –.77,
p  .001). (B) The correlation between age of onset of cannabis use and
Kicer in the whole striatum (r ¼ .51, p ¼ .027), which remained signiﬁcant
when controlling for current age (r ¼ .49, p ¼ .04).
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was no signiﬁcant difference between Ki cer in tobacco smokers
and nontobacco smokers in any of the regions examined (all
ps .1). Within the whole sample and within each group, there
was no relationship between Ki cer and daily cigarette use among
tobacco cigarette smokers in the whole striatum (r ¼ .26, p ¼ .91
[whole sample], r ¼ .10, p ¼ .81 [control subjects]; r ¼ .18, p ¼ .52
[cannabis users]) and its functional subdivisions (data available on
request). Within the whole sample and within each group, there
were no signiﬁcant relationships (all ps  .1) between whole
striatal Ki cer and other substances used (listed in Table 1).
To examine whether cannabis dependency/abuse was asso-
ciated with reduced Ki cer , we divided the cannabis user group
into subjects that met DSM-IV diagnostic criteria for cannabis
dependency or abuse (n ¼ 10) and those who did not meet
criteria (n ¼ 9). One-way analysis of variance found a signiﬁcant
effect of group on whole striatal Ki cer (F2,37 ¼ 4.02, p ¼ .027,
Figure 4). Post hoc t tests showed signiﬁcant differences between
the cannabis dependency/abuse and nondependency/nonabuse
cannabis user subgroups (t17 ¼ 2.80, p ¼ .012) and between
the cannabis dependency/abuse subgroup and control subjects
(t27 ¼ 2.67, p ¼ .013), but not between the nondependency/
nonabuse subgroup and the control group (p ¼ .60). When
examining the striatal subdivisions, signiﬁcant differences in Ki cer
between the cannabis dependency/abuse and nondependency/
nonabuse cannabis user subgroups were observed in the asso-
ciative subdivision only (t17 ¼ 2.89, p ¼ .010).
The Relationship Between Striatal Dopamine Synthesis
Capacity and Cannabis-Induced Psychotic Symptoms
Within the cannabis user group, the mean (SD) increase in PSI
psychotic symptom subscale score after consuming cannabis was
9.9 (5.1). There was no signiﬁcant correlation between striatal Ki cerwww.sobp.org/journaland increase in transient psychotic-like symptoms following
cannabis use (r ¼ .32, p ¼ .19; Figure 5).
Discussion
Our main ﬁnding is that striatal dopamine synthesis capacity is
lower in current cannabis users than matched nonuser control
subjects. In users, lower dopamine synthesis capacity was
associated with greater current cannabis use, which explained
59% of variance in striatal dopamine synthesis capacity, and
Figure 4. Striatal dopamine synthesis dopamine synthesis capacity in
subjects who met DSM-IV criteria for a diagnosis of cannabis dependence
or abuse (n ¼ 10), regular cannabis users who did not meet diagnostic
criteria (n ¼ 9), and nonuser control subjects (n ¼ 19). There were
signiﬁcant differences between cannabis dependence/abuse versus can-
nabis users who did not meet criteria (t17 ¼ 2.80, p ¼ .012) and cannabis
dependence/abuse versus control group (t27 ¼ 2.67, p ¼ .013). There was
no signiﬁcant difference between controls versus cannabis users who did
not meet dependence/abuse criteria (t26 ¼ .54, p ¼ .60). Error bars
indicate standard deviations.
Figure 5. The relationship between the striatal inﬂux rate constant Ki cer
and transient induction of cannabis-induced psychotic-like symptoms in
the cannabis users. There was no signiﬁcant relationship between the two
variables (r ¼ .32, p ¼ .19). PSI, Psychotomimetic States Inventory.
M.A.P. Bloomﬁeld et al. BIOL PSYCHIATRY 2014;75:470–478 475earlier age of onset of use, but not with cannabis-induced
psychotic-like symptoms.
Importantly, we also found that the lower levels of dopamine
synthesis capacity in cannabis users compared with nonusers
were driven by users who met diagnostic criteria for abuse and
dependence. These ﬁndings are inconsistent with our hypothesis
that elevated dopamine synthesis capacity underlies the link
between cannabis and risk of psychosis.
Our results extend previous ﬁndings in current (70) and
recently abstinent cannabis users (43), which found reduced
dopamine receptor density was associated with higher current
cannabis use and lower dopamine release in the associative
striatum was associated with earlier age of onset of cannabis.
Although these studies (43,44,70) and a further study in ex-users
(45) have reported estimates of the number of lifetime uses of
cannabis and our sample is comparable to these, measures of the
amount or type of cannabis consumed have not been reported,
such that direct comparisons of cannabis use across the studies
cannot be made. Our ﬁndings of reduced dopamine synthesis
capacity in dependent subjects may reﬂect a “blunted” dopamine
system, as observed with other drugs of addiction (7). Taken with
ﬁndings from these and other studies (8–11), there is mounting
evidence that dopaminergic dysfunction provides a biomarker of
addiction severity.
Although the case–control design of this study is not able to
detect a causative relationship between cannabis use and
dopamine dysfunction, our ﬁndings suggestive of dose effects
warrant further research into potential causative mechanisms.
Animal studies indicate increased dopaminergic function in
response to acute THC treatment. However, there is evidence of
a biphasic dose-dependent dopamine response to THC (71),suggesting higher cannabis exposures may reduce dopamine
synthesis capacity, in line with our ﬁndings. Furthermore, with the
exception of perinatal studies (72), animal data on dopaminergic
effects of long-term and high dose cannabis exposures are sparse,
and the longest duration of THC administration has been 21 days
(42,73–75). Of these, one study (74) in Sprague-Dawley rats
reported that long-term treatment with THC was associated with
reduced striatal tyrosine hydroxylase gene expression and con-
current supersensitivity of D2/3 receptors, and a separate study
(75) in catechol-O-methyltransferase mutant mice found chronic
treatment with THC in adolescence was associated with reduced
dopaminergic cell size in the ventral tegmental area.
One explanation for our ﬁndings is that chronic cannabis use is
associated with dopaminergic down-regulation. This might
underlie amotivation and reduced reward sensitivity in chronic
cannabis users (76). Alternatively, preclinical evidence suggests
that low dopamine neurotransmission may predispose an indi-
vidual to substance use (77). However, this is inconsistent with
ﬁndings that recently abstinent and former cannabis users show
neither altered dopamine receptor availability (44,45,70) nor altered
dopamine release (43), suggesting that altered dopaminergic
function during chronic cannabis use is normalized by abstinence,
as is observed with amphetamine in vervet monkeys (78).
In this study, we investigated dopaminergic function in
cannabis users who experience a transient increase in
psychotic-like experiences when acutely intoxicated with canna-
bis. The lack of relationship between the induction of psychotic-
like experiences and dopaminergic function suggests that our
ﬁndings would generalize to cannabis users in general, but this
requires conﬁrmation in future studies.
Our ﬁndings suggest that elevated striatal dopamine synthesis
capacity is unlikely to be the mechanism underlying the link
between cannabis and psychosis. Our study focused on the
striatum because dopaminergic changes there have been reliably
linked to psychosis (22) but we cannot exclude the possibility
that dopaminergic changes in extrastriatal regions underliewww.sobp.org/journal
476 BIOL PSYCHIATRY 2014;75:470–478 M.A.P. Bloomﬁeld et al.cannabis-induced psychotic symptoms. A previous study (79)
using single photon emission computed tomography reported a
signiﬁcant increase in temporal cortex D2/3 receptor availability
in antipsychotic-naive ﬁrst-episode patients with psychosis
who tested positive for cannabis compared with those who did
not. Alternatively, the mechanism may be mediated via non-
dopaminergic systems, such as direct effects on cannabinoid
receptors (80).
Nevertheless, ﬁndings that striatal dopamine release in
patients with comorbid schizophrenia and substance dependence
is blunted but still associated with amphetamine-induced psy-
chotic symptoms (81) supports the possibility that other aspects
of striatal dopaminergic function are altered by cannabis or that
cannabis use interacts with other risk factors for schizophrenia to
induce hyperdopaminergia. In support of this, early work in Wistar
rats (82) found THC decreased striatal dopamine uptake com-
pared with vehicle, but increases in striatal dopamine uptake
were observed when THC-treated rats were housed under
“stressful” versus “normal” conditions. Earlier age of onset of
cannabis use increases psychosis risk and may interfere with
normal brain development (83). Another possibility is thus that
cannabis use during key developmental periods alters the
regulation of dopaminergic function to make it more susceptible
to subsequent stressors that could underlie an increased risk of
psychosis. Additional prospective studies on the effects of chronic
cannabis exposure are therefore warranted.
Study Limitations
One potential limitation of this study is that subjects con-
sumed their own cannabis rather than a standard preparation.
However, we tested individuals while intoxicated, measured levels
of THC in samples of the cannabis our subjects were using, and
conﬁrmed it contained high levels of THC in all subjects (mean
THC content ¼ 8.7%). There was no ﬁxed interval between
cannabis exposure and PET, meaning that heavier cannabis users
may have had a shorter interval between exposure and scan. It
therefore remains possible that differences in the time since last
cannabis use contribute to the differences between the depend-
ent/abuser and nondependent groups, rather than dependency
or abuse per se. In addition, lack of association between cannabis-
induced psychotic symptoms may be due to variable interval
between cannabis exposure and PET. However, in terms of acute
effects of cannabis, only one of three molecular imaging studies
of the acute effects of THC in healthy volunteers have found
evidence of dopamine release (84–86), suggesting that acute
effects of THC on dopaminergic function may not be large or
consistent in humans. Given that THC and its metabolites have an
elimination half-life of about 7 days (87) and all our cannabis
users were regular, long-term users who had consumed cannabis
within the past 7 days (median time since last consumption ¼ 14
hours), our subjects were unlikely to be acutely withdrawing.
Our measures of substance use rely on self-report, and we
were not able to independently verify substance use histories
beyond ongoing cannabis use in the user group and no recent
use of other drugs in all participants. As would be expected,
higher rates of other substance use were reported in cannabis
users, although, with the exception of tobacco, the use of other
substances was low in both groups. Our ﬁndings remained
signiﬁcant after covarying for all other drug use, suggesting that
use of other substances does not underlie our ﬁndings, although
it should be noted that ANCOVA may be less able to adjust for
factors when groups differ signiﬁcantly in covariates (88) and
should be considered exploratory. We therefore cannot excludewww.sobp.org/journalthe possibility that group differences in other drug use contrib-
uted to the results observed.
Although cannabis users in our sample reported higher levels
of ecstasy use than control subjects, ecstasy has been associated
with increased dopamine synthesis capacity (89), so this is
unlikely to explain our ﬁndings. More of the cannabis users
smoked cigarettes than control subjects. The effects of cigarette
smoking on presynaptic dopamine function are unclear; tobacco
use has been associated with reduced amphetamine-induced
dopamine release (90) but increased dopamine synthesis capacity
(91). In addition, tobacco smoking may inﬂuence [18F]-DOPA
kinetics via cerebral blood ﬂow effects (92), which, if regionally
selective, could affect our outcome measure. However, we did not
ﬁnd a relationship between levels of cigarette consumption and
dopamine synthesis capacity, suggesting this did not inﬂuence
our results, although additional research is needed to determine
the effect of tobacco smoking on dopaminergic function.
Conclusion
Our results show that regular long-term cannabis use is
associated with a dose-dependent reduction in dopamine syn-
thesis capacity in the corpus striatum, particularly in those
meeting diagnostic criteria for cannabis abuse or dependence.
However, we found no relationship between dopaminergic
function and cannabis-induced psychotic-like symptoms. These
ﬁndings question the prevailing assumption that cannabis
increases the risk of schizophrenia by inducing the same
dopaminergic alterations seen in schizophrenia.
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Abstract
Rationale Cannabis is the most widely used illicit drug in the
world, and regular use has been associated with reduced
motivation, i.e. apathy. Regular long-term cannabis use has
been associated with reduced dopamine synthesis capacity.
The mesolimbic dopaminergic system mediates the process-
ing of incentive stimuli bymodifying their motivational value,
which in turn is modulated by endocannabinoid signalling.
Thus, it has been proposed that dopaminergic dysfunction
underlies the apathy associated with chronic cannabis use.
Objectives The aim of this study was to examine the relation-
ship between dopaminergic function and subjective apathy in
cannabis users.
Methods Wemeasured dopamine synthesis capacity (indexed
as the influx rate constant Ki
cer) via 3,4-dihydroxy-6-[18F]-
fluoro-l-phenylalanine positron emission tomography and
subjective apathy using the self-rated Apathy Evaluation
Scale (AES-S) in 14 regular cannabis users.
Results All subjects scored in excess of 34 points on the AES-
S (median [interquartile range] 59.5 [7.5]), indicative of sig-
nificant apathy based on normative data. Ki
cer was inversely
correlated to AES-S score in the whole striatum and its asso-
ciative functional subdivision (Spearman’s rho=−0.64, p=
0.015 [whole striatum]; rho=−0.69, p=0.006 [associative])
but not in the limbic or sensorimotor striatal subdivisions.
There were no significant relationships between AES-S and
current cannabis consumption (rho=0.28, p=0.34) or age of
first cannabis use (rho=0.25, p=0.40).
Conclusions These findings indicate that the reduction in
striatal dopamine synthesis capacity associated with chronic
cannabis use may underlie reduced reward sensitivity and
amotivation associated with chronic cannabis use.
Keywords Apathy . Cannabis . Drugs . Dopamine .
Imaging .Motivation . PET
Introduction
Cannabis is a widely used recreational drug (Anthony et al.
1994; United Nations Office on Drugs and Crime 2010).
Heavy cannabis use has been associated with educational
and occupational under-achievement in several (Brook et al.
2002; Fergusson et al. 2003; Gruber et al. 2003; Kandel et al.
1986; Macleod et al. 2004; Horwood et al. 2010) but not all
studies (Reilly et al. 1998). Over 100 years ago, the Indian
Hemp Commission reported that heavy cannabis use was
associated with apathy (Indian Hemp Drugs Commission
1893). Since then, there is evidence that regular use of the
drug is associated with apathy (Looby and Earleywine 2007;
McGlothin and West 1968; Tennant and Groesbeck 1972;
Verdejo-Garcia et al. 2006), defined as reduced motivation
for goal-directed behaviour (Levy and Dubois 2006; Marin
1991). Thus, reduced motivation, i.e. apathy, has been
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proposed to be one factor potentially involved in impaired
educational and occupational outcomes associated with heavy
cannabis use (Fergusson et al. 2003).
In support of this, heavy chronic cannabis use has been
found to produce apathetic behaviours in rhesus monkeys
(Paule et al. 1992). However, there is limited evidence of
amotivational effects of cannabis from laboratory studies in
humans using operant conditioning paradigms (Cherek et al.
2002) and that this may be related to heavy use of the drug
(Mendelson et al. 1976; Lane et al. 2005).
The main psychoactive substance in cannabis is Δ9-
tetrahydrocannabinol (THC) (Wachtel et al. 2002). THC was
originally described as an agonist of endocannabinoid CB1
receptors (Felder et al. 1992); however, there is growing
evidence of partial agonist properties from both in vitro (Sim
et al. 1996; Petitet et al. 1998; Shen and Thayer 1999;
Breivogel and Childers 2000; Govaerts et al. 2004; Kelley
and Thayer 2004) and in vivo (Paronis et al. 2012) studies.
There is evidence both from studies in animal models and
humans that THC administration disrupts reinforced behav-
iour (Stiglick and Kalant 1983; Kamien et al. 1994; Lane and
Cherek 2002; Lane et al. 2004; Foltin et al. 1989).
A key function of the mesolimbic dopaminergic system is
to mediate the processing of incentive stimuli by modifying
their motivational value (Berridge and Robinson 1998), which
is modulated by endocannabinoid signalling (Fernandez-Ruiz
et al. 2010; Melis et al. 2012; Melis and Pistis 2012). Animal
studies indicate that the acute effects of THC include increase
dopaminergic neuron firing rates (French 1997), whilst the
chronic effects of THC include reduced presynaptic dopami-
nergic function (Ginovart et al. 2012). However, only two of
four molecular imaging studies in human volunteers found
that acute THC resulted in striatal dopamine release (Barkus
et al. 2011; Bossong et al. 2009; Kuepper et al. 2013; Stokes
et al. 2009), suggesting that the effect is not consistent and that
it may be greater for those who are at clinical risk of psychotic
disorder. Yet, studies in recently abstinent and current chronic
cannabis users have found that reduced striatal dopamine
release was associated with earlier age of onset of cannabis
use and reduced dopamine receptor density is associated with
greater current use (Albrecht et al. 2013; Urban et al. 2012). A
functional magnetic resonance imaging (fMRI) study has
reported attenuated striatal reward processing in chronic can-
nabis users (van Hell et al. 2010). Therefore, it has been
proposed that attenuated mesolimbic dopaminergic transmis-
sion due to long-term cannabis use results in a mesolimbic
reward system that is hyporesponsive to non-drug stimuli (van
Hell et al. 2010), in line with the reward deficiency hypothesis
(Blum et al. 2000; Koob and Le Moal 2005). Whilst only a
limited number of studies have examined processing of drug
and non-drug stimuli within the samemodel, there is evidence
to support the hypothesis that complementary processes co-
occur within an individual to give rise to both hypersensitivity
to drug reward and hyposensitivity to non-drug rewards
(Garavan et al. 2000; Wrase et al. 2007; Zijlstra et al. 2009).
However, it has also been proposed that amotivational symp-
toms in cannabis users could be attributed to coexisting de-
pressive symptoms (Musty and Kaback 1995).
Treatment with the dopamine precursor levodopa and
pramipexole, a dopamine D2 agonist, has both been found to
improve apathy in patients with Parkinson’s disease
(Czernecki et al. 2002; Lemke et al. 2006), where striatal
hypodopaminergia has been found to be related with apathy
in depressed patients with Parkinson’s disease (Remy et al.
2005). We have recently found that cannabis users exhibit
reduced striatal dopamine synthesis capacity indexed using
positron emission tomography (PET) and 3,4-dihydroxy-
6-[18F]-fluoro-l-phenylalanine ([18F]-DOPA) uptake compared
to non-users (Bloomfield et al. 2013). Studies of macaque
monkeys have found that mesolimbic dopamine pathway loss,
induced via 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) lesions, predicted apathetic behaviour (Brown et al.
2012; Schneider et al. 1988) and that apathy was inversely
correlated to [18F]-DOPA uptake in the nucleus accumbens
and dorsal striatum(Brown et al. 2012). We therefore
hypothesised that apathy in cannabis users would be inversely
correlated with striatal dopaminergic function.
Methods
Our study was approved by the Administration of Radioactive
Substances Advisory Committee (ARSAC) and the National
Research Ethics Service. We conducted the study in accor-
dance with the Declaration of Helsinki and Good Clinical
Practice. All our subjects provided informed written consent
to participate.
Cannabis users
We included 14 regular cannabis users (defined as at least
weekly cannabis use for >1 year; mean [SD] age 20.4 [1.3]
years, 13 males, one female) recruited from an ongoing cohort
study (Morgan et al. 2011) who participated in a larger study
investigating whether cannabis users exhibit elevated dopa-
mine synthesis capacity (Bloomfield et al. 2013). Inclusion
criteria for all subjects were: minimum age 18 years; good
physical health with no history of major medical condition;
capacity to give written informed consent; current, at least
weekly use of cannabis and the induction of psychotic-like
symptoms in response to smoking cannabis, which was de-
fined as a positive change on the psychotic items score of the
Psychotomimetic States Inventory (PSI) (Mason et al. 2008)
measured 5 min after smoking their usual amount of cannabis
(i.e. when acutely intoxicated) compared to when not intoxi-
cated with the drug. All users consumed their own cannabis
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and testing occurred in the presence of a researcher in the
environment where users normally consumed cannabis in their
usual drug-taking context (e.g. at home). Cannabis-induced
psychotic-like symptoms ceased within 2 h of consumption,
and no subject met the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition, Text Revision (DSM-IV TR)
criteria for a diagnosis of a psychotic disorder. The psychotic
items from the PSI covered ‘Perceptual Distortions’,
‘Delusional Thinking’, ‘Cognitive Disorganization’ and
‘Paranoia’. Each item is rated on a four-point scale from ‘not
at all’ (score=0) to ‘strongly’ (score=3). A sample of the
cannabis that each participant smoked was taken on the day
of testing and analysed for levels of THC (Forensic Science
Service, Birmingham, UK). Exclusion criteria for all subjects
were current or past psychiatric illness, substance dependency
or abuse (except Cannabis and Nicotine Use Disorders) using
the Structured Clinical Interview for DSM-IV (SCID) (First
et al. 1996), a history of serious mental illness (including
psychosis) in a first degree relative determined via the Family
Interview for Genetic Studies (FIGS) (NIMH Genetics
Initiative 1992), evidence of an at-risk mental state for psycho-
sis (Phillips et al. 2000), DSM-IV TR (American Psychiatric
2005) and contra-indications to PET (including pregnancy and
breast-feeding).
We obtained detailed drug histories from all subjects using
structured interview, the Cannabis Experience Questionnaire
(CEQ) (Barkus et al. 2006), and timeline follow-back. We
estimated lifetime cannabis use as the total number of spliffs
(cannabis cigarettes; joints) consumed. We chose the time
taken to smoke an eighth of cannabis (1/8oz; approximately
3.5 g, representing the standard unit of sale in Britain) as the
primary index of cannabis use as this provides a measure of
the amount of current drug consumption (shorter time indicat-
ing greater consumption). Reporting the actual amount of
cannabis used (Temple et al. 2011) is likely to be more
accurate than subjective recall of the number of spliffs con-
sumed because of variability in cannabis dose between spliffs
(Temple et al. 2011) but also inconsistencies in self-reported
cannabis use (Akinci et al. 2001; Buchan et al. 2002) although
there is some evidence of agreement between self-reported
drug use and drug tests (Harrison et al. 2007). The median
(interquartile range, IQR) time to smoke an ‘eighth’ was 3.8
(6.0)days, and the mean (SD) age of onset of regular cannabis
use was 16.3 (2.2)years.
PET data acquisition
All subjects underwent an [18F]-DOPA scan using an ECAT
HR+ 962 PET scanner (CTI/Siemens, Knoxville, TN, USA)
in 3D mode, with an axial field of view of 15.5 cm, which we
performed as previously reported (Egerton et al. 2010). We
asked subjects to abstain from cannabis and fast for 12 h
(mean [SD] time since last cannabis exposure=30.1 [34.4]h)
and to refrain from smoking tobacco for 2 h before imaging.
Subjects were instructed to fast for a fixed interval as a
precautionary approach to minimise variations in plasma large
neutral amino acids which compete with tyrosine for uptake
into the central nervous system (Oldendorf 1973) and stimu-
late hepatic incorporation of tyrosine into proteins (Harper
et al. 1970). Large neutral amino acids therefore are capable
of markedly lowering plasma tyrosine concentrations (Moja
et al. 1996; Palmour et al. 1998) and catecholamine metabo-
lites in both the cerebrospinal fluid (Palmour et al. 1998) and
striatum (Biggio et al. 1976) within hours. The resultant
increased variability in tyrosine and phenylalanine availability
increases the likelihood of altered responses to dopamine-
mediated pharmacological challenges (reviewed in Milner
and Wurtman 1986; Tam and Roth 1997).
All subjects reported no use of drugs other than cannabis,
tobacco, alcohol and caffeine in the 1 week before PET scan.
On the day of the PET scan, urine drug screen (Monitect
HC12, Branan Medical Corporation, Irvine, CA, USA) con-
firmed no recent drug use, other than cannabis, and a negative
urinary pregnancy test was required in all female subjects. A
research clinician (MAPB) assessed psychotic symptoms
using the Positive and Negative Syndrome Scale (PANSS)
and Comprehensive Assessment of At-Risk Mental States
(CAARMS) at the time of scanning. No subjects had psychot-
ic symptoms at the time of scanning (mean [SD] PANSS
positive score cannabis users=7.3 [0.5]) nor met CAARMS
criteria for an At Risk Mental State. Thirty minutes before
PET scanning, subjects completed the 18-item self-rated
Apathy Evaluation Scale (AES-S) (Marin et al. 1991).
We administered oral carbidopa 150 mg and entacapone
400 mg 1 h before imaging (Sawle et al. 1994) to all subjects
in order to reduce the formation of radiolabelled [18F]-DOPA
metabolites(Cumming et al. 1993; Guttman et al. 1993). We
restricted head movement using a head strap and then marked
andmonitored head position via laser crosshairs and a camera.
We performed a 10-min transmission scan before radiotracer
injection for attenuation and scatter correction. We injected
approximately 180 MBq of [18F]-DOPA as an intravenous
bolus 30 s after the start of emission recording. We acquired
emission data in 3D mode for 95 min, re-binned into 26 time-
frames (30-s background frame, four 60-s frames, three 120-s
frames, three 180-s frames and 15 300-s frames).
Region-of-interest analysis
We denoised the nonattenuation-corrected dynamic images
using a level 2, order 64 Battle–Lemarie wavelet filter
(Turkheimer et al. 1999) and realigned individual frames to
a single frame acquired 10 min after the [18F]-DOPA injection
using a mutual information algorithm (Studholme et al. 1996)
to correct for head movement. We then applied the transfor-
mation parameters to the corresponding attenuation-corrected
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frames and combined the realigned frames to create a
movement-corrected dynamic image (from 6 to 95 min fol-
lowing [18F]-DOPA administration) for analysis.
The region-of-interest (ROI) analysis was performed blind
to group status by one of us (M.A.P.B). A summation (add)
image was created from each movement-corrected dynamic
image using RPM (Gunn et al. 1997).
We defined standardised ROIs bilaterally in the whole stria-
tum and its functional subdivisions, i.e. the associative
(precommissural dorsal caudate, precommissural dorsal putamen
and postcommissural caudate), limbic (ventral) and sensorimotor
(postcommissural putamen) subdivisions and the cerebellum (as
the reference region) in Montreal Neurologic Institute space
(Egerton et al. 2010; Martinez et al. 2003) to create an ROI map.
We normalised an [18F]-DOPA template from a previous
study (McGowan et al. 2004) with the ROI map to each
individual PET summation (add) image using statistical para-
metric mapping software (SPM5, http://fil.ion.ucl.ac.uk/spm).
This allowed us to place ROIs automatically on individual
[18F]-DOPA PET images, thus removing observer bias. ROIs
were then double-checked on each subject’s PET scan to
verify anatomical accuracy blind to group.
We calculated the influx rate constant of [18F]-DOPA up-
take in each ROI relative to the cerebellum [Ki
cer (min−1)]
using the Patlak graphical analysis adapted for a reference
tissue input function (Hartvig et al. 1991, 1997; Hoshi et al.
1993; Patlak and Blasberg 1985). We have previously dem-
onstrated good test–retest reliability for striatal Ki
cer deter-
mined this way (Egerton et al. 2010).
Statistical analysis
We assessed normality of distributions using the one-sample
Kolmogorov–Smirnov test. Relationships between Ki
cer,
levels of cannabis use and apathy severity were tested using
Pearson’s correlation coefficient for normally distributed data
and Spearman’s rank correlation coefficient for non-normally
distributed data. Statistical significancewas defined as p<0.05
(two-tailed). Our primary outcome measure was Ki
cer in the
whole striatum. We conducted exploratory analyses in the
striatal sub-divisions (presented uncorrected for multiple com-
parisons). Exploratory analyses between sub-groups were
conducted using independent samples t tests for normally
distributed data and Mann–Witney U tests for non-normally
distributed data.
Results
Subject characteristics and scan parameters
All users consumed the drug as a spliff with tobacco. The
mean (SD) age of initiation of at least weekly cannabis use
was 16.3 (2.2)years. The median (IQR) lifetime exposure to
cannabis and time taken to smoke an eighthwas 2,080 (4,641)
spliffs and 3.8 (6.0)days, respectively. Seven users met DSM-
IV criteria for cannabis abuse or dependence. Subjects’ char-
acteristics are reported in Table 1. Urine drug screen was
positive for THC and negative for all other substances (am-
phetamine; opiates; cocaine; methamphetamine; benzodiaze-
pines) in every user.
Striatal dopaminergic function
The relationship between striatal dopamine synthesis capacity
and apathy
All subjects scored in excess of 34 points on the AES-S
(median [IQR] 59.5 [7.5]), indicative of significant ‘apathy’
Table 1 Sample characteristics and scan parameters
Sample characteristic Cannabis users
(n=14)
Age (years) [mean (SD)] 20.4 (1.3)
Sex (n) 13 male, 1 female
Handedness (n) 12 right, 2 left
Ethnicity (n) 11 WB, 3AB
AES-S [median (IQR)] 59.5 (7.5)
Cannabis usea
Cannabis use (g of cannabis/month)
[median (IQR)]
28.1 (90.0)
THC content of cannabis (%) [mean (SD)] 8.6 (4.0)
Time since last cannabis exposure (h)
[median (IQR)]
14.1 (19.1)
Time taken to smoke an eighth of cannabis
(days) [median (IQR)]
3.8 (6.0)
Duration of at least weekly cannabis
use (years) [mean (SD)]
4.9 (2.0)
Age of onset cannabis use (years) [mean (SD)] 15.5 (1.6)
Increase in PSI psychotic symptom
subscale [mean (SD)]
8.4 (4.5)
CEQ Immediate Effects Subscale [mean (SD)] 90.1 (9.4)
CEQ After Effects Subscale [mean (SD)] 30.2 (13.3)
Scan parameter
Injected dose (MBq) [mean (SD)] 185.1 (5.4)
Specific activity (MBq/μmol) [mean (SD)] 27.9 (13.1)
Whole striatal volume (mm3) [mean (SD)] 17,811.11 (1,325.85)
Associative striatal volume (mm3)
[mean (SD)]
10,787.73 (1,336.46)
Limbic striatal volume (mm3) [mean (SD)] 2,354.99 (1,136.64)
Sensorimotor striatal volume (mm3)
[mean (SD)]
4,668.38 (486.64)
AB Asian British, CEQ Cannabis Experiences Questionnaire, PSI Psy-
chotomimetic States Inventory, WB White British
a Drug use reported in 3 months prior to scan
2254 Psychopharmacology (2014) 231:2251–2259
based on normative data from a healthy population non-
cannabis using sample (mean [SD]=24.4 [4.5]) (Kant et al.
1998). There was no significant difference in apathy scores
between subjects who met DSM-IV criteria for abuse or
dependence and users who did not meet criteria (p=0.71),
and there was no significant difference in Ki
cer between those
subgroups in the whole striatum (t12=1.96, p=0.07) or any of
its subdivisions (data available on request). Dopamine synthe-
sis capacity in each ROI and the relationships between dopa-
mine synthesis capacity and apathy for each of the ROIs are
given in Table 2. There were no significant relationships
between apathy and the volumes of any of the ROIs examined
(all p>0.1). We found that Ki
cer was inversely correlated to
AES-S score in the whole striatum and its associative subdi-
vision (Spearman’s rho=−0.64, p=0.015 [whole striatum];
rho=−0.69, p=0.006 [associative]) but not in the limbic or
sensorimotor subdivisions (Fig. 1). Cook’s D and leverage
analysis indicated that these correlations were not driven by
outlying data points. Our findings of an inverse relationship
between apathy and Ki
cer in the whole striatum and its asso-
ciative subdivision remained significant when co-varying for
the respective striatal volume (rdf=−0.6111, p=0.03 [whole
striatum]; rdf=−0.6211, p=0.03 [associative]) and for recent
tobacco and alcohol use (rdf=−0.6310, p=0.03 [whole stria-
tum]; rdf=−0.6510, p=0.02 [associative]).
There were no significant relationships between AES-S
and current cannabis consumption (rho=0.28, p=0.34) or
age of first cannabis use (rho=0.25, p=0.40), suggesting that
it is not related to recent use or age of first use of cannabis per
se. In addition, there were no significant relationships between
the time since last cannabis exposure and apathy (rho=−0.39,
p=0.17) or Ki
cer (rho=−0.24, p=0.41). Furthermore, there was
no relationship between apathy and psychotogenic response to
cannabis (rho=0.11, p=0.70). However, there was no signif-
icant relationship between Apathy and the CEQ After Effects
scale (rho=−0.06, p=0.83), and there was no significant rela-
tionship between the CEQ After Effects scale and whole
striatal Ki
cer (r=−0.46, p=0.88). Four subjects reported a
family history of depression in a first degree relative.
There was no significant difference in Ki
cer between
subjects with and without a family history of depression
(tdf=0.3412, p=0.74).
Discussion
Our main finding is that within chronic cannabis users, there is
an inverse relationship between striatal dopamine synthesis
capacity and apathy. To our knowledge, this is the first study
to investigate the relationship between apathy and striatal
dopamine synthesis capacity in regular active cannabis users.
Our results suggest that the reduction in striatal dopamine
synthesis capacity associated with regular cannabis use may
underlie the reduced reward sensitivity and amotivation asso-
ciated with chronic cannabis use (van Hell et al. 2010), ac-
counting for 40 % of the variance in apathy. Whilst our study
was cross-sectional so we cannot infer causality, this interpre-
tation is supported by preclinical lesion studies (Schneider
et al. 1988) that show lowering dopamine results in apathy
and that apathy is inversely related to reduced dopamine
function in both patients with Parkinson’s disease (Remy
et al. 2005) and lesioned animals (Brown et al. 2012). A
further possibility could be that our cannabis users were in a
state of withdrawal; however, THC and its metabolites have
an elimination half-life of about 7 days (Maykut 1985), and all
our cannabis users were regular, long-term users who had
consumed cannabis within the past 7 days (median time since
last consumption=14.1 h) and so this would be unlikely.
Our results extend previous findings of attenuated striatal
response to reward anticipation activity in cannabis users (van
Hell et al. 2010). Long-term cannabis use has been associated
with apathy (Looby and Earleywine 2007; McGlothin and
Table 2 Dopamine synthesis capacity in each ROI and the relationships
between dopamine synthesis capacity and apathy for each of the ROIs
Ki
cer (min−1) Relationship between
Ki
cer and AES-S
ROI Mean SD rho p
STR 0.0127 0.0007 −0.636 0.015
AST 0.0121 0.0008 −0.691 0.006
LS 0.0133 0.0008 −0.364 0.200
SMST 0.0140 0.0009 −0.244 0.400
AST associative striatum, LST limbic striatum, SMST sensorimotor stria-
tum, STR whole striatum
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Fig. 1 The relationship between whole striatal dopamine synthesis ca-
pacity (Ki
cer) and apathy (AES-S score) (rho=−0.64, p=0.015)
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West 1968; Tennant and Groesbeck 1972). The very high
apathy scores in our sample are striking, and to our knowl-
edge, the scale we used has not previously been administered
in cannabis users. One study has, however, attributed
amotivational symptoms to coexisting depressive symptoms
(Musty and Kaback 1995). Yet, none of the subjects in our
studymet the threshold for a DSM-IV (TR) diagnosis of major
depressive episode or disorder, or indeed any DSM-IV (TR)
diagnosis except for Cannabis Use Disorders. However, as we
did not include depressive symptom scales in this study, we
cannot exclude the possibility that sub-clinical depressive
symptoms have contributed to our findings. Since apathy is
also a symptom of depression, further studies to disentangle
the relationship between apathy and depressive symptoms and
their possible effects on the day-to-day lives of heavy chronic
cannabis users are therefore warranted.
The striatum has been conceptualised as the interface be-
tween motivation and action (Mogenson and Yang 1991).
Whilst we did not find a relationship between apathy and
dopamine synthesis capacity in the limbic striatal subdivision
which has been described as being involved in motivation
(Martinez et al. 2003), our findings of a significant relation-
ship between apathy and dopamine synthesis capacity in the
dorsal (associative) striatum fit with findings from the Brown
et al. (2012) study. The associative subdivision of the striatum
is part of the corticostriatal–thalamo-cortical loop projecting
to and from associative areas of cortex including the dorsolat-
eral prefrontal cortex (Joel andWeiner 2000) which has dense
interconnections with premotor areas involved in motor plan-
ning (Barbas 2000) and therefore goal-directed behaviour.
One limitation of our study is that the cannabis users were
long-term regular users who were sensitive to the
psychotogenic effects of cannabis, as indicated by both the
CEQ Immediate Effects scale and increase in PSI psychotic
scale, and so our findings may not generalise to less heavy
users. However, we previously found no relationship between
dopamine synthesis capacity and cannabis-induced psychotic-
like symptoms (Bloomfield et al. 2013) and in the present
study found no relationship between apathy and
psychotogenic response to cannabis, suggesting that this is
unlikely to be influencing our results. Our measures of apathy
were subjective, and we did not record observed behavioural
data. Therefore, we cannot exclude the possibility that long-
term cannabis use is associated with bias when completing
this scale, although data exploring this possibility are lacking.
Likewise, our measures of cannabis use relied on self-report,
and we were not able to verify substance use histories beyond
active current cannabis use. Although there is some heteroge-
neity in our sample in terms of DSM-IV criteria, cannabis
users in the study were at least weekly users of the drug with
mean duration of regular use was 4.9 years and within this
sample there was no DSM-IV subgroup effect on apathy
score. We did not find relationships between the CEQ After
Effects scale and dopamine synthesis capacity or apathy. This
may reflect the fact that CEQ asks users about experiences
after the initial effects of cannabis have worn off but which are
felt to be directly related to using cannabis vs. the AES-S
asking subjects to report how they have been feeling over the
last 4 weeks. In addition, the After Effects scale includes items
that are unrelated to amotivation including disinhibition, para-
noia and depersonalisation. A further limitation of our study is
that we did not examine apathy in non-user controls.
Conclusion
Cannabis is now second only to heroin as the most frequently
reported primary illicit drug among those entering specialised
treatment for the first time (European Monitoring Centre for
Drugs and Drug Addiction 2013) and half of young people
reporting any cannabis use in the preceeding 12 months feel
they should either stop or reduce their use (Terry-McElrath
et al. 2008). However, in terms of Prochaska and
DiClemente’s (1982) trans-theoretical model, the motivation
for change amongst cannabis users is low (Fernandez-
Artamendi et al. 2013). Our findings of an inverse relationship
between striatal dopamine synthesis capacity and apathy in
cannabis users suggest that reduced dopamine synthesis ca-
pacity may underlie this and represent a biologically driven
self-perpetuating barrier to treatment. Cannabis use is associ-
ated with a variety of mental illness outcomes, and our find-
ings may also have implications for understanding the biology
of the psychiatric sequelae of cannabis use.
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Tobacco addiction is a global public health problem. Addiction to tobacco is thought to involve the effects of nicotine on the
dopaminergic system. Only one study has previously investigated dopamine synthesis capacity in cigarette smokers. This study, exclusively
in male volunteers, reported increased dopamine synthesis capacity in heavy smokers compared with non-smokers. We sought to
determine whether dopamine synthesis capacity was elevated in a larger sample of cigarette smokers that included females. Dopamine
synthesis capacity was measured in 15 daily moderate smokers with 15 sex- and age-matched control subjects who had never smoked
tobacco. Dopamine synthesis capacity (indexed as the influx rate constant Ki
cer) was measured with positron emission tomography and
3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine. There was no significant group difference in dopamine synthesis capacity between smokers
and non-smoker controls in the whole striatum (t28¼ 0.64, p¼ 0.53) or any of its functional subdivisions. In smokers, there were no
significant relationships between the number of cigarettes smoked per day and dopamine synthesis capacity in the whole striatum
(r¼  0.23, p¼ 0.41) or any striatal subdivision. These findings indicate that moderate smoking is not associated with altered striatal
dopamine synthesis capacity.
Neuropsychopharmacology (2014) 39, 2397–2404; doi:10.1038/npp.2014.87; published online 7 May 2014
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INTRODUCTION
Tobacco addiction is a major global public health problem
(Ezzati and Lopez, 2003). Only 3–5% of self-quitters achieve
prolonged abstinence for 6–12 months after quitting
(Hughes et al, 2004). Treatment of tobacco addiction is
successful in less than 19% of cases (West et al, 2000),
indicating that there is a pressing need to develop improved
treatments (Menossi et al, 2013). The development of better
therapies for tobacco addiction is likely to need greater
understanding of the neurobiological changes associated
with tobacco use. Addiction to tobacco is thought to involve
the effects of nicotine, its main addictive component
(Stolerman et al, 1995), on the dopaminergic system
(Balfour et al, 2000; Pidoplichko et al, 1997) as nicotinic
receptors have been identified on nigrostriatal and meso-
limbic dopaminergic neurons (Clarke and Pert, 1985).
Supporting this, studies in rodents and non-human
primates show that tobacco or nicotine increase dopamine
neuron firing (Grenhoff et al, 1986; Zhang and Sulzer, 2004),
increase dopamine release (Dewey et al, 1999; Gallezot et al,
2013; Marenco et al, 2004; Pontieri et al, 1996), and increase
dopamine synthesis (Tsukada et al, 2005) in the striatum.
In humans, tobacco use has been associated with both
increased striatal dopamine synthesis capacity (Salokangas
et al, 2000) and dopamine release in response to acute
cigarette use in smokers (Brody et al, 2004; Le Foll et al,
2013). However, two studies found that acute nicotine use
did not elicit a significant dopamine release in smokers
(Barrett et al, 2004; Montgomery et al, 2007), although these
did find that the subjective hedonic response to acute
nicotine was related to dopamine release. Smoking-induced
dopamine release has been associated with a reduction in
craving and the severity of tobacco dependence (Brody et al,
2004). Yet, unlike other drugs of addiction, drug-related
(ie, smoking-related) cues did not result in significant
dopamine release in smokers when compared with neutral
images (Chiuccariello et al, 2013). Interestingly, one study
(Busto et al, 2009) found that tobacco dependence was
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associated with reduced amphetamine-induced striatal
dopamine release, although this is likely exacerbated by
comorbid depression. These findings may reflect differences
in the study design (Gallezot et al, 2013), the influence of
other factors, such as sex effects, co-morbidity, or genetic
variants (Dierker et al, 2002; Kendler et al, 1993; Lerman
et al, 1998; Zhang et al, 2006), or the difficulty of imaging
dopamine changes that are comparatively small (Egerton
et al, 2010). In terms of other aspects of dopaminergic
function, a large study on the dopamine transporter did not
find an association between smoking and dopamine
transporter availability (Thomsen et al, 2013).
As discussed above, studies indicate that striatal dopa-
mine synthesis may be altered by nicotine exposure.
Dopamine synthesis capacity can be indexed in humans
using a radiolabeled dopamine precursor, L-3,4-dihydrox-
yphenylalanine (L-DOPA) with positron emission tomo-
graphy (PET; Kumakura and Cumming, 2009). Our primary
hypothesis was, therefore, that cigarette smokers would
have increased dopamine synthesis capacity compared with
non-smoker controls. To our knowledge, only one study has
investigated dopamine synthesis capacity in cigarette smokers.
This study, exclusively in male volunteers, found that striatal
uptake of [18F]-DOPA was 16–29% higher in smokers than
non-smokers (Salokangas et al, 2000). However, as this
sample was exclusively of males and there is evidence of sex
differences in the release of dopamine in response to nicotine
(Dluzen and Anderson, 1997), we sought to determine
whether dopamine synthesis capacity was elevated in a
larger sample of cigarette smokers that included females
and did not have a history of psychiatric co-morbidity
including depression and alcohol use disorders.
MATERIALS AND METHODS
A case–control design was used to compare striatal [18F]-
DOPA uptake in smokers to that in non-smokers. The study
was conducted in accordance with the Declaration of
Helsinki and followed National Research Ethics Service
and the Administration of Radioactive Substances Advisory
Committee approval. All participants received full informa-
tion about the study and gave informed written consent to
take part.
Participants
Participants were recruited through advertisements in the
press. The non-smokers were matched to the smokers on
the basis of age (within 5 years) and sex. Inclusion criteria
for all subjects were: minimum age 18 years, good physical
health with no history of major medical condition, and
capacity to give written informed consent. The exclusion
criteria for all participants were: presence of any significant
current medical disorder or treatment including history of
head injury resulting in loss of consciousness and any
neurological disorder; contraindications to PET including
pregnancy or breast-feeding; a diagnosis of past or current
psychiatric disorders including personality disorder using
the Structured Clinical Interview for DSM-IV (SCID; First
et al, 1996) including alcohol or any other substance
dependence or abuse (apart from Nicotine Use Disorders in
cigarette smokers); evidence of an At Risk Mental State for
Psychosis; drug use other than alcohol or cigarettes in the
3 months before PET scanning; a family history of any
psychotic disorder in first- or second-degree relatives. All
participants provided urine samples to screen for drug use
(Monitect HC12, Branan Medical Corporation, Irvine,
California), and in women, for pregnancy test. Participants
were excluded if either sample came back with positive
result on the day of the scan. No subject was taking psy-
chotropic medication at the time of study participation.
Smoking Data
Smoking data were collected via a semi-structured ques-
tionnaire for assessing exposure to cigarettes and alcohol
(from the Cannabis Experiences Questionnaire interview;
Barkus et al, 2006). The non-smoker group was defined as
those with no lifetime use of tobacco.
PET
All participants were asked to not to eat or drink (except
water), and refrain from alcohol for 12 h before the scan.
The smokers were allowed tobacco 3 h before the scan. This
time period was selected so that nicotine levels were at steady
state (Benowitz et al, 1982). In addition, this is a similar
time period to the only other study that has investigated
dopamine synthesis capacity in smokers (Salokangas et al,
2000). Less than 2 h would coincide with peak plasma nico-
tine levels and longer durations would likely be measuring
the dopamine system in a state of nicotine withdrawal.
Imaging data from the PET scans were obtained on a
Siemens CTI ECAT HRþ 962 PET scanner (Siemens, Erlanger,
Germany) in three-dimensional mode with an axial field of
view of 15.5 cm. One hour before the scan, participants
received 400mg entacapone, a peripheral catechol-0-methy-
ltransferase inhibitor, and 150mg carbidopa, a peripheral
aromatic acid decarboxylase inhibitor, in order to increase
specific signal detection, as these compounds decrease the
formation of radiolabeled metabolites that may cross the
blood–brain barrier (Cumming et al, 1993; Guttman et al,
1993). A 10min transmission scan was conducted before the
radiotracer injection using a 150-MBq cesium-137 rotating
point source to correct for scatter and attenuation. Partici-
pants were positioned in the scanner with the orbitomeatal
line parallel to the transaxial plane of the tomograph.
Head position was marked and monitored via laser cross-
hairs and a camera, and movement was minimized using a
head strap.
A 17MeV GE PET-trace cyclotron was used for radio-
nuclide production. The gas target was filled with 18O2 and
bombarded at 40 mA for 30min followed by a passivation
bombardment of 0.1% F2 in argon at 20 mA for 20min. This
produced [18F]-F by the 18O(p,n) 18F reaction. An electro-
philic fluorination procedure was then used to synthesize 6-
[18F]fluoro-L-DOPA. In brief, [18F]F2 was bubbled through
a solution of 6-trimethylstannyl-L-DOPA (60mg) stirring in
Deutero-chloroform (5ml) over 20min at 5 1C. 6M HCl
(2ml) was added and the chloroform evaporated at 70 1C.
The resulting aqueous mixture was heated at reflux for
10min before allowing to cool. The cooled crude mixture
was purified by semi-prep high-pressure liquid chromato-
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graphy polymer X column eluting with ammonium acetate
buffer. The peak corresponding to [18F]-L-DOPA eluted at
15min was stabilized with 1mg ascorbic acid and sodium
phosphate dibasic. Typical yields were 2.96–3.33 GBq. For
quality assurance purposes, a sample was taken from each
synthesis and analyzed by reverse phase high-pressure
liquid chromatography to confirm identity and purity. To
be able to proceed with the injection, a radiochemical purity
of 95.0% or higher was required. Approximately 180MBq
of [18F]-DOPA was administered as a bolus intravenous
injection 30 s after the start of the emission scan. Emission
data were acquired as 26 frames of increasing duration over
the 90min scan. This comprised a 30-s background frame,
4 60-s frames, 3 120-s frames, 3 180-s frames, and finally
15 300-s frames.
Image Analysis
To correct for head movement in the scanner, non-
attenuation-corrected dynamic images were denoized using
a level 2, order 64 Battle-Lemarie wavelet filter. We used
nonattenuation-corrected images used for the realignment
algorithm as they include greater scalp signal, improving
re-alignment compared with attenuated-corrected images
(Turkheimer et al, 1999). Frames were realigned to a single
‘reference’ frame, acquired 10min post-injection, employ-
ing a mutual information algorithm (Studholme et al, 1996).
The transformation parameters were then applied to the
corresponding attenuated-corrected dynamic images. The
realigned frames were then summated, creating a move-
ment-corrected dynamic image, which was used in the
analysis. The cerebellar reference region (Kumakura and
Cumming, 2009) was defined using a probabilistic atlas
(Martinez et al, 2003), and as previously described, regions
of interest (ROI) in the whole striatum and its functional
sub-divisions were delineated to create an ROI map
(Egerton et al, 2010). The functional subdivisions of the
striatum reflect the topographical arrangement of corticos-
triatal projections. Projections to the sensorimotor striatum
come from the motor cortex and related areas for instance
the premotor cortex, primary motor cortex, and supple-
mentary motor cortex; projections to the associative
striatum start in associative regions such as dorsolateral
prefrontal cortex; and projections to the limbic striatum are
from limbic areas such as the amgydala and hippocampus
(Haber, 2003). SPM5 (http://www.fil.ion.ucl.ac.uk/spm) was
then used to normalize the ROI map together with the
tracer-specific ([18F]-DOPA) template (Egerton et al, 2010,
Howes et al, 2009) to each individual PET summation
image. This nonlinear transformation procedure allowed
ROIs to be automatically placed on individual [18F]-DOPA
PET dynamic images. The influx constant (Ki
cer, written as
Ki in some previous publications (Howes et al, 2009)) for
the entire striatal ROI and the functional subdivisions
bilaterally were calculated compared with uptake in the
reference region using a graphical approach adapted for a
reference tissue input function (Egerton et al, 2010).
Statistical Analysis
Normality of distribution and homogeneity of variance were
assessed using Kolmogorov–Smirnov and Levene’s tests,
respectively. Group (smoker vs non-smoker) differences in
demographic and imaging variables were determined using
independent samples t-tests for normally distributed data,
Mann–Witney U-tests for non-normally distributed data,
and the w2 test for dichotomous variables. The influence of
sex on group differences in Ki
cer was determined using a
two-way analysis of variance. Within the smoker group, the
relationship between Ki
cer and level of cigarette consumption
was tested using Pearson’s product-moment correlation
coefficient. A two-tailed significance level of p¼ 0.05 was
employed throughout. A power calculation determined that
we needed a sample size of 15 per group to have 80% or
greater power to detect the effect size reported in the
Salokangas et al, study (Cohen’s d¼ 1.1) at this significance
level.
RESULTS
Subject Characteristics and Scan Parameters
Fifteen smokers were recruited into the study. All smokers
consumed tobacco as a cigarette. Mean (SD) cigarette
consumption was 8.1 (4.1) per day (range: 1–17). Twelve
smokers met DSM-IV(TR) criteria for Nicotine Depen-
dence. Mean (SD) cigarette consumption was 9.6 (2.9) per
day in smokers who met Dependency criteria (range: 5–17).
Mean (SD) cigarette consumption was 2.0 (1.0) per day in
smokers who did not meet criteria.
Fifteen non-smoker control subjects were matched to the
smoker group for age (±5 years) and sex. Group demogra-
phics are reported in Table 1. Urine drug screens were negative
for all substances (cannabis, amphetamine, opiates, cocaine,
methamphetamine, benzodiazepines) in every subject.
Subjects were well matched for age and sex. There was no
significant group difference in the amount of radioactivity
or specific activity of [18F]-DOPA administered (Table 1).
No subjects had a history of alcohol dependence or abuse
according to DSM-IV(TR) criteria and subjects were well
matched for alcohol use. There was no relationship between
age and Ki
cer in the whole striatum (r¼  0.10, p¼ 0.62) or
its subdivisions in the whole sample or in either group (data
available on request).
Striatal Dopaminergic Function
There was no significant group difference in Ki
cer in the
whole striatum (Figure 1), or any striatal subdivision (Table 2).
No significant differences in Ki
cer were detected after remov-
ing the three smokers who did not meet DSM-IV(TR)
diagnostic criteria for nicotine dependency from the
analysis (t25¼ 0.85, p¼ 0.40).
The Relationship between Striatal Dopamine Synthesis
Capacity and Tobacco Use
In smokers, there were no significant relationships between
the number of cigarettes smoked per day and Ki
cer in the
whole striatum (r¼  0.23, p¼ 0.41; Figure 2), or any striatal
subdivision (associative: r¼  0.16, p¼ 0.57; sensorimotor:
r¼  0.33, p¼ 0.23; limbic: r¼  0.22, p¼ 0.44).
To examine whether nicotine dependency was specifically
associated with elevated Ki
cer, we divided the tobacco user
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group into subjects who met DSM-IV(TR) diagnostic
criteria for nicotine dependency (n¼ 12), and those who
did not meet criteria (n¼ 3). Mean (SD) Kicer was 0.0127
(0.0010) min 1 in smokers meeting Nicotine Dependence
criteria and 0.0131 (0.0019) min 1 in smokers who did not
meet criteria. t-Tests showed no significant differences
between the nicotine dependency sub-group and non-
smoker controls (t25¼ 0.85, p¼ 0.40). There was no
significant relationship between tobacco use and dopamine
synthesis capacity in the whole striatum (r¼ 0.18, p¼ 0.57)
or any of its functional subdivisions (data available on
request) within the nicotine-dependent sub-group.
Sex
We performed a further explorative analysis to examine for
possible sex effects. Mean (SD) Ki
cer was 0.0127 (0.0008)
min 1 in females and 0.0130 (0.0012) min 1 in males.
Among males, mean (SD) Ki
cer was 0.0130 (0.0013) min 1 in
smokers and 0.0131 (0.0010) min 1 in non-smokers.
Among females, mean (SD) Ki
cer was 0.0125 (0.0010) min 1
Figure 1 Whole striatal dopamine synthesis capacity (indexed as the
influx rate constant Ki
cer) in smokers compared to non-smokers. Error bars
indicate standard deviations.
Table 1 Sample Characteristics and Scan Parameters
Non-smoker controls Smokers Pa
Sample characteristic
Age (years), mean (SD) 29.5 (11.1) 29.9 (10.3) 0.92
Sex (m:f) (n) 10 : 5 10 : 5 1.00
Ethnicityb (n) 8WB, 3BB, 2AB, 1ME, 1OE 12WB, 1BB, 1AB1 1ME 0.12
Tobacco smokers (n) 0 15 0.00
Tobacco use (cigarettes/day), mean(SD) 0.0 (0.0) 8.1 (4.1) 0.00
Cigarettes smoked before PET scan, mean (SD) 0.0 (0.0) 0.8 (0.4) 0.00
Alcohol users (n) 13 11 0.36
Alcoholc use (UK alcohol units/week), mean (SD) 7.1 (8.7) 11.2 (8.7) 0.21
Scan parameter
Injected dose (MBq), mean (SD) 182.4 182.7 0.87
Specific activity (MBq/mmol), mean (SD) 30.1 27.5 0.62
Abbreviations: AB, Asian British; BB, black British; ME, mixed ethnicity; OE, other ethnicity; WB, white British.
aIndependent-samples t-tests for variables with normal data distributions; Mann–Whitney U-tests for variables with non-normal data distributions; w2 tests for
dichotomous variables.
bGroups were compared on a dichotomized ethnicity variable (white British vs ethnic minority).
c1 UK alcohol unit¼ 10ml (B7.88 g) alcohol.
Table 2 [18F]-DOPA Ki
cer (min 1) by Group
ROI Non-smoker controls
(n¼15)
Smokers
(n¼15)
Group
comparisona
Mean SD Mean SD tdf p
STR 0.0130 0.0010 0.0128 0.0012 0.6428 0.53
AST 0.0126 0.0010 0.0122 0.0011 0.8428 0.41
LST 0.0132 0.0017 0.0135 0.0012 0.6328 0.53
SMST 0.0141 0.0011 0.0138 0.0016 0.6728 0.51
Abbreviations: AST, associative striatum; Ki
cer, influx rate constant; LST, limbic
striatum; ROI, region of interest; SMST, sensorimotor striatum; STR, whole striatum.
aIndependent-samples t-tests.
Figure 2 The relationship between tobacco use and dopamine synthesis
capacity (indexed as the influx rate constant Ki
cer) in smokers.
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in smokers and 0.0130 (0.0006) min 1 in non-smokers.
Two-way analysis of variance did not reveal a significant
interaction between smoking status and sex on dopamine
synthesis capacity in the whole striatum (F1,26¼ 0.23,
p¼ 0.64) or any functional subdivision (associative stria-
tum: F1,26¼ 0.08, p¼ 0.79; sensorimotor striatum: F1,26¼
0.34, p¼ 0.54; limbic striatum: F1,26¼ 0.73, p¼ 0.40).
DISCUSSION
This study found no evidence for altered striatal dopamine
synthesis in tobacco smokers compared with non-smokers,
or relationship between the levels of daily cigarette smoking
and dopamine synthesis capacity. Furthermore, we did
not find an effect of nicotine dependence on dopamine
synthesis capacity. Our findings are therefore not consistent
with our hypothesis that dopamine synthesis capacity
would be elevated in smokers compared with non-smokers.
These negative findings are in contrast to a previous
report of elevated dopamine synthesis capacity in 9 male
smokers compared with 10 non-smokers (Salokangas et al,
2000). Although striatal dopamine synthesis capacity may
be higher in females (Laakso et al, 2002), this was not
evident in our sample. The subjects in the study by Salokangas
et al were heavy smokers (at least 15 cigarettes/day, mean
19.8 cigarettes/day compared with mean 8.1 cigarettes/day
in our study), which could explain the difference with our
findings. Although we found no evidence of a relationship
between Ki
cer and the level of daily cigarette consumption,
this may indicate that elevations in presynaptic dopamine
synthesis capacity are only apparent in heavy smokers.
The study by Salokangas et al (2000) used the same
methodology as a previous study by Hietala et al (1999), ie,
Carbidopa 100mg only was administered 90min before PET
scan (Personal Communication from Professor Salokangas),
followed by measurement of radiolabeled metabolites in the
arterial input function. This is in comparison to the carbi-
dopa 150mg and entacapone 400mg administered 1 h
before PET scan followed by a cerebellar reference region
approach in the present study. To our knowledge, data on
the effects of smoking on the pharmacodynamics of entaca-
pone are lacking. Entacapone undergoes rapid hepatic
metabolism via the uridine 5’-diphospho-glucuronosyl-
transferase pathway (Lautala et al, 2000). Data from studies
in humans (Bock and Ko¨hle, 2004) and mice models
(Villard et al, 1998) indicate that cigarette smoke is a potent
inducer of uridine 5’-diphospho-glucuronosyltransferase,
which would thus lead to a faster elimination of entacapone
and therefore a potential reduction in plasma [18F]-DOPA
in smokers vs controls whom have had entacapone
administered. As our reference region approach theoreti-
cally eliminates the plasma input function, we would predict
the main effect of any potential reduction in plasma [18F]-
DOPA to result in increased variability of Ki
cer without
altering mean Ki
cer. However, there are limited data directly
comparing Ki values obtained via a tissue reference region
and arterial plasma input function method, as was the case
in the study by Salokangas et al (2000). Sossi et al (2003)
reported a comparison between a reference region and
arterial input function approach. In that study, Sossi et al
used the occipital lobe as the reference region, rather than
the cerebellum used in our study. Therefore, it remains
possible that a difference in entacapone metabolism in
smokers may be underlying the disparity in results between
our study and that of Salokangas et al (2000). Nevertheless,
the entry into and exit from the brain of radiolabeled
plasma metabolites may affect graphical analysis (Boyes
et al, 1986; Cumming et al, 1987) and could bias results if
metabolism is selectively altered in one group. Compared
with non-smokers, smokers have reduced CSF levels of the
dopamine metabolite homovanillic acid (Geracioti et al,
1999) and there is evidence of reduced MAO-A and MAO-B
activity in smokers (Fowler et al, 1996a, b). However, as
these differences would, if anything, reduces the production
of radiolabeled metabolites in smokers, they are unlikely to
explain the failure to detect an elevation in smokers. In
summary, even if entacapone clearance is higher in our
smoker group, we remain unable to conclude that it would
be sufficient to impact metabolite production within our
experimental window. Furthermore, even if there was a
sufficient impact on metabolite production, our use of a
reference region approach would be expected to be
sufficiently robust to overcome this problem.
Survey data in Great Britain indicate that over the last few
decades there has been a gradual decline in the number of
cigarettes consumed per day among smokers, such that the
average number of cigarettes smoked per day is now 12 for
men and 11 for women (Office for National Statistics, 2013).
Our sample of moderate smokers is therefore in the same
range as that of the general population. Overall our findings
and those of Salokangas et al thus indicate that there is no
markedly altered dopamine function in moderate smokers,
but alterations are apparent in heavy smokers. A further
contributing factor for the discrepancy in findings from
those of the study by Salokangas et al and the present study
is that the nicotine content of cigarettes has decreased since
the former. However, we did not collect data on the type of
cigarette consumed by each tobacco-smoking subject,
which would have enabled an estimation of the amount of
nicotine consumed. Despite proposals for nicotine reduc-
tion policies (Benowitz and Henningfield, 1994), which have
intended for the nicotine content of cigarettes to be
reduced, there is some evidence that the nicotine yield of
cigarettes in American brands may, in fact, have increased
since the Salokangas study (Connolly et al, 2007). Future
studies assessing both the effects of heavy vs moderate
smoking and nicotine dose of cigarettes on dopaminergic
function are therefore warranted.
Study Limitations
Although our sample size was larger than the only other
study to investigate dopamine synthesis capacity in
smokers, it is important to consider the possibility of a
type II error in our findings. We had 84% power to detect
the effect size (Cohen’s d¼ 1.12) seen in the Salokangas et al
study, which is above the 80% power threshold convention-
ally considered adequate. Nevertheless, even at this power,
there is a 16% chance that a true effect of this magnitude
has been missed. As we only included moderate smokers, a
limitation of our study would be that we did not include a
group of heavy smokers for comparison. A potential
limitation of the correlation between cigarette use and
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dopamine synthesis capacity is that seven of the smokers in
our study consumed 10 cigarettes per day, which likely
reflects the fact that tobacco in the United Kingdom is sold
in packets of 10 and 20 cigarettes, but limits the power of
the correlational analysis. Our sample contained five female
subjects per group and so was underpowered to detect sex–
group interactions, indicating that these analyses should
only be considered exploratory. Gonadal hormones may
influence dopaminergic function. However, we did not
assess this or phase of the menstrual cycle in the females.
A further limitation of our study is that we did not include
the Fagerstro¨m Test for Nicotine Dependence, which would
have enabled the exploration of the relationships between
dopamine synthesis capacity and subjective craving. Like-
wise, we did not measure plasma nicotine, cotinine, or
carbon dioxide levels. Future studies would therefore benefit
from including these measures in larger sample sizes.
Implications for Understanding Tobacco Addiction
The role of the dopamine system in drug reinforcement has
long been accepted from animal studies (eg, Koob, 1992)
and there is mounting evidence that dysregulated dopamine
function is central to addiction behaviors in humans (as
reviewed by Volkow et al, 2011). There is growing evidence
that chronic drug abuse is associated with abnormal striatal
dopaminergic functioning in humans, as has been found
with alcohol (Heinz et al, 2005), cannabis (Bloomfield et al,
2013), cocaine (Wu et al, 1997), methamphetamine (Wang
et al, 2012), and ecstasy (Tai et al, 2011). However, our
study suggests that dopamine dysregulation may only
become apparent at higher levels of use, either because it
is below the level of detection with more moderate use, or
because it is a cumulative consequence of heavy use.
CONCLUSIONS
This study found that moderate smoking was not associated
with marked effects on striatal dopamine synthesis capacity,
in contrast to a previous finding of elevated dopamine
synthesis capacity in heavy smokers. Further studies in
smokers of presynaptic dopaminergic function using heavy
and moderate smokers are warranted to determine whether
dopaminergic effects only become evident with heavier use.
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 Appendix 2 – Key Psychometric Assessments  
Aberrant Salience Inventory (ASI) 
Apathy Evaluation Scale (self-rated) (AES-S) 
Back Anxiety Inventory (BAI)  
Beck Depression Inventory (BDI)  
Cannabis Experience Questionnaire (CEQ) 
Childhood Experiences of Care and Abuse (CECA)  
Childhood Trauma Questionnaire (CTQ)  
Comprehensive Assessment for At Risk Mental State (CAARMS)  
Impact of Invents Scale (IES-6) 
Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE) 
Psychotomimetic States Inventory (PSI)  
Structured Clinical Interview for DSM-IV (SCID)   
 
ASI, p. 1 
ASI 
 
Instructions: Please read the following statements and answer them yes (Y) or no (N) as 
they apply to you. Please do not consider thoughts or experiences that you have had only 
under the influence of drugs or alcohol.  
 
 Yes No 
1) Do certain trivial things ever suddenly seem especially important or 
significant to you? 
Y N 
2) Do you sometimes feel like you are on the verge of something really big, 
but you’re not sure what it is? 
Y N 
3) Do your senses sometimes seem sharpened? Y N 
4) Do you ever feel like you are rapidly approaching the height of your 
intellectual powers? 
Y N 
5) Do you sometimes notice small details that you have not noticed before 
that seem important? 
Y N 
6) Do you sometimes feel like it is important for you to figure something 
out, but you’re not sure what it is? 
Y N 
7) Do you ever go through periods where you feel especially religious or 
mystical? 
Y N 
8) Do you ever have difficulty telling if you are thrilled, frightened, pained, 
or anxious? 
Y N 
9) Do you ever go through periods of heightened awareness? Y N 
10) Do you ever feel the need to make sense of seemingly random situations 
or occurrences? 
Y N 
11) Do you sometimes feel like you are finding the missing piece to a 
puzzle? 
Y N 
12) Do you sometimes feel that you can hear with a greater clarity? Y N 
13) Do normally trivial observations sometimes take on an ominous 
significance? 
Y N 
14) Do you go through periods in which songs sometimes seem to have an 
important meaning for your life? 
Y N 
15) Do you sometimes attribute importance to objects which you normally 
would not? 
Y N 
16) Do you sometimes feel like you are on the verge of figuring out 
something really big or important, but you aren’t sure what it is? 
Y N 
17) Has your sense of taste ever seemed more acute? Y N 
18) Do you ever feel like the mysteries of the universe are revealing 
themselves to you? 
Y N 
19) Do you go through periods in which you feel over-stimulated by things 
or experiences that are normally manageable? 
Y N 
20) Do you often become fascinated by the little things around you? Y N 
21) Do your senses ever seem extremely strong or clear? Y N 
22) Do you ever feel like a whole world is opening up to you? Y N 
23) Do you ever feel that your boundaries between inner and outer 
sensations have been removed? 
Y N 
ASI, p. 2 
24) Do you sometimes feel like the world is changing and you are searching 
for an explanation? 
Y N 
25) Do you ever perceive an overwhelming significance to things that are 
usually not significant to you? 
Y N 
26) Do you ever have a feeling of inexpressible urgency, and you are not 
sure what to do? 
Y N 
27) Have you sometimes become interested in people, events, places, or 
ideas that normally would not make an impression on you? 
Y N 
28) Do your thoughts and perceptions ever come faster than can be 
assimilated? 
Y N 
29) Do you sometimes notice things that you haven’t noticed before that 
take on special significance? 
Y N 
 
Apathy Evaluation Scale (Self-rated) 
 
Name: ___________________________________________ Date: ___/___/___ 
 
For each statement, circle the answer that best describes the subject’s thoughts, feelings, and activity 
in the past 4 weeks. 
 
1. I am interested in things. 
 
NOT AT ALL  SLIGHTLY  SOMEWHAT A LOT 
 
2. I get things done during the day. 
 
NOT AT ALL SLIGHTLY  SOMEWHAT A LOT 
 
3. Getting things started on my own is important to me. 
 
NOT AT ALL SLIGHTLY  SOMEWHAT  A LOT 
 
4. I am interested in having new experiences. 
 
NOT AT ALL SLIGHTLY  SOMEWHAT  A LOT 
 
5. I am interested in learning new things 
 
NOT AT ALL SLIGHTLY  SOMEWHAT  A LOT 
 
6. I put little effort into anything. 
 
NOT AT ALL SLIGHTLY   SOMEWHAT  A LOT 
 
7. I approach life with intensity. 
 
NOT AT ALL SLIGHTLY  SOMEWHAT A LOT       
8. Seeing a job through to the end is important to me. 
 
NOT AT ALL SLIGHTLY  SOMEWHAT A LOT 
 
9. I spend time doing things that interest me. 
 
NOT AT ALL  SLIGHTLY  SOMEWHAT A LOT 
 
 
10. Someone has to tell me what to do each day. 
 
NOT AT ALL  SLIGHTLY  SOMEWHAT A LOT 
 11. I am less concerned about my problems than I should be. 
 
NOT AT ALL  SLIGHTLY  SOMEWHAT A LOT 
 
12. I have friends. 
 
NOT AT ALL  SLIGHTLY  SOMEWHAT  A LOT 
 
13. Getting together with friends is important to me. 
 
NOT AT ALL  SLIGHTLY  SOMEWHAT  A LOT 
 
14. When something good happens, I get excited. 
 
NOT AT ALL  SLIGHTLY   SOMEWHAT A LOT 
 
15. I have an accurate understanding of my problems. 
 
NOT AT ALL  SLIGHTLY   SOMEWHAT  A LOT 
 
16. Getting things done during the day is important to me. 
 
NOT AT ALL  SLIGHTLY  SOMEWHAT A LOT 
 
17. I have initiative. 
 
NOT AT ALL  SLIGHTLY    SOMEWHAT A LOT 
18. I have motivation. 
 
NOT AT ALL  SLIGHTLY   SOMEWHAT A LOT 
 
 
 
 
 
The Apathy Evaluation Scale was developed by Robert S. Marin, M.D.  Development and validation 
studies are described in RS Marin, RC Biedrzycki, S Firinciogullari: “Reliability and Validity of the 
Apathy Evaluation Scale,” Psychiatry Research, 38:143-162, 1991  
 
 Beck Anxiety Inventory 
 
Below is a list of common symptoms of anxiety.   Please carefully read each item in the list.  Indicate how much you 
have been bothered by that symptom during the past month, including today, by circling the number in the 
corresponding space in the column next to each symptom. 
 
 
Not At All Mildly but it 
didn’t bother me 
much.  
Moderately - it 
wasn’t pleasant at 
times 
Severely – it 
bothered me a lot 
Numbness or tingling 0 1 2 3 
Feeling hot 0 1 2 3 
Wobbliness in legs 0 1 2 3 
Unable to relax 0 1 2 3 
Fear of worst 
happening 
0 1 2 3 
Dizzy or lightheaded 0 1 2 3 
Heart pounding/racing 0 1 2 3 
Unsteady 0 1 2 3 
Terrified or afraid 0 1 2 3 
Nervous 0 1 2 3 
Feeling of choking 0 1 2 3 
Hands trembling 0 1 2 3 
Shaky / unsteady 0 1 2 3 
Fear of losing control 0 1 2 3 
Difficulty in breathing 0 1 2 3 
Fear of dying 0 1 2 3 
Scared 0 1 2 3 
Indigestion 0 1 2 3 
Faint / lightheaded 0 1 2 3 
Face flushed 0 1 2 3 
Hot/cold sweats 0 1 2 3 
Column Sum     
 
Scoring - Sum each column.   Then sum the column totals to achieve a grand score.  Write that 
score here ____________ . 
Interpretation 
 
A grand sum between 0 – 21 indicates very low anxiety.  That is usually a good thing.  However, it is 
possible that you might be unrealistic in either your assessment which would be denial or that you have 
learned to “mask” the symptoms commonly associated with anxiety.   Too little “anxiety” could indicate that 
you are detached from yourself, others, or your environment.   
 
A grand sum between 22 – 35 indicates moderate anxiety.  Your body is trying to tell you something.  Look 
for patterns as to when and why you experience the symptoms described above.  For example, if it occurs 
prior to public speaking and your job requires a lot of presentations you may want to find ways to calm 
yourself before speaking or let others do some of the presentations.  You may have some conflict issues that 
need to be resolved.  Clearly, it is not “panic” time but you want to find ways to manage the stress you feel. 
 
A grand sum that exceeds 36 is a potential cause for concern.  Again, look for patterns or times when you 
tend to feel the symptoms you have circled.  Persistent and high anxiety is not a sign of personal weakness or 
failure.  It is, however, something that needs to be proactively treated or there could be significant impacts to 
you mentally and physically.  You may want to consult a counselor if the feelings persist. 
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Beck Depression Inventory
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Mood/Depression Assessment Questionnaire
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I would now like to ask you some questions about your childhood and adolescence. We are interested in different 
experiences you may have had before you were 17 years of age. Some of the experiences I want to ask about may 
bring back upsetting or painful memories, so if at any time you do not wish to answer a question please say so. Of 
course, all information you provide will be treated in the strictest confidence. 
1. Who were your main parent figures, before age 17?  [If necessary, continue on a separate sheet] 
 
0 =   
No mother, 
father figure 
1 =  
Natural mother, 
father 
2 = 
Step-mother, 
father 
3 = 
Grandmother, 
father 
4 = 
 Other 
  
1. Family 
arrangement 
A.    Mother figure B.    Father figure C.    Your age at start 
1. First O0       O1        O2        O3         O4 O0       O1        O2        O3         O4 0 
2. Second O0       O1        O2        O3         O4 O0       O1        O2        O3         O4  
3. Third O0       O1        O2        O3         O4 O0       O1        O2        O3         O4  
4. Fourth O0       O1        O2        O3         O4 O0       O1        O2        O3         O4  
5. Fifth O0       O1        O2        O3         O4 O0       O1        O2        O3         O4  
6. Sixth O0       O1        O2        O3         O4 O0       O1        O2        O3         O4  
 
 
2. Did one or both of your parents die, before age 17?   
2.a.       Did your mother die? O0 No O1 Yes 
2.b.      Did your father die? O0 No O1 Yes 
2.c.       If yes, how old were you when your mother died?     
2.d.       If yes, how old were you when your father died?     
 
3. Were you ever separated from a parent (longer than six months), before age 17?   
3.a.       Separated from mother? O0 No O1 Yes 
3.b.       Separated from father? O0 No O1 Yes 
3.c.       If yes, how old were you at your first separation from mother?     
3.d.       If yes, how old were you at your first separation from father?     
3.e.       How long were you separated, in months?     
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3.f. What was the main reason for the separation?   
O1 Parental Illness O2 Divorce, Separation O3 Work O4 Never knew parent  
O5 Own illness O6 Boarding school O7 Migration O8 Other  
              
3.g.         Specify: ……………………………………………………………………………………………….. 
 
 
 
 
Before the age of 17 years … 
 0-11 years 12-16 years 
4. Did you ever change schools? (other than change from primary 
to secondary) 
O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
5. Were you ever expelled from school? O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
6. Did you ever run away from home? (i.e., stayed away for more 
than two nights) 
O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
7. Were you ever taken into care? (i.e., children’s home, fostered) O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
8. Were there ever times when your family was significantly short 
of money? 
O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
9. Were your basic needs ever neglected? (for food, clean 
clothing, etc.) 
O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
10. Were there ever frequent arguments or extreme tensions 
between your parents? 
O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
11. Were you ever tormented or treated cruelly by a parent or a 
member of household? 
O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
12. Were you ever hit or slapped on a number of occasions, 
sufficient to cause harm? 
O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
13. Ever had any unwanted sexual experiences? O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
14. Any adults could go to with problems or to discuss feelings? O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
15. Others own age could go to with problems or to discuss 
feelings? 
O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
16. Ever felt lonely for a significant period? (i.e., 6 months or 
more)? 
O0 No O1 Yes O2 Refused 
to answer 
O0 No O1 Yes O2 Refused 
to answer 
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Notes: 
----------------------------------------------------------------------------------------------------------------------------- --------------------------
--------------------------------------------------------------------------------------------------------- ----------------------------------------------
----------------------------------------------------------------------------------------------------------------------------- --------------------------
-------------------------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------------- --------------------------
------------------------------------------------------------------------------------------------------------------------------------------ -------------
---------------------------------------------------------------------------------------------------------------------- ---------------------------------
----------------------------------------------------------------------------------------------------------------------------- --------------------------
-------------------------------------------------------------------------------------------------------------------------------------------------------  
----------------------------------------------------------------------------------------------------------------------------- --------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------ -
----------------------------------------------------------------------------------------------------------------------------- --------------------------
----------------------------------------------------------------------------------------------------------------------------- -------------------------- 
 
 
 
    
   (Note for DATA ENTRY: open EU_BULL, Bullying) 
 
 
       
 CHILDHOOD TRAUMA QUESTIONNAIRE  
 CTQ,  English, EU GEI, 4-d, September 2010, Page 1 
 
STUDIE: EU GEI  Date of Birth 
 Subject number: |    |  EU |    |__|  -  |    |    |    |_  |  |__|__|-|__|__|-| 1 | 9 |__|__| 
        
Time interval: lifetime    Period – Replicat  | 0 |__|-| 0 |__|      
    Interviewer: ………………………………………… Date  |__|__|-|__|__|-| 2 | 0 |__|__| 
        
  
 
 
 
 
 
 
For each question, tick the box under the response that best describes how you feel. 
[ALL participants should be given the CTQ to complete on their own. Assistance may be provided if the 
person has difficulty reading the questions.] 
 
Before the age of 17: Never Rarely Sometimes Often Very often 
1. I didn’t have enough to eat O1 O2 O3 O4 O5 
2. I knew that there was someone to take care of me and protect me O1 O2 O3 O4 O5 
3. People in my family called me things like “stupid”, “lazy”, or “ugly” O1 O2 O3 O4 O5 
4. My parents were too drunk or high to take care of the family O1 O2 O3 O4 O5 
5. There was someone in my family who helped me feel that I was 
important or special 
O1 O2 O3 O4 O5 
6. I had to wear dirty clothes O1 O2 O3 O4 O5 
7. I felt loved O1 O2 O3 O4 O5 
8. I thought that my parents wished I had never been born O1 O2 O3 O4 O5 
9. I got hit so hard by someone in my family that I had to see a doctor or go 
to the hospital 
O1 O2 O3 O4 O5 
10. People in my family hit me so hard that it left me with bruises or marks O1 O2 O3 O4 O5 
11. I was punished with a belt, a board, a cord, or some other hard object O1 O2 O3 O4 O5 
12. People in my family looked out for each other O1 O2 O3 O4 O5 
13. People in my family said hurtful or insulting things to me O1 O2 O3 O4 O5 
14. I believe that I was physically abused O1 O2 O3 O4 O5 
15. I got hit or beaten so badly that it was noticed by someone like a teacher, 
neighbor, or doctor 
O1 O2 O3 O4 O5 
16. I felt that someone in my family hated me O1 O2 O3 O4 O5 
17. People in my family felt close to each other O1 O2 O3 O4 O5 
18. Someone tried to touch me in a sexual way, or tried to make me touch 
them 
O1 O2 O3 O4 O5 
19. Someone threatened to hurt me or tell lies about me unless I did 
something sexual with them 
O1 O2 O3 O4 O5 
20. Someone tried to make me do sexual things or watch sexual things 
  
O1 O2 O3 O4 O5 
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Before the age of 17: Never Rarely Sometimes Often Very often 
21. Someone molested me O1 O2 O3 O4 O5 
22. I believe that I was emotionally abused O1 O2 O3 O4 O5 
23. There was someone to take me to the doctor if I needed it O1 O2 O3 O4 O5 
24. I believe that I was sexually abused O1 O2 O3 O4 O5 
25. My family was a source of strength and support O1 O2 O3 O4 O5 
 
 
 CAARMS- December 2006 
 
  
 
 
A. Yung, L. Phillips, M.B. Simmons, J. Ward, K. Thompson, P. French, P. McGorry 
 
 
 
NAME:  ______________________ 
 
ID #:  ______________________ 
 
Rater:  ______________________ 
 
Date:  _____  /  _____  /  _____ 
 
 
 
 
 
 
© 2006 Yung, Phillips, Simmons, Ward, Thompson, French, McGorry 
 CAARMS- December 2006 
 
 
OVERVIEW OF THE CAARMS 
 
Aims:  
• To determine if an individual meets the criteria for ‘Ultra High Risk’ status. 
• To rule out, or confirm criteria for acute psychosis. 
• To map a range of psychopathology and functioning factors, over time in young people at ultra high-risk of 
psychosis. 
 
Structure of the CAARMS: 
• Ratings are made on a range of subscales that target different areas of psychopathology and functioning.  
From these ratings it is then possible to extract information relating to the above aims.   
 
Overview of Symptoms and Functioning - Longitudinal Change: 
• At the first interview (not follow-up interviews), the CAARMS aims to obtain a general overview of the history 
of change from the premorbid state in the respondent.  All available information should be used.   
• Record the time of first noted change - date and age of respondent in years: 
Date: ……………………………… 
Age:  ……………………………… 
 
• Note first ever symptoms or signs: 
………………………………………..…… 
………………………………………..…… 
………………………………………..…… 
………………………………………..…… 
………………………………………..…… 
 
• Overview of course since then - map on timeline e.g.:   
 
 
 
 
 
 
 
 
 
 First change   Worst ever   Present state  Time 
 
 
 
 
• Current time line: 
 
 
 
 
 
 
 
 
 
 First change   Worst ever   Present state  Time 
 
 
 
 CAARMS- December 2006 
 
 
INDEX 
 
 
1:  POSITIVE SYMPTOMS       page 
1.1 UNUSUAL THOUGHT CONTENT      1 
1.2 NON-BIZARRE IDEAS        3 
1.3 PERCEPTUAL ABNORMALITIES      5 
1.4 DISORGANISED SPEECH       7 
 
2:  COGNITIVE CHANGE ATTENTION/CONCENTRATION 
2.1 SUBJECTIVE EXPERIENCE        9 
2.2 OBSERVED COGNITIVE CHANGE      11 
 
3:  EMOTIONAL DISTURBANCE 
3.1 SUBJECTIVE EMOTIONAL DISTURBANCE     12 
3.2 OBSERVED BLUNTER AFFECT      14 
3.3 OBSERVED INAPPROPRIATE AFFECT     15 
 
4:  NEGATIVE SYMPTOMS 
4.1 ALOGIA         16 
4.2 AVOLITION/APATHY        17 
4.3 ANHEDONIA         18 
 
5: BEHAVIOURAL CHANGE 
5.1 SOCIAL ISOLATION        19 
5.2 IMPAIRED ROLE FUNCTION       20 
5.3 DISORGANISING/ODD/STIGMATISING BEHAVIOUR    21 
5.4 AGGRESSION/DANGEROUS BEHAVIOUR     22 
 
6: MOTOR/PHYSICAL CHANGES 
6.1 SUBJECTIVE COMPLAINTS OF IMPAIRED MOTOR FUNCTIONING  23 
6.2 INFORMANT REPORTED OR OBSERVED CHANGES IN MOTOR  
FUNCTIONING         24 
6.3 SUBJECTIVE COMPLAINTS OF IMPAIRED BODILY SENSATION  25 
6.4 SUBJECTIVE COMPLAINTS OF IMPAIRED AUTONOMIC     
FUNCTIONING         26 
 
7: GENERAL PSYCHOPATHOLOGY 
7.1 MANIA          27 
7.2 DEPRESSION         29 
7.3 SUICIDALITY AND SELF HARM      31 
7.4 MOOD SWINGS/LABILITY       32 
7.5 ANXIETY         33 
7.6 OCD SYMPTOMS        34 
7.7 DISSOCIATIVE SYMPTOMS       35 
7.8 IMPAIRED TOLERANCE TO NORMAL STRESS    36 
 
8: INCLUSION CRITERIA       37 
 
9: PSYCHOSIS THRESHOLD      38 
 
        
Positive Symptoms 
 
CAARMS- December 2006 
1
 
1: POSITIVE SYMPTOMS 
 
 
1.1 UNUSUAL THOUGHT CONTENT 
 
 
Delusional Mood and Perplexity (‘Non Crystallized Ideas’) 
• Have you had the feeling that something odd is going on that 
you can’t explain? What is it like? 
• Do you feel puzzled by anything?  Do familiar surroundings feel 
strange? 
• Do you feel that you have changed in some way? 
• Do you feel that others, or the world, have changed in some 
way? 
 
 
 
 
 
 
Ideas of Reference 
 
 
Bizarre Ideas (‘Crystallized Ideas’) 
• Made thoughts, feelings, impulses:  Have you felt that 
someone, or something, outside yourself has been controlling 
your thoughts, feelings, actions or urges?  Have you had 
feelings or impulses that don’t seem to come from yourself? 
• Somatic Passivity:  Do you get any strange sensations in your 
body? Do you know what causes them? Could it be due to 
other people or forces outside yourself? 
• Thought Insertion:  Have you felt that ideas or thoughts that are 
not your own have been put into your head? How do you know 
they are not your own?  Where do they come from? 
• Thought Withdrawal:  Have you ever felt that ideas or thoughts 
are being taken out of your head? How does that happen? 
• Thought Broadcasting:  Are your thoughts broadcast so that 
other people know what you are thinking? 
• Thoughts Being Read:  Can other people read your mind? 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Ideas of Reference: Have you felt that things that were 
happening around you had a special meaning, or that people 
were trying to give you messages?  What is it like?  How did it 
start? 
 
 
 
 
 
 
 
Positive Symptoms 
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UNUSUAL THOUGHT CONTENT- GLOBAL RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Psychotic 
and Severe 
No unusual 
thought 
content. 
Mild 
elaboration of 
conventional 
beliefs as held 
by a 
proportion of 
the population 
Vague sense 
that something 
is different, or 
not quite right 
with the world, 
a sense that 
things have 
changed but 
not able to be 
clearly 
articulated.   
Subject not 
concerned/ 
worried about 
this 
experience. 
A feeling of 
perplexity. A 
stronger 
sense of 
uncertainty 
regarding 
thoughts than 
2.   
  
 Referential 
ideas that 
certain events, 
objects or 
people have a 
particular and 
unusual 
significance. 
Feeling that 
experience 
may be 
coming from 
outside the 
self. Belief not 
held with 
conviction, 
subject able to 
question. 
Does not 
result in 
change in 
behaviour. 
Unusual 
thoughts that 
contain 
completely 
original and 
highly 
improbable 
material.  
Subject can 
doubt (not 
held with 
delusional 
conviction), or 
which the 
subject does 
not believe all 
the time.   
May result in 
some change 
in behaviour, 
but minor.   
Unusual 
thoughts 
containing 
original and 
highly 
improbable 
material held 
with delusional 
conviction (no 
doubt). 
 May have 
marked impact 
on behaviour. 
 
 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
 
Level of Distress (In Relation to Symptoms) 
 
 
0                 100 
Not At All Distressed              Extremely Distressed 
   
 
Positive Symptoms 
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1.2 NON-BIZARRE IDEAS 
 
 
Non-Bizarre Ideas (‘Crystallized Ideas’) 
• Suspiciousness, Persecutory Ideas: Has anybody been giving 
you a hard time or trying to hurt you?  Do you feel like people 
have been talking about you, laughing at you, or watching you? 
What is it like? How do you know this? 
• Grandiose Ideas: Have you been feeling that you are especially 
important in some way, or that you have powers to do things 
that other people can’t do? 
• Somatic Ideas: Have you had the feeling that something odd is 
going on with your body that you can’t explain? What is it like? 
Do you feel that your body has changed in some way, or that 
there is a problem with your body shape? 
• Ideas of Guilt:  Do you feel you deserve punishment for 
anything you have done wrong? 
• Nihilistic Ideas: Have you ever felt that you, or a part of you, did 
not exist, or was dead?  Do you ever feel that the world does 
not exist? 
• Jealous Ideas:  Are you a jealous person? Do you worry about 
relationships that your spouse/girlfriend/boyfriend has with 
other people? 
• Religious Ideas:  Are you very religious? Have you had any 
religious experiences? 
• Erotomanic Ideas:  Is anyone in love with you? Who? How do 
you know this?  Do you return his/her feelings? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive Symptoms 
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NON-BIZARRE IDEAS - GLOBAL RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Psychotic 
and Severe 
No non-
bizarre ideas. 
Subtle 
changes that 
could be 
reality based. 
Eg. Very self-
conscious. 
Increased self-
consciousness. 
Eg. Feeling 
that others look 
at the subject, 
or talk about 
the subject. 
Or feeling of 
increased self- 
importance.  
Subject able to 
question. 
Odd or 
unusual 
thoughts but 
whose 
content is not 
entirely 
implausible- 
may be some 
logical 
evidence. 
More 
evidence 
than rating of 
4. 
Content of 
thoughts not 
original i.e. 
jealousy, mild 
paranoia.   
Clearly 
idiosyncratic 
beliefs, which 
although 
’possible’ have 
arisen without 
logical 
evidence. 
Less evidence 
than rating of 
3. 
Eg. Thoughts 
that others 
wish the 
subject harm, 
which can be 
easily 
dismissed. 
Thoughts of 
having special 
powers, which 
can be easily 
dismissed. 
Unusual 
thoughts 
about which 
there is some 
doubt (not 
held with 
delusional 
conviction), or 
which the 
subject does 
not believe all 
the time.   
May result in 
some change 
in behaviour, 
but minor.   
Unusual 
thoughts 
containing 
original and 
highly 
improbable 
material held 
with delusional 
conviction (no 
doubt). 
 May have 
marked impact 
on behaviour. 
 
 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use/stress 
noted 
Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
 
Level of Distress (In Relation to Symptoms) 
 
 
0                 100 
Not At All Distressed              Extremely Distressed 
   
Positive Symptoms – Perceptual Abnormalities 
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1.3 PERCEPTUAL ABNORMALITIES 
 
Visual Changes 
• Distortions, illusions:  Is there a change in the way things look to 
you?  Do things somehow look different, or abnormal? Are there 
alterations in colour, or brightness of objects (things seeming 
brighter, or duller in colour)? Are there alterations in the size and 
shape of objects? Do things seem to be moving? 
• Hallucinations:  Do you have visions, or see things that may not 
really be there? Do you ever seen things that others can’t, or 
don’t seem to? What do you see? At the time that you see these 
things, how real do they seem?  Do you realise they are not real 
at the time, or only later? 
 
 
 
 
 
 
 
 
 
 
 
 
Auditory Changes 
• Distortions, illusions:  Is there any change in the way things 
sound to you?  Do things somehow sound different, or 
abnormal?  Does your hearing seem more acute, or have 
increased sensitivity? Does your hearing seem muted, or less 
acute? 
• Hallucinations:  Do you ever hear things that may not really be 
there?  Do you ever hear things that other people seem not to 
(such as sounds or voices)? What do you hear? At the time you 
hear these things, how real do they seem?  Do you realise they 
are not real at the time, or only later?   
 
 
 
 
 
 
 
 
 
 
 
Olfactory Changes 
• Distortions, illusions:  Does your sense of smell seem to be 
different, such as more, or less intense, than usual?  
• Hallucinations:  Do you ever smell things that other people don’t 
notice?  At the time, do these smells seem real?  Do you realise 
they are not real at the time, or only later?   
 
 
 
 
 
 
Gustatory Changes 
• Distortions, illusions:  Does your sense of taste seem to be 
different, such as more, or less intense, than usual?  
• Hallucinations:  Do you ever get any odd tastes in your mouth? 
At the time that you taste these things, how real do they seem?  
Do you realise they are not real at the time, or only later? 
 
 
 
 
 
 
 
Tactile Changes  
• Distortions, illusions, hallucinations:  Do you ever get strange 
feelings on, or just beneath, your skin?  At the time that you feel 
these things, how real do they seem?  Do you realise they are 
not real at the time, or only later? 
 
 
 
 
 
 
Somatic Changes  
NOTE: Probes also used to rate Impaired Bodily Sensation, p.26 
• Distortions, illusions:  Do you ever get strange feelings in your 
body (eg feel that parts of your body have changed in some way, 
or that things are working differently)? Do you feel/think that 
there is a problem with some part, or all of your body, i.e. that it 
looks different to others, or is different in some way? How real 
does this seem? 
• Hallucinations:  Have you noticed any change in your bodily 
sensations, such as increased, or reduced intensity? Or unusual 
bodily sensations such as pulling feelings, aches, burning, 
numbness, vibrations?   
 
 
 
 
 
 
 
 
 
 
Positive Symptoms – Perceptual Abnormalities 
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PERCEPTUAL ABNORMALITIES - GLOBAL RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Psychotic but 
not severe 
6 
Psychotic 
and severe 
No abnormal 
perceptual 
experience. 
 Heightened, or 
dulled 
perceptions, 
distortions, 
illusions (eg 
lights/ 
shadows). 
Not 
particularly 
distressing. 
Hypnogogic/ 
hypnopompic 
experiences 
More puzzling 
experiences:  
more 
intense/vivid 
distortions/ 
illusions, 
indistinct 
murmuring, 
etc.  
Subject 
unsure of 
nature of 
experiences. 
  Able to 
dismiss.  
 Not 
distressing. 
Derealisation/ 
depersonalisn 
Much clearer 
experiences 
than 3 such as 
name being 
called, hearing 
phone ringing 
etc, but may 
be fleeting/ 
transient.   
Able to give 
plausible 
explanation for 
experience.  
May be 
associated 
with mild 
distress.   
True 
hallucinations 
i.e. hearing 
voices or 
conversation, 
feeling 
something 
touching body.  
 Subject able 
to question 
experience 
with effort. 
 May be 
frightening or 
associated 
with some 
distress.  
 
True 
hallucinations 
which the 
subject believes 
are true at the 
time of, and 
after, 
experiencing 
them.  
May be very 
distressing 
 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
 
 
Level of Distress (In Relation to Symptoms) 
 
 
0                 100 
Not At All Distressed              Extremely Distressed 
   
Positive Symptoms – Disorganised Speech 
CAARMS- December 2006 
7
 
1.4 DISORGANISED SPEECH  
  
 NOTE: Probes also used to rate Alogia, p. 16 
 
Subjective Change: 
• Do you notice any difficulties with your speech, or ability 
to communicate with others?  
• Do you have trouble finding the correct word at the 
appropriate time?  
• Do you ever use words that are not quite right, or totally 
irrelevant?   
• Have you found yourself going off on tangents when 
speaking and never getting to the point?  Is this a recent 
change?   
• Are you aware that you are talking about irrelevant 
things, or going off the track?   
• Do other people ever seem to have difficulty in 
understanding what you are trying to say/trouble getting 
your message across?   
• Do you ever find yourself repeating the words of others? 
• Do you ever have to use gesture or mime to 
communicate due to trouble getting your message 
across? How bad is this?  
• Does it ever make you want to stay silent and not say 
anything? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objective Rating of Disorganised Speech 
 
• Is it difficult to follow what the subject is saying at times 
due to using incorrect words, being circumstantial or 
tangential?   
• Is the subject vague, overly abstract or concrete? Can 
responses be condensed? 
• Do they go off the subject often and get lost in their 
words?  Do they appear to have difficulty finding the right 
words?   
• Do they repeat words that you have used or adopt 
strange words (or ‘non-words’) in the course of regular 
conversation? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive Symptoms – Disorganised Speech 
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DISORGANISED SPEECH- GLOBAL RATING SCALE 
 
0 
Never, absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Psychotic 
Normal logical 
speech, no 
disorganisation
, no problems 
communicating 
or being 
understood. 
 Slight 
subjective 
difficulties 
eg 
problems 
getting 
message 
across.   
Not 
noticeable 
by others. 
Somewhat vague, 
some evidence of 
circumstantiality, 
or irrelevance in 
speech.   
Feeling of not 
being understood. 
Clear 
evidence of 
mild 
disconnect
ed speech 
and thought 
patterns.  
Links 
between 
ideas rather 
tangential.  
Increased 
feeling of 
frustration 
in 
conversatio
n. 
Marked 
circumstantiality, 
or tangentiality in 
speech, but 
responds to 
structuring in 
interview.   
 May have to 
resort to gesture, 
or mime to 
communicate. 
Lack of 
coherence, 
unintelligibl
e speech, 
significant 
difficulty 
following 
line of 
thought.  
Loose 
association
s in 
speech. 
 
 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
 
 
Level of Distress (In Relation to Symptoms) 
 
 
0                 100 
Not At All Distressed              Extremely Distressed 
   
Cognitive Change – Subjective Experience 
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2:  COGNITIVE CHANGE - ATTENTION/CONCENTRATION 
 
2.1 SUBJECTIVE EXPERIENCE (HUBER’S BASIC SYMPTOM) 
 
Concentration and Attention Problems: 
• Have you had difficulty concentrating (difficulty listening to 
others, watching television, reading)?   
• Is it more of an effort to think about, or concentrate on things? 
 
 
 
 
 
 
 
Selective Attention Problems: 
• Is it difficult to pay attention to just one thing?   
• Are you distracted by other things easily?   
• Have you been feeling overwhelmed, or confused by all the 
things that have been happening in the environment around 
you? 
 
 
 
 
 
 
 
Thought Form Problems: 
 NOTE: See also Alogia, p. 16 
• Do your thoughts ever seem to stop, get blocked, or disappear 
(e.g. do you have ‘trances’, or ‘blank spells’)?  Can you 
describe this more fully?   
• Do you ever experience racing or confused, jumbled thoughts? 
• Do other things, as well as your thoughts, seem to stop e.g. 
attention, hearing, sight, memory, speech, or movement?   
• Do you ever lose your sense of personal identity? What do you 
think was the cause of this?  
 
 
 
 
 
 
 
 
 
 
Comprehension Difficulties: 
• Do you have trouble following what others are saying?  
• Do you sometimes require sentences to be repeated, 
especially long sentences?   
• Do you sometimes not understand figures of speech and so 
on?   
• Is this a change for you, or have you always had trouble with 
this?  
• Do you ever have trouble picking up the emotional tone of 
conversations (eg. not recognising sarcasm, or irony)?  
• Is it ever hard to understand non-verbal forms of 
communication i.e. gestures? How bad is this? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Memory Problems: 
NOTE: See also Dissociative Symptoms, p.36 
• Have you had memory problems?   
• Have you ever felt as if there were large gaps in your memory?  
• Are they present all the time, or do they come and go?  Have 
you noticed if the memory problems come at times of stress?   
 
 
 
 
 
 
 
Cognitive Change – Subjective Experience 
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SUBJECTIVE COGNITIVE CHANGE- SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No subjective 
difficulty with 
concentration
/attention. 
Subject aware 
of some 
changes, but 
attributable 
perhaps to 
extraneous 
factors.  
 Subject has 
difficulty in 
pinpointing 
changes. 
Mild, but 
definite 
problems eg 
some difficulty 
concentrating 
while reading, 
or watching TV. 
 Concentrating 
requires more 
effort.   
OR 
Slight 
impairment in 
memory, but 
passing. 
Subjectively 
feeling 
muddled, or 
confused, 
racing, or 
slowed 
thoughts, 
difficulty 
understanding 
conversations. 
Occ. episodes 
of thought 
blocking. 
OR 
 Memory 
problems more 
evident but do 
not interfere 
with everyday 
functioning.  
 
Subjective 
feeling of 
being unable 
to think 
properly, 
confused, 
unable to 
understand 
others.   
More regular 
episodes of 
thought 
blocking 
OR 
Memory 
difficulties 
impair 
conversation, 
results in 
frequent 
misplacing of 
items. 
Marked 
inattentiveness, 
feeling 
confused and 
overwhelmed at 
times, 
distracted by 
other things in 
the 
environment.  
Frequent 
episodes of 
thought block.   
OR 
 Memory 
difficulties 
noted by 
others, 
distressing.  
 
Subject 
reports 
extreme 
difficulty 
focussing on 
interview.  
Interview 
suspended 
due to 
impossibility 
of patient to 
concentrate 
or severe 
thought 
blocking. 
OR  
Severe 
memory 
problems.   
 
 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Cognitive Change- Observed  
CAARMS- December 2006 
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2.2 OBSERVED COGNITIVE CHANGE 
 
 
Observed Inattentiveness During Interview 
• Subject appears inattentive - looks away during interview, does 
not pick up the topic during a discussion, shifts focus of attention.   
• Attention may be drawn to noise in adjoining room, objects around 
the room, interviewer’s clothing etc 
 
 
 
 
 
 
 
 
 
 
Observed Inattentiveness During Mental Status Testing  
 
• The subject may perform poorly on simple tests of intellectual 
functioning in spite of adequate education and intellectual ability.   
• This is assessed by having the subject spell the word ‘world’ 
backwards and by serial 7s or serial 3s for a series of 5 
subtractions. 
• D L R O W 
• 100, 93, 86, 79, 72  
• 100, 97, 94, 91, 88 
 
 
 
 
 
 
 
 
 
 
 
OBSERVED COGNITIVE CHANGE – SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No 
abnormalities 
observed. 
Some 
questionable 
inattentiveness
- may be 
explained by 
other events. 
Mild problems 
with 
concentration. 
Objectively may 
be observed to 
shift focus of 
attention from 
interview 1 to 3 
times.  
Not quite 
understanding 
what others are 
saying or the 
emotional tone 
of the 
conversation. 
Moderate 
concentration 
problems 
during 
interview.  
Mild disruption 
to flow of 
interview as a 
result. 
Poor 
concentration 
and attention 
significantly 
affect ability to 
perform tasks.  
Distractibility 
clearly 
observed to 
interfere with 
flow of the 
interview. 
 Severe 
concentration 
and attention 
difficulties  
Extremely 
difficult to 
conduct 
interview, or 
pursue a topic 
due to 
preoccupation 
with irrelevant 
stimuli. 
 
Inability to 
concentrate at 
all. 
Impossible to 
conduct 
interview due 
to 
preoccupation 
with irrelevant 
stimuli.  
 
 
 
Emotional Disturbance -Subjective  
CAARMS- December 2006 
12
 
3:  EMOTIONAL DISTURBANCE 
 
3.1 SUBJECTIVE EMOTIONAL DISTURBANCE (HUBER’S BASIC SYMPTOM) 
 
Impaired Emotional Functioning:  
NOTE: See also Anhedonia, p. 18; Depression, p.29 
 
• Have you noticed any change in your feelings, or emotions 
e.g. feel like you have no feelings, feel your emotions are 
’empty’, or that your emotions are somehow not genuine?  
• Has there been any change in the way you are using your 
emotions?  
• Have you still been able to enjoy things, or experience 
pleasure?  
• Do you find that even when something sad happens, you 
are no longer able to feel sadness? Or when something 
happy happens, you can no longer feel happy? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in Affect: 
Facial expressions:  
• Have you noticed any change in your facial expressions?  
• Have people commented on your facial expression, saying it 
is blank, or hard to know what you are thinking? 
 
 
Eye contact:  
• Has there been a change in the way you interact with other 
people e.g. do you find it hard to look at people when you 
speak to them?  
• Has anyone commented on this? 
 
 
Speech:   
• Have you noticed a change in the way you talk, such as 
your voice becoming monotonous? 
• Have people told you that you have a monotonous way of 
talking?  
• Do they seem to find you boring? 
 
Inappropriate affect:   
• Have you ever felt different on the inside from the way you 
look to others?  
• Like your appearance was uncoordinated with your 
emotions? Would you smile, or laugh when talking about 
something that was sad, or not funny at all? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Emotional Disturbance -Subjective  
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SUBJECTIVE EMOTIONAL DISTURBANCE - SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No subjective 
change in 
feelings, or 
emotions. 
 Subjectively 
sporadic, mild, 
but definite 
problems 
reported eg 
not able to 
enjoy things 
as much as 
previously.  
Some feeling 
of blunting of 
emotional 
responses. 
Affect is 
inappropriate, 
but not 
sustained. 
Subjectively, 
more frequent, 
or continuous 
problems. 
Some feeling 
of blunting of 
emotional 
responses. 
More 
pervasive 
feeling of 
inappropriate 
affect, but 
subject able to 
control 
somewhat. 
Subject 
describes 
more marked 
change in 
emotions eg 
not able to 
express, or 
experience 
feelings as 
before. 
Sense of 
distance when 
with others. 
Inappropriate 
affect more 
difficult to hide 
from others. 
Subject 
describes 
feeling of 
having no 
feelings, or 
emotions feel 
empty, or not 
genuine.  
Unable to feel 
sad at all. 
Severe degree 
of distance 
from others. 
Inappropriate 
affect 
interferes with 
relationships. 
Subject 
reports 
constant 
emotional 
blunting,  
OR 
Inappropriate 
affect. 
 
 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Emotional Disturbance – Observed Blunted 
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3.2 OBSERVED BLUNTED AFFECT 
NOTE: Incorporate informant information as well as interviewer’s impression 
  
• Rate observed evidence of blunting of affect. For example, 
diminished facial expressions, reduced emotional tone in speech, 
reduced expressive movements and gestures.   
 
• The rater may also feel a diminished ability to engage the subject.   
 
 
 
 
 
 
OBSERVED BLUNTED AFFECT – SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe, not 
psychotic 
6 
Extreme/ 
psychotic 
No 
abnormalities 
observed by 
interviewer, 
or others. 
 Slight degree 
of constriction 
of affect may 
be observed. 
Observable 
constriction of 
emotional 
field.   
Avoidance or 
failure to 
display 
feelings.  
Reduced 
emotional 
expressivity.  
Interviewer 
feels a sense 
of ‘distance’, 
or decreased 
rapport. 
More marked 
degree of 
dullness or 
blockade.   
Definite 
decrease in 
sense of 
rapport 
observed by 
interviewer.   
May have 
been reported, 
or commented 
on by 
informants. 
Minimal 
evidence of 
affective 
display 
Gross blunting 
of affect.   
No 
spontaneous 
emotional 
expression 
observed 
during 
interview.  
Definitely 
reported by 
informants. 
 
 
Onset date: ________________ Offset date: ________________ 
(Do not score if relying on interviewer’s report only- -3 on database) 
 
Frequency and Duration 
(Do not score if relying on interviewer’s report only- -3 on database) 
 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
 
Emotional Disturbance – Observed Inappropriate 
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3.3  OBSERVED INAPPROPRIATE AFFECT 
NOTE: Incorporate informant information as well as interviewer’s impression 
 
 
• Also rate clear-cut inappropriate affect (affect clearly 
discordant from the content of speech, or ideation 
(e.g. giggling when speaking of something sad). 
 
 
 
 
 
 
 
 
 
 
OBSERVED INAPPROPRIATE AFFECT- SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No 
abnormalities 
observed by 
interviewer, 
or others. 
 Mild 
inappropriate 
affect during 
interview, or 
reported 
occasionally 
by others.  
Subject 
appears able 
to control. 
More 
pervasive 
inappropriate 
emotion 
displayed.  
Does not 
dominate 
interview.  
Subject 
appears able 
to control 
somewhat. 
More often 
reported by 
others- 
distracting 
during 
interview. 
Inappropriate 
affect reported 
frequently.  
Interferes with 
social 
relationships 
and flow of 
interview. 
Inappropriate 
affect 
throughout 
interview.  
Severely 
impacts on 
ability to 
conduct 
interview.   
Reported by 
others as 
occurring most 
of the time. 
 
 
Onset date: ________________ Offset date: ________________ 
(Do not score if relying on interviewer’s report only- Enter-3 on database) 
 
Frequency and Duration 
(Do not score if relying on interviewer’s report only- Enter -3 on database) 
 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
 
Negative Symptoms - Alogia 
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4: NEGATIVE SYMPTOMS 
 
4.1 ALOGIA 
NOTE: Refer also to Cognitive Change, p.9; Disorganised Speech, p. 7 
 
• Have you noticed problems trying to form 
conversations - i.e. hard to find words, thought 
blocking? 
 
• Are the subject’s responses to questions vague, or 
convey little information?  Does the subject take a 
long time to respond to questions, but when 
prompted, displays an awareness of the question?   
 
 
 
 
 
 
 
 
ALOGIA - SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No observed, 
or reported 
changes in 
speech. 
Subject 
unsure about 
recent 
changes. 
  Changes 
may be 
attributable to 
external 
factors, but 
subject 
unsure. 
Very mild 
changes in 
ability to 
speak 
spontaneously 
Subject 
reports feeling 
“blocked” in 
their thinking. 
Difficulty 
finding words 
for thoughts. 
  Not reported 
by others. 
Difficulty 
expressing 
self in words - 
finding words, 
or more 
regular 
instances of 
thought 
blocking 
 Observable 
by others, but 
not constant 
difficulty.   
Subject 
responds to 
prompting. 
More marked 
poverty of 
speech, or 
thought 
blocking 
Does not 
significantly 
interfere with 
school, or 
work 
functioning. 
Unable to 
express 
oneself 
adequately, 
or severe 
thought 
blocking 
May 
experience 
infrequent 
periods of 
mutism as a 
result of 
word finding 
and 
expression 
difficulties. 
Marked poverty 
of speech or 
thought 
blocking.  
Seriously 
hinders flow of 
interview.   
Subject may be 
mute at times.  
Interferes 
significantly with 
ability to 
perform in 
social, 
occupation and 
educational 
settings. 
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Negative Symptoms - Avolition 
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4.2 AVOLITION/APATHY (HUBER’S BASIC SYMPTOM) 
 
Subjective Experience:   
• Have you felt lacking in energy- mental and physical? Are you tired, 
or lacking in motivation, or ‘get up and go’? Lack of will power? Lack 
of physical strength? 
• To what extent does this interfere with activities such as going to 
school/work and other everyday tasks?  How are you spending your 
days? 
Observed Avolition/Apathy:   
NOTE: Refer also to Disorganising/Odd/Stigmatising Behaviours, p.21 
• Has the subject indicated difficulty maintaining the level of his/her 
usual social, or occupational/educational commitments?   
• Does the subject appear to be looking after him/herself adequately- 
cleanliness/hygiene/general self-care?   
 
 
 
 
 
 
 
 
 
 
 
 
Avolition/Apathy - Severity Rating Scale 
0 
Never, absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Mod. Severe 
5 
Severe 
6 
Extreme 
No observed, 
or reported 
changes in 
energy. 
Subject unsure 
about recent 
changes.   
Changes may 
be attributable 
to external 
factors, but 
unclear. 
Feeling 
fatigued, 
things are an 
effort.   
May not 
initiate 
activities as 
much as 
previously.   
Still able to 
perform 
everyday 
tasks.   
Does not 
interfere with 
schoolwork, 
or work 
attendance. 
Feeling of 
reduced 
energy, or 
will power. 
Decreased 
attendance 
at 
school/work, 
or not 
performing 
usual tasks 
to usual 
ability.   
Not 
everyday 
and not 
reported by 
others.   
More marked 
reduction in energy/ 
motivation. 
Some interference 
with normal 
functioning eg tasks 
take longer to do, 
subject doesn’t 
bother to do some 
things. 
May miss school, or 
work a few times a 
week or frequently 
run late. 
May be unable to 
attend to personal 
hygiene as usual,  
Daily reduction 
in energy, drive, 
will power, 
physical 
strength, or 
motivation.   
Interferes with 
normal 
functioning eg 
missing school, 
or work most 
day.   
Spends 
significant 
portions of time 
lying around.   
Clear impact on 
personal 
hygiene  
Extreme and 
continuous 
disability eg 
unable to 
perform 
normal tasks, 
confined to 
house, no will 
power, or 
volition.   
Unable to 
attend 
school/work 
at all due to 
motivation. 
Marked 
impact on 
personal 
hygiene 
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month 
to twice a 
week – less 
than one hour 
per occasion  
 
Once a month to twice 
a week – more than 
one hour per occasion 
OR 
3 to 6 times a week  - 
less than one hour per 
occasion 
3 to 6 times a 
week  - more than 
an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous  
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Negative Symptoms - Anhedonia 
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4.3 ANHEDONIA 
 
NOTE:  Refer also to Depression, p. 29 
 
• Have you been able to enjoy social activities/work/study 
as much as usual? 
 
• Have you noticed a decrease in your level of interest in 
things you usually enjoy?   
 
• Has this interfered with your ability to perform activities, 
e.g. going to school/work/participating in events? 
 
 
 
 
 
 
 
 
ANHEDONIA- SEVERITY RATING SCALE 
 
0 
Never, absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No observed, 
or reported 
changes in 
affect, speech, 
activity level, or 
attentiveness. 
Some mild 
decrease in 
interest in 
events, but 
may be 
attributable to 
external cause 
(i.e. dislikes 
topic at school).
Some mild 
decrease in 
interest or 
enjoyment of 
activities. 
Not interfering 
with ability to 
perform them. 
Moderate 
reduction in 
interest or 
enjoyment  of 
activities such 
as school/work. 
  May affect 
school/work 
performance.  
Some regular 
experience of 
pleasure or 
humour but 
decreased in 
extent and 
quality.   
May impact on 
work/school 
attendance. 
  Others 
concerned by 
associated 
withdrawal and 
isolation. 
Rarely gains 
sense of 
enjoyment/ 
interest from 
tasks.  At times 
able to enjoy 
something, but 
short lived.  
 Poor 
attendance at 
school/work. 
  Very 
noticeable by 
others. 
No enjoyment 
or interest at all 
in tasks.  
Marked lack of 
interest.   
Isolated and 
withdrawn. 
 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Behavioural Change – Social Isolation 
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5: BEHAVIOURAL CHANGE  
Consider informant information as well as subjective report 
 
5.1 SOCIAL ISOLATION 
• Have you stayed at home more often than usual recently?  Has this 
been by choice?   
• Have you felt uncomfortable around others recently?   
• Have you wanted to be alone more than usual recently? Has there 
been a reason for this?  Have others commented on this?   
• Have you missed important social events/school/work due to this?  
  
Questions for informants:  
• Has the subject been staying at home, perhaps in their room alone, 
more often than in the past?  If so, do you know the reason for this?  
• Have they missed social events/work/school due to this?   
• Do they appear to want to spend time alone at present (more so 
than usual)? 
 
 
 
 
 
 
 
 
 
 
 
SOCIAL ISOLATION- SEVERITY RATING SCALE 
0 
Never, absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No change in 
level of social 
activity. 
 Subject feels 
that she/he 
does not want 
to fulfill all 
social/role 
functions. 
Wanting to be 
alone, but able 
to motivate 
self. 
Isolating self 
at times, but 
not marked. 
  Able to fulfill 
main role 
functions 
involving 
interactions 
with others. 
  May miss 
some social 
activities. 
Intolerant of 
being around 
others for long 
periods of time.  
Social 
withdrawal 
commented n by 
others.   
May miss 2-3 
days week of 
school/work 
because of 
wanting to be 
alone.   
Missing more 
days than not 
of 
work/school, 
spending 
greater part 
of day alone. 
Isolated from 
others for 
extended 
periods (i.e. 
days) 
  
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Behavioural Change – Impaired Role Function 
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5.2 IMPAIRED ROLE FUNCTION 
 
NOTE: See also Depression, p. 29 
 
• Have you been able to attend school/work as usual recently?   
• Has your school/work performance dropped recently?   
• Have you been less interested in your work/school recently?  Have 
others commented on this?  Is there a reason for this?  (Phrase 
questions appropriately i.e. for job seekers etc) 
 
Questions for Informants:  
• Have you noticed a change in attendance at work/school recently?   
• Does the subject appear as capable at achieving normal tasks as 
usual? 
 
 
 
 
 
 
 
 
 
IMPAIRED ROLE FUNCTION- SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No recent 
change in 
role function. 
 Subject 
reports mild 
impairment in 
performance 
of usual 
activities.  
 Not noted by 
informants. 
Usual tasks 
performed 
with less care 
than usual. 
Missing 
occasional 
day of 
work/school.  
Noted as mild 
by informants. 
Around half of 
usual time 
spent on 
normal daily 
tasks.   
Decreased 
quality of task 
performance 
noted by 
others. 
Marked 
impairment of 
role 
functioning. 
Spending 
about half of 
day in aimless 
activity. 
Subject 
attempting no 
role function 
whatsoever  
  
 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Behavioural Change – Odd Behaviour 
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5.3 DISORGANISING/ODD/STIGMATISING BEHAVIOUR   
NOTE: See also Avolition, p.17; OCD, p.34; Social Isolation, p. 19 
 
• Has there been anything about your lifestyle recently that others might 
regard as unusual, or odd?  (Attempt to sensitively assess peculiar 
behaviours such as hoarding, talking to self, odd movements etc.)   
• Have you been able to look after yourself as well as usual (Bathing, 
eating etc)?   Has this been reported by others?  
 
Questions for Informants:   
• Have you noticed the subject behaving in an odd manner recently? 
• Have you felt there is something strange about their behaviour? Has 
this been commented on by others?   
• Have you noticed that they are hoarding goods, talking to self, moving 
in a bizarre fashion etc? 
 
 
 
 
 
 
 
 
 
 
DISORGANISED/ODD/STIGMATISING BEHAVIOUR- SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No change 
in 
behaviour 
noted by 
subject, 
informants, 
or in 
interview. 
 Some reduction in 
self care, social 
isolation, but not 
marked. 
Subject able to 
motivate self to 
rectify this 
change. 
Slightly odd 
behaviour that 
would not 
normally attract 
attention of 
others, or 
conducted in 
private. 
May require 
pressure from 
others to 
maintain 
social/ 
occupational 
commitments, 
or self care.  
Able to be 
motivated.   
Occasional 
odd behaviour 
that is 
noticeable by 
others (ie. 
giggling to 
self). 
Mildly 
eccentric 
behaviour - 
clearly 
noticeable by 
others (ie   
talking to 
self/hoarding 
Not constant. 
Clearly 
bizarre 
behaviour 
that attracts 
attention of 
others.  
Sometimes 
resulting in 
intervention 
by others. 
Very poor self- 
care.   
Eccentric 
behaviours 
dominate clinical 
picture.  
May result in 
intervention by 
others.   
Odd behaviours 
may have 
negative impact 
on physical 
health.  
Extreme social 
isolation.   
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Behavioural Change – Aggression 
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5.4 AGGRESSION/DANGEROUS BEHAVIOUR 
 
• Have you been feeling angry, or irritable recently?  Has there been a 
reason for this?  Have you felt more irritated than usual at small 
things?  Have you been in more arguments with others than usual 
recently?  Have you been taking more risks (i.e. when driving) 
recently than usual?  Have others commented that your behaviour is 
becoming risky, or unsafe?  Have you felt like striking out at people 
or objects recently (more so than usual)?  
• Have you become so angry at someone that you have had thoughts 
of hurting them, or destroying their property?  Have you acted on 
these thoughts?   
Questions for Informants:   
• Has the subject been acting in an aggressive or dangerous manner 
recently?  Have there been any recent episodes of anger 
outbursts/physical confrontation?  Is this how the subject normally 
behaves?  Have others commented on a change in their level of 
anger, or irritability?  Has the subject destroyed property lately (in 
association with anger)?  Have you felt safe with the subject recently 
(i.e. when driving, at otherwise normal times)? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGGRESSION/DANGEROUS BEHAVIOUR- SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No 
aggressive, 
or 
dangerous 
behaviour 
reported by 
the subject 
or others. 
 Slight 
irritability but 
not 
associated 
with rise in 
aggressive 
behaviour.   
May be 
attributed to 
events by 
subject. 
More marked 
increase in 
irritability/anger 
towards 
self/others.  
 May be 
expressed 
verbally, or 
physically in 
restrained 
manner (i.e 
punching pillow 
etc).   
May be noted 
by subject only. 
Marked 
increase in 
irritability 
towards others 
expressed in 
increased 
propensity to 
verbal 
confrontations 
with threat of 
physical 
aggression.   
Noted by 
others and 
subject. 
Aggressive 
behaviour 
results in 
property 
damage, or 
harm to 
others.   
Subject 
reports some 
level of 
control over 
anger. 
Dangerousness 
in conjunction 
with anger at very 
destructive level, 
resulting in some 
considerable 
physical damage 
to others, or 
property.   
Dominates 
clinical picture.   
May attract 
attention of police 
etc. 
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Motor Physical Changes - Subjective 
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6: MOTOR/PHYSICAL CHANGES 
 
6.1 SUBJECTIVE COMPLAINTS OF IMPAIRED MOTOR FUNCTIONING 
(HUBER’S BASIC SYMPTOM) 
 
Disorganised Movement: 
• Have you noticed any change in the way you are moving e.g. 
clumsiness, lack of coordination, trouble organising your activities, or 
movements, loss of spontaneous movements?  
• Have you noticed if your ability to perform some movements is 
distracted by other things?  
• Does it require more effort or energy to perform some movements? 
 
Mannerisms, Posturing: 
• Have you developed any new movements, or poses (e.g. developed a 
nervous habit, a characteristic way of doing something, mimicking 
others, assuming certain postures)? What is your explanation for this? 
 
 
 
 
 
 
 
 
 
 
 
 
SUBJECTIVE MOTOR CHANGE- SEVERITY RATING SCALE 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No 
abnormal 
movements, 
or somatic 
difficulties 
reported by 
subject. 
 Mild changes 
only. 
Feeling 
clumsier, more 
uncoordinated 
than usual, 
feeling slightly 
slowed down. 
Occasional 
grimace, or 
mildly unusual 
gait 
Experien-
ces noted 
in column 
1, but the 
subject 
feels a 
more 
noticeable 
change. 
 Reports 
control over 
Changes such 
as loss of 
coordination.  
Movements 
distracted by 
other things.  
Different gait, 
new poses, tics 
or mannerisms 
Loss of some 
previous 
abilities.   
Experiences 
noted in 
column 4, but 
more 
distressing.   
May include 
episodes of 
mutism, 
bizarre 
postures, 
copying 
others 
movements. 
Clearly distorted, 
or idiosyncratic 
movements, 
which dominate 
the clinical 
picture.   
Gross 
mannerisms, 
bizarre postures. 
Mute, or almost 
mute, with only 
very occasional 
spontaneous 
movements. 
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Motor/Physical Change - Observed 
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6.2 INFORMANT REPORTED OR OBSERVED CHANGES IN MOTOR FUNCTIONING 
 
Disorganised Movement: 
• Have you noticed any change in the way they are moving e.g. 
clumsiness, lack of coordination, trouble organising activities, or 
movements, loss of spontaneous movements?  
• Have you noticed if their ability to perform some movements is 
distracted by other things?  
• Does it require more effort or energy for them to perform some 
movements? 
 
Mannerisms, Posturing: 
• Have they developed any new movements, or poses (e.g. developed 
a nervous habit, a characteristic way of doing something, mimicking 
others, assuming certain postures)? What is their explanation for this? 
 
 
 
 
 
 
 
 
 
 
 
OBSERVED MOTOR CHANGE- SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No abnormal 
movements, 
or somatic 
difficulties 
observed or 
reported by 
others. 
 Others report 
mild changes 
such eg. more 
clumsy, 
uncoordinated 
than usual, 
occasional 
grimace, or 
mildly unusual 
gait. 
Experiences 
noted in 
column 2, but 
more marked.  
Subject 
appears to 
have some 
control over 
them. 
Others report 
that subject 
having 
difficulty 
performing 
usual tasks 
i.e. driving.   
Has also 
developed 
new 
movements 
i.e. gait, new 
stance/ 
mannerisms. 
Some 
mimicking 
may also be 
reported. 
Episodes of 
mutism and 
bizarre 
posturing 
reported.   
Not sustained- 
subject able to 
stop with 
assistance 
and effort. 
Clearly 
distorted, or 
idiosyncratic 
movements, 
which 
dominate the 
clinical picture.  
Gross 
mannerisms, 
bizarre 
postures.   
Mute, or 
almost mute, 
with only very 
occasional 
spontaneous 
movements. 
 
 
Motor/Physical Change – Impaired Sensation 
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6.3 SUBJECTIVE COMPLAINTS OF IMPAIRED BODILY SENSATION  
(HUBER’S BASIC SYMPTOM)  
 
 
NOTE: Refer also to p. 5 Perceptual Abnormalities 
 
• Subjects say that there is something wrong with their bodily 
sensations.  
• This includes disagreeable, but qualitatively normal sensations e.g 
pulling sensations, aches, pains, itching, burning, numbness, or 
qualitatively abnormal, unusual, or bizarre sensations may be 
described such as ‘rustling’ sensations in the eyes, vibrations, 
crawling sensations  
• Do you ever get strange feelings in your body (eg feel that parts of 
your body have changed in some way, or that things are working 
differently)?  
• Do you feel/think that there is a problem with some part, or all of 
your body, i.e. that it looks different to others, or is different in 
some way? How real does this seem? 
 
 
 
 
 
 
 
 
 
 
 
 
IMPAIRED BODILY SENSATION- SEVERITY RATING SCALE  
 
0  
Absent 
1 
Questionable 
2  
Mild, 
3  
Moderate 
4  
Moderately 
severe 
5  
Severe 
6  
Extreme 
Subject 
reports no 
change 
noticed in 
bodily 
sensations. 
 
 Subject 
notices 
occasional 
slight 
differences in 
bodily 
sensations. 
 
Not constant, 
able to ignore. 
More intense 
changes to 
bodily 
sensations 
reported. 
 
Less able to 
ignore. 
Occasional 
bizarre bodily 
sensation. 
 
Subject 
unsure of 
experience.   
Subject 
reports more 
unusual, or 
bizarre 
sensations.  
Very 
distracting, 
Subject 
reports 
extremely 
bizarre and 
unusual bodily 
sensations. 
 
 May be 
distressing. 
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Motor/Physical Change – Autonomic 
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6.4 SUBJECTIVE COMPLAINTS OF IMPAIRED AUTONOMIC FUNCTIONING  
(HUBER’S BASIC SYMPTOM) 
 
Subjects may complain of something wrong with one, or more of their 
autonomic systems such as: 
• The feeling of the heart racing, or going too slow, breathing too 
fast, or too deeply,  
• Nausea,  
• Increased sensitivity to the weather,  
• Having to urinate more often, constipation,  
• Poor sleep etc. 
 
 
 
 
 
 
 
 
IMPAIRED AUTONOMIC FUNCTIONING: SEVERITY RATING SCALE  
 
0  
Absent 
1 
Questionable 
2  
Mild, 
3  
Moderate 
4  
Moderately 
severe 
5  
Severe 
6  
Extreme 
Nothing 
reported. 
 
 
 
 Subject 
reports 
occasional 
change to 
autonomic 
functioning – 
e.g. fleeting 
panic 
sensations.   
No real impact 
on usual 
activities. 
More enduring 
changes 
perceived – 
e.g. poor 
sleep over a 
number of 
nights. 
Mild 
interference 
with usual 
activities. 
Numerous 
changes may 
be experienced 
simultaneously.  
Moderate 
interference 
with usual 
activities 
Changes in 
autonomic 
functioning 
are 
distressing. 
Results in 
more 
marked 
disruption to 
usual 
activities 
Subject 
reports 
constant and 
intense 
changes to 
autonomic 
functions. 
Very 
distressing. 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Psychopathology - Mania  
CAARMS- December 2006 
27
 
7:  GENERAL PSYCHOPATHOLOGY 
 
7.1 MANIA 
 
NOTE: See also Dangerous Behaviour/Aggression, p. 22 
 
• Would you describe your mood as ‘high’, or ‘hyper’ recently?   
 
• Have you been feeling excessively cheerful and had more energy 
than usual?  How long has this feeling lasted?   
 
• Have you felt out of control at these times?   
 
• Has this feeling been in response to a substance, or event that has 
occurred (i.e. finished exams, new boyfriend/girlfriend etc)?   
 
• Have you been able to stay awake doing things for longer periods 
of time than usual?   
 
• Have you been sleeping less than usual?   
 
• Have you found yourself spending more money than usual, or 
acting in ways you would not normally (i.e. heightened sexual drive, 
reckless behaviour etc)?   
 
• Have you found your self, or have others described you, talking 
more than usual and faster than usual?   
 
• Have people commented on your mood, or energy, saying you 
seem more energetic than usual, or out of control?   
 
• Have you been feeling more irritable than usual recently?  Has 
there been a reason for this?   
 
• Have you been feeling better about yourself recently?  
 
• Have you felt that you are special in some way, or have special 
powers, or skills?   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psychopathology - Mania  
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MANIA- SEVERITY RATING SCALE  
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No 
observed, 
or 
reported 
elevation 
in mood.   
No 
change in 
self -
opinion/ 
energy. 
 Cheerful without 
much reason. 
Unaccountable 
feelings of well-
being that 
persist or  
Mild lability in 
mood  
Evidence of 
over-confidence 
with no real 
reason –within 
normal limits  
&/OR 
Some mild 
irritability 
Reports 
excessive 
feelings of 
well-being, or 
cheerfulness 
without 
underlying 
reason 
Inappropriate 
to 
circumstances 
sometimes. 
  More marked 
level of 
excitement. 
  More 
prominent 
feels of self-
importance. 
Overvalued 
ideas not 
delusional  
&/OR 
Moderate 
irritability 
More persistent 
feelings of 
optimism, 
happiness, or 
elevated mood.  
 Mood able to be 
shifted only with 
difficulty.   
Subject aware of 
inappropriateness 
of feelings.   
Behaviour may 
reflect the 
heightened mood.  
Clear cut 
grandiosity/belief 
in special powers - 
not all the time.   
More marked 
irritability 
evident/reported 
by others. 
Mood 
elevated and 
inappropriate 
most of the 
time.   
Some 
delusional 
beliefs about 
own powers/ 
abilities. 
Highly 
distractable/ 
loosening of 
associations. 
Interview 
difficult. 
Subject reports 
feeling elated, 
euphoric, 
marked 
increase in 
energy, 
restlessness.  
Behaviour may 
be destructive- 
excessive 
spending of 
money/sexual 
activity etc.   
Delusional 
beliefs of 
grandiosity/ 
power.  
 Easily 
distractable, 
interview very 
difficult.   
Subject 
obviously 
irritable. 
 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Psychopathology - Depression  
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7.2 DEPRESSION       
 
NOTE: Refer also to: Avolition, p.17; Anhedonia, p.18; Role Functioning, p.20; Suicidality, p.31 
 
• How would you describe your mood recently?   
 
 
• Have you been feeling sad, or low?  How often have you felt 
this way?   
 
 
• Out of 10, what would be your average mood? Your lowest 
mood?   
 
 
• Have you been able to enjoy activities, or feel good about 
yourself at all?   
 
 
• How have you been feeling about the future (assess 
helplessness/hopelessness)?   
 
 
• Has your interest in activities/events been lower than usual?   
 
 
• Have you been able to complete, or start tasks you have been 
set (assess motivation)? 
 
 
• How has your sleep been recently (assess change in sleep 
pattern/insomnia)? 
 
 
• What has your appetite been like recently? Have you lost any 
weight? 
 
 
• Have any events occurred recently that might account for these 
feelings (death/relationship issues/job/school)? 
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DEPRESSION- SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No reported 
depressed 
mood.   
No physical 
signs of 
depression. 
 Some feelings 
of sadness.   
Does not 
dominate 
clinical picture.  
Able to 
distract self 
from 
depressive 
thoughts.   
Depressive 
themes not 
spontaneously 
volunteered. 
Evidence of 
more 
sustained 
lowered mood.  
More difficult 
to shift mood.  
Lowered 
mood may be 
impacting on 
level of 
motivation, but 
not 
significantly 
interfering with 
role 
functioning.   
May be 
slightly tearful, 
or sad 
expression in 
interview. 
Stronger 
observational 
evidence of 
lowered mood. 
Reduced 
ability to react 
to pleasurable 
events.   
More regular 
‘tearful 
episodes’. 
Severe 
depression - 
mood not able 
to be shifted.   
No evidence 
of delusional 
component.   
Some 
suicidality, but 
not acted 
upon.   
Biological 
changes 
consistent with 
lowered mood 
evident 
(appetite/sleep 
disturbance).   
Very low 
energy. 
Abject misery.  
Delusional 
component to 
mood – i.e. 
nihilistic.   
More marked 
feelings of 
suicidality and 
associated 
behaviour. 
 
 
Onset date: ________________ Offset date: ________________ 
 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
General Psychopathology - Suicidality 
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7.3 SUICIDALITY AND SELF HARM 
  
• Have you had any thoughts recently about harming, or killing 
yourself?  How often have you felt this way? 
 
• Have you had any thoughts of what you would do to achieve 
this? 
 
• Have you acted on those thoughts at all?  What happened?   
 
 
 
 
 
 
SUICIDALITY- SEVERITY RATING SCALE  
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
Not present.  Occasional 
thoughts of 
being tired of 
living.   
Occasional 
thought of 
self-harm.   
No suicidal 
thoughts, or 
plans. 
Feeling of 
being better 
off dead.   
Suicidal 
thoughts, with 
only vague 
plan.  
Able to be 
distracted 
from thoughts 
with some 
effort.   
OR 
Minor actions 
of self-harm 
(slight 
scratches etc).
Thoughts of 
suicide more 
frequent with 
associated 
plan.   
May be more 
seriously 
considering 
attempt with 
specific plan.  
OR  
Impulsive 
attempts using 
non-lethal 
method, or 
with 
knowledge of 
potential for 
being found. 
Clear 
expression of 
wanting to kill 
self.  
OR  
Potentially 
serious, or 
lethal attempt 
with 
knowledge of 
possible 
rescue. 
Specific plan 
and attempt.  
OR 
Serious 
attempt that 
clearly could 
have been 
fatal. 
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Psychopathology – Mood Swings  
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7.4 MOOD SWINGS/LABILITY 
 
• Have you experienced mood swings recently?   
• Have you felt that your moods have been up and down for no 
apparent reason?   
• Do you find yourself happy one moment, and sad the next (or 
irritable), with no explanation?  
•  How often does this happen?  
•  Has this occurred in response to drugs, or events that have 
happened?  Have others commented on this?   
• How often has this occurred?   
 
 
 
 
 
 
 
 
 
 
 
 
MOOD SWINGS- SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No evidence, 
or reported 
mood 
swings. 
 Subject 
reports feeling 
mood changes 
more easily 
than usual.  
 
More marked 
changes in 
response to 
external 
events.   
 
Not 
noticed/report-
ed by others. 
Subject 
reports more 
extreme 
changes in 
mood. 
 
Feeling that 
mood is out of 
control some 
of the time. 
More 
pervasive 
experience of 
mood swings.  
 
Noted by 
others.   
 
Distressing.  
Interferes with 
normal 
activities. 
Mood swings 
experienced 
more days 
than not.   
 
Significant 
interference 
with normal 
activities. 
Subject 
reports that 
mood changes 
constantly and 
completely out 
of control.   
 
Unable to 
maintain 
normal level of 
activity. 
 
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Psychopathology - Anxiety  
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7.5 ANXIETY 
 
 
• Have you been feeling nervous, or anxious recently?  Has there 
been a reason for this?  How often have you felt this way?   
• How long does this feeling remain for?   
• Have you felt panicky lately?   
• Have you had times when you have felt breathless, heart racing, 
sweaty palms, tingling fingers, for no apparent reason?   
• Do you have a phobia/are you afraid of dogs, spiders, enclosed 
places, crowds etc?   
• Have you felt nervous around others recently (differentiate social 
anxiety from suspiciousness)? 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANXIETY- SEVERITY RATING SCALE  
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No evidence, 
or reporting 
of anxiety. 
 Minor worries. 
Able to 
distract self 
from these. 
&/OR 
Mild physical 
signs of 
anxiety. 
Moderate 
concerns, but 
level of 
anxiety is 
within 
appropriate 
range for 
event  
&/OR 
 Moderate 
physical 
symptoms of 
anxiety. 
Level of 
anxiety 
interfering 
slightly with 
normal 
activities.  
Some 
preoccupation 
with trigger.  
&/OR 
More marked 
physical signs.  
More marked 
preoccupation 
with fears, 
sense of 
dread. 
&/OR 
Intrusive, 
distressing 
physical 
symptoms of 
anxiety 
Level of 
anxiety 
disabling, 
feeling of 
panic, terrified.
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Psychopathology - OCD  
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7.6 OCD SYMPTOMS 
 
• Do you have distressing, or intrusive thoughts that go round and 
round in your head that you cannot stop?  
• Do you have any repetitive behaviours that you feel compelled to 
perform?   
• Do you have anything that you do to stop ‘bad things’ from 
occurring (rituals/superstitions etc)?   
• Do you have to have things a certain way, or you feel extremely 
anxious?   
• Do you repeatedly check things, like light switches/gas/electrical 
appliances are switched off/doors locked etc?   
 
 
 
 
 
 
 
 
 
 
 
OCD SYMPTOMS- SEVERITY RATING SCALE 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No 
obsessional 
thoughts, or 
ruminations.   
No 
compulsive 
behaviour. 
 Some 
reported 
ruminating or 
compulsions, 
but not 
interfering with 
normal 
activities.   
Not time 
consuming 
Able to be 
distracted. 
Some 
compulsive 
behaviours in 
response to 
obsessional 
thinking, but 
subject able to 
control.  
&/OR 
Compulsions 
do not distract 
from other 
activities. 
Obsessional 
thinking 
distracting. 
interferes with 
ability to 
perform 
normal 
work/study.   
&/OR 
Compulsions 
not restricted 
to home, or 
private 
environment 
Obsessional 
thinking or 
compulsions 
markedly 
distressing.  
&/OR  
Compulsions 
almost 
constantly - 
noticed by 
others. 
Obsessional 
thoughts have 
quasi- 
delusional 
quality.   
&/OR 
Compulsions 
interfere with 
other activities, 
or are 
threatening to 
physical health 
(ie, hoarding 
garbage, 
excessive 
cleansing of 
body). 
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Psychopathology – Dissociative   
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7.7 DISSOCIATIVE SYMPTOMS 
 
Depersonalisation: 
Have you experienced yourself as being unreal, as if you were 
outside your own body?  
Or that part of your body did not belong to you? 
 
Derealisation:  
NOTE: See also Nihilistic Ideas, p.3 
Have you had the feeling that things around you were unreal?  
 
Dissociative Memory Problems:  
NOTE: See also Cognitive Change, p.9 
Have you ever found yourself a long way from your usual range of 
travel without any memory of how you got there?   
Were you under stress then? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISSOCIATIVE SYMPTOMS- SEVERITY RATING SCALE 
 
0 
Never, absent 
1 
Questiona
ble 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No reported 
feelings of 
depersonalis-
ation/ 
dissociation. 
 Mild feeling of 
depersonalis-
ation/ 
derealisation. 
Not 
distressing, or 
distracting. 
More marked 
dissociative 
experiences.  
Some concern 
expressed by 
subject about 
these, but not 
marked 
concern. 
Dissociative 
experiences 
associated 
with 
heightened 
concern/ 
Distress about 
these 
experiences. 
Distress as a 
result of 
dissociative 
experiences.   
Interferes 
somewhat 
with usual 
activities (i.e. 
has to leave 
work/school/ 
social 
situation). 
Feelings of 
depersonalis-
ation/derealisati
on extremely 
distressing.   
Feeling of 
extreme 
distance from 
others.  
Marked periods 
of time when 
subject not able 
to describe what 
they have been 
doing, where 
they have been 
etc. 
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Psychopathology – Impaired tolerance to Stress  
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7.8 IMPAIRED TOLERANCE TO NORMAL STRESS  
(HUBER’S BASIC SYMPTOM) 
 
 
• Have you noticed a change in the way you have been coping 
with everyday stress?  
• Have you felt less able to cope with, or tolerate everyday stress 
than before?  
• When subjected to everyday stressors have you found yourself 
becoming excitable, uneasy, tense, nervous or anxious?  
• Have you found that ordinary stressors increase other difficulties 
you have been experiencing? 
 
 
 
 
 
 
 
 
 
IMPAIRED TOLERANCE TO STRESS- SEVERITY RATING SCALE 
 
0 
Never, 
absent 
1 
Questionable 
2 
Mild 
3 
Moderate 
4 
Moderately 
severe 
5 
Severe 
6 
Extreme 
No 
subjectively 
impaired 
tolerance to 
normal 
stress. 
 Mild, or rare 
feeling of not 
coping as well 
as before. 
Feeling 
mildly 
stressed in 
response to 
situations 
which would 
normally be 
coped with 
easily.   
Mild anxiety 
with 
everyday 
stressors, 
but still able 
to cope with 
them. 
More marked 
feeling of high 
anxiety, or 
tension with 
everyday 
stressors, but 
able to perform 
everyday tasks.  
Feeling unable 
to cope with 
more stressful 
situations.   
May feel 
anxious for no 
reason 
infrequently. 
Feelings of 
high anxiety, 
or tension 
with 
everyday 
stressors.   
Sometimes 
anxious for 
no reason at 
all. 
Extreme 
disability eg. 
even trivial 
events, or 
minor concerns 
result in 
feelings of 
being 
overwhelmed 
and panicked.  
Very anxious all 
of the time, 
even if there is 
no apparent 
reason.   
Unable to adapt 
to novel 
situations. 
 
Onset date: ________________ Offset date: ________________ 
 
Frequency and Duration 
0 1 2 3 4 5 6 
Absent Less than 
once a 
month 
Once a month to 
twice a week – 
less than one 
hour per 
occasion  
 
Once a month to 
twice a week – more 
than one hour per 
occasion 
OR 
3 to 6 times a week  - 
less than one hour 
per occasion 
3 to 6 times a 
week  - more 
than an hour per 
occasion  
OR  
daily – less than 
an hour per occ.  
Daily – more 
than an hour 
per occ.  
OR 
several times 
a day  
Continuous 
 
Pattern of Symptoms 
0 1 2 
No relation to substance use noted Occurs in relation to substance use 
and at other times as well 
Noted only in relation to substance 
use 
Inclusion Criteria 
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8: INCLUSION CRITERIA 
 
INTAKE CRITERIA CHECKLIST 
 
Group 1: Vulnerability Group  
This criterion identifies young people at risk of psychosis due to the combination of a trait risk factor and a significant 
deterioration in mental state and/or functioning  
                              YES         NO 
• Family history of psychosis in first degree relative OR Schizotypal Personality Disorder in identified 
patient 
? ? 
PLUS   
• 30% drop in SOFAS score from premorbid level, sustained for a month, occurred within past 12 months  
       OR SOFAS score of 50 or less for past 12 months or longer 
? ? 
CRITERION MET FOR GROUP 1 – Vulnerability Group ? ? 
 
 
Group 2: Attenuated Psychosis Group  
This criterion identifies young people at risk of psychosis due to a subthreshold psychotic syndrome.  That is, they have 
symptoms which do not reach threshold levels for psychosis due to subthreshold intensity (the symptoms are not severe 
enough) or they have psychotic symptoms but at a subthreshold frequency (the symptoms do not occur often enough). 
                       YES         NO 
2a) Subthreshold intensity:   
• Global Rating Scale Score of 3-5 on Unusual Thought Content subscale, 3-5 on Non-Bizarre Ideas 
subscale, 3-4 on Perceptual Abnormalities subscale and/or 4-5 on Disorganised Speech subscales of 
the CAARMS 
? ? 
PLUS   
• Frequency Scale Score of 3-6 on Unusual Thought Content, Non-Bizarre Ideas, Perceptual 
Abnormalities and/or Disorganised Speech subscales of the CAARMS for at least a week  
? ? 
2b) Subthreshold frequency:   
• Global Rating Scale Score of 6 on Unusual Thought Content, 6 on Non-Bizarre Ideas, 5-6 on 
Perceptual Abnormalities and/or 6 on Disorganised Speech subscales of the CAARMS 
  
PLUS   
• Frequency Scale Score of 3 on Unusual Thought Content, Non-Bizarre Ideas, Perceptual 
Abnormalities and/or Disorganised Speech subscales of the CAARMS  
? ? 
PLUS (for both categories)   
• Symptoms present in past year ? ? 
PLUS (for both categories)   
• 30% drop in SOFAS score from premorbid level, sustained for a month, occurred within past 12 months  
       OR SOFAS score of 50 or less for past 12 months or longer 
? ? 
CRITERION MET FOR GROUP 2 – Attenuated Psychosis Group ? ? 
  
 
Group 3: BLIPS Group   
This criterion identifies young people at risk of psychosis due to a recent history of frank psychotic symptoms that resolved 
spontaneously (without antipsychotic medication) within one week. 
                YES        NO 
• Global Rating Scale Score of 6 on Unusual Thought Content subscale, 6 on Non-Bizarre Ideas, 5 or 6 
on Perceptual Abnormalities subscale and/or 6 on Disorganised Speech subscales of the CAARMS 
? ? 
PLUS   
• Frequency Scale Score of 4-6 on Unusual Thought Content, Non-Bizarre Ideas, Perceptual 
Abnormalities and/or Disorganised Speech subscales 
? ? 
PLUS   
• Each episode of symptoms is present for less than one week and symptoms spontaneously remit 
on every occasion.   
? ? 
PLUS   
• Symptoms occurred during last year ? ? 
PLUS   
• 30% drop in SOFAS score from premorbid level, sustained for a month, occurred within past 12 months  
       OR SOFAS score of 50 or less for past 12 months or longer 
? ? 
CRITERION MET FOR GROUP 3 – BLIPS Group ? ? 
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9: PSYCHOSIS THRESHOLD /ANTI-PSYCHOTIC TREATMENT THRESHOLD 
 
 
                       YES        NO 
• Severity Scale Score of 6 on Unusual Thought Content subscale, 6 on Non-Bizarre Ideas, 5 or 6 on 
Perceptual Abnormalities subscale and/or 6 on Disorganised Speech subscales of the CAARMS 
? ? 
PLUS   
• Frequency Scale Score of greater than or equal to 4 on Unusual Thought Content, Non-Bizarre 
Ideas, Perceptual Abnormalities and/or Disorganised Speech subscales 
? ? 
PLUS   
• Symptoms present for longer than one week  ? ? 
PSYCHOSIS THRESHOLD CRITERION MET ? ? 
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SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE (SOFAS)1. 
 
Consider social and occupational functioning on a continuum from excellent functioning to grossly impaired 
functioning.  Include impairments in functioning due to physical limitations, as well as due to mental impairments.  to 
be counted, impairment must be a direct consequence of mental and physical health problems: the effects of lack of 
opportunity and other environmental limitations are not to be considered. 
 
Code (Note: use intermediate codes when appropriate e.g., 45, 68, 72).  RATING: 
_____________ 
 
100 Superior functioning in a wide range of activities 
│ 
91 
 
90 Good functioning in all areas, occupational and socially effective 
│ 
81 
 
80 No more than a slight impairment in social, occupational, or school functioning (e.g.  
│ infrequent interpersonal conflict, temporarily falling behind in schoolwork). 
71 
 
70 Some difficulty in social, occupational or school functioning, but generally functioning    
│ well, has some meaningful interpersonal relationships 
61 
 
60 Moderate difficulty in social, occupational or school functioning (e.g. few friends, conflicts  
│ with peers, co-workers). 
51 
 
50  Serious impairment in social, occupational, or school functioning (e.g., no friends, unable 
│ to keep a job) 
41 
 
40 major impairment in several areas such as work or school, family relations (e.g. depressed 
│ man avoids friends, neglects family and is unable to work: child frequently beats up    
31 younger children, is defiant at home, and is failing school) 
 
30 Inability to function in almost all areas (e.g. stays in bed all say, no job, home or friends) 
│ 
21 
 
20 Occasionally fails to maintain minimal personal hygiene.  Unable to function 
│ independently. 
11 
 
10 Persistent inability to maintain minimal personal hygiene.  Unable to function without  
│ harming self or others without considerable external support (e.g. nursing care and         
1 supervision) 
 
0 Inadequate information 
 
                                                     
1 Note: the rating of overall psychological functioning on a scale of 0-100 was operationalized by Luborsky in the Health-Sickness Rating Scale 
(Luborsky L: “Clinicians Judgements of  Mental Health” Archives of General Psychiatry 7: 401-417, 1962).  Spitzer and colleagues developed a 
revision of the Health-Sickness Rating Scale called the Global Assessment Scale (GAS) (Endicott J, Spitzer RL, Fleiss JL et al: “The Global 
Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance” Archives of General Psychiatry 33: 766-771, 1976). 
The SOFAS is derived from the GAS and its development is described in Goldman HH, Skodol AF, Lave TR: “Revising Axis V for DSM-IV: A 
Review of Measures of Social Functioning: American Journal of Psychiatry 149; 1148-1156, 1992 
 
BRIEF IMPACT OF EVENTS (IES-6)               
  Brief Impact of Events, Short version, English, EU GEI, 4-D, Sept 2010, Page 19 
 
The following is a list of difficulties people sometimes have after stressful life events. In relation to any of the above 
events you have experienced in both childhood and the 12 months pre-onset [researcher summarize events] - or indeed 
for any event or difficulty that occurred at another time (PROBE!!!) - Please indicate the extent to which you have 
experienced the following difficulties in the PAST SEVEN DAYS. How much were you distressed or bothered by 
these difficulties? Check one number for each item. If it has not occurred at all in the last seven days then please tick 
'not at all'. If no events, do not complete. 
  
 Not at all A little bit Moderately Quite a bit Extremely 
1. I thought about it when I didn’t mean to O0 O1 O2 O3 O4 
2. I felt watchful or on-guard O0 O1 O2 O3 O4 
3. Other things kept making me think about it O0 O1 O2 O3 O4 
4. I was aware that I still had a lot of feelings about it, 
but I didn’t deal with them. 
O0 O1 O2 O3 O4 
5. I tried not to think about it O0 O1 O2 O3 O4 
6. I had trouble concentrating O0 O1 O2 O3 O4 
7. I had dreams about it O0 O1 O2 O3 O4 
8. Pictures about it popped into my mind O0 O1 O2 O3 O4 
 
 
8a.    Which of the events, difficulties that you have mentioned, doe these experiences mostly relate to? (specify and note whether 
occurred before onset) 
 
……………………………………………………………………………………………………………………………………………. 
 
 
    
          (Note for DATA ENTRY: open EU_SEAT, Social Environment Assessment Tool) 
O-LIFE  ID_________ Date ____/ _____ / _____   
 
 
Please read these instructions before completing the questionnaire: 
These questions relate to your thoughts, feelings, experiences and preferences. There 
are no right or wrong answers or trick questions so please be as honest as possible.  
For each question please choose either YES or NO and circle this on the form.  Please 
do not spend too much time thinking about it – choose the answer closest to your 
own. 
 
1. Do you often hesitate when you are going to say something in a group of people 
whom you more or less know? 
2. Do you often overindulge in alcohol or food? 
3. Are the sounds you hear in your daydreams really clear and distinct? 
4. Do you enjoy many different kinds of play and recreation?  
5. Do your thoughts sometimes seem as real as actual events in your life? 
6. Does it often happen that nearly every thought immediately and automatically 
suggests an enormous number of ideas? 
7. When in a group of people do you usually prefer to let someone else be the centre 
of attention? 
8. Do you frequently have difficulty in starting to do things?  
9. Has dancing or the idea of it always seemed dull to you? 
10. When you catch a train do you often arrive at the last minute?  
11. Is trying new foods something you have always enjoyed?  
12. Do you often change between intense liking and disliking of the same person? 
13. Have you ever cheated at a game?  
14. Are there very few things that you have ever really enjoyed doing? 
15. Do you at times have an urge to do something harmful or shocking?  
16. Do you often worry about things you should not have done or said?  
17. Are your thoughts sometimes so strong that you can almost hear them?  
18. Are you usually in an average sort of mood, not too high and not too low?  
19. Would you take drugs which may have strange or dangerous effects?  
20. Do you think you could learn to read other's minds if you wanted to?  
21. When in a crowded room, do you often have difficulty in following a 
conversation? 
22. No matter how hard you try to concentrate do unrelated thoughts creep into your 
mind?  
23. Are you easily hurt when people find fault with you or the work you do?  
24. Do you stop to think things over before doing anything? 
25. Have you ever felt that you have special, almost magical powers?  
O-LIFE  ID_________ Date ____/ _____ / _____   
 
 
26. Are you much too independent to really get involved with other people? 
27. Do ideas and insights sometimes come to you so fast that you cannot express them 
all?  
28. Do you easily lose your courage when criticised or failing in something?  
29. Can some people make you aware of them just by thinking about you?  
30. Does a passing thought ever seem so real it frightens you?  
31. Have you ever blamed someone for doing something you know was really your 
fault?  
32. Are you a person whose mood goes up and down easily? 
33. Does your voice ever seem distant or faraway?  
34. Do you think having close friends is not as important as some people say? 
35. Are you rather lively? 
36. Are you sometimes so nervous that you are `blocked'?  
37. Do you find it difficult to keep interested in the same thing for a long time?  
38. Do you dread going into a room by yourself where other people have already 
gathered and are talking?  
39. Does it often feel good to massage your muscles when they are tired or sore?  
40. Do you sometimes feel that your accidents are caused by mysterious forces? 
41. Do you like mixing with people? 
42. On seeing a soft thick carpet have you sometimes had the impulse to take off your 
shoes and walk barefoot on it? 
43. Do you often have difficulties in controlling your thoughts?  
44. Do the people in your daydreams seem so true to life that you sometimes think 
they are real? 
45. Are people usually better off if they stay aloof from emotional involvements with 
people?  
46. Can just being with friends make you feel really good?  
47. Is your hearing sometimes so sensitive that ordinary sounds become 
uncomfortable? 
48. Have you often felt uncomfortable when your friends touch you? 
49. When things are bothering you do you like to talk to other people about it? 
50. Do you have many friends? 
51. Would being in debt worry you?  
52. Do you think people spend too much time safeguarding their future with savings 
and insurance? 
53. Do you ever have the urge to break or smash things?  
54. Do you often feel that there is no purpose to life?  
O-LIFE  ID_________ Date ____/ _____ / _____   
 
 
55. Do you worry about awful things that might happen?  
56. Have you ever felt the urge to injure yourself?  
57. Would it make you nervous to play the clown in front of other people?  
58. Have you felt that you might cause something to happen just by thinking too much 
about it? 
59. Have you had very little fun from physical activities like walking, swimming, or 
sports?  
60. Do you feel so good at controlling others that it sometimes scares you? 
61. Are you easily distracted from work by daydreams? 
62. Are you easily confused if too much happens at the same time?  
63. Do you ever have a sense of vague danger or sudden dread for reasons that you do 
not understand?  
64. Is it true that your relationships with other people never get very intense?  
65. Have you sometimes had the feeling of gaining or losing energy when certain 
people look at you or touch you?  
66. Do you worry too long after an embarrassing experience? 
67. Do you love having your back massaged?  
68. Do you consider yourself to be pretty much an average kind of person?  
69. Have you ever taken advantage of someone?  
70. Would you like other people to be afraid of you?  
71. Have you ever thought you heard people talking only to discover that it was in 
fact some nondescript noise?  
72. Have you occasionally felt as though your body did not exist? 
73. Do you often feel lonely? 
74. Do you often have an urge to hit someone?  
75. Do you often experience an overwhelming sense of emptiness?  
76. On occasions, have you seen a person's face in front of you when no one was in 
fact there?  
77. Is it fun to sing with other people?  
78. Do you often have days when indoor lights seem so bright that they bother your 
eyes? 
79. Have you wondered whether the spirits of the dead can influence the living?  
80. Do people who try to get to know you better usually give up after a while? 
81. Do you often feel `fed up'?  
82. Have you felt as though your head or limbs were somehow not your own? 
83. When you look in the mirror does your face sometimes seem quite different from 
usual? 
O-LIFE  ID_________ Date ____/ _____ / _____   
 
 
84. Do people who drive carefully annoy you?  
85. Would you call yourself a nervous person?  
86. Can you usually let yourself go and enjoy yourself at a lively party?  
87. Do you ever suddenly feel distracted by distant sounds that you are not normally 
aware of? 
88. Do you sometimes talk about things you know nothing about? 
89.  When in the dark do you often see shapes and forms even though there's nothing 
there? 
90. Have you sometimes sensed an evil presence around you, even though you could 
not see it? 
91. Is it hard for you to make decisions? 
92. Do you find the bright lights of a city exciting to look at?  
93. Does your sense of smell sometimes become unusually strong? 
94. Do you usually have very little desire to buy new kinds of food?  
95. Do you ever feel that your speech is difficult to understand because the words are 
all mixed up and don't make sense?  
96. Do you often feel like doing the opposite of what other people suggest, even 
though you know they are right?  
97. Do you like going out a lot? 
98. Do you feel very close to your friends? 
99. Do you ever feel sure that something is about to happen, even though there does 
not seem to be any reason for you thinking that?  
100. Do you often feel the impulse to spend money which you know you can't afford? 
101. Are you easily distracted when you read or talk to someone?   
102. Do you feel that making new friends isn't worth the energy it takes? 
103. Do you believe in telepathy? 
104. Do you prefer watching television to going out with other people? 
 
 
Thank you very much for taking the time and effort to fill this in. 
O-LIFE  ID_________ Date ____/ _____ / _____   
 
 
 
1.              Y           N 36.            Y           N 71.             Y           N 
2.              Y           N 37.            Y           N 72.             Y           N 
3.              Y           N 38.            Y           N 73.             Y           N 
4.              Y           N 39.            Y           N 74.             Y           N 
5.              Y           N 40.            Y           N 75.             Y           N 
6.              Y           N 41.            Y           N 76.             Y           N 
7.              Y           N 42.            Y           N 77.             Y           N 
8.              Y           N 43.            Y           N 78.             Y           N 
9.              Y           N 44.            Y           N 79.             Y           N 
10.            Y           N 45.            Y           N 80.             Y           N 
11.            Y           N 46.            Y           N 81.             Y           N 
12.            Y           N 47.            Y           N 82.             Y           N 
13.            Y           N 48.            Y           N 83.             Y           N 
14.            Y           N 49.            Y           N 84.             Y           N 
15.            Y           N 50.            Y           N 85.             Y           N 
16.            Y           N 51.            Y           N 86.             Y           N 
17.            Y           N 52.            Y           N 87.             Y           N 
18.            Y           N 53.            Y           N 88.             Y           N 
19.            Y           N 54.            Y           N 89.             Y           N 
20.            Y           N 55.            Y           N 90.             Y           N 
21.            Y           N 56.            Y           N 91.             Y           N 
22.            Y           N 57.            Y           N 92.             Y           N 
23.            Y           N 58.            Y           N 93.             Y           N 
24.            Y           N 59.            Y           N 94.             Y           N 
25.            Y           N 60.            Y           N 95.             Y           N 
26.            Y           N 61.            Y           N 96.             Y           N 
27.            Y           N 62.            Y           N 97.             Y           N 
28.            Y           N 63.            Y           N 98.             Y           N 
29.            Y           N 64.            Y           N 99.             Y           N 
30.            Y           N 65.            Y           N 100.           Y           N 
31.            Y           N 66.            Y           N 101.           Y           N 
32.            Y           N 67.            Y           N 102.           Y           N 
33.            Y           N 68.            Y           N 103.           Y           N 
34.            Y           N 69.            Y           N 104.           Y           N 
35.            Y           N 70.             Y           N Thanks for completing this 
 
  
          Please complete the following questions by circling the number that best describes your experience at the moment 
 
 Not at all Slightly Moderately Strongly 
1. You enjoy mixing with people  0 1 2 3 
2. You hesitate even when you know what you are going to say 0 1 2 3 
3. Your mood is going up and down a lot  0 1 2 3 
4. You feel that you can predict what is about to happen  0 1 2 3 
5. You feel more sensitive to light or the colour or brightness of things 0 1 2 3 
6. You feel close to people  0 1 2 3 
7. You think you are being talked about  0 1 2 3 
8. It is more difficult than normal to follow conversations with people  0 1 2 3 
9. You feel rather indifferent about things  0 1 2 3 
10. Your mind jumps a lot from one thing to another  0 1 2 3 
11. You think people are saying or doing things to annoy you  0 1 2 3 
12. You think other people can read your mind  0 1 2 3 
13. You find it more difficult than usual to start doing things  0 1 2 3 
14. You are bothered by the idea that people are watching you  0 1 2 3 
15. You find activities less enjoyable than usual  0 1 2 3 
16. Your mind is so full of ideas that you can’t concentrate on one thing  0 1 2 3 
17. You feel that people have it in for you  0 1 2 3 
18. It is fun to do things with other people  0 1 2 3 
19. You feel that you have special or magical powers  0 1 2 3 
20. Your sense of smell is unusually strong or different  0 1 2 3 
21. You want to be the centre of attention more than usual  0 1 2 3 
22. Your experience of time is unnaturally fast or slow  0 1 2 3 
23. You feel that no one understands you  0 1 2 3 
Please turn over 
  
 Not at all Slightly Moderately Strongly 
24. You feel rather uninvolved with other people  0 1 2 3 
25. People can put thoughts into your mind  0 1 2 3 
26. You are experiencing something very special or important  0 1 2 3 
27. Your hearing has become very sensitive  0 1 2 3 
28. You find it difficult to think clearly  0 1 2 3 
29. You stop to think things over before doing them  0 1 2 3 
30. Your speech is difficult to understand because your words are all mixed up  0 1 2 3 
31. You feel that you might cause something to happen just by thinking about it  0 1 2 3 
32. You feel as though your head, limbs or body have somehow changed  0 1 2 3 
33. You feel that you deserved to be punished in some way  0 1 2 3 
34. When you try to concentrate many unrelated thoughts pop into your mind  0 1 2 3 
35. Your thoughts are sometimes so strong that you can almost hear them  0 1 2 3 
36. You have seen a person's face in front of you when no one was in fact there  0 1 2 3 
37. Your thoughts stop suddenly, interrupting what you are saying  0 1 2 3 
38. You have a vague sense of danger or sudden dread for reasons you don’t understand  0 1 2 3 
39. You would feel uncomfortable if your friends touch you  0 1 2 3 
40. You feel that you can read other people’s minds  0 1 2 3 
41. Ideas and insights come to you so fast that you can’t express them all  0 1 2 3 
42. You think people are laughing about you behind your back  0 1 2 3 
43. You have the feeling of gaining or losing energy when people look at or touch you  0 1 2 3 
44. You can sense an evil presence around you, even though you cannot see it  0 1 2 3 
45. You can see shapes and forms even though they aren’t there  0 1 2 3 
46. You are easily distracted when doing something or talking to someone  0 1 2 3 
47. You are confused by too much happening at the same time  0 1 2 3 
48. You believe you are a special person with an important mission  0 1 2 3 
  
Highlighted pink are reversed.  
Example Structured Clinical Interview for DSM‐IV (SCID) 
 
Psychiatric History 
 
Have you ever seen a mental health professional or your doctor for psychiatric reasons? Y / 
N 
Have you or anyone in your family been diagnosed with any of the following (by a mental 
health professional)? 
Depression    Y / N ____________________________________ 
Bipolar Disorder   Y / N ____________________________________ 
Anxiety Disorders   Y / N ____________________________________ 
Schizophrenia    Y / N ____________________________________ 
ADHD     Y / N ____________________________________ 
 
Have you ever been hospitalized for a psychiatric illness?            Y / N 
 
Details:___________________________________________________________________
__________ _______________________________________________________ 
 
DSM-IV Screening 
Instructions:  
? = Inadequate information   1 = false/absent   2 = sub-threshold   3 = true/present 
Mood Disorder Questions 
Has there ever been a period of time when you were feeling down or 
depressed most of the day, nearly every day?  How long did it last?
  ?    1    2    3 
  
Have you ever lost interest or pleasure in things you usually enjoyed?  
Was it nearly every day?  How long did it last? 
  ?    1     2   3 
 
If yes, check symptoms present at the time:  
Low mood 
  Loss of enjoyment most of time 
  Sleeping difficulties 
  Loss of appetite or weight 
  Lack of energy 
  Lack of concentration  
  Feelings of guilt 
  Pessimism about things 
  Suicidal ideas or attempts 
 
Has there ever been a time when you were feeling so good, “high” or hyper 
that other people thought you were not your normal self, or you were so  
hyper that you got into trouble?  Or were you so irritable that you found 
yourself shouting at people or starting fights?  How long did it last? 
  ?  1    2    3 
 
Anxiety Screening Questions 
Have you ever had a panic attack when you suddenly felt frightened or  
suddenly developed a lot of physical symptoms?  
  ?   1   2   3 
 Psychosis Screening Questions 
Has it ever seemed like people were talking about you or taking special  
notice of you? What about anyone going out of his/her way to give you a hard  
time, or trying to hurt you? 
?    1   2   3 
Did you ever feel you were especially important in some way, or had special  
powers to do things others couldn’t? Have you ever been able to hear things  
that others couldn’t, such as noises or the voices of people whispering or  
talking? 
 
?    1   2   3 
 
 
 
 
Pharmacotherapy: 
Are you taking, or have you ever taken, any prescription medications for depression or 
anxiety? Anything to help you sleep? Any other medications for any emotional problems? 
 
Medication    Dose  Date/Response 
____________________________________________________________________________
_______ 
____________________________________________________________________________
_______ ___________________________________________ 
 
Were you ever afraid of going out of the house alone, being in crowds,  
standing in a line, or traveling on buses or trains? 
  ?   1   2   3 
In the last 6 months, have you been particularly nervous or anxious?   ?  1    2   3 
  
SUMMARISED SCID MKv3 
  
Depressions 
A1- Has there ever been a period of time when you were feeling depressed or down most of the day  
nearly every day – as long as 2 weeks?                                                                               ?    1    2    
3 
 
A2 – Lost interest or pleasure in things you usually enjoyed – most of the day nearly every day – 
 as long as 2 weeks?                                                                                                             ?    1    2    
3 
 
Mania 
A16 – Have you had a period of time when you were feeling so good, “high” or hyper 
that other people thought you were not your normal self, or you got into trouble?   -  
as long as one week?                                                                                                           ?    1    2    
3 
 
If no: What about a period of time when you were so irritable that you found 
yourself shouting at people or starting arguments?  - as long as one week? 
 (4 days for hypomania)                                                                                                         ?    1    2    
3 
 
Dysthymic 
A45 – For the past couple of years have you been bothered by depressed mood most of the day,  
more days than most?                                                                                                            ?    1    2    
3 
 
Psychotic Symptoms 
B1 - Has it ever seemed like people were talking about you or taking special  
notice of you? (Delusion of reference)                                                                                   ?    1    2    
3 
 
B2 - What about anyone going out of his/her way to give you a hard  
time, or trying to hurt you? (Persecutory delusion)                                                                 ?    1    2    
3 
 
B3 - Did you ever feel you were especially important in some way, or had special  
powers to do things that other people couldn’t do? (Grandiose delusion)                             ?    1    2    
3. 
 
B5 – Did you ever believe someone could read your mind? (Other delusions) 
 
B6 – Have you ever been able to hear things that other people couldn’t hear, such as noises  
or the voices of people whispering or talking? (Auditory hallucinations)                                ?    1    2    
3 
 
B7 – Did you ever have visions or see things that people couldn’t see?                               ?    1    2    
3 
 
B8 – What about strange sensations on your body or skin?                                                  ?    1    2    
3 
 
B9 – What about smelling or tasting things that other people couldn’t smell or taste?          ?    1    2    
3 
 
B10-15 (Catatonic, Disorganised, Inappropriate Behaviour, Disorganised speech, 
 Negative symptoms).                                                                                                             ?    1    2    
3 
 
E2: If possible alcohol abuse: (all these should be recurrent) 
Did you ever miss work or school because intoxicated or hung over?                                   ?    1    2    
3 
Did you ever drink in a situation in which it might have been dangerous to drink at all?        ?    1    2    
3 
Did your drinking ever get you into trouble with the law?                                                       ?    1    2    
3 
Did your drinking ever cause problems with other people such as family members?            ?    1    2    
3 
 
E17 Any drug taking? Use above 
Did you ever miss work or school because intoxicated or hung over?                                   ?    1    2    
3 
Did you ever drink in a situation in which it might have been dangerous to drink at all?        ?    1    2    
3 
Did your drinking ever get you into trouble with the law?                                                        ?    1    2    
3 
Did your drinking ever cause problems with other people such as family members?             ?    1    2    
3 
 
 
Panic attacks 
F1: Have you ever had a panic attack when you suddenly felt frightened or  
suddenly developed a lot of physical symptoms?                                                                  ?    1    2    
3  
 
Obsessions 
F25: Bothered by thoughts that don’t make sense and kept coming back, even whe 
 you try not to have them – like hurting someone when you don’t want to, or being  
contaminated by germs or dirt?                                                                                             ?    1    2    
3 
 
PTSD 
F39 – Sometimes things happen to people that are very upsetting – things such as being 
in a life-threatening situation such as a major disaster, a very serious accident or fire, 
being physically assaulted or raped, seeing another person killed or badly hurt or hearing 
about something horrible that has happened to someone  you are very close to. At any 
time during your life have any of these things happened to you?                           
?    1    2    3 
 
If trauma experienced, ask if affects the way they get on with work, life and socializing in their day-
to-day activities. 
 
 
Other Anxiety disorders 
 
F65 - Were you ever afraid of going out of the house alone, being in crowds, standing in a line, or  
standing on buses or trains? (Agrophobia)                                                                       ?    1    
2    3 
 
F66 – Is there anything that you have been afraid to do for felt uncomfortable doing in  
front of other people, such as speaking, eating or writing? (Social)                                 ?    1    2    3 
 
F67 – Are there any other things that you are especially afraid of seeing such as blood, heights,  
closed places, or certain kinds of animals or insects?                                                     ?    1    2    3 
 
F68 – Over the last 6 months have you been particularly nervous or anxious?              ?    1    2    3 
 
Somatoform 
F72 and F73 – Do you worry much about your physical health and does you doctor think  
you worry too much?                                                                                                        ?    1    2    3 
 
F74 – Some people are very bothered about the way they look. 
 Is that a problem for you?                                                                                                ?    1    2    3              
 
Eating disorders 
F75 – Have you ever had a time when you weighed much less than other people thought  
you ought to weigh? (Anorexia)                                                                                        ?    1    2    3 
 F76 – Have you often had times when your eating was out of control (Bulimia)               ?    1    2    3 
 
